

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
14 October 2004 (14.10.2004)

PCT

(10) International Publication Number
WO 2004/087746 A2

(51) International Patent Classification⁷: **C07K 14/00**

(21) International Application Number:
PCT/EP2004/003398

(22) International Filing Date: 31 March 2004 (31.03.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
03450078.5 31 March 2003 (31.03.2003) EP

(71) Applicant (for all designated States except US): **INTER-CELL AG** [AT/AT]; Campus Vienna Biocenter 6, A-1030 Vienna (AT).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **MEINKE, Andreas** [DE/AT]; Piettegassee 26/1, A-3013 Pressbaum (AT). **MIN BUI, Duc** [VN/AT]; Rudolf Zeller Gasse 70/6/9, A-1230 Vienna (AT). **NAGY, Eszter** [HU/AT]; Taborstrasse 9, A-1020 Vienna (AT).

(74) Agent: **SONN & PARTNER PATENTANWÄLTE**; Riemergasse 14, A-1010 Vienna (AT).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM,

AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for all designations
- of inventorship (Rule 4.17(iv)) for US only

Published:

- without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: **S. EPIDERMIDIS ANTIGENS**

(57) Abstract: The present invention discloses isolated nucleic acid molecules encoding a hyperimmune serum reactive antigen or a fragment thereof as well as hyperimmune serum reactive antigens or fragments thereof from *S. epidermidis*, methods for isolating such antigens and specific uses thereof.

WO 2004/087746 A2

This Page Blank (uspro)

S. EPIDERMIDIS ANTIGENS

The present invention relates to isolated nucleic acid molecules, which encode antigens for *Staphylococcus epidermidis*, which are suitable for use in preparation of pharmaceutical medicaments for the prevention and treatment of bacterial infections caused by *Staphylococcus epidermidis*.

Staphylococci are opportunistic pathogens, which can cause illnesses, which range from minor infections to life threatening diseases. Of the large number of *Staphylococci* at least 3 are commonly associated with human disease: *S. aureus*, *S. epidermidis* and rarely *S. saprophyticus* (Crossley, K.B. and Archer G.L, eds. (1997). *The Staphylococci in Human Disease*. Churchill Livingstone Inc.) *Staphylococcal* infections are imposing an increasing threat in hospitals worldwide. The appearance and disease causing capacity of *Staphylococci* are related to the widespread use of antibiotics, which induced and continue to induce multi-drug resistance. Both *S. aureus* and *S. epidermidis* have become resistant to many commonly used antibiotics, most importantly to methicillin (MRSA) and vancomycin (VISA). Drug resistance is an increasingly important public health concern, and soon many infections caused by *staphylococci* may be untreatable by antibiotics. In addition to its adverse effect on public health, antimicrobial resistance contributes to higher health care costs, since treating resistant infections often requires the use of more toxic and more expensive drugs, and can result in longer hospital stays for infected patients. Moreover, even with the help of effective antibiotics, the most serious *staphylococcal* infections have 30-50% mortality.

Every human being is colonized with *S. epidermidis*. The normal habitats of *S. epidermidis* are the skin and the mucous membrane. Generally, the established flora of the nose prevents acquisition of new strains. However, colonization with other strains may occur when antibiotic treatment is given that leads to elimination of the susceptible carrier strain. Because this situation occurs in the hospitals, patients may become colonized with resistant nosocomial *Staphylococci*.

Staphylococci become potentially pathogenic as soon as the natural balance between microorganisms and the immune system gets disturbed, when natural barriers (skin, mucous membrane) are breached. The coagulase-positive *S. aureus* is the most pathogenic *staphylococcal* species, feared by surgeons for a long time. Most frequently it causes surgical wound infections, and induces the formation of abscesses. *S. epidermidis* causes diseases mostly related to the presence of

foreign bodies and the use of devices, such as catheter related infections, cerebrospinal fluid shunt infections, peritonitis in dialysed patients (mainly CAPD), endocarditis in individuals with prosthetic valves. This is exemplified in immunocompromised individuals such as oncology patients and premature neonates in whom coagulase-negative staphylococcal infections frequently occur in association with the use of intravascular device. The increase in incidence is related to the increased use of these devices and increasing number of immuno-compromised patients.

The pathogenesis of staphylococci is multifactorial. In order to initiate infection the pathogen has to gain access to the cells and tissues of the host, that is adhere. Since adherence is obviously a crucial step in the initiation of foreign body infections, *S. epidermidis* is equipped with a number of cell surface molecules, which promote adherence to foreign material and through that mechanism establish infection in the host. A characteristic of many pathogenic strains of *S. epidermidis* is the production of a slime resulting in biofilm formation. The slime is predominantly a secreted teichoic acid, normally found in the cell wall of the staphylococci. This ability to form a biofilm on the surface of a prosthetic device is probably a significant determinant of virulence for these bacteria, since this prevents phagocytosis of the bacteria. A further means of staphylococci to cause damage to its host are the secreted products, such as enterotoxins, exotoxins, and tissue damaging enzymes. The toxins kill or misguide immune cells, which are important in the host defence. The several different types of toxins are responsible for most of the symptoms during infections.

For all the above-mentioned reasons there remains a need for an effective preventive and therapeutic treatment, but until today there is no effective preventive or therapeutic vaccine approved. It has been shown that an antibody deficiency state contributes to staphylococcal persistence, suggesting that anti-staphylococcal antibodies are important in host defence. Antibodies - added as passive immunisation or induced by active vaccination - directed towards surface components could both, prevent bacterial adherence, neutralize toxins and promote phagocytosis. An effective vaccine offers great potential for patients facing elective surgery in general, and those receiving endovascular devices, in particular. Moreover, patients suffering from chronic diseases, which decrease immune responses or undergoing continuous ambulatory peritoneal dialysis are likely to benefit from such a vaccine.

A vaccine can contain a whole variety of different antigens. Examples of anti-

gens are whole-killed or attenuated organisms, subfractions of these organisms/tissues, proteins, or, in their most simple form, peptides. Antigens can also be recognized by the immune system in form of glycosylated proteins or peptides and may also be or contain polysaccharides or lipids. Short peptides can be used since for example cytotoxic T-cells (CTL) recognize antigens in form of short usually 8-11 amino acids long peptides in conjunction with major histocompatibility complex (MHC). B-cells can recognize linear epitopes as short as 4-5 amino acids, as well as three-dimensional structures (conformational epitopes). In order to obtain sustained, antigen-specific immune responses, adjuvants need to trigger immune cascades that involve all cells of the immune system necessary. Primarily, adjuvants are acting, but are not restricted in their mode of action, on so-called antigen presenting cells (APCs). These cells usually first encounter the antigen(s) followed by presentation of processed or unmodified antigen to immune effector cells. Intermediate cell types may also be involved. Only effector cells with the appropriate specificity are activated in a productive immune response. The adjuvant may also locally retain antigens and co-injected other factors. In addition the adjuvant may act as a chemoattractant for other immune cells or may act locally and/or systemically as a stimulating agent for the immune system.

Approaches to develop a vaccine have focused until today mainly on *S. aureus* (Shinefield, H. et al., 2002). Therefore it would be of great value to develop a vaccine targeting *S. epidermidis* or preferentially both *Staphylococci*.

The present inventors have developed a method for identification, isolation and production of hyperimmune serum reactive antigens from a specific pathogen, especially from *Staphylococcus aureus* and *Staphylococcus epidermidis* (WO 02/059148). Importantly for the present invention, the selection of sera for the identification of antigens from *S. epidermidis* is different from that applied to the previous screens.

Individuals undergoing continuous peritoneal dialysis represent one of the most important groups of patients infected by *S. epidermidis*. *Staphylococci* preferentially infect patients with foreign bodies such as dialysis catheters. Peritoneal dialysis patients suffer from peritonitis mainly caused by *S. aureus* and coagulase negative staphylococci, especially *S. epidermidis*. In order to identify antigens expressed by *S. epidermidis* in humans during peritonitis, human serum samples were collected from patients undergoing peritoneal dialysis for an extended period of time and suffered from peritonitis caused by *S. epidermidis* within the previous 12 months, and thus considered to be in the late

convalescent phase of the disease. It has been firmly established that patients with serious staphylococcal diseases - such as peritonitis - develop antibodies, which sustain for up to a year.

The problem underlying the present invention was to provide means for the development of medicaments such as vaccines against *S. epidermidis* infection. More particularly, the problem was to provide an efficient and relevant set of nucleic acid molecules or hyperimmune serum reactive antigens from *S. epidermidis* that can be used for the manufacture of said medicaments.

Therefore, the present invention provides an isolated nucleic acid molecule encoding a hyperimmune serum reactive antigen or a fragment thereof comprising a nucleic acid sequence, which is selected from the group consisting of:

- a) a nucleic acid molecule having at least 70% sequence identity to a nucleic acid molecule selected from Seq ID No 1, 4, 6-9, 11-13, 15, 17, 19, 21, 25-26, 28-31.
- b) a nucleic acid molecule which is complementary to the nucleic acid molecule of a),
- c) a nucleic acid molecule comprising at least 15 sequential bases of the nucleic acid molecule of a) or b)
- d) a nucleic acid molecule which anneals under stringent hybridisation conditions to the nucleic acid molecule of a), b), or c)
- e) a nucleic acid molecule which, but for the degeneracy of the genetic code, would hybridise to the nucleic acid molecule defined in a), b), c) or d).

According to a preferred embodiment of the present invention the sequence identity is at least 80%, preferably at least 95%, especially 100%.

Furthermore, the present invention provides an isolated nucleic acid molecule encoding a hyperimmune serum reactive antigen or a fragment thereof comprising a nucleic acid sequence selected from the group consisting of

- a) a nucleic acid molecule having at least 96% sequence identity to a nucleic acid molecule selected from Seq ID No 2-3, 5, 10, 14, 16, 18, 22-24, 27,
- b) a nucleic acid molecule which is complementary to the nucleic acid molecule of a),
- c) a nucleic acid molecule comprising at least 15 sequential bases of the nucleic acid molecule of a) or b)
- d) a nucleic acid molecule which anneals under stringent hybridisation conditions to the nucleic acid molecule of a), b) or c),

- e) a nucleic acid molecule which, but for the degeneracy of the genetic code, would hybridise to the nucleic acid defined in a), b), c) or d).

According to another aspect, the present invention provides an isolated nucleic acid molecule comprising a nucleic acid sequence selected from the group consisting of

- a) a nucleic acid molecule selected from Seq ID No 20.
- b) a nucleic acid molecule which is complementary to the nucleic acid of a),
- c) a nucleic acid molecule which, but for the degeneracy of the genetic code, would hybridise to the nucleic acid defined in a), b), c) or d).

Preferably, the nucleic acid molecule is DNA or RNA.

According to a preferred embodiment of the present invention, the nucleic acid molecule is isolated from a genomic DNA, especially from a *S. epidermidis* genomic DNA.

According to the present invention a vector comprising a nucleic acid molecule according to any of the present invention is provided.

In a preferred embodiment the vector is adapted for recombinant expression of the hyperimmune serum reactive antigens or fragments thereof encoded by the nucleic acid molecule according to the present invention.

The present invention also provides a host cell comprising the vector according to the present invention.

According to another aspect the present invention further provides a hyperimmune serum-reactive antigen comprising an amino acid sequence being encoded by a nucleic acid molecule according to the present invention.

In a preferred embodiment the amino acid sequence (polypeptide) is selected from the group consisting of Seq ID No 32, 35, 37-40, 42-44, 46, 48, 50, 52, 56-57, 59-62.

In another preferred embodiment the amino acid sequence (polypeptide) is selected from the group consisting of Seq ID No 33-34, 36, 41, 45, 47, 49, 53-55, 58.

In a further preferred embodiment the amino acid sequence (polypeptide) is selected from the group consisting of Seq ID No 51.

According to a further aspect the present invention provides fragments of hyperimmune serum-reactive antigens selected from the group consisting of peptides comprising amino acid sequences of column "predicted immunogenic aa" and "location of identified immunogenic region" of Table 1; the serum reactive epitopes of Table 2, especially peptides comprising amino acids 6-28, 54-59, 135-147, 193-205, 274-279, 284-291, 298-308, 342-347, 360-366, 380-386, 408-425, 437-446, 457-464, 467-477, 504-510, 517-530, 535-543, 547-553, 562-569, 573-579, 592-600, 602-613, 626-631, 638-668 and 396-449 of Seq ID No 32; 5-24, 101-108, 111-117, 128-142, 170-184, 205-211, 252-267, 308-316, 329-337, 345-353, 360-371, 375-389, 393-399, 413-419, 429-439, 446-456, 471-485, 495-507, 541-556, 582-588, 592-602, 607-617, 622-628, 630-640 and 8-21 of Seq ID No 33; 10-20, 23-33, 40-45, 59-65, 72-107, 113-119, 127-136, 151-161 and 33-59 of Seq ID No 34; 4-16, 28-34, 39-61, 66-79, 100-113, 120-127, 130-137, 142-148, 150-157, 192-201, 203-210, 228-239, 245-250, 256-266, 268-278, 288-294, 312-322, 336-344, 346-358, 388-396, 399-413, 425-430, 445-461, 464-470, 476-482, 486-492, 503-511, 520-527, 531-541, 551-558, 566-572, 609-625, 635-642, 650-656, 683-689, 691-705, 734-741, 750-767, 782-789, 802-808, 812-818, 837-844, 878-885, 907-917, 930-936 and 913-933 of Seq ID No 35; 5-12, 20-27, 46-78, 85-92, 104-112, 121-132, 150-167, 179-185, 200-213, 221-227, 240-264, 271-279, 282-290, 311-317 and 177-206 of Seq ID No 36; 18-24, 31-40, 45-51, 89-97, 100-123, 127-132, 139-153, 164-170, 184-194, 200-205, 215-238, 244-255, 257-270, 272-280, 289-302, 312-318, 338-348, 356-367 and 132-152 of Seq ID No 37; 7-16, 39-45, 73-83, 90-98, 118-124, 130-136, 194-204, 269-280, 320-327, 373-381, 389-397, 403-408, 424-430, 436-441, 463-476, 487-499, 507-514, 527-534, 540-550, 571-577, 593-599, 620-629, 641-647, 650-664, 697-703, 708-717, 729-742, 773-790, 794-805, 821-828, 830-837, 839-851, 858-908, 910-917, 938-947, 965-980, 1025-1033, 1050-1056, 1073-1081, 1084-1098, 1106-1120, 1132-1140, 1164-1170, 1185-1194, 1201-1208, 1215-1224, 1226-1234, 1267-1279, 1325-1331, 1356-1364, 1394-1411, 1426-1439, 1445-1461, 1498-1504, 1556-1561, 1564-1573, 1613-1639, 1648-1655, 1694-1714, 1748-1755, 1778-1785, 1808-1813, 1821-1827, 1829-1837, 1846-1852, 1859-1865, 1874-1883, 1895-1900, 1908-1913, 1931-1937, 1964-1981, 1995-2005, 2020-2033, 2040-2047, 2103-2109, 2118-2127, 2138-2144, 2166-2175, 2180-2187, 2220-2225, 2237-2242, 2247-2253, 2273-2281, 2286-2306, 2314-2320, 2323-2345, 2350-2355, 2371-2384, 2415-2424, 2426-2431, 2452-2472, 2584-2589, 2610-2621, 2638-2655, 2664-2670, 2681-2690, 2692-2714, 2724-2730 and 687-730 of Seq ID No 38; 10-40, 53-59, 79-85, 98-104, 117-122, 130-136, 144-158, 169-175, 180-185, 203-223, 232-237, 243-254, 295-301 and 254-292 of Seq ID No 39; 28-50, 67-85, 93-115, 120-134, 144-179, 240-249, 328-340, 354-360, 368-400, 402-417, 419-427, 429-445, 447-455, 463-468, 472-480, 485-500, 502-510, 512-534, 537-546,

553-558, 582-594, 619-637, 645-654, 690-709, 735-745, 749-756, 786-792, 275-316 and 378-401 of Seq ID No 40; 5-16, 21-30, 33-40, 52-74, 101-108, 116-122, 164-182, 185-219, 256-261, 273-279, 285-291, 297-304, 312-328, 331-338, 355-362, 364-371, 373-401, 411-423 and 191-208 of Seq ID No 41; 34-55, 67-74, 85-93, 105-115, 138-152, 161-171, 182-189, 197-205, 213-219, 232-239, 241-248, 250-263, 272-277, 288-299 and 216-231 of Seq ID No 42; 21-27, 32-37, 43-51, 67-74, 82-92, 94-100, 106-112, 140-149, 153-159, 164-182, 193-215, 222-227, 260-267, 308-322, 330-340, 378-387, 396-403, 417-432, 435-441, 448-465, 476-482, 488-498, 500-510 and 214-280 of Seq ID No 43; 4-21, 29-52, 80-87, 104-123, 126-133, 141-157, 182-189, 194-202, 214-220, 227-235, 242-252 and 33-108 of Seq ID No 44; 12-18, 20-27, 29-59, 64-72, 84-90, 96-103, 109-121, 125-155, 164-177, 179-186, 188-201, 216-227, 235-253, 259-274, 276-294, 296-310, 322-339, 341-348, 369-379, 398-403, 409-421 and 76-96 of Seq ID No 45; 4-15, 24-41, 71-80, 104-111, 113-119, 123-130, 139-149, 168-178, 187-200 and 4-45 of Seq ID No 46; 13-19, 32-37, 44-56 and 1-14 of Seq ID No 47; 6-11, 16-35, 75-81, 95-100, 126-139, 206-214, 225-233, 241-259, 268-276, 319-325, 339-360, 371-401, 435-441, 452-459, 462-472, 491-503, 505-516, 549-556, 567-580, 590-595, 612-622, 624-630, 642-648, 656-662, 687-693, 698-704, 706-712, 736-750, 768-777, 784-789, 812-818, 847-858, 894-900, 922-931, 938-949, 967-984, 986-992, 1027-1032, 1041-1054, 1082-1088, 1091-1097, 1119-1124, 1234-1240, 1250-1258, 1274-1289, 1299-1305, 1392-1398, 1400-1405, 1429-1442, 1460-1474, 1505-1514, 1531-1537, 1540-1552, 1558-1571, 1582-1587, 1616-1623, 1659-1666, 1671-1677, 1680-1686, 1698-1704, 1706-1712, 1768-1774, 1783-1797, 1814-1819, 1849-1855, 1870-1876, 1890-1897, 1947-1953, 1972-1980, 1999-2013, 2044-2051, 2068-2084, 2093-2099, 2122-2131, 2142-2147, 2156-2163, 2170-2179, 2214-2220, 2235-2245, 2271-2281, 2287-2293, 2308-2317, 2352-2362, 2373-2378, 2387-2407, 2442-2448, 2458-2474, 2507-2516, 2531-2537, 2540-2551, 2555-2561, 2586-2599, 2617-2627, 2644-2649, 2661-2675, 2685-2692, 2695-2707, 2733-2739, 2741-2747, 2774-2783, 2788-2795, 2860-2870, 2891-2903, 2938-2947, 2973-2980, 2993-2999, 3004-3030, 3046-3059, 3066-3077, 3082-3088, 3120-3132, 3144-3149, 3153-3169, 3200-3212, 3232-3256, 3276-3290, 3308-3322, 3330-3338, 3353-3360, 3363-3371, 3390-3408, 3431-3447, 3454-3484, 3503-3515, 3524-3541, 3543-3550, 3560-3567, 3586-3599, 3616-3621, 3642-3647, 3663-3679, 213-276, 579-621 and 1516-1559 of Seq ID No 48; 19-41, 43-49, 55-62, 67-74, 114-121, 130-140, 188-197, 208-217, 226-232, 265-287, 292-299, 301-319, 372-394, 400-410, 421-427 and 12-56 of Seq ID No 49; 6-12, 44-51, 53-60, 67-88, 91-100, 104-123, 137-142, 148-158, 161-168, 175-201, 204-210, 222-231, 239-253, 258-264, 272-282 and 60-138 of Seq ID No 50; 4-63, 69-104, 110-121, 124-131, 134-152, 161-187, 204-221, 223-237, 239-296, 298-310, 331-365, 380-405, 423-451, 470-552, 554-562, 574-581, 592-649, 651-658, 661-671, 673-707, 713-734, 741-748, 758-765, 773-790 and 509-528 of Seq ID No 51; 89-94,

102-115, 123-129, 181-188, 200-206, 211-235, 239-249, 267-281, 295-310, 316-321, 331-341, 344-359, 365-386, 409-422, 443-453, 495-506, 514-521, 539-547, 553-560, 563-570, 586-596, 621-626, 633-638, 651-657, 666-683, 697-705, 731-739, 761-768, 865-883 and 213-265 of Seq ID No 52; 5-20, 24-34, 37-43, 92-102, 134-139, 156-162, 184-191, 193-205, 207-213, 225-231, 241-247, 259-267, 269-286, 337-350, 365-372, 378-386, 399-413, 415-421, 447-457, 467-481 and 145-183 of Seq ID No 53; 12-19, 29-41, 43-57, 80-98, 106-141, 143-156, 172-183, 185-210, 214-220, 226-234, 278-287 and 237-287 of Seq ID No 54; 5-12, 32-48, 50-72, 75-81, 88-94 and 16-40 of Seq ID No 55; 4-21, 29-42, 48-62, 65-80, 95-101, 103-118, 122-130, 134-140, 143-152, 155-165, 182-192, 198-208, 232-247, 260-268, 318-348, 364-369, 380-391, 403-411, 413-424 and 208-230 of Seq ID No 56; 4-18, 65-75, 82-92, 123-140, 144-159, 166-172, 188-194 and 174-195 of Seq ID No 57; 7-20, 58-71, 94-101, 110-119, 199-209, 231-242, 247-254, 267-277, 282-290, 297-306, 313-319, 333-342, 344-369, 390-402, 414-431, 436-448, 462-471 and 310-350 of Seq ID No 58; 4-25, 37-44, 53-59, 72-78, 86-99, 119-128, 197-203, 209-218, 220-226, 233-244, 246-254, 264-271, 277-289, 407-430, 437-445, 464-472, 482-488, 503-509 and 308-331 of Seq ID No 59; 4-12, 14-43, 52-58 and 43-58 of Seq ID No 60; 4-14, 21-29, 35-49 and 38-50 of Seq ID No 61; 4-19, 31-37, 58-72, 94-108 and 1-72 of Seq ID No 62.

The present invention also provides a process for producing a *S. epidermidis* hyperimmune serum reactive antigen or a fragment thereof according to the present invention comprising expressing one or more of the nucleic acid molecules according to the present invention in a suitable expression system.

Moreover, the present invention provides a process for producing a cell, which expresses a *S. epidermidis* hyperimmune serum reactive antigen or a fragment thereof according to the present invention comprising transforming or transfecting a suitable host cell with the vector according to the present invention.

According to the present invention a pharmaceutical composition, especially a vaccine, comprising a hyperimmune serum-reactive antigen or a fragment thereof as defined in the present invention or a nucleic acid molecule as defined in the present invention is provided.

In a preferred embodiment the pharmaceutical composition further comprises an immunostimulatory substance, preferably selected from the group comprising polycationic polymers, especially polycationic peptides, immunostimulatory deoxynucleotides (ODNs), peptides containing at least two LysLeuLys motifs, es-

pecially KLKL5KLK, neuroactive compounds, especially human growth hormone, album, Freund's complete or incomplete adjuvants or combinations thereof.

In a more preferred embodiment the immunostimulatory substance is a combination of either a polycationic polymer and immunostimulatory deoxynucleotides or of a peptide containing at least two LysLeuLys motifs and immunostimulatory deoxynucleotides.

In a still more preferred embodiment the polycationic polymer is a polycationic peptide, especially polyarginine.

According to the present invention the use of a nucleic acid molecule according to the present invention or a hyperimmune serum-reactive antigen or fragment thereof according to the present invention for the manufacture of a pharmaceutical preparation, especially for the manufacture of a vaccine against *S. epidermidis* infection, is provided.

Also an antibody, or at least an effective part thereof, which binds at least to a selective part of the hyperimmune serum-reactive antigen or a fragment thereof according to the present invention is provided herewith.

In a preferred embodiment the antibody is a monoclonal antibody.

In another preferred embodiment the effective part of the antibody comprises Fab fragments.

In a further preferred embodiment the antibody is a chimeric antibody.

In a still preferred embodiment the antibody is a humanized antibody.

The present invention also provides a hybridoma cell line, which produces an antibody according to the present invention.

Moreover, the present invention provides a method for producing an antibody according to the present invention, characterized by the following steps:

- initiating an immune response in a non-human animal by administering an hyperimmune serum-reactive antigen or a fragment thereof, as defined in the invention, to said animal,
- removing an antibody containing body fluid from said animal, and
- producing the antibody by subjecting said antibody containing body fluid to

further purification steps.

Accordingly, the present invention also provides a method for producing an antibody according to the present invention, characterized by the following steps:

- initiating an immune response in a non-human animal by administering an hyperimmune serum-reactive antigen or a fragment thereof, as defined in the present invention, to said animal,
- removing the spleen or spleen cells from said animal,
- producing hybridoma cells of said spleen or spleen cells,
- selecting and cloning hybridoma cells specific for said hyperimmune serum-reactive antigens or a fragment thereof,
- producing the antibody by cultivation of said cloned hybridoma cells and optionally further purification steps.

The antibodies provided or produced according to the above methods may be used for the preparation of a medicament for treating or preventing *S. epidermidis* infections.

According to another aspect the present invention provides an antagonist, which binds to a hyperimmune serum-reactive antigen or a fragment thereof according to the present invention.

Such an antagonist capable of binding to a hyperimmune serum-reactive antigen or fragment thereof according to the present invention may be identified by a method comprising the following steps:

- a) contacting an isolated or immobilized hyperimmune serum-reactive antigen or a fragment thereof according to the present invention with a candidate antagonist under conditions to permit binding of said candidate antagonist to said hyperimmune serum-reactive antigen or fragment, in the presence of a component capable of providing a detectable signal in response to the binding of the candidate antagonist to said hyperimmune serum reactive antigen or fragment thereof; and
- b) detecting the presence or absence of a signal generated in response to the binding of the antagonist to the hyperimmune serum reactive antigen or the fragment thereof.

An antagonist capable of reducing or inhibiting the interaction activity of a hyperimmune serum-reactive antigen or a fragment thereof according to the present invention to its interaction partner may be identified by a method com-

prising the following steps:

- a) providing a hyperimmune serum reactive antigen or a hyperimmune fragment thereof according to the present invention,
- b) providing an interaction partner to said hyperimmune serum reactive antigen or a fragment thereof, especially an antibody according to the present invention,
- c) allowing interaction of said hyperimmune serum reactive antigen or fragment thereof to said interaction partner to form an interaction complex,
- d) providing a candidate antagonist,
- e) allowing a competition reaction to occur between the candidate antagonist and the interaction complex ,
- f) determining whether the candidate antagonist inhibits or reduces the interaction activities of the hyperimmune serum reactive antigen or the fragment thereof with the interaction partner.

The hyperimmune serum reactive antigens or fragments thereof according to the present invention may be used for the isolation and/or purification and/or identification of an interaction partner of said hyperimmune serum reactive antigen or fragment thereof.

The present invention also provides a process for in vitro diagnosing a disease related to expression of a hyperimmune serum-reactive antigen or a fragment thereof according to the present invention comprising determining the presence of a nucleic acid sequence encoding said hyperimmune serum reactive antigen or fragment thereof according to the present invention or the presence of the hyperimmune serum reactive antigen or fragment thereof according to the present invention.

The present invention also provides a process for in vitro diagnosis of a bacterial infection, especially a *S. epidermidis* infection, comprising analyzing for the presence of a nucleic acid sequence encoding said hyperimmune serum reactive antigen or fragment thereof according to the present invention or the presence of the hyperimmune serum reactive antigen or fragment thereof according to the present invention.

Moreover, the present invention provides the use of a hyperimmune serum reactive antigen or fragment thereof according to the present invention for the generation of a peptide binding to said hyperimmune serum reactive antigen or fragment thereof, wherein the peptide is an anticaline.

The present invention also provides the use of a hyperimmune serum-reactive antigen or fragment thereof according to the present invention for the manufacture of a functional nucleic acid, wherein the functional nucleic acid is selected from the group comprising aptamers and spiegelmers.

The nucleic acid molecule according to the present invention may also be used for the manufacture of a functional ribonucleic acid, wherein the functional ribonucleic acid is selected from the group comprising ribozymes, antisense nucleic acids and siRNA.

The present invention advantageously provides an efficient and relevant set of isolated nucleic acid molecules and their encoded hyperimmune serum reactive antigens or fragments thereof identified from *S. epidermidis* using an antibody preparation from a human plasma pool and surface expression libraries derived from the genome of *S. epidermidis*. Thus, the present invention fulfils a widely felt demand for *S. epidermidis* antigens, vaccines, diagnostics and products useful in procedures for preparing antibodies and for identifying compounds effective against *S. epidermidis* infection.

An effective vaccine should be composed of proteins or polypeptides, which are expressed by all strains and are able to induce high affinity, abundant antibodies against cell surface components of *S. epidermidis*. The antibodies should be IgG1 and/or IgG3 for opsonization, and any IgG subtype and IgA for neutralisation of adherence and toxin action. A chemically defined vaccine must be definitely superior compared to a whole cell vaccine (attenuated or killed), since components of *S. epidermidis*, which might cross-react with human tissues or inhibit opsonization can be eliminated, and the individual proteins inducing protective antibodies and/or a protective immune response can be selected.

The approach, which has been employed for the present invention, is based on the interaction of staphylococcal proteins or peptides with the antibodies present in human sera. The antibodies produced against *S. epidermidis* by the human immune system and present in human sera are indicative of the in vivo expression of the antigenic proteins and their immunogenicity. In addition, the antigenic proteins as identified by the bacterial surface display expression libraries using pools of pre-selected sera, are processed in a second and third round of screening by individual selected or generated sera. Thus the present invention supplies an efficient and relevant set of staphylococcal antigens as a pharmaceutical composition, especially a vaccine preventing infection by *S. epidermidis*.

In the antigen identification program for identifying a relevant and efficient set of antigens according to the present invention, three different bacterial surface expression libraries are screened with a serum pool derived from a serum collection, which has been tested against antigenic compounds of *S. epidermidis*, such as whole cell extracts and culture supernatant proteins in order to be considered hyperimmune and therefore relevant in the screening method applied for the present invention. The antibodies produced against staphylococci by the human immune system and present in human sera are indicative of the *in vivo* expression of the antigenic proteins and their immunogenicity.

The expression libraries as used in the present invention should allow expression of all potential antigens, e.g. derived from all surface proteins of *S. epidermidis*. Bacterial surface display libraries will be represented by a recombinant library of a bacterial host displaying a (total) set of expressed peptide sequences of staphylococci on a number of selected outer membrane proteins (LamB, FhuA) at the bacterial host membrane (Georgiou, G., 1997; Etz, H. et al., 2001). One of the advantages of using recombinant expression libraries is that the identified hyperimmune serum-reactive antigens may be instantly produced by expression of the coding sequences of the screened and selected clones expressing the hyperimmune serum-reactive antigens without further recombinant DNA technology or cloning steps necessary.

The comprehensive set of antigens identified by the described program according to the present invention is analysed further by one or more additional rounds of screening. Therefore individual antibody preparations or antibodies generated against selected peptides, which were identified as immunogenic are used. According to a preferred embodiment the individual antibody preparations for the second round of screening are derived from patients who have suffered from an acute infection with staphylococci, especially from patients who show an antibody titer above a certain minimum level, for example an antibody titer being higher than 80 percentile, preferably higher than 90 percentile, especially higher than 95 percentile of the human (patient or healthy individual) sera tested. Using such high titer individual antibody preparations in the second screening round allows a very selective identification of the hyperimmune serum-reactive antigens and fragments thereof from *S. epidermidis*.

Following the screening procedure, the selected antigenic proteins, expressed as recombinant proteins or *in vitro* translated products, in case it can not be

expressed in prokaryotic expression systems, or the identified antigenic peptides (produced synthetically) are tested in a second screening by a series of ELISA and Western blotting assays for the assessment of their immunogenicity with a large human serum collection (> 100 uninfected, > 50 patients sera).

It is important that the individual antibody preparations (which may also be the selected serum) allow a selective identification of the most promising candidates of all the hyperimmune serum-reactive antigens from all the promising candidates from the first round. Therefore, preferably at least 10 individual antibody preparations (i.e. antibody preparations (e.g. sera) from at least 10 different individuals having suffered from an infection to the chosen pathogen) should be used in identifying these antigens in the second screening round. Of course, it is possible to use also less than 10 individual preparations, however, selectivity of the step may not be optimal with a low number of individual antibody preparations. On the other hand, if a given hyperimmune serum-reactive antigen (or an antigenic fragment thereof) is recognized by at least 10 individual antibody preparations, preferably at least 30, especially at least 50 individual antibody preparations, identification of the hyperimmune serum-reactive antigen is also selective enough for a proper identification. Hyperimmune serum-reactivity may of course be tested with as many individual preparations as possible (e.g. with more than 100 or even with more than 1,000).

Therefore, the relevant portion of the hyperimmune serum-reactive antibody preparations according to the method of the present invention should preferably be at least 10, more preferred at least 30, especially at least 50 individual antibody preparations. Alternatively (or in combination) hyperimmune serum-reactive antigens may preferably be also identified with at least 20%, preferably at least 30%, especially at least 40% of all individual antibody preparations used in the second screening round.

According to a preferred embodiment of the present invention, the sera from which the individual antibody preparations for the second round of screening are prepared (or which are used as antibody preparations), are selected by their titer against *S. epidermidis* (e.g. against a preparation of this pathogen, such as a lysate, cell wall components and recombinant proteins). Preferably, some are selected with a total IgA titer above 4,000 U, especially above 6,000 U, and/or an IgG titer above 10,000 U, especially above 12,000 U (U = units, calculated from the OD405nm reading at a given dilution) when the whole organism (total lysate or whole cells) is used as antigen in the ELISA.

The antibodies produced against staphylococci by the human immune system and present in human sera are indicative of the in vivo expression of the antigenic proteins and their immunogenicity. The recognition of linear epitopes by antibodies can be based on sequences as short as 4-5 amino acids. Of course it does not necessarily mean that these short peptides are capable of inducing the given antibody in vivo. For that reason the defined epitopes, polypeptides and proteins are further to be tested in animals (mainly in mice) for their capacity to induce antibodies against the selected proteins in vivo.

The preferred antigens are located on the cell surface or are secreted, and are therefore accessible extracellularly. Antibodies against cell wall proteins are expected to serve two purposes: to inhibit adhesion and to promote phagocytosis. Antibodies against secreted proteins are beneficial in neutralisation of their function as toxin or virulence component. It is also known that bacteria communicate with each other through secreted proteins. Neutralizing antibodies against these proteins will interrupt growth-promoting cross-talk between or within streptococcal species. Bioinformatic analyses (signal sequences, cell wall localisation signals, transmembrane domains) proved to be very useful in assessing cell surface localisation or secretion. The experimental approach includes the isolation of antibodies with the corresponding epitopes and proteins from human serum, and the generation of immune sera in mice against (poly)peptides selected by the bacterial surface display screens. These sera are then used in a third round of screening as reagents in the following assays: cell surface staining of staphylococci grown under different conditions (FACS, microscopy), determination of neutralizing capacity (toxin, adherence), and promotion of opsonization and phagocytosis (in vitro phagocytosis assay).

For that purpose, bacterial *E. coli* clones are directly injected into mice and immune sera are taken and tested in the relevant in vitro assay for functional opsonic or neutralizing antibodies. Alternatively, specific antibodies may be purified from human or mouse sera using peptides or proteins as substrate.

Host defence against *S. epidermidis* relies mainly on innate immunological mechanisms. Inducing high affinity antibodies of the opsonic and neutralizing type by vaccination helps the innate immune system to eliminate bacteria and toxins. This makes the method according to the present invention an optimal tool for the identification of staphylococcal antigenic proteins.

The skin and mucous membranes are formidable barriers against invasion by sta-

phylcocci. However, once the skin or the mucous membranes are breached the first line of non-adaptive cellular defence begins its co-ordinate action through complement and phagocytes, especially the polymorphonuclear leukocytes (PMNs). These cells can be regarded as the cornerstones in eliminating invading bacteria. As staphylococci are primarily extracellular pathogens, the major anti-staphylococcal adaptive response comes from the humoral arm of the immune system, and is mediated through three major mechanisms: promotion of opsonization, toxin neutralisation, and inhibition of adherence. It is believed that opsonization is especially important, because of its requirement for an effective phagocytosis. For efficient opsonization the microbial surface has to be coated with antibodies and complement factors for recognition by PMNs through receptors to the Fc fragment of the IgG molecule or to activated C3b. After opsonization, staphylococci are phagocytosed and killed. Antibodies bound to specific antigens on the cell surface of bacteria serve as ligands for the attachment to PMNs and to promote phagocytosis. The very same antibodies bound to the adhesins and other cell surface proteins are expected to neutralize adhesion and prevent colonization. The selection of antigens as provided by the present invention is thus well suited to identify those that will lead to protection against infection in an animal model or in humans.

According to the antigen identification method used herein, the present invention can surprisingly provide a set of novel nucleic acids and novel hyperimmune serum reactive antigens and fragments thereof of *S. epidermidis*, among other things, as described below. According to one aspect, the invention particularly relates to the nucleotide sequences encoding hyperimmune serum reactive antigens which sequences are set forth in the Sequence listing Seq ID No: 1-31 and the corresponding encoded amino acid sequences representing hyperimmune serum reactive antigens are set forth in the Sequence Listing Seq ID No 32-62.

In a preferred embodiment of the present invention, a nucleic acid molecule is provided which exhibits 70% identity over their entire length to a nucleotide sequence set forth with Seq ID No 1, 4, 6-9, 11-13, 15, 17, 19, 21, 25-26, 28-31. Most highly preferred are nucleic acids that comprise a region that is at least 80% or at least 85% identical over their entire length to a nucleic acid molecule set forth with Seq ID No 1, 4, 6-9, 11-13, 15, 17, 19, 21, 25-26, 28-31. In this regard, nucleic acid molecules at least 90%, 91%, 92%, 93%, 94%, 95%, or 96% identical over their entire length to the same are particularly preferred. Furthermore, those with at least 97% are highly preferred, those with at least 98% and at least 99% are particularly highly preferred, with at

least 99% or 99.5% being the more preferred, with 100% identity being especially preferred. Moreover, preferred embodiments in this respect are nucleic acids which encode hyperimmune serum reactive antigens or fragments thereof (polypeptides) which retain substantially the same biological function or activity as the mature polypeptide encoded by said nucleic acids set forth in the Seq ID No 1, 4, 6-9, 11-13, 15, 17, 19, 21, 25-26, 28-31.

Identity, as known in the art and used herein, is the relationship between two or more polypeptide sequences or two or more polynucleotide sequences, as determined by comparing the sequences. In the art, identity also means the degree of sequence relatedness between polypeptide or polynucleotide sequences, as the case may be, as determined by the match between strings of such sequences. Identity can be readily calculated. While there exist a number of methods to measure identity between two polynucleotide or two polypeptide sequences, the term is well known to skilled artisans (e.g. Sequence Analysis in Molecular Biology, von Heinje, G., Academic Press, 1987). Preferred methods to determine identity are designed to give the largest match between the sequences tested. Methods to determine identity are codified in computer programs. Preferred computer program methods to determine identity between two sequences include, but are not limited to, GCG program package (Devereux, J. et al., 1984), BLASTP, BLASTN, and FASTA (Altschul, S. et al., 1990).

According to another aspect of the invention, nucleic acid molecules are provided which exhibit at least 96% identity to the nucleic acid sequence set forth with Seq ID No 2-3, 5, 10, 14, 16, 18, 22-24, 27.

According to a further aspect of the present invention, nucleic acid molecules are provided which are identical to the nucleic acid sequences set forth with Seq ID No 20.

The nucleic acid molecules according to the present invention can as a second alternative also be a nucleic acid molecule which is at least essentially complementary to the nucleic acid described as the first alternative above. As used herein complementary means that a nucleic acid strand is base pairing via Watson-Crick base pairing with a second nucleic acid strand. Essentially complementary as used herein means that the base pairing is not occurring for all of the bases of the respective strands but leaves a certain number or percentage of the bases unpaired or wrongly paired. The percentage of correctly pairing bases is preferably at least 70 %, more preferably 80 %, even more

preferably 90 % and most preferably any percentage higher than 90 %. It is to be noted that a percentage of 70 % matching bases is considered as homology and the hybridization having this extent of matching base pairs is considered as stringent. Hybridization conditions for this kind of stringent hybridization may be taken from Current Protocols in Molecular Biology (John Wiley and Sons, Inc., 1987). More particularly, the hybridization conditions can be as follows:

- Hybridization performed e.g. in 5 x SSPE, 5 x Denhardt's reagent, 0.1% SDS, 100 g/mL sheared DNA at 68°C
- Moderate stringency wash in 0.2xSSC, 0.1% SDS at 42°C
- High stringency wash in 0.1xSSC, 0.1% SDS at 68°C

Genomic DNA with a GC content of 50% has an approximate T_M of 96°C. For 1% mismatch, the T_M is reduced by approximately 1°C.

In addition, any of the further hybridization conditions described herein are in principle applicable as well.

Of course, all nucleic acid sequence molecules which encode the same polypeptide molecule as those identified by the present invention are encompassed by any disclosure of a given coding sequence, since the degeneracy of the genetic code is directly applicable to unambiguously determine all possible nucleic acid molecules which encode a given polypeptide molecule, even if the number of such degenerated nucleic acid molecules may be high. This is also applicable for fragments of a given polypeptide, as long as the fragments encode a polypeptide being suitable to be used in a vaccination connection, e.g. as an active or passive vaccine.

The nucleic acid molecule according to the present invention can as a third alternative also be a nucleic acid which comprises a stretch of at least 15 bases of the nucleic acid molecule according to the first and second alternative of the nucleic acid molecules according to the present invention as outlined above. Preferably, the bases form a contiguous stretch of bases. However, it is also within the scope of the present invention that the stretch consists of two or more moieties, which are separated by a number of bases.

The present nucleic acids may preferably consist of at least 20, even more preferred at least 30, especially at least 50 contiguous bases from the sequences disclosed herein. The suitable length may easily be optimized due to the planned area of use (e.g. as (PCR) primers, probes, capture molecules (e.g. on

a (DNA) chip), etc.). Preferred nucleic acid molecules contain at least a contiguous 15 base portion of one or more of the predicted immunogenic amino acid sequences listed in tables 1 and 2, especially the sequences of table 2 with scores of more than 10, preferably more than 20, especially with a score of more than 25. Specifically preferred are nucleic acids containing a contiguous portion of a DNA sequence of any sequence in the sequence protocol of the present application which shows 1 or more, preferably more than 2, especially more than 5, non-identical nucleic acid residues compared to the published *Staphylococcus epidermidis* strain RP62A genome (<http://www.tigr.org/tldb/mdb/mdbin-progress.html>) and/or any other published *S. epidermidis* genome sequence or parts thereof. Specifically preferred non-identical nucleic acid residues are residues, which lead to a non-identical amino acid residue. Preferably, the nucleic acid sequences encode for polypeptides having at least 1, preferably at least 2, preferably at least three different amino acid residues compared to the published *S. epidermidis* counterparts mentioned above. Also such isolated polypeptides, being fragments of the proteins (or the whole protein) mentioned herein e.g. in the sequence listing, having at least 6, 7, or 8 amino acid residues and being encoded by these nucleic acids are preferred.

The nucleic acid molecule according to the present invention can as a fourth alternative also be a nucleic acid molecule which anneals under stringent hybridisation conditions to any of the nucleic acids of the present invention according to the above outlined first, second, and third alternative. Stringent hybridisation conditions are typically those described herein.

Finally, the nucleic acid molecule according to the present invention can as a fifth alternative also be a nucleic acid molecule which, but for the degeneracy of the genetic code, would hybridise to any of the nucleic acid molecules according to any nucleic acid molecule of the present invention according to the first, second, third, and fourth alternative as outlined above. This kind of nucleic acid molecule refers to the fact that preferably the nucleic acids according to the present invention code for the hyperimmune serum reactive antigens or fragments thereof according to the present invention. This kind of nucleic acid molecule is particularly useful in the detection of a nucleic acid molecule according to the present invention and thus the diagnosis of the respective microorganisms such as *S. epidermidis* and any disease or diseased condition where this kind of microorganisms is involved. Preferably, the hybridisation would occur or be preformed under stringent conditions as described in connection with the fourth alternative described above.

Nucleic acid molecule as used herein generally refers to any ribonucleic acid molecule or deoxyribonucleic acid molecule, which may be unmodified RNA or DNA or modified RNA or DNA. Thus, for instance, nucleic acid molecule as used herein refers to, among other, single- and double-stranded DNA, DNA that is a mixture of single- and double-stranded RNA, and RNA that is a mixture of single- and double-stranded regions, hybrid molecules comprising DNA and RNA that may be single-stranded or, more typically, double-stranded, or triple-stranded, or a mixture of single- and double-stranded regions. In addition, nucleic acid molecule as used herein refers to triple-stranded regions comprising RNA or DNA or both RNA and DNA. The strands in such regions may be from the same molecule or from different molecules. The regions may include all of one or more of the molecules, but more typically involve only a region of some of the molecules. One of the molecules of a triple-helical region often is an oligonucleotide. As used herein, the term nucleic acid molecule includes DNAs or RNAs as described above that contain one or more modified bases. Thus, DNAs or RNAs with backbones modified for stability or for other reasons are "nucleic acid molecule" as that term is intended herein. Moreover, DNAs or RNAs comprising unusual bases, such as inosine, or modified bases, such as tritylated bases, to name just two examples, are nucleic acid molecule as the term is used herein. It will be appreciated that a great variety of modifications have been made to DNA and RNA that serve many useful purposes known to those of skill in the art. The term nucleic acid molecule as it is employed herein embraces such chemically, enzymatically or metabolically modified forms of nucleic acid molecule, as well as the chemical forms of DNA and RNA characteristic of viruses and cells, including simple and complex cells, inter alia. The term nucleic acid molecule also embraces short nucleic acid molecules often referred to as oligonucleotide(s). "Polynucleotide" and "nucleic acid" or "nucleic acid molecule" are often used interchangeably herein.

Nucleic acid molecules provided in the present invention also encompass numerous unique fragments, both longer and shorter than the nucleic acid molecule sequences set forth in the sequencing listing of the *S. epidermidis* coding regions, which can be generated by standard cloning methods. To be unique, a fragment must be of sufficient size to distinguish it from other known nucleic acid sequences, most readily determined by comparing any selected *S. epidermidis* fragment to the nucleotide sequences in computer databases such as GenBank.

Additionally, modifications can be made to the nucleic acid molecules and polypeptides that are encompassed by the present invention. For example, nucleotide substitutions can be made which do not affect the polypeptide encoded by

the nucleic acid, and thus any nucleic acid molecule which encodes a hyperimmune serum reactive antigen or fragments thereof is encompassed by the present invention.

Furthermore, any of the nucleic acid molecules encoding hyperimmune serum reactive antigens or fragments thereof provided by the present invention can be functionally linked, using standard techniques such as standard cloning techniques, to any desired regulatory sequences, whether a *S. epidermidis* regulatory sequence or a heterologous regulatory sequence, heterologous leader sequence, heterologous marker sequence or a heterologous coding sequence to create a fusion protein.

Nucleic acid molecules of the present invention may be in the form of RNA, such as mRNA or cRNA, or in the form of DNA, including, for instance, cDNA and genomic DNA obtained by cloning or produced by chemical synthetic techniques or by a combination thereof. The DNA may be triple-stranded, double-stranded or single-stranded. Single-stranded DNA may be the coding strand, also known as the sense strand, or it may be the non-coding strand, also referred to as the anti-sense strand.

The present invention further relates to variants of the herein above described nucleic acid molecules which encode fragments, analogs and derivatives of the hyperimmune serum reactive antigens and fragments thereof having a deduced *S. epidermidis* amino acid sequence set forth in the Sequence Listing. A variant of the nucleic acid molecule may be a naturally occurring variant such as a naturally occurring allelic variant, or it may be a variant that is not known to occur naturally. Such non-naturally occurring variants of the nucleic acid molecule may be made by mutagenesis techniques, including those applied to nucleic acid molecules, cells or organisms.

Among variants in this regard are variants that differ from the aforementioned nucleic acid molecules by nucleotide substitutions, deletions or additions. The substitutions, deletions or additions may involve one or more nucleotides. The variants may be altered in coding or non-coding regions or both. Alterations in the coding regions may produce conservative or non-conservative amino acid substitutions, deletions or additions. Preferred are nucleic acid molecules encoding a variant, analog, derivative or fragment, or a variant, analogue or derivative of a fragment, which have a *S. epidermidis* sequence as set forth in the Sequence Listing, in which several, a few, 5 to 10, 1 to 5, 1 to 3, 2, 1 or no amino acid(s) is substituted, deleted or added, in any combination. Espe-

cially preferred among these are silent substitutions, additions and deletions, which do not alter the properties and activities of the S. epidermidis polypeptides set forth in the Sequence Listing. Also especially preferred in this regard are conservative substitutions.

The peptides and fragments according to the present invention also include modified epitopes wherein preferably one or two of the amino acids of a given epitope are modified or replaced according to the rules disclosed in e.g. {Tourdot, S. et al., 2000}, as well as the nucleic acid sequences encoding such modified epitopes.

It is clear that also epitopes derived from the present epitopes by amino acid exchanges improving, conserving or at least not significantly impeding the T cell activating capability of the epitopes are covered by the epitopes according to the present invention. Therefore the present epitopes also cover epitopes, which do not contain the original sequence as derived from S. epidermidis, but trigger the same or preferably an improved T cell response. These epitopes are referred to as "heteroclitic"; they need to have a similar or preferably greater affinity to MHC/HLA molecules, and the need the ability to stimulate the T cell receptors (TCR) directed to the original epitope in a similar or preferably stronger manner.

Heteroclitic epitopes can be obtained by rational design i.e. taking into account the contribution of individual residues to binding to MHC/HLA as for instance described by {Rammensee, H. et al., 1999}, combined with a systematic exchange of residues potentially interacting with the TCR and testing the resulting sequences with T cells directed against the original epitope. Such a design is possible for a skilled man in the art without much experimentation.

Another possibility includes the screening of peptide libraries with T cells directed against the original epitope. A preferred way is the positional scanning of synthetic peptide libraries. Such approaches have been described in detail for instance by {Hemmer, B. et al., 1999} and the references given therein.

As an alternative to epitopes represented by the present derived amino acid sequences or heteroclitic epitopes, also substances mimicking these epitopes e.g. "peptidemimetica" or "retro-inverso-peptides" can be applied.

Another aspect of the design of improved epitopes is their formulation or modi-

fication with substances increasing their capacity to stimulate T cells. These include T helper cell epitopes, lipids or liposomes or preferred modifications as described in WO 01/78767.

Another way to increase the T cell stimulating capacity of epitopes is their formulation with immune stimulating substances for instance cytokines or chemokines like interleukin-2, -7, -12, -18, class I and II interferons (IFN), especially IFN-gamma, GM-CSF, TNF-alpha, flt3-ligand and others.

As discussed additionally herein regarding nucleic acid molecule assays of the invention, for instance, nucleic acid molecules of the invention as discussed above, may be used as a hybridization probe for RNA, cDNA and genomic DNA to isolate full-length cDNAs and genomic clones encoding polypeptides of the present invention and to isolate cDNA and genomic clones of other genes that have a high sequence similarity to the nucleic acid molecules of the present invention. Such probes generally will comprise at least 15 bases. Preferably, such probes will have at least 20, at least 25 or at least 30 bases, and may have at least 50 bases. Particularly preferred probes will have at least 30 bases, and will have 50 bases or less, such as 30, 35, 40, 45, or 50 bases.

For example, the coding region of a nucleic acid molecule of the present invention may be isolated by screening a relevant library using the known DNA sequence to synthesize an oligonucleotide probe. A labeled oligonucleotide having a sequence complementary to that of a gene of the present invention is then used to screen a library of cDNA, genomic DNA or mRNA to determine to which members of the library the probe hybridizes.

The nucleic acid molecules and polypeptides of the present invention may be employed as reagents and materials for development of treatments of and diagnostics for disease, particularly human disease, as further discussed herein relating to nucleic acid molecule assays, inter alia.

The nucleic acid molecules of the present invention that are oligonucleotides can be used in the processes herein as described, but preferably for PCR, to determine whether or not the S. epidermidis genes identified herein in whole or in part are present and/or transcribed in infected tissue such as blood. It is recognized that such sequences will also have utility in diagnosis of the stage of infection and type of infection the pathogen has attained. For this and other purposes the arrays comprising at least one of the nucleic acids according to the present invention as described herein, may be used.

The nucleic acid molecules according to the present invention may be used for the detection of nucleic acid molecules and organisms or samples containing these nucleic acids. Preferably such detection is for diagnosis, more preferable for the diagnosis of a disease related or linked to the present or abundance of *S. epidermidis*.

Eukaryotes (herein also "individual(s)"), particularly mammals, and especially humans, infected with *S. epidermidis* may be identifiable by detecting any of the nucleic acid molecules according to the present invention detected at the DNA level by a variety of techniques. Preferred nucleic acid molecules candidates for distinguishing a *S. epidermidis* from other organisms can be obtained.

The different polypeptides described herein can have therapeutic and/or diagnostic utilities. The present application identifies different immunogenic polypeptides, and immunogenic polypeptide regions, characteristic of *S. epi*. An immunogenic polypeptide region can be present by itself or part of a longer length polypeptide. The polypeptides and polypeptide regions can be used in diagnostic applications to provide an indication as to whether a person is, or has been, infected with *S. epi*. For example, a polypeptide containing an *S. epi* immunogenic region can be used to generate *S. epi* antibodies, which can be used to detect the presence of *S. epi* in serum; and a polypeptide containing an *S. epi* immunogenic region can be used to detect the presence of *S. epi* antibodies in serum.

The invention provides a process for diagnosing disease, arising from infection with *S. epidermidis*, comprising determining from a sample isolated or derived from an individual an increased level of expression of a nucleic acid molecule having the sequence of a nucleic acid molecule set forth in the Sequence Listing. Expression of nucleic acid molecules can be measured using any one of the methods well known in the art for the quantitation of nucleic acid molecules, such as, for example, PCR, RT-PCR, Rnase protection, Northern blotting, other hybridisation methods and the arrays described herein.

Isolated as used herein means separated "by the hand of man" from its natural state; i.e., that, if it occurs in nature, it has been changed or removed from its original environment, or both. For example, a naturally occurring nucleic acid molecule or a polypeptide naturally present in a living organism in its natural state is not "isolated," but the same nucleic acid molecule or polypeptide separated from the coexisting materials of its natural state is "isol-

ated", as the term is employed herein. As part of or following isolation, such nucleic acid molecules can be joined to other nucleic acid molecules, such as DNAs, for mutagenesis, to form fusion proteins, and for propagation or expression in a host, for instance. The isolated nucleic acid molecules, alone or joined to other nucleic acid molecules such as vectors, can be introduced into host cells, in culture or in whole organisms. Introduced into host cells in culture or in whole organisms, such DNAs still would be isolated, as the term is used herein, because they would not be in their naturally occurring form or environment. Similarly, the nucleic acid molecules and polypeptides may occur in a composition, such as a media formulations, solutions for introduction of nucleic acid molecules or polypeptides, for example, into cells, compositions or solutions for chemical or enzymatic reactions, for instance, which are not naturally occurring compositions, and, therein remain isolated nucleic acid molecules or polypeptides within the meaning of that term as it is employed herein.

The nucleic acids according to the present invention may be chemically synthesized. Alternatively, the nucleic acids can be isolated from *S. epidermidis* by methods known to the one skilled in the art.

According to another aspect of the present invention, a comprehensive set of novel hyperimmune serum reactive antigens and fragments thereof are provided by using the herein described antigen identification method. In a preferred embodiment of the invention, a hyperimmune serum-reactive antigen comprising an amino acid sequence being encoded by any one of the nucleic acids molecules herein described and fragments thereof are provided. In another preferred embodiment of the invention a novel set of hyperimmune serum-reactive antigens which comprises amino acid sequences selected from a group consisting of the polypeptide sequences as represented in Seq ID No 32, 35, 37-40, 42-44, 46, 48, 50, 52, 56-57, 59-62 and fragments thereof are provided. In a further preferred embodiment of the invention hyperimmune serum-reactive antigens, which comprise amino acid sequences selected from a group consisting of the polypeptide sequences as represented in Seq ID No 33-34, 36, 41, 45, 47, 49, 53-55, 58 and fragments thereof are provided. In a still preferred embodiment of the invention hyperimmune serum-reactive antigens which comprise amino acid sequences selected from a group consisting of the polypeptide sequences as represented in Seq ID No 51 and fragments thereof are provided.

The hyperimmune serum reactive antigens and fragments thereof as provided in the invention include any polypeptide set forth in the Sequence Listing as well

as polypeptides which have at least 70% identity to a polypeptide set forth in the Sequence Listing, preferably at least 80% or 85% identity to a polypeptide set forth in the Sequence Listing, and more preferably at least 90% similarity (more preferably at least 90% identity) to a polypeptide set forth in the Sequence Listing and still more preferably at least 95%, 96%, 97%, 98%, 99% or 99.5% similarity (still more preferably at least 95%, 96%, 97%, 98%, 99%, or 99.5% identity) to a polypeptide set forth in the Sequence Listing and also include portions of such polypeptides with such portion of the polypeptide generally containing at least 4 amino acids and more preferably at least 8, still more preferably at least 30, still more preferably at least 50 amino acids, such as 4, 8, 10, 20, 30, 35, 40, 45 or 50 amino acids.

The invention also relates to fragments, analogs, and derivatives of these hyperimmune serum reactive antigens and fragments thereof. The terms "fragment", "derivative" and "analog" when referring to an antigen whose amino acid sequence is set forth in the Sequence Listing, means a polypeptide which retains essentially the same or a similar biological function or activity as such hyperimmune serum reactive antigen and fragment thereof.

The fragment, derivative or analog of a hyperimmune serum reactive antigen and fragment thereof may be 1) one in which one or more of the amino acid residues are substituted with a conserved or non-conserved amino acid residue (preferably a conserved amino acid residue) and such substituted amino acid residue may or may not be one encoded by the genetic code, or 2) one in which one or more of the amino acid residues includes a substituent group, or 3) one in which the mature hyperimmune serum reactive antigen or fragment thereof is fused with another compound, such as a compound to increase the half-life of the hyperimmune serum reactive antigen and fragment thereof (for example, polyethylene glycol), or 4) one in which the additional amino acids are fused to the mature hyperimmune serum reactive antigen or fragment thereof, such as a leader or secretory sequence or a sequence which is employed for purification of the mature hyperimmune serum reactive antigen or fragment thereof or a pro-protein sequence. Such fragments, derivatives and analogs are deemed to be within the scope of those skilled in the art from the teachings herein.

Among the particularly preferred embodiments of the invention in this regard are the hyperimmune serum reactive antigens set forth in the Sequence Listing, variants, analogs, derivatives and fragments thereof, and variants, analogs and derivatives of fragments. Additionally, fusion polypeptides comprising such hyperimmune serum reactive antigens, variants, analogs, derivatives and frag-

ments thereof, and variants, analogs and derivatives of the fragments are also encompassed by the present invention. Such fusion polypeptides and proteins, as well as nucleic acid molecules encoding them, can readily be made using standard techniques, including standard recombinant techniques for producing and expression of a recombinant polynucleic acid encoding a fusion protein.

Among preferred variants are those that vary from a reference by conservative amino acid substitutions. Such substitutions are those that substitute a given amino acid in a polypeptide by another amino acid of like characteristics. Typically seen as conservative substitutions are the replacements, one for another, among the aliphatic amino acids Ala, Val, Leu and Ile; interchange of the hydroxyl residues Ser and Thr, exchange of the acidic residues Asp and Glu, substitution between the amide residues Asn and Gln, exchange of the basic residues Lys and Arg and replacements among the aromatic residues Phe and Tyr.

Further particularly preferred in this regard are variants, analogs, derivatives and fragments, and variants, analogs and derivatives of the fragments, having the amino acid sequence of any polypeptide set forth in the Sequence Listing, in which several, a few, 5 to 10, 1 to 5, 1 to 3, 2, 1 or no amino acid residues are substituted, deleted or added, in any combination. Especially preferred among these are silent substitutions, additions and deletions, which do not alter the properties and activities of the polypeptide of the present invention. Also especially preferred in this regard are conservative substitutions. Most highly preferred are polypeptides having an amino acid sequence set forth in the Sequence Listing without substitutions.

The hyperimmune serum reactive antigens and fragments thereof of the present invention are preferably provided in an isolated form, and preferably are purified to homogeneity.

Also among preferred embodiments of the present invention are polypeptides comprising fragments of the polypeptides having the amino acid sequence set forth in the Sequence Listing, and fragments of variants and derivatives of the polypeptides set forth in the Sequence Listing.

In this regard a fragment is a polypeptide having an amino acid sequence that entirely is the same as part but not all of the amino acid sequence of the afore mentioned hyperimmune serum reactive antigen and fragment thereof, and variants or derivative, analogs, fragments thereof. Such fragments may be "free-standing", i.e., not part of or fused to other amino acids or poly-

peptides, or they may be comprised within a larger polypeptide of which they form a part or region. Also preferred in this aspect of the invention are fragments characterised by structural or functional attributes of the polypeptide of the present invention, i.e. fragments that comprise alpha-helix and alpha-helix forming regions, beta-sheet and beta-sheet forming regions, turn and turn-forming regions, coil and coil-forming regions, hydrophilic regions, hydrophobic regions, alpha amphipathic regions, beta-amphipathic regions, flexible regions, surface-forming regions, substrate binding regions, and high antigenic index regions of the polypeptide of the present invention, and combinations of such fragments. Preferred regions are those that mediate activities of the hyperimmune serum reactive antigens and fragments thereof of the present invention. Most highly preferred in this regard are fragments that have a chemical, biological or other activity of the hyperimmune serum reactive antigen and fragments thereof of the present invention, including those with a similar activity or an improved activity, or with a decreased undesirable activity. Particularly preferred are fragments comprising receptors or domains of enzymes that confer a function essential for viability of *S. epidermidis* or the ability to cause disease in humans. Further preferred polypeptide fragments are those that comprise or contain antigenic or immunogenic determinants in an animal, especially in a human.

An antigenic fragment is defined as a fragment of the identified antigen, which is for itself antigenic or may be made antigenic when provided as a haptén. Therefore, also antigens or antigenic fragments showing one or (for longer fragments) only a few amino acid exchanges are enabled with the present invention, provided that the antigenic capacities of such fragments with amino acid exchanges are not severely deteriorated on the exchange(s), i.e., suited for eliciting an appropriate immune response in an individual vaccinated with this antigen and identified by individual antibody preparations from individual sera.

Preferred examples of such fragments of a hyperimmune serum-reactive antigen are selected from the group consisting of peptides comprising amino acid sequences of column "predicted immunogenic aa", and "Location of identified immunogenic region" of Table 1; the serum reactive epitopes of Table 2, especially peptides comprising amino acid 6-28, 54-59, 135-147, 193-205, 274-279, 284-291, 298-308, 342-347, 360-366, 380-386, 408-425, 437-446, 457-464, 467-477, 504-510, 517-530, 535-543, 547-553, 562-569, 573-579, 592-600, 602-613, 626-631, 638-668 and 396-449 of Seq ID No 32; 5-24, 101-108, 111-117, 128-142, 170-184, 205-211, 252-267, 308-316, 329-337, 345-353, 360-371, 375-389,

393-399, 413-419, 429-439, 446-456, 471-485, 495-507, 541-556, 582-588, 592-602, 607-617, 622-628, 630-640 and 8-21 of Seq ID No 33; 10-20, 23-33, 40-45, 59-65, 72-107, 113-119, 127-136, 151-161 and 33-59 of Seq ID No 34; 4-16, 28-34, 39-61, 66-79, 100-113, 120-127, 130-137, 142-148, 150-157, 192-201, 203-210, 228-239, 245-250, 256-266, 268-278, 288-294, 312-322, 336-344, 346-358, 388-396, 399-413, 425-430, 445-461, 464-470, 476-482, 486-492, 503-511, 520-527, 531-541, 551-558, 566-572, 609-625, 635-642, 650-656, 683-689, 691-705, 734-741, 750-767, 782-789, 802-808, 812-818, 837-844, 878-885, 907-917, 930-936 and 913-933 of Seq ID No 35; 5-12, 20-27, 46-78, 85-92, 104-112, 121-132, 150-167, 179-185, 200-213, 221-227, 240-264, 271-279, 282-290, 311-317 and 177-206 of Seq ID No 36; 18-24, 31-40, 45-51, 89-97, 100-123, 127-132, 139-153, 164-170, 184-194, 200-205, 215-238, 244-255, 257-270, 272-280, 289-302, 312-318, 338-348, 356-367 and 132-152 of Seq ID No 37; 7-16, 39-45, 73-83, 90-98, 118-124, 130-136, 194-204, 269-280, 320-327, 373-381, 389-397, 403-408, 424-430, 436-441, 463-476, 487-499, 507-514, 527-534, 540-550, 571-577, 593-599, 620-629, 641-647, 650-664, 697-703, 708-717, 729-742, 773-790, 794-805, 821-828, 830-837, 839-851, 858-908, 910-917, 938-947, 965-980, 1025-1033, 1050-1056, 1073-1081, 1084-1098, 1106-1120, 1132-1140, 1164-1170, 1185-1194, 1201-1208, 1215-1224, 1226-1234, 1267-1279, 1325-1331, 1356-1364, 1394-1411, 1426-1439, 1445-1461, 1498-1504, 1556-1561, 1564-1573, 1613-1639, 1648-1655, 1694-1714, 1748-1755, 1778-1785, 1808-1813, 1821-1827, 1829-1837, 1846-1852, 1859-1865, 1874-1883, 1895-1900, 1908-1913, 1931-1937, 1964-1981, 1995-2005, 2020-2033, 2040-2047, 2103-2109, 2118-2127, 2138-2144, 2166-2175, 2180-2187, 2220-2225, 2237-2242, 2247-2253, 2273-2281, 2286-2306, 2314-2320, 2323-2345, 2350-2355, 2371-2384, 2415-2424, 2426-2431, 2452-2472, 2584-2589, 2610-2621, 2638-2655, 2664-2670, 2681-2690, 2692-2714, 2724-2730 and 687-730 of Seq ID No 38; 10-40, 53-59, 79-85, 98-104, 117-122, 130-136, 144-158, 169-175, 180-185, 203-223, 232-237, 243-254, 295-301 and 254-292 of Seq ID No 39; 28-50, 67-85, 93-115, 120-134, 144-179, 240-249, 328-340, 354-360, 368-400, 402-417, 419-427, 429-445, 447-455, 463-468, 472-480, 485-500, 502-510, 512-534, 537-546, 553-558, 582-594, 619-637, 645-654, 690-709, 735-745, 749-756, 786-792, 275-316 and 378-401 of Seq ID No 40; 5-16, 21-30, 33-40, 52-74, 101-108, 116-122, 164-182, 185-219, 256-261, 273-279, 285-291, 297-304, 312-328, 331-338, 355-362, 364-371, 373-401, 411-423 and 191-208 of Seq ID No 41; 34-55, 67-74, 85-93, 105-115, 138-152, 161-171, 182-189, 197-205, 213-219, 232-239, 241-248, 250-263, 272-277, 288-299 and 216-231 of Seq ID No 42; 21-27, 32-37, 43-51, 67-74, 82-92, 94-100, 106-112, 140-149, 153-159, 164-182, 193-215, 222-227, 260-267, 308-322, 330-340, 378-387, 396-403, 417-432, 435-441, 448-465, 476-482, 488-498, 500-510 and 214-280 of Seq ID No 43; 4-21, 29-52, 80-87, 104-123, 126-133, 141-157, 182-189, 194-202, 214-220, 227-235, 242-252 and 33-108 of Seq ID No 44; 12-18,

20-27, 29-59, 64-72, 84-90, 96-103, 109-121, 125-155, 164-177, 179-186, 188-201, 216-227, 235-253, 259-274, 276-294, 296-310, 322-339, 341-348, 369-379, 398-403, 409-421 and 76-96 of Seq ID No 45; 4-15, 24-41, 71-80, 104-111, 113-119, 123-130, 139-149, 168-178, 187-200 and 4-45 of Seq ID No 46; 13-19, 32-37, 44-56 and 1-14 of Seq ID No 47; 6-11, 16-35, 75-81, 95-100, 126-139, 206-214, 225-233, 241-259, 268-276, 319-325, 339-360, 371-401, 435-441, 452-459, 462-472, 491-503, 505-516, 549-556, 567-580, 590-595, 612-622, 624-630, 642-648, 656-662, 687-693, 698-704, 706-712, 736-750, 768-777, 784-789, 812-818, 847-858, 894-900, 922-931, 938-949, 967-984, 986-992, 1027-1032, 1041-1054, 1082-1088, 1091-1097, 1119-1124, 1234-1240, 1250-1258, 1274-1289, 1299-1305, 1392-1398, 1400-1405, 1429-1442, 1460-1474, 1505-1514, 1531-1537, 1540-1552, 1558-1571, 1582-1587, 1616-1623, 1659-1666, 1671-1677, 1680-1686, 1698-1704, 1706-1712, 1768-1774, 1783-1797, 1814-1819, 1849-1855, 1870-1876, 1890-1897, 1947-1953, 1972-1980, 1999-2013, 2044-2051, 2068-2084, 2093-2099, 2122-2131, 2142-2147, 2156-2163, 2170-2179, 2214-2220, 2235-2245, 2271-2281, 2287-2293, 2308-2317, 2352-2362, 2373-2378, 2387-2407, 2442-2448, 2458-2474, 2507-2516, 2531-2537, 2540-2551, 2555-2561, 2586-2599, 2617-2627, 2644-2649, 2661-2675, 2685-2692, 2695-2707, 2733-2739, 2741-2747, 2774-2783, 2788-2795, 2860-2870, 2891-2903, 2938-2947, 2973-2980, 2993-2999, 3004-3030, 3046-3059, 3066-3077, 3082-3088, 3120-3132, 3144-3149, 3153-3169, 3200-3212, 3232-3256, 3276-3290, 3308-3322, 3330-3338, 3353-3360, 3363-3371, 3390-3408, 3431-3447, 3454-3484, 3503-3515, 3524-3541, 3543-3550, 3560-3567, 3586-3599, 3616-3621, 3642-3647, 3663-3679, 213-276, 579-621 and 1516-1559 of Seq ID No 48; 19-41, 43-49, 55-62, 67-74, 114-121, 130-140, 188-197, 208-217, 226-232, 265-287, 292-299, 301-319, 372-394, 400-410, 421-427 and 12-56 of Seq ID No 49; 6-12, 44-51, 53-60, 67-88, 91-100, 104-123, 137-142, 148-158, 161-168, 175-201, 204-210, 222-231, 239-253, 258-264, 272-282 and 60-138 of Seq ID No 50; 4-63, 69-104, 110-121, 124-131, 134-152, 161-187, 204-221, 223-237, 239-296, 298-310, 331-365, 380-405, 423-451, 470-552, 554-562, 574-581, 592-649, 651-658, 661-671, 673-707, 713-734, 741-748, 758-765, 773-790 and 509-528 of Seq ID No 51; 89-94, 102-115, 123-129, 181-188, 200-206, 211-235, 239-249, 267-281, 295-310, 316-321, 331-341, 344-359, 365-386, 409-422, 443-453, 495-506, 514-521, 539-547, 553-560, 563-570, 586-596, 621-626, 633-638, 651-657, 666-683, 697-705, 731-739, 761-768, 865-883 and 213-265 of Seq ID No 52; 5-20, 24-34, 37-43, 92-102, 134-139, 156-162, 184-191, 193-205, 207-213, 225-231, 241-247, 259-267, 269-286, 337-350, 365-372, 378-386, 399-413, 415-421, 447-457, 467-481 and 145-183 of Seq ID No 53; 12-19, 29-41, 43-57, 80-98, 106-141, 143-156, 172-183, 185-210, 214-220, 226-234, 278-287 and 237-287 of Seq ID No 54; 5-12, 32-48, 50-72, 75-81, 88-94 and 16-40 of Seq ID No 55; 4-21, 29-42, 48-62, 65-80, 95-101, 103-118, 122-130, 134-140, 143-152, 155-165, 182-192, 198-208, 232-247, 260-268, 318-348, 364-369, 380-

- 31 -

391, 403-411, 413-424 and 208-230 of Seq ID No 56; 4-18, 65-75, 82-92, 123-140, 144-159, 166-172, 188-194 and 174-195 of Seq ID No 57; 7-20, 58-71, 94-101, 110-119, 199-209, 231-242, 247-254, 267-277, 282-290, 297-306, 313-319, 333-342, 344-369, 390-402, 414-431, 436-448, 462-471 and 310-350 of Seq ID No 58; 4-25, 37-44, 53-59, 72-78, 86-99, 119-128, 197-203, 209-218, 220-226, 233-244, 246-254, 264-271, 277-289, 407-430, 437-445, 464-472, 482-488, 503-509 and 308-331 of Seq ID No 59; 4-12, 14-43, 52-58 and 43-58 of Seq ID No 60; 4-14, 21-29, 35-49 and 38-50 of Seq ID No 61; 4-19, 31-37, 58-72, 94-108 and 1-72 of Seq ID No 62, and fragments comprising at least 6, preferably more than 8, especially more than 10 aa of said sequences. All these fragments individually and each independently form a preferred selected aspect of the present invention.

All linear hyperimmune serum reactive fragments of a particular antigen may be identified by analysing the entire sequence of the protein antigen by a set of peptides overlapping by 1 amino acid with a length of at least 10 amino acids. Subsequently, non-linear epitopes can be identified by analysis of the protein antigen with hyperimmune sera using the expressed full-length protein or domain polypeptides thereof. Assuming that a distinct domain of a protein is sufficient to form the 3D structure independent from the native protein, the analysis of the respective recombinant or synthetically produced domain polypeptide with hyperimmune serum would allow the identification of conformational epitopes within the individual domains of multi-domain proteins. For those antigens where a domain possesses linear as well as conformational epitopes, competition experiments with peptides corresponding to the linear epitopes may be used to confirm the presence of conformational epitopes.

It will be appreciated that the invention also relates to, among others, nucleic acid molecules encoding the aforementioned fragments, nucleic acid molecules that hybridise to nucleic acid molecules encoding the fragments, particularly those that hybridise under stringent conditions, and nucleic acid molecules, such as PCR primers, for amplifying nucleic acid molecules that encode the fragments. In these regards, preferred nucleic acid molecules are those that correspond to the preferred fragments, as discussed above.

The present invention also relates to vectors, which comprise a nucleic acid molecule or nucleic acid molecules of the present invention, host cells which are genetically engineered with vectors of the invention and the production of hyperimmune serum reactive antigens and fragments thereof by recombinant techniques.

- 32 -

A great variety of expression vectors can be used to express a hyperimmune serum reactive antigen or fragment thereof according to the present invention. Generally, any vector suitable to maintain, propagate or express nucleic acids to express a polypeptide in a host may be used for expression in this regard. In accordance with this aspect of the invention the vector may be, for example, a plasmid vector, a single or double-stranded phage vector, a single or double-stranded RNA or DNA viral vector. Starting plasmids disclosed herein are either commercially available, publicly available, or can be constructed from available plasmids by routine application of well-known, published procedures. Preferred among vectors, in certain respects, are those for expression of nucleic acid molecules and hyperimmune serum reactive antigens or fragments thereof of the present invention. Nucleic acid constructs in host cells can be used in a conventional manner to produce the gene product encoded by the recombinant sequence. Alternatively, the hyperimmune serum reactive antigens and fragments thereof of the invention can be synthetically produced by conventional peptide synthesizers. Mature proteins can be expressed in mammalian cells, yeast, bacteria, or other cells under the control of appropriate promoters. Cell-free translation systems can also be employed to produce such proteins using RNAs derived from the DNA construct of the present invention.

Host cells can be genetically engineered to incorporate nucleic acid molecules and express nucleic acid molecules of the present invention. Representative examples of appropriate hosts include bacterial cells, such as staphylococci, streptococci, *E. coli*, *Streptomyces* and *Bacillus subtilis* cells; fungal cells, such as yeast cells and *Aspergillus* cells; insect cells such as *Drosophila* S2 and *Spodoptera* Sf9 cells; animal cells such as CHO, COS, Hela, C127, 3T3, BHK, 293 and Bowes melanoma cells; and plant cells.

The invention also provides a process for producing a *S. epidermidis* hyperimmune serum reactive antigen and a fragment thereof comprising expressing from the host cell a hyperimmune serum reactive antigen or fragment thereof encoded by the nucleic acid molecules provided by the present invention. The invention further provides a process for producing a cell, which expresses a *S. epidermidis* hyperimmune serum reactive antigen or a fragment thereof comprising transforming or transfecting a suitable host cell with the vector according to the present invention such that the transformed or transfected cell expresses the polypeptide encoded by the nucleic acid contained in the vector.

The polypeptide may be expressed in a modified form, such as a fusion protein, and may include not only secretion signals but also additional heterologous

functional regions. Thus, for instance, a region of additional amino acids, particularly charged amino acids, may be added to the N- or C-terminus of the polypeptide to improve stability and persistence in the host cell, during purification or during subsequent handling and storage. Also, regions may be added to the polypeptide to facilitate purification. Such regions may be removed prior to final preparation of the polypeptide. The addition of peptide moieties to polypeptides to engender secretion or excretion, to improve stability or to facilitate purification, among others, are familiar and routine techniques in the art. A preferred fusion protein comprises a heterologous region from immunoglobulin that is useful to solubilize or purify polypeptides. For example, EP-A-O 42-3, 5, 10, 14, 16, 18, 22-24, 27 533 (Canadian counterpart 2045869) discloses fusion proteins comprising various portions of constant region of immunoglobulin molecules together with another protein or part thereof. In drug discovery, for example, proteins have been fused with antibody Fc portions for the purpose of high-throughout screening assays to identify antagonists. See for example, {Bennett, D. et al., 1995} and {Johanson, K. et al., 1995}.

The *S. epidermidis* hyperimmune serum reactive antigen or a fragment thereof can be recovered and purified from recombinant cell cultures by well-known methods including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, hydroxylapatite chromatography and lectin chromatography.

The hyperimmune serum reactive antigens and fragments thereof according to the present invention can be produced by chemical synthesis as well as by biotechnological means. The latter comprise the transfection or transformation of a host cell with a vector containing a nucleic acid according to the present invention and the cultivation of the transfected or transformed host cell under conditions, which are known to the ones skilled in the art. The production method may also comprise a purification step in order to purify or isolate the polypeptide to be manufactured. In a preferred embodiment the vector is a vector according to the present invention.

The hyperimmune serum reactive antigens and fragments thereof according to the present invention may be used for the detection of the organism or organisms in a sample containing these organisms or polypeptides derived thereof. Preferably such detection is for diagnosis, more preferable for the diagnosis of a disease, most preferably for the diagnosis of a diseases related or linked to the presence or abundance of Gram-positive bacteria, especially bacteria selected

- 34 -

from the group comprising staphylococci, streptococci and lactococci. More preferably, the microorganisms are selected from the group comprising *Staphylococcus aureus* and *Staphylococcus saprophyticus*, especially the microorganism is *Staphylococcus epidermidis*.

The present invention also relates to diagnostic assays such as quantitative and diagnostic assays for detecting levels of the hyperimmune serum reactive antigens and fragments thereof of the present invention in cells and tissues, including determination of normal and abnormal levels. Thus, for instance, a diagnostic assay in accordance with the invention for detecting over-expression of the polypeptide compared to normal control tissue samples may be used to detect the presence of an infection, for example, and to identify the infecting organism. Assay techniques that can be used to determine levels of a polypeptide, in a sample derived from a host are well known to those of skill in the art. Such assay methods include radioimmunoassays, competitive-binding assays, Western Blot analysis and ELISA assays. Among these, ELISAs frequently are preferred. An ELISA assay initially comprises preparing an antibody specific to the polypeptide, preferably a monoclonal antibody. In addition, a reporter antibody generally is prepared which binds to the monoclonal antibody. The reporter antibody is attached to a detectable reagent such as radioactive, fluorescent or enzymatic reagent, such as horseradish peroxidase enzyme.

The hyperimmune serum reactive antigens and fragments thereof according to the present invention may also be used for the purpose of or in connection with an array. More particularly, at least one of the hyperimmune serum reactive antigens and fragments thereof according to the present invention may be immobilized on a support. Said support typically comprises a variety of hyperimmune serum reactive antigens and fragments thereof whereby the variety may be created by using one or several of the hyperimmune serum reactive antigens and fragments thereof according to the present invention and/or hyperimmune serum reactive antigens and fragments thereof being different. The characterizing feature of such array as well as of any array in general is the fact that at a distinct or predefined region or position on said support or a surface thereof, a distinct polypeptide is immobilized. Because of this any activity at a distinct position or region of an array can be correlated with a specific polypeptide. The number of different hyperimmune serum reactive antigens and fragments thereof immobilized on a support may range from as little as 10 to several 1000 different hyperimmune serum reactive antigens and fragments thereof. The density of hyperimmune serum reactive antigens and fragments thereof per cm² is in a preferred embodiment as little as 10 peptides/polypeptides per

- 35 -

cm² to at least 400 different peptides/polypeptides per cm² and more particularly at least 1000 different hyperimmune serum reactive antigens and fragments thereof per cm².

The manufacture of such arrays is known to the one skilled in the art and, for example, described in US patent 5,744,309. The array preferably comprises a planar, porous or non-porous solid support having at least a first surface. The hyperimmune serum reactive antigens and fragments thereof as disclosed herein, are immobilized on said surface. Preferred support materials are, among others, glass or cellulose. It is also within the present invention that the array is used for any of the diagnostic applications described herein. Apart from the hyperimmune serum reactive antigens and fragments thereof according to the present invention also the nucleic acid molecules according to the present invention may be used for the generation of an array as described above. This applies as well to an array made of antibodies, preferably monoclonal antibodies as, among others, described herein.

In a further aspect the present invention relates to an antibody directed to any of the hyperimmune serum reactive antigens and fragments thereof, derivatives or fragments thereof according to the present invention. The present invention includes, for example, monoclonal and polyclonal antibodies, chimeric, single chain, and humanized antibodies, as well as Fab fragments, or the product of a Fab expression library. It is within the present invention that the antibody may be chimeric, i. e. that different parts thereof stem from different species or at least the respective sequences are taken from different species.

Antibodies generated against the hyperimmune serum reactive antigens and fragments thereof corresponding to a sequence of the present invention can be obtained by direct injection of the hyperimmune serum reactive antigens and fragments thereof into an animal or by administering the hyperimmune serum reactive antigens and fragments thereof to an animal, preferably a non-human. The antibody so obtained will then bind the hyperimmune serum reactive antigens and fragments thereof itself. In this manner, even a sequence encoding only a fragment of a hyperimmune serum reactive antigen and fragments thereof can be used to generate antibodies binding the whole native hyperimmune serum reactive antigen and fragments thereof. Such antibodies can then be used to isolate the hyperimmune serum reactive antigens and fragments thereof from tissue expressing those hyperimmune serum reactive antigens and fragments thereof.

- 36 -

For preparation of monoclonal antibodies, any technique known in the art, which provides antibodies produced by continuous cell line cultures can be used. (as described originally in {Kohler, G. et al., 1975}).

Techniques described for the production of single chain antibodies (U.S. Patent No. 4,946,778) can be adapted to produce single chain antibodies to immunogenic hyperimmune serum reactive antigens and fragments thereof according to this invention. Also, transgenic mice, or other organisms such as other mammals, may be used to express humanized antibodies to immunogenic hyperimmune serum reactive antigens and fragments thereof according to this invention.

Alternatively, phage display technology or ribosomal display could be utilized to select antibody genes with binding activities towards the hyperimmune serum reactive antigens and fragments thereof either from repertoires of PCR amplified v-genes of lymphocytes from humans screened for possessing respective target antigens or from naïve libraries {McCafferty, J. et al., 1990}; {Marks, J. et al., 1992}. The affinity of these antibodies can also be improved by chain shuffling {Clackson, T. et al., 1991}.

If two antigen binding domains are present, each domain may be directed against a different epitope - termed 'bispecific' antibodies.

The above-described antibodies may be employed to isolate or to identify clones expressing the hyperimmune serum reactive antigens and fragments thereof or purify the hyperimmune serum reactive antigens and fragments thereof of the present invention by attachment of the antibody to a solid support for isolation and/or purification by affinity chromatography.

Thus, among others, antibodies against the hyperimmune serum reactive antigens and fragments thereof of the present invention may be employed to inhibit and/or treat infections, particularly bacterial infections and especially infections arising from *S. epidermidis*.

Hyperimmune serum reactive antigens and fragments thereof include antigenically, epitopically or immunologically equivalent derivatives, which form a particular aspect of this invention. The term "antigenically equivalent derivative" as used herein encompasses a hyperimmune serum reactive antigen and fragments thereof or its equivalent which will be specifically recognized by certain antibodies which, when raised to the protein or hyperimmune serum reactive antigen and fragments thereof according to the present invention, inter-

ferre with the interaction between pathogen and mammalian host. The term "immunologically equivalent derivative" as used herein encompasses a peptide or its equivalent which when used in a suitable formulation to raise antibodies in a vertebrate, the antibodies act to interfere with the interaction between pathogen and mammalian host.

The hyperimmune serum reactive antigens and fragments thereof, such as an antigenically or immunologically equivalent derivative or a fusion protein thereof can be used as an antigen to immunize a mouse or other animal such as a rat or chicken. The fusion protein may provide stability to the hyperimmune serum reactive antigens and fragments thereof. The antigen may be associated, for example by conjugation, with an immunogenic carrier protein, for example bovine serum albumin (BSA) or keyhole limpet haemocyanin (KLH). Alternatively, an antigenic peptide comprising multiple copies of the protein or hyperimmune serum reactive antigen and fragments thereof, or an antigenically or immunologically equivalent hyperimmune serum reactive antigen and fragments thereof, may be sufficiently antigenic to improve immunogenicity so as to obviate the use of a carrier.

Preferably the antibody or derivative thereof is modified to make it less immunogenic in the individual. For example, if the individual is human the antibody may most preferably be "humanized", wherein the complementarity determining region(s) of the hybridoma-derived antibody has been transplanted into a human monoclonal antibody, for example as described in {Jones, P. et al., 1986} or {Tempest, P. et al., 1991}.

The use of a polynucleotide of the invention in genetic immunization will preferably employ a suitable delivery method such as direct injection of plasmid DNA into muscle, delivery of DNA complexed with specific protein carriers, coprecipitation of DNA with calcium phosphate, encapsulation of DNA in various forms of liposomes, particle bombardment {Tang, D. et al., 1992}, {Eisenbraun, M. et al., 1993} and in vivo infection using cloned retroviral vectors {Seeger, C. et al., 1984}.

In a further aspect the present invention relates to a peptide binding to any of the hyperimmune serum reactive antigens and fragments thereof according to the present invention, and a method for the manufacture of such peptides whereby the method is characterized by the use of the hyperimmune serum reactive antigens and fragments thereof according to the present invention and the basic steps are known to the one skilled in the art.

Such peptides may be generated by using methods according to the state of the art such as phage display or ribosome display. In case of phage display, basically a library of peptides is generated, in form of phages, and this kind of library is contacted with the target molecule, in the present case a hyperimmune serum reactive antigen and fragments thereof according to the present invention. Those peptides binding to the target molecule are subsequently removed, preferably as a complex with the target molecule, from the respective reaction. It is known to the one skilled in the art that the binding characteristics, at least to a certain extent, depend on the particularly realized experimental set-up such as the salt concentration and the like. After separating those peptides binding to the target molecule with a higher affinity or a bigger force, from the non-binding members of the library, and optionally also after removal of the target molecule from the complex of target molecule and peptide, the respective peptide(s) may subsequently be characterised. Prior to the characterisation optionally an amplification step is realized such as, e. g. by propagating the peptide encoding phages. The characterisation preferably comprises the sequencing of the target binding peptides. Basically, the peptides are not limited in their lengths, however, peptides having a length from about 8 to 20 amino acids are preferably obtained in the respective methods. The size of the libraries may be about 102 to 1018, preferably 108 to 1015 different peptides, however, is not limited thereto.

A particular form of target binding hyperimmune serum reactive antigens and fragments thereof are the so-called "anticalines" which are, among others, described in German patent application DE 197 42 706.

In a further aspect the present invention relates to functional nucleic acids interacting with any of the hyperimmune serum reactive antigens and fragments thereof according to the present invention, and a method for the manufacture of such functional nucleic acids whereby the method is characterized by the use of the hyperimmune serum reactive antigens and fragments thereof according to the present invention and the basic steps are known to the one skilled in the art. The functional nucleic acids are preferably aptamers and spiegelmers.

Aptamers are D-nucleic acids, which are either single stranded or double stranded and which specifically interact with a target molecule. The manufacture or selection of aptamers is, e. g., described in European patent EP 0 533 838. Basically the following steps are realized. First, a mixture of nucleic acids, i. e. potential aptamers, is provided whereby each nucleic acid typically com-

prises a segment of several, preferably at least eight subsequent randomised nucleotides. This mixture is subsequently contacted with the target molecule whereby the nucleic acid(s) bind to the target molecule, such as based on an increased affinity towards the target or with a bigger force thereto, compared to the candidate mixture. The binding nucleic acid(s) are/is subsequently separated from the remainder of the mixture. Optionally, the thus obtained nucleic acid(s) is amplified using, e.g. polymerase chain reaction. These steps may be repeated several times giving at the end a mixture having an increased ratio of nucleic acids specifically binding to the target from which the final binding nucleic acid is then optionally selected. These specifically binding nucleic acid(s) are referred to as aptamers. It is obvious that at any stage of the method for the generation or identification of the aptamers samples of the mixture of individual nucleic acids may be taken to determine the sequence thereof using standard techniques. It is within the present invention that the aptamers may be stabilized such as, e. g., by introducing defined chemical groups which are known to the one skilled in the art of generating aptamers. Such modification may for example reside in the introduction of an amino group at the 2'-position of the sugar moiety of the nucleotides. Aptamers are currently used as therapeutical agents. However, it is also within the present invention that the thus selected or generated aptamers may be used for target validation and/or as lead substance for the development of medicaments, preferably of medicaments based on small molecules. This is actually done by a competition assay whereby the specific interaction between the target molecule and the aptamer is inhibited by a candidate drug whereby upon replacement of the aptamer from the complex of target and aptamer it may be assumed that the respective drug candidate allows a specific inhibition of the interaction between target and aptamer, and if the interaction is specific, said candidate drug will, at least in principle, be suitable to block the target and thus decrease its biological availability or activity in a respective system comprising such target. The thus obtained small molecule may then be subject to further derivatisation and modification to optimise its physical, chemical, biological and/or medical characteristics such as toxicity, specificity, biodegradability and bioavailability.

Spiegelmers and their generation or manufacture is based on a similar principle. The manufacture of Spiegelmers is described in international patent application WO 98/08856. Spiegelmers are L-nucleic acids, which means that they are composed of L-nucleotides rather than D-nucleotides as aptamers are. Spiegelmers are characterized by the fact that they have a very high stability in biological systems and, comparable to aptamers, specifically interact with the target molecule against which they are directed. In the process of generat-

ing spiegelmers, a heterogeneous population of D-nucleic acids is created and this population is contacted with the optical antipode of the target molecule, in the present case for example with the D-enantiomer of the naturally occurring L-enantiomer of the hyperimmune serum reactive antigens and fragments thereof according to the present invention. Subsequently, those D-nucleic acids are separated which do not interact with the optical antipode of the target molecule. But those D-nucleic acids interacting with the optical antipode of the target molecule are separated, optionally identified and/or sequenced and subsequently the corresponding L-nucleic acids are synthesized based on the nucleic acid sequence information obtained from the D-nucleic acids. These L-nucleic acids, which are identical in terms of sequence with the aforementioned D-nucleic acids interacting with the optical antipode of the target molecule, will specifically interact with the naturally occurring target molecule rather than with the optical antipode thereof. Similar to the method for the generation of aptamers it is also possible to repeat the various steps several times and thus to enrich those nucleic acids specifically interacting with the optical antipode of the target molecule.

In a further aspect the present invention relates to functional nucleic acids interacting with any of the nucleic acid molecules according to the present invention, and a method for the manufacture of such functional nucleic acids whereby the method is characterized by the use of the nucleic acid molecules and their respective sequences according to the present invention and the basic steps are known to the one skilled in the art. The functional nucleic acids are preferably ribozymes, antisense oligonucleotides and siRNA.

Ribozymes are catalytically active nucleic acids, which preferably consist of RNA, which basically comprises two moieties. The first moiety shows a catalytic activity whereas the second moiety is responsible for the specific interaction with the target nucleic acid, in the present case the nucleic acid coding for the hyperimmune serum reactive antigens and fragments thereof according to the present invention. Upon interaction between the target nucleic acid and the second moiety of the ribozyme, typically by hybridisation and Watson-Crick base pairing of essentially complementary stretches of bases on the two hybridising strands, the catalytically active moiety may become active which means that it catalyses, either intramolecularly or intermolecularly, the target nucleic acid in case the catalytic activity of the ribozyme is a phosphodiesterase activity. Subsequently, there may be a further degradation of the target nucleic acid, which in the end results in the degradation of the target nucleic acid as well as the protein derived from the said target nucleic acid. Ribozymes, their use

and design principles are known to the one skilled in the art, and, for example described in {Doherty, E. et al., 2001} and {Lewin, A. et al., 2001}.

The activity and design of antisense oligonucleotides for the manufacture of a medicament and as a diagnostic agent, respectively, is based on a similar mode of action. Basically, antisense oligonucleotides hybridise based on base complementarity, with a target RNA, preferably with a mRNA, thereby activating RNase H. RNase H is activated by both phosphodiester and phosphorothioate-coupled DNA. Phosphodiester-coupled DNA, however, is rapidly degraded by cellular nucleases with the exception of phosphorothioate-coupled DNA. These resistant, non-naturally occurring DNA derivatives do not inhibit RNase H upon hybridisation with RNA. In other words, antisense polynucleotides are only effective as DNA RNA hybrid complexes. Examples for this kind of antisense oligonucleotides are described, among others, in US-patent US 5,849,902 and US 5,989,912. In other words, based on the nucleic acid sequence of the target molecule which in the present case are the nucleic acid molecules for the hyper-immune serum reactive antigens and fragments thereof according to the present invention, either from the target protein from which a respective nucleic acid sequence may in principle be deduced, or by knowing the nucleic acid sequence as such, particularly the mRNA, suitable antisense oligonucleotides may be designed based on the principle of base complementarity.

Particularly preferred are antisense-oligonucleotides, which have a short stretch of phosphorothioate DNA (3 to 9 bases). A minimum of 3 DNA bases is required for activation of bacterial RNase H and a minimum of 5 bases is required for mammalian RNase H activation. In these chimeric oligonucleotides there is a central region that forms a substrate for RNase H that is flanked by hybridising "arms" comprised of modified nucleotides that do not form substrates for RNase H. The hybridising arms of the chimeric oligonucleotides may be modified such as by 2'-O-methyl or 2'-fluoro. Alternative approaches used methylphosphate or phosphoramidate linkages in said arms. Further embodiments of the antisense oligonucleotide useful in the practice of the present invention are P-methoxyoligonucleotides, partial P-methoxyoligodeoxyribonucleotides or P-methoxyoligonucleotides.

Of particular relevance and usefulness for the present invention are those antisense oligonucleotides as more particularly described in the above two mentioned US patents. These oligonucleotides contain no naturally occurring 5' to 3'-linked nucleotides. Rather the oligonucleotides have two types of nucleotides: 2'-deoxyphosphorothioate, which activate RNase H, and 2'-modified nuc-

leotides, which do not. The linkages between the 2'-modified nucleotides can be phosphodiester, phosphorothioate or P-ethoxyphosphodiester. Activation of RNase H is accomplished by a contiguous RNase H-activating region, which contains between 3 and 5 2'-deoxyphosphorothioate nucleotides to activate bacterial RNase H and between 5 and 10 2'- deoxyphosphorothioate nucleotides to activate eucaryotic and, particularly, mammalian RNase H. Protection from degradation is accomplished by making the 5' and 3' terminal bases highly nucle-ase resistant and, optionally, by placing a 3' terminal blocking group.

More particularly, the antisense oligonucleotide comprises a 5' terminus and a 3' terminus; and from position 11 to 59 5'□3'-linked nucleotides independently selected from the group consisting of 2'-modified phosphodiester nucleotides and 2'-modified P-alkyloxyphosphotriester nucleotides; and wherein the 5'-terminal nucleoside is attached to an RNase H-activating region of between three and ten contiguous phosphorothioate-linked deoxyribonucleotides, and wherein the 3'-terminus of said oligonucleotide is selected from the group consisting of an inverted deoxyribonucleotide, a contiguous stretch of one to three phosphorothioate 2'-modified ribonucleotides, a biotin group and a P-alkyloxyphosphotriester nucleotide.

Also an antisense oligonucleotide may be used wherein not the 5' terminal nucleoside is attached to an RNase H-activating region but the 3' terminal nucleoside as specified above. Also, the 5' terminus is selected from the particular group rather than the 3' terminus of said oligonucleotide.

The nucleic acids as well as the hyperimmune serum reactive antigens and fragments thereof according to the present invention may be used as or for the manufacture of pharmaceutical compositions, especially vaccines. Preferably such pharmaceutical composition, preferably vaccine is for the prevention or treatment of diseases caused by, related to or associated with *S. epidermidis*. In so far another aspect of the invention relates to a method for inducing an immunological response in an individual, particularly a mammal, which comprises inoculating the individual with the hyperimmune serum reactive antigens and fragments thereof of the invention, or a fragment or variant thereof, adequate to produce antibodies to protect said individual from infection, particularly *Staphylococcus* infection and most particularly *S. epidermidis* infections.

Yet another aspect of the invention relates to a method of inducing an immunological response in an individual which comprises, through gene therapy or otherwise, delivering a nucleic acid functionally encoding hyperimmune serum

reactive antigens and fragments thereof, or a fragment or a variant thereof, for expressing the hyperimmune serum reactive antigens and fragments thereof, or a fragment or a variant thereof in vivo in order to induce an immunological response to produce antibodies or a cell mediated T cell response, either cytokine-producing T cells or cytotoxic T cells, to protect said individual from disease, whether that disease is already established within the individual or not. One way of administering the gene is by accelerating it into the desired cells as a coating on particles or otherwise.

A further aspect of the invention relates to an immunological composition which, when introduced into a host capable of having induced within it an immunological response, induces an immunological response in such host, wherein the composition comprises recombinant DNA which codes for and expresses an antigen of the hyperimmune serum reactive antigens and fragments thereof of the present invention. The immunological response may be used therapeutically or prophylactically and may take the form of antibody immunity or cellular immunity such as that arising from CTL or CD4+ T cells.

The hyperimmune serum reactive antigens and fragments thereof of the invention or a fragment thereof may be fused with a co-protein which may not by itself produce antibodies, but is capable of stabilizing the first protein and producing a fused protein which will have immunogenic and protective properties. This fused recombinant protein preferably further comprises an antigenic co-protein, such as Glutathione-S-transferase (GST) or beta-galactosidase, relatively large co-proteins which solubilise the protein and facilitate production and purification thereof. Moreover, the co-protein may act as an adjuvant in the sense of providing a generalized stimulation of the immune system. The co-protein may be attached to either the amino or carboxy terminus of the first protein.

Also, provided by this invention are methods using the described nucleic acid molecule or particular fragments thereof in such genetic immunization experiments in animal models of infection with *S. epidermidis*. Such fragments will be particularly useful for identifying protein epitopes able to provoke a prophylactic or therapeutic immune response. This approach can allow for the subsequent preparation of monoclonal antibodies of particular value from the requisite organ of the animal successfully resisting or clearing infection for the development of prophylactic agents or therapeutic treatments of *S. epidermidis* infection in mammals, particularly humans.

- 44 -

The hyperimmune serum reactive antigens and fragments thereof may be used as an antigen for vaccination of a host to produce specific antibodies which protect against invasion of bacteria, for example by blocking adherence of bacteria to damaged tissue. Examples of tissue damage include wounds in skin or connective tissue caused e.g. by mechanical, chemical or thermal damage or by implantation of indwelling devices, or wounds in the mucous membranes, such as the mouth, mammary glands, urethra or vagina.

The present invention also includes a vaccine formulation, which comprises the immunogenic recombinant protein together with a suitable carrier. Since the protein may be broken down in the stomach, it is preferably administered parenterally, including, for example, administration that is subcutaneous, intramuscular, intravenous, intradermal intranasal or transdermal. Formulations suitable for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the bodily fluid, preferably the blood, of the individual; and aqueous and non-aqueous sterile suspensions which may include suspending agents or thickening agents. The formulations may be presented in unit-dose or multi-dose containers, for example, sealed ampoules and vials, and may be stored in a freeze-dried condition requiring only the addition of the sterile liquid carrier immediately prior to use. The vaccine formulation may also include adjuvant systems for enhancing the immunogenicity of the formulation, such as oil-in-water systems and other systems known in the art. The dosage will depend on the specific activity of the vaccine and can be readily determined by routine experimentation.

According to another aspect, the present invention relates to a pharmaceutical composition comprising such a hyperimmune serum-reactive antigen or a fragment thereof as provided in the present invention for *S. epidermidis*. Such a pharmaceutical composition may comprise one or more hyperimmune serum reactive antigens or fragments thereof against *S. epidermidis*. Optionally, such *S. epidermidis* hyperimmune serum reactive antigens or fragments thereof may also be combined with antigens against other pathogens in a combination pharmaceutical composition. Preferably, said pharmaceutical composition is a vaccine for preventing or treating an infection caused by *S. epidermidis* and/or other pathogens against which the antigens have been included in the vaccine.

According to a further aspect, the present invention relates to a pharmaceutical composition comprising a nucleic acid molecule encoding a hyperimmune serum-reactive antigen or a fragment thereof as identified above for *S. epidermidis*.

Such a pharmaceutical composition may comprise one or more nucleic acid molecules encoding hyperimmune serum reactive antigens or fragments thereof against *S. epidermidis*. Optionally, such *S. epidermidis* nucleic acid molecules encoding hyperimmune serum reactive antigens or fragments thereof may also be combined with nucleic acid molecules encoding antigens against other pathogens in a combination pharmaceutical composition. Preferably, said pharmaceutical composition is a vaccine for preventing or treating an infection caused by *S. epidermidis* and/or other pathogens against which the antigens have been included in the vaccine.

The pharmaceutical composition may contain any suitable auxiliary substances, such as buffer substances, stabilisers or further active ingredients, especially ingredients known in connection of pharmaceutical composition and/or vaccine production.

A preferable carrier/or excipient for the hyperimmune serum-reactive antigens, fragments thereof or a coding nucleic acid molecule thereof according to the present invention is an immunostimulatory compound for further stimulating the immune response to the given hyperimmune serum-reactive antigen, fragment thereof or a coding nucleic acid molecule thereof. Preferably the immunostimulatory compound in the pharmaceutical preparation according to the present invention is selected from the group of polycationic substances, especially polycationic peptides, immunostimulatory nucleic acids molecules, preferably immunostimulatory deoxynucleotides, alum, Freund's complete adjuvants, Freund's incomplete adjuvants, neuroactive compounds, especially human growth hormone, or combinations thereof.

It is also within the scope of the present invention that the pharmaceutical composition, especially vaccine, comprises apart from the hyperimmune serum reactive antigens, fragments thereof and/or coding nucleic acid molecules thereof according to the present invention other compounds which are biologically or pharmaceutically active. Preferably, the vaccine composition comprises at least one polycationic peptide. The polycationic compound(s) to be used according to the present invention may be any polycationic compound, which shows the characteristic effects according to the WO 97/30721. Preferred polycationic compounds are selected from basic polypeptides, organic polycations, basic polyamino acids or mixtures thereof. These polyamino acids should have a chain length of at least 4 amino acid residues (WO 97/30721). Especially preferred are substances like polylysine, polyarginine and polypeptides containing more than 20 %, especially more than 50 % of basic amino acids in a range of more than 8,

especially more than 20, amino acid residues or mixtures thereof. Other preferred polycations and their pharmaceutical compositions are described in WO 97/30721 (e.g. polyethyleneimine) and WO 99/38528. Preferably these polypeptides contain between 20 and 500 amino acid residues, especially between 30 and 200 residues.

These polycationic compounds may be produced chemically or recombinantly or may be derived from natural sources.

Cationic (poly)peptides may also be anti-microbial with properties as reviewed in {Ganz, T., 1999}. These (poly)peptides may be of prokaryotic or animal or plant origin or may be produced chemically or recombinantly (WO 02/13857). Peptides may also belong to the class of defensins (WO 02/13857). Sequences of such peptides can be, for example, found in the Antimicrobial Sequences Database under the following internet address:

<http://www.bbcm.univ.trieste.it/~tossi/pag2.html>

Such host defence peptides or defensives are also a preferred form of the polycationic polymer according to the present invention. Generally, a compound allowing as an end product activation (or down-regulation) of the adaptive immune system, preferably mediated by APCs (including dendritic cells) is used as polycationic polymer.

Especially preferred for use as polycationic substances in the present invention are cathelicidin derived antimicrobial peptides or derivatives thereof (International patent application WO 02/13857, incorporated herein by reference), especially antimicrobial peptides derived from mammalian cathelicidin, preferably from human, bovine or mouse.

Polycationic compounds derived from natural sources include HIV-REV or HIV-TAT (derived cationic peptides, antennapedia peptides, chitosan or other derivatives of chitin) or other peptides derived from these peptides or proteins by biochemical or recombinant production. Other preferred polycationic compounds are cathelin or related or derived substances from cathelin. For example, mouse cathelin is a peptide, which has the amino acid sequence NH₂-RLAGLLRKGGEKI-GEKLLKIGOKIKNFFQKLVPQPE-COOH. Related or derived cathelin substances contain the whole or parts of the cathelin sequence with at least 15-20 amino acid residues. Derivations may include the substitution or modification of the natural amino acids by amino acids, which are not among the 20 standard amino

acids. Moreover, further cationic residues may be introduced into such cathelin molecules. These cathelin molecules are preferred to be combined with the antigen. These cathelin molecules surprisingly have turned out to be also effective as an adjuvant for an antigen without the addition of further adjuvants. It is therefore possible to use such cathelin molecules as efficient adjuvants in vaccine formulations with or without further immunactivating substances.

Another preferred polycationic substance to be used according to the present invention is a synthetic peptide containing at least 2 KLK-motifs separated by a linker of 3 to 7 hydrophobic amino acids (International patent application WO 02/32451, incorporated herein by reference).

The pharmaceutical composition of the present invention may further comprise immunostimulatory nucleic acid(s). Immunostimulatory nucleic acids are e. g. neutral or artificial CpG containing nucleic acids, short stretches of nucleic acids derived from non-vertebrates or in form of short oligonucleotides (ODNs) containing non-methylated cytosine-guanine di-nucleotides (CpG) in a certain base context (e.g. described in WO 96/02555). Alternatively, also nucleic acids based on inosine and cytidine as e.g. described in the WO 01/93903, or deoxynucleic acids containing deoxy-inosine and/or deoxyuridine residues (described in WO 01/93905 and PCT/EP 02/05448, incorporated herein by reference) may preferably be used as immunostimulatory nucleic acids for the present invention. Preferably, the mixtures of different immunostimulatory nucleic acids may be used according to the present invention.

It is also within the present invention that any of the aforementioned polycationic compounds is combined with any of the immunostimulatory nucleic acids as aforementioned. Preferably, such combinations are according to the ones as described in WO 01/93905, WO 02/32451, WO 01/54720, WO 01/93903, WO 02/13857 and PCT/EP 02/05448 and the Austrian patent application A 1924/2001, incorporated herein by reference.

In addition or alternatively such vaccine composition may comprise apart from the hyperimmune serum reactive antigens and fragments thereof, and the coding nucleic acid molecules thereof according to the present invention a neuroactive compound. Preferably, the neuroactive compound is human growth factor as, e.g. described in WO 01/24822. Also preferably, the neuroactive compound is combined with any of the polycationic compounds and/or immunostimulatory nucleic acids as afore-mentioned.

In a further aspect the present invention is related to a pharmaceutical composition. Such pharmaceutical composition is, for example, the vaccine described herein. Also a pharmaceutical composition is a pharmaceutical composition which comprises any of the following compounds or combinations thereof: the nucleic acid molecules according to the present invention, the hyperimmune serum reactive antigens and fragments thereof according to the present invention, the vector according to the present invention, the cells according to the present invention, the antibody according to the present invention, the functional nucleic acids according to the present invention and the binding peptides such as the anticalines according to the present invention, any agonists and antagonists screened as described herein. In connection therewith any of these compounds may be employed in combination with a non-sterile or sterile carrier or carriers for use with cells, tissues or organisms, such as a pharmaceutical carrier suitable for administration to a subject. Such compositions comprise, for instance, a media additive or a therapeutically effective amount of a hyperimmune serum reactive antigen and fragments thereof of the invention and a pharmaceutically acceptable carrier or excipient. Such carriers may include, but are not limited to, saline, buffered saline, dextrose, water, glycerol, ethanol and combinations thereof. The formulation should suit the mode of administration.

The pharmaceutical compositions may be administered in any effective, convenient manner including, for instance, administration by topical, oral, anal, vaginal, intravenous, intraperitoneal, intramuscular, subcutaneous, intranasal or intradermal routes among others.

In therapy or as a prophylactic, the active agent may be administered to an individual as an injectable composition, for example as a sterile aqueous dispersion, preferably isotonic.

Alternatively the composition may be formulated for topical application, for example in the form of ointments, creams, lotions, eye ointments, eye drops, ear drops, mouthwash, impregnated dressings and sutures and aerosols, and may contain appropriate conventional additives, including, for example, preservatives, solvents to assist drug penetration, and emollients in ointments and creams. Such topical formulations may also contain compatible conventional carriers, for example cream or ointment bases, and ethanol or oleyl alcohol for lotions. Such carriers may constitute from about 1 % to about 98 % by weight of the formulation; more usually they will constitute up to about 80 % by weight of the formulation.

In addition to the therapy described above, the compositions of this invention may be used generally as a wound treatment agent to prevent adhesion of bacteria to matrix proteins exposed in wound tissue and for prophylactic use in dental treatment as an alternative to, or in conjunction with, antibiotic prophylaxis.

A vaccine composition is conveniently in injectable form. Conventional adjuvants may be employed to enhance the immune response. A suitable unit dose for vaccination is 0.05-5 µg antigen / per kg of body weight, and such dose is preferably administered 1-3 times and with an interval of 1-3 weeks.

With the indicated dose range, no adverse toxicological effects should be observed with the compounds of the invention, which would preclude their administration to suitable individuals.

In a further embodiment the present invention relates to diagnostic and pharmaceutical packs and kits comprising one or more containers filled with one or more of the ingredients of the aforementioned compositions of the invention. The ingredient(s) can be present in a useful amount, dosage, formulation or combination. Associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, reflecting approval by the agency of the manufacture, use or sale of the product for human administration.

In connection with the present invention any disease related use as disclosed herein such as, e. g. use of the pharmaceutical composition or vaccine, is particularly a disease or diseased condition which is caused by, linked or associated with Staphylococci, more preferably, *S. epidermidis*. In connection therewith it is to be noted that *S. epidermidis* comprises several strains including those disclosed herein. A disease related, caused or associated with the bacterial infection to be prevented and/or treated according to the present invention includes besides other diseases mostly those related to the presence of foreign bodies and the use of devices, such as catheters, cerebrospinal fluid shunt infections, peritonitis and endocarditis in humans.

In a still further embodiment the present invention is related to a screening method using any of the hyperimmune serum reactive antigens or nucleic acids according to the present invention. Screening methods as such are known to the one skilled in the art and can be designed such that an agonist or an antagon-

ist is screened. Preferably an antagonist is screened which in the present case inhibits or prevents the binding of any hyperimmune serum reactive antigen and fragment thereof according to the present invention to an interaction partner. Such interaction partner can be a naturally occurring interaction partner or a non-naturally occurring interaction partner.

The invention also provides a method of screening compounds to identify those, which enhance (agonist) or block (antagonist) the function of hyperimmune serum reactive antigens and fragments thereof or nucleic acid molecules of the present invention, such as its interaction with a binding molecule. The method of screening may involve high-throughput.

For example, to screen for agonists or antagonists, the interaction partner of the nucleic acid molecule and nucleic acid, respectively, according to the present invention, maybe a synthetic reaction mix, a cellular compartment, such as a membrane, cell envelope or cell wall, or a preparation of any thereof, may be prepared from a cell that expresses a molecule that binds to the hyperimmune serum reactive antigens and fragments thereof of the present invention. The preparation is incubated with labelled hyperimmune serum reactive antigens and fragments thereof in the absence or the presence of a candidate molecule, which may be an agonist or antagonist. The ability of the candidate molecule to bind the binding molecule is reflected in decreased binding of the labelled ligand. Molecules which bind gratuitously, i. e., without inducing the functional effects of the hyperimmune serum reactive antigens and fragments thereof, are most likely to be good antagonists. Molecules that bind well and elicit functional effects that are the same as or closely related to the hyperimmune serum reactive antigens and fragments thereof are good agonists.

The functional effects of potential agonists and antagonists may be measured, for instance, by determining the activity of a reporter system following interaction of the candidate molecule with a cell or appropriate cell preparation, and comparing the effect with that of the hyperimmune serum reactive antigens and fragments thereof of the present invention or molecules that elicit the same effects as the hyperimmune serum reactive antigens and fragments thereof. Reporter systems that may be useful in this regard include but are not limited to colorimetric labelled substrate converted into product, a reporter gene that is responsive to changes in the functional activity of the hyperimmune serum reactive antigens and fragments thereof, and binding assays known in the art.

Another example of an assay for antagonists is a competitive assay that com-

- 51 -

binds the hyperimmune serum reactive antigens and fragments thereof of the present invention and a potential antagonist with membrane-bound binding molecules, recombinant binding molecules, natural substrates or ligands, or substrate or ligand mimetics, under appropriate conditions for a competitive inhibition assay. The hyperimmune serum reactive antigens and fragments thereof can be labelled such as by radioactivity or a colorimetric compound, such that the molecule number of hyperimmune serum reactive antigens and fragments thereof bound to a binding molecule or converted to product can be determined accurately to assess the effectiveness of the potential antagonist.

Potential antagonists include small organic molecules, peptides, polypeptides and antibodies that bind to a hyperimmune serum reactive antigen and fragments thereof of the invention and thereby inhibit or extinguish its activity. Potential antagonists also may be small organic molecules, a peptide, a polypeptide such as a closely related protein or antibody that binds to the same sites on a binding molecule without inducing functional activity of the hyperimmune serum reactive antigens and fragments thereof of the invention.

Potential antagonists include a small molecule, which binds to and occupies the binding site of the hyperimmune serum reactive antigens and fragments thereof thereby preventing binding to cellular binding molecules, such that normal biological activity is prevented. Examples of small molecules include but are not limited to small organic molecules, peptides or peptide-like molecules.

Other potential antagonists include antisense molecules (see {Okano, H. et al., 1991}; OLIGODEOXYNUCLEOTIDES AS ANTISENSE INHIBITORS OF GENE EXPRESSION; CRC Press, Boca Ration, FL (1988), for a description of these molecules).

Preferred potential antagonists include derivatives of the hyperimmune serum reactive antigens and fragments thereof of the invention.

As used herein the activity of a hyperimmune serum reactive antigen and fragment thereof according to the present invention is its capability to bind to any of its interaction partner or the extent of such capability to bind to its or any interaction partner.

In a particular aspect, the invention provides the use of the hyperimmune serum reactive antigens and fragments thereof, nucleic acid molecules or inhibitors of the invention to interfere with the initial physical interaction between a pathogen and mammalian host responsible for sequelae of infection. In particu-

- 52 -

lar the molecules of the invention may be used: i) in the prevention of adhesion of *S. epidermidis* to mammalian extracellular matrix proteins on in-dwelling devices or to extracellular matrix proteins in wounds; ii) to block protein mediated mammalian cell invasion by, for example, initiating phosphorylation of mammalian tyrosine kinases {Rosenshine, I. et al., 1992} to block bacterial adhesion between mammalian extracellular matrix proteins and bacterial proteins which mediate tissue damage; iv) to block the normal progression of pathogenesis in infections initiated other than by the implantation of in-dwelling devices or by other surgical techniques.

Each of the DNA coding sequences provided herein may be used in the discovery and development of antibacterial compounds. The encoded protein upon expression can be used as a target for the screening of antibacterial drugs. Additionally, the DNA sequences encoding the amino terminal regions of the encoded protein or Shine-Delgarno or other translation facilitating sequences of the respective mRNA can be used to construct antisense sequences to control the expression of the coding sequence of interest.

The antagonists and agonists may be employed, for instance, to inhibit diseases arising from infection with *Staphylococcus*, especially *S. epidermidis*, such as sepsis.

In a still further aspect the present invention is related to an affinity device such affinity device comprises as least a support material and any of the hyperimmune serum reactive antigens and fragments thereof according to the present invention, which is attached to the support material. Because of the specificity of the hyperimmune serum reactive antigens and fragments thereof according to the present invention for their target cells or target molecules or their interaction partners, the hyperimmune serum reactive antigens and fragments thereof allow a selective removal of their interaction partner(s) from any kind of sample applied to the support material provided that the conditions for binding are met. The sample may be a biological or medical sample, including but not limited to, fermentation broth, cell debris, cell preparation, tissue preparation, organ preparation, blood, urine, lymph liquid, liquor and the like.

The hyperimmune serum reactive antigens and fragments thereof may be attached to the matrix in a covalent or non-covalent manner. Suitable support material is known to the one skilled in the art and can be selected from the group comprising cellulose, silicon, glass, aluminium, paramagnetic beads, starch and

dextrane.

The present invention is further illustrated by the following figures, examples and the sequence listing from which further features, embodiments and advantages may be taken. It is to be understood that the present examples are given by way of illustration only and not by way of limitation of the disclosure.

In connection with the present invention

Figure 1 shows the characterization of the selected human high titre sera specific for *S. epidermidis*.

Figure 2 shows the characterization of the small fragment genomic library, LSE-70, from *Staphylococcus epidermidis* RP62A.

Figure 3 shows the selection of bacterial cells by MACS using biotinylated human IgGs.

Figure 4 shows an example for the gene distribution study with the identified antigens.

Table 1 shows the summary of the screens performed with genomic *S. epidermidis* libraries and human serum and the gene distribution data for selected antigens.

The figures to which it might be referred to in the specification are described in the following in more details.

Figure 1 shows the characterization and selection of human serum samples for identification of *S. epidermidis* antigens. (A) ELISA: Total anti-*S. epidermidis* IgGs were measured by standard ELISA using total bacterial lysate as coating antigen at two different serum dilutions. Five sera (EP.1-5) were selected from a serum collection obtained from patients with *S. epidermidis* peritonitis. C, control serum from a patient with unrelated infection. (B) Immunoblot analysis: Selected high titer sera were characterized by immunoblotting using total bacterial lysates prepared from eight different *S. epidermidis* clinical isolates (lanes 1-8), as well as from *S. epidermidis* strain RP62A (lane C). In each lane, ~20µg total lysate proteins extracted from bacteria grown in BHI medium overnight were loaded. A representative immunoblot is shown for the EP.4 serum. The membrane was incubated with EP.4 serum at a dilution of 5,000 and developed

with anti-human IgG secondary reagent. Mw, Protein standards (kDa).

Figure 2A shows the fragment size distribution of the *Staphylococcus epidermidis* RP62A small fragment genomic library, LSE-70. After sequencing 572 randomly selected clones, sequences were trimmed to eliminate vector residues and the numbers of clones with various genomic fragment sizes were plotted. (B) Graphic illustration of the distribution of the same set of randomly sequenced clones of LSE-70 over the *S. epidermidis* chromosome. Circles indicate matching sequences to annotated ORFs in +/+ and +/- orientation. Rectangles represent fully matched clones to non-coding chromosomal sequences in +/+ and +/- orientation. Diamonds position the best match of all chimeric clone sequences. Numeric distances in base pairs are indicated over the circular genome for orientation. Partitioning of various clone sets within the library is given in numbers and percentage at the bottom of the figure.

Figure 3A shows the MACS selection with biotinylated human IgGs. The LSE-70 library in pMAL9.1 was screened with 10µg biotinylated, human serum (P15-IgG) in the first and second selection round. As negative control, no serum was added to the library cells for screening. Number of cells selected after the 1st and 2nd elution are shown for each selection round. Figure 3B shows the reactivity of specific clones (1-26) isolated by bacterial surface display as analysed by Western blot analysis with the human serum (P15-IgG) used for selection by MACS at a dilution of 1:3,000. As a loading control the same blot was also analysed with antibodies directed against the platform protein LamB at a dilution of 1:5,000. LB, Extract from a clone expressing LamB without foreign peptide insert.

Figure 4 shows the PCR analysis for the gene distribution of ORF1163 with the respective oligonucleotides. The predicted size of the PCR fragments is approximately 1,000 bp. The 31 coagulase negative *Staphylococcus* and 11 *S. epidermidis* strains used for analysis are marked in the figure; N, no genomic DNA added; P, genomic DNA from *S. epidermidis* RP62A, which served as template for library construction.

Table 1: Immunogenic proteins identified by bacterial surface display.

A, LSE-70 library in lamB with P15-IgG (804), B, LSE-150 library in fhuA with P15-IgG (826), C, LSA-300 library in fhuA with P15-IgG (729), *, prediction of antigenic sequences longer than 5 amino acids was performed with the program ANTIGENIC {Kolaskar, A. et al., 1990}. \$, Fourty-two coagulase negative Sta-

phyllococcus or *S. epidermidis* strains were tested by PCR with oligonucleotides specific for the genes encoding relevant antigens. Since 6 of the 31 CNS strains were negative for all genes analysed, we eliminated these data from the summary, because these strains are most likely not closely related to *S. epidermidis*.

EXAMPLES

Example 1: Preparation of antibodies from human serum

Experimental procedures

Peptide synthesis

Peptides were synthesized in small scale (4 mg resin; up to 288 in parallel) using standard F-moc chemistry on a Rink amide resin (PepChem, Tübingen, Germany) using a SyroII synthesizer (MultisynTech, Witten, Germany). After the sequence was assembled, peptides were elongated with Fmoc-epsilon-aminohexanoic acid (as a linker) and biotin (Sigma, St. Louis, MO; activated like a normal amino acid). Peptides were cleaved off the resin with 93%TFA, 5% triethylsilane, and 2% water for one hour. Peptides were dried under vacuum and freeze dried three times from acetonitrile/water (1:1). The presence of the correct mass was verified by mass spectrometry on a Reflex III MALDI-TOF (Bruker, Bremen Germany). The peptides were used without further purification.

Enzyme linked immune assay (ELISA).

For serum characterization: ELISA plates (Maxisorb, Millipore) were coated with 5-10 µg/ml total protein diluted in coating buffer (0.1M sodium carbonate pH 9.2). Three dilutions of sera (2,000X, 10,000X, 50,000X) were made in PBS-BSA. For peptide serology: Biotin-labeled peptides were coating on Streptavidin ELISA plates (EXICON) at 10 µg/ml concentration according to the manufacturer's instructions. Sera were tested at two dilutions, 200X and 1,000X.

Highly specific Horse Radish Peroxidase (HRP)-conjugated anti-human IgG or anti-human IgA secondary antibodies (Southern Biotech) were used according to the manufacturers' recommendations (dilution: 1,000x). Antigen-antibody complexes were quantified by measuring the conversion of the substrate (ABTS) to colored product based on OD405nm readings in an automated ELISA reader (TECAN SUNRISE). Following manual coating, peptide plates were processed and analyzed by the Gemini 160 ELISA robot (TECAN) with a built-in reader (GENIOS, TECAN).

Immunoblotting

- 56 -

Total bacterial lysate and culture supernatant samples were prepared from in vitro grown *S. epidermidis* RP62A. 10 to 25µg total protein/lane was separated by SDS-PAGE using the BioRad Mini-Protean 3 Cell electrophoresis system and proteins transferred to nitrocellulose membrane (ECL, Amersham Pharmacia). After overnight blocking in 5% milk, antisera at 2,000x dilution were added, and HRPo labeled anti-mouse IgG was used for detection.

Preparation of bacterial antigen extracts

Total bacterial lysate: Bacteria were lysed by repeated freeze-thaw cycles: incubation on dry ice/ethanol-mixture until frozen (1 min), then thawed at 37°C (5 min): repeated 3 times. This was followed by sonication and collection of supernatant by centrifugation (3,500 rpm, 15 min, 4°C).

Culture supernatant: After removal of bacteria, the supernatant of overnight grown bacterial cultures was precipitated with ice-cold ethanol (100%): 1 part supernatant/3 parts ethanol incubated o/n at -20°C. Precipitates were collected by centrifugation (2,600 g, for 15 min) and dried. Dry pellets were dissolved either in PBS for ELISA, or in urea and SDS-sample buffer for SDS-PAGE and immunoblotting. The protein concentration of samples was determined by Bradford assay.

Purification of antibodies for genomic screening. Five sera from the patient group were selected based on the overall anti-staphylococcal titers for a serum pool used in the screening procedure. Antibodies against *E. coli* proteins were removed by incubating the heat-inactivated sera with whole cell *E. coli* cells (DH5α, transformed with pHI11, grown under the same condition as used for bacterial surface display). Highly enriched preparations of IgGs from the pooled, depleted sera were generated by protein G affinity chromatography, according to the manufacturer's instructions (UltraLink Immobilized Protein G, Pierce). IgA antibodies were purified also by affinity chromatography using biotin-labeled anti-human IgA (Southern Biotech) immobilized on Streptavidin-agarose (GIBCO BRL). The efficiency of depletion and purification was checked by SDS-PAGE, Western blotting, ELISA and protein concentration measurements.

The antibodies produced against *S. epidermidis* by the human immune system and present in human sera are indicative of the in vivo expression of the antigenic proteins and their immunogenicity. These molecules are essential for the identification of individual antigens in the approach as described in the present invention, which is based on the interaction of the specific anti-staphylococcal antibodies and the corresponding *S. epidermidis* peptides or proteins. To gain access to relevant antibody repertoires, human sera were collected from

convalescent patients with *S. epidermidis* infections, namely peritonitis.

The sera were characterized for anti-*S. epidermidis* antibodies by a series of ELISA and immunoblotting assays. Bacterial lysate proteins prepared from *S. epidermidis* RP62A cultured overnight (stationary phase) in BHI (Brain Heart Infusion) growth medium have been used as staphylococcal antigens. Both IgG and IgA antibody levels were determined. Five sera having the highest antibody levels were pooled, and IgG prepared for use in bacterial surface display in order to identify antigenic proteins.

The titers were compared at given dilutions where the response was linear. Sera were ranked based on the reactivity against multiple staphylococcal components, and the highest ones were selected for further analysis by immunoblotting (Figure 1). This extensive antibody characterization approach has led to the unambiguous identification of anti-staphylococcal hyperimmune sera.

Example 2: Generation of highly random, frame-selected, small-fragment, genomic DNA libraries of *Staphylococcus epidermidis*

Experimental procedures

Preparation of staphylococcal genomic DNA. 50 ml BHI medium was inoculated with *S. epidermidis* RP62A bacteria from a frozen stab and grown with aeration and shaking for 18 h at 37°C. The culture was then harvested, centrifuged with 1,600x g for 15 min and the supernatant was removed. Bacterial pellets were washed 3 x with PBS and carefully re-suspended in 0.5 ml of Lysozyme solution (100 mg/ml). 0.1 ml of 10 mg/ml heat treated RNase A and 20 U of RNase T1 were added, mixed carefully and the solution was incubated for 1 h at 37°C. Following the addition of 0.2 ml of 20 % SDS solution and 0.1 ml of Proteinase K (10 mg/ml) the tube was incubated overnight at 55°C. 1/3 volume of saturated NaCl was then added and the solution was incubated for 20 min at 4°C. The extract was pelleted in a microfuge (13,000 rpm) and the supernatant transferred into a new tube. The solution was extracted with PhOH/CHCl₃/IAA (25:24:1) and with CHCl₃/IAA (24:1). DNA was precipitated at room temperature by adding 0.6x volume of Isopropanol, spooled from the solution with a sterile Pasteur pipette and transferred into tubes containing 80% ice-cold ethanol. DNA was recovered by centrifuging the precipitates with 10-12,000x g, then dried on air and dissolved in ddH₂O.

Preparation of small genomic DNA fragments. Genomic DNA fragments were mechanically sheared into fragments ranging in size between 150 and 300 bp using a

cup-horn sonicator (Bandelin Sonoplus UV 2200 sonicator equipped with a BB5 cup horn, 10 sec. pulses at 100 % power output) or into fragments of size between 50 and 70 bp by mild DNase I treatment (Novagen). It was observed that sonication yielded a much tighter fragment size distribution when breaking the DNA into fragments of the 150-300 bp size range. However, despite extensive exposure of the DNA to ultrasonic wave-induced hydromechanical shearing force, subsequent decrease in fragment size could not be efficiently and reproducibly achieved. Therefore, fragments of 50 to 70 bp in size were obtained by mild DNase I treatment using Novagen's shotgun cleavage kit. A 1:20 dilution of DNase I provided with the kit was prepared and the digestion was performed in the presence of MnCl₂ in a 60 µl volume at 20°C for 5 min to ensure double-stranded cleavage by the enzyme. Reactions were stopped with 2 µl of 0.5 M EDTA and the fragmentation efficiency was evaluated on a 2% TAE-agarose gel. This treatment resulted in total fragmentation of genomic DNA into near 50-70 bp fragments. Fragments were then blunt-ended twice using T4 DNA Polymerase in the presence of 100 µM each of dNTPs to ensure efficient flushing of the ends. Fragments were used immediately in ligation reactions or frozen at -20°C for subsequent use.

Description of the vectors. The vector pMAL4.31 was constructed on a pASK-IBA backbone {Skerra, A., 1994} with the beta-lactamase (bla) gene exchanged with the Kanamycin resistance gene. In addition the bla gene was cloned into the multiple cloning site. The sequence encoding mature beta-lactamase is preceded by the leader peptide sequence of ompA to allow efficient secretion across the cytoplasmic membrane. Furthermore a sequence encoding the first 12 amino acids (spacer sequence) of mature beta-lactamase follows the ompA leader peptide sequence to avoid fusion of sequences immediately after the leader peptidase cleavage site, since e.g. clusters of positive charged amino acids in this region would decrease or abolish translocation across the cytoplasmic membrane {Kajava, A. et al., 2000}. A SmaI restriction site serves for library insertion. An upstream FseI site and a downstream NotI site, which were used for recovery of the selected fragment, flank the SmaI site. The three restriction sites are inserted after the sequence encoding the 12 amino acid spacer sequence in such a way that the bla gene is transcribed in the -1 reading frame resulting in a stop codon 15 bp after the NotI site. A +1 bp insertion restores the bla ORF so that beta-lactamase protein is produced with a consequent gain of Ampicillin resistance.

The vector pMAL9.1 was constructed by cloning the lamB gene into the multiple cloning site of pEH1 {Hashemzadeh-Bonehi, L. et al., 1998}. Subsequently, a se-

quence was inserted in lamB after amino acid 154, containing the restriction sites FseI, SmaI and NotI. The reading frame for this insertion was constructed in such a way that transfer of frame-selected DNA fragments excised by digestion with FseI and NotI from plasmid pMAL4.31 yields a continuous reading frame of lamB and the respective insert.

The vector pHIE11 was constructed by cloning the fhuA gene into the multiple cloning site of pEH1. Thereafter, a sequence was inserted in fhuA after amino acid 405, containing the restriction site FseI, XbaI and NotI. The reading frame for this insertion was chosen in a way that transfer of frame-selected DNA fragments excised by digestion with FseI and NotI from plasmid pMAL4.31 yields a continuous reading frame of fhuA and the respective insert.

Cloning and evaluation of the library for frame selection. Genomic *S. epidermidis* DNA fragments were ligated into the SmaI site of the vector pMAL4.31. Recombinant DNA was electroporated into DH10B electrocompetent *E. coli* cells (GIBCO BRL) and transformants plated on LB-agar supplemented with Kanamycin (50 µg/ml) and Ampicillin (50 µg/ml). Plates were incubated over night at 37°C and colonies collected for large scale DNA extraction. A representative plate was stored and saved for collecting colonies for colony PCR analysis and large-scale sequencing. A simple colony PCR assay was used to initially determine the rough fragment size distribution as well as insertion efficiency. From sequencing data the precise fragment size was evaluated, junction intactness at the insertion site as well as the frame selection accuracy (3n+1 rule).

Cloning and evaluation of the library for bacterial surface display. Genomic DNA fragments were excised from the pMAL4.31 vector, containing the *S. epidermidis* library with the restriction enzymes FseI and NotI. The entire population of fragments was then transferred into plasmids pMAL9.1 (LamB) or pHIE11 (FhuA), which have been digested with FseI and NotI. Using these two restriction enzymes, which recognise an 8 bp GC rich sequence, the reading frame that was selected in the pMAL4.31 vector is maintained in each of the platform vectors. The plasmid library was then transformed into *E. coli* DH5alpha cells by electroporation. Cells were plated onto large LB-agar plates supplemented with 50 µg/ml Kanamycin and grown over night at 37°C at a density yielding clearly visible single colonies. Cells were then scraped off the surface of these plates, washed with fresh LB medium and stored in aliquots for library screening at -80°C.

Results

Libraries for frame selection. Two libraries (LSE-70 and LSE-150) were generated in the pMAL4.31 vector with sizes of approximately 70, 150 and 300 bp, respectively. For each library, ligation and subsequent transformation of approximately 1 µg of pMAL4.31 plasmid DNA and 50 ng of fragmented genomic *S. epidermidis* DNA yielded 4×10^5 to 2×10^6 clones after frame selection. To assess the randomness of the libraries, approximately 600 randomly chosen clones of LSE-70 were sequenced. The bioinformatic analysis showed that of these clones only very few were present more than once. Furthermore, it was shown that 90% of the clones fell in the size range between 16 and 61 bp with an average size of 34 bp (Figure 2). Almost all sequences followed the 3n+1 rule, showing that all clones were properly frame selected.

Bacterial surface display libraries. The display of peptides on the surface of *E. coli* required the transfer of the inserts from the LSE libraries from the frame selection vector pMAL4.31 to the display plasmids pMAL9.1 (LamB) or pHIE11 (FhuA). Genomic DNA fragments were excised by FseI and NotI restriction and ligation of 5ng inserts with 0.1µg plasmid DNA and subsequent transformation into DH5alpha cells resulted in $2-5 \times 10^6$ clones. The clones were scraped off the LB plates and frozen without further amplification.

Example 3: Identification of highly immunogenic peptide sequences from *S. epidermidis* using bacterial surface displayed genomic libraries and human serum

Experimental procedures

MACS screening. Approximately 2.5×10^8 cells from a given library were grown in 5 ml LB-medium supplemented with 50 µg/ml Kanamycin for 2 h at 37°C. Expression was induced by the addition of 1 mM IPTG for 30 min. Cells were washed twice with fresh LB medium and approximately 2×10^7 cells re-suspended in 100 µl LB medium and transferred to an Eppendorf tube.

10 µg of biotinylated, human IgGs purified from serum was added to the cells and the suspension incubated over night at 4°C with gentle shaking. 900 µl of LB medium was added, the suspension mixed and subsequently centrifuged for 10 min at 6,000 rpm at 4°C (For IgA screens, 10 µg of purified IgAs were used and these captured with biotinylated anti-human-IgG secondary antibodies). Cells were washed once with 1 ml LB and then re-suspended in 100 µl LB medium. 10 µl of MACS microbeads coupled to streptavidin (Miltenyi Biotech, Germany) were ad-

- 61 -

ded and the incubation continued for 20 min at 4°C. Thereafter 900 µl of LB medium was added and the MACS microbead cell suspension was loaded onto the equilibrated MS column (Miltenyi Biotech, Germany) which was fixed to the magnet. (The MS columns were equilibrated by washing once with 1 ml 70% EtOH and twice with 2 ml LB medium.)

The column was then washed three times with 3 ml LB medium. After removal of the magnet, cells were eluted by washing with 2 ml LB medium. After washing the column with 3 ml LB medium, the 2 ml eluate was loaded a second time on the same column and the washing and elution process repeated. The loading, washing and elution process was performed a third time, resulting in a final eluate of 2 ml.

A second round of screening was performed as follows. The cells from the final eluate were collected by centrifugation and re-suspended in 1 ml LB medium supplemented with 50 µg/ml Kanamycin. The culture was incubated at 37°C for 90 min and then induced with 1 mM IPTG for 30 min. Cells were subsequently collected, washed once with 1 ml LB medium and suspended in 10 µl LB medium. Since the volume was reduced, 10 µg of human, biotinylated IgGs was added and the suspension incubated over night at 4°C with gentle shaking. All further steps were exactly the same as in the first selection round. Cells selected after two rounds of selection were plated onto LB-agar plates supplemented with 50 µg/ml Kanamycin and grown over night at 37°C.

Evaluation of selected clones by sequencing and Western blot analysis. Selected clones were grown over night at 37°C in 3 ml LB medium supplemented with 50 µg/ml Kanamycin to prepare plasmid DNA using standard procedures. Sequencing was performed at MWG (Germany).

For Western blot analysis approximately 10 to 20 µg of total cellular protein was separated by 10% SDS-PAGE and blotted onto HybondC membrane (Amersham Pharmacia Biotech, England). The LamB or FhuA fusion proteins were detected using human serum as the primary antibody at a dilution of approximately 1:5,000 and anti-human IgG or IgA antibodies coupled to HRP at a dilution of 1:5,000 as secondary antibodies. Detection was performed using the ECL detection kit (Amersham Pharmacia Biotech, England). Alternatively, rabbit anti FhuA or mouse anti LamB antibodies were used as primary antibodies in combination with the respective secondary antibodies coupled to HRP for the detection of the fusion proteins.

Results

Screening of bacterial surface display libraries by magnetic activated cell sorting (MACS) using biotinylated Igs. The libraries LSE-70 in pMAL9.1 and LSE-150 in pHIE11 were screened with a pool of biotinylated, human IgG from patient sera (see Example 1: Preparation of antibodies from human serum). In addition, a *S. aureus* library (LSA-300 in pHIE11) was also screened with the same serum pool, P15-IgG. The selection procedure was performed as described under Experimental procedures. Figure 3A shows a representative example of a screen with the LSE-70 library and P15-IgGs. As can be seen from the colony count after the first selection cycle from MACS screening, the total number of cells recovered at the end is drastically reduced from approximately 3×10^7 cells to app. 2×10^4 cells, whereas the selection without antibodies added showed a reduction to about 1×10^4 cells (Figure 3A). After the second round, a similar number of cells was recovered with P15-IgG, while app. 8-fold fewer cells were recovered when no IgGs from human serum were added, clearly showing that selection was dependent on *S. epidermidis* specific antibodies. To evaluate the performance of the screen, 26 selected clones were picked randomly and subjected to Western blot analysis with the same, pooled serum (Figure 3B). This analysis revealed that 70% of the selected clones showed reactivity with antibodies present in the relevant serum whereas the control strain expressing LamB without a *S. epidermidis* specific insert did not react with the same serum. In general, the rate of reactivity was observed to lie within the range of 35 to 75%. Colony PCR analysis showed that all selected clones contained an insert in the expected size range.

Subsequent sequencing of a larger number of randomly picked clones (600 to 1000 per screen) led to the identification of the gene and the corresponding peptide or protein sequence that was specifically recognized by the human serum used for screening. The frequency with which a specific clone is selected reflects at least in part the abundance and/or affinity of the specific antibodies in the serum used for selection and recognizing the epitope presented by this clone. Table 1 summarizes the data obtained for the three performed screens, but lists only those genes, which have not been identified by previous screens. All clones that are presented in Table 1 have been verified by Western blot analysis using whole cellular extracts from single clones to show the indicated reactivity with the pool of human serum used in the respective screen. As can be seen from Table 1, distinct regions of the identified ORF are identified as immunogenic, since variably sized fragments of the proteins are displayed on the surface by the platform proteins. The screen with the *S. aureus* library revealed one novel antigen, which had not been identified in previous screens.

It is further worth noticing that most of the genes identified by the bacterial surface display screen encode proteins that are either attached to the surface of *S. epidermidis* and/or are secreted. This is in accordance with the expected role of surface attached or secreted proteins in virulence of *S. epidermidis*.

Example 4: Gene distribution studies with highly immunogenic proteins identified from *S. epidermidis*.

Gene distribution of staphylococcal antigens by PCR. An ideal vaccine antigen would be an antigen that is present in all, or the vast majority of strains of the target organism to which the vaccine is directed. In order to establish whether the genes encoding the identified *Staphylococcus epidermidis* antigens occur ubiquitously in *S. epidermidis* and coagulase negative *Staphylococcus* strains, PCR was performed on a series of independent *S. epidermidis* and coagulase negative *Staphylococcus* isolates with primers specific for the gene of interest. Oligonucleotide sequences as primers were designed for all identified ORFs yielding products of approximately 1,000 bp, if possible covering all identified immunogenic epitopes. Genomic DNA of all *Staphylococcus* strains was prepared as described under Example 2. PCR was performed in a reaction volume of 25 µl using Taq polymerase (1U), 200 nM dNTPs, 10 pMol of each oligonucleotide and the kit according to the manufacturers instructions (Invitrogen, The Netherlands). As standard, 30 cycles (1x: 5min. 95°C, 30x: 30sec. 95°C, 30sec. 56°C, 30sec. 72°C, 1x 4min. 72°C) were performed, unless conditions had to be adapted for individual primer pairs.

Results

Exemplarily, a number of genes encoding immunogenic proteins were tested by PCR for their presence in 42 different coagulase negative *Staphylococcus* (CNS) or *S. epidermidis* strains. Figure 4 shows the PCR reaction for ORF1163 with all indicated 42 strains. It was expected that not all of the CNS strains represent *S. epidermidis* isolates. Therefore it was not surprising that 6 of the 31 CNS strains were negative for all genes analysed. Some of the eight selected genes encoding identified antigens and analysed by PCR, were present in many strains tested (e.g. ORF0026, ORF0217 and ORF1163), rendering them as good candidates for further development. A few genes were present in only a smaller number of the tested 42 strains (e.g. ORF0742 and ORF2700). This result may indicate the absence of the gene in the analysed isolates, or it could be due to a variation in the sequence used for the oligonucleotide for the PCR analysis. Interestingly, none of the eight analysed genes showed any variation in size. Sequen-

- 64 -

cing of the generated PCR fragment from one strain and subsequent comparison to the RP62A strain confirmed the amplification of the correct DNA fragment. Importantly, the identified antigens, which are well conserved in all strains in sequence and size constitute novel vaccine candidates to prevent infections by *S. epidermidis*. As can be seen in Table 1, 20 of the listed 30 *S. epidermidis* antigens have a homolog in *S. aureus* COL with at least 50% sequence identity at the amino acid level, 4 have homologs with an identity below 50% and 6 antigens do not possess a homologous sequence in *S. aureus* COL. This indicates that several of the antigens have also the potential to show cross-protection with other Staphylococcal strains such as *S. aureus*.

References

- Altschul, S., et al. (1990). *Journal of Molecular Biology* 215: 403-10.
- Bennett, D., et al. (1995). *J Mol Recognit* 8: 52-8.
- Clackson, T., et al. (1991). *Nature* 352: 624-8.
- Crossley, K.B. and Archer G.L., eds (1997). *The Staphylococci in Human Disease*. Churchill Livingstone Ing.
- Devereux, J., et al. (1984). *Nucleic acids research* 12: 387-95.
- Doherty, E., et al. (2001). *Annu Rev Biophys Biomol Struct* 30: 457-475.
- Eisenbraun, M., et al. (1993). *DNA Cell Biol* 12: 791-7.
- Etz, H., et al. (2001). *J Bacteriol* 183: 6924-35.
- Ganz, T. (1999). *Science* 286: 420-421.
- Georgiou, G. (1997). *Nature Biotechnology* 15: 29-34.
- Hashemzadeh-Bonehi, L., et al. (1998). *Mol Microbiol* 30: 676-678.
- Heinje, von G (1987) e.g. *Sequence Analysis in Molecular Biology*, Academic Press
- Hemmer, B., et al. (1999). *Nat Med* 5: 1375-82.
- Johanson, K., et al. (1995). *J Biol Chem* 270: 9459-71.
- Jones, P., et al. (1986). *Nature* 321: 522-5.
- Kajava, A., et al. (2000). *J Bacteriol* 182: 2163-9.
- Kohler, G., et al. (1975). *Nature* 256: 495-7.
- Kolaskar, A., et al. (1990). *FEBS Lett* 276: 172-4.
- Lewin, A., et al. (2001). *Trends Mol Med* 7: 221-8.
- Marks, J., et al. (1992). *Biotechnology (N Y)* 10: 779-83.
- McCafferty, J., et al. (1990). *Nature* 348: 552-4.
- Okano, H., et al. (1991). *J Neurochem* 56: 560-7.
- Oligodeoxynucleotides as antisense Inhibitors of Gene Expression; CRC Press, Boca Ration, FL (1988) for a description o these molecules
- Rammensee, H., et al. (1999). *Immunogenetics* 50: 213-9.
- Rosenshine, I., et al. (1992). *Infect Immun* 60: 2211-7.
- Seeger, C., et al. (1984). *Proc Natl Acad Sci U S A* 81: 5849-52.
- Shinefield, H., et al. (2002). *N Engl J Med* 346: 491-6.
- Skerra, A. (1994). *Gene* 151: 131-5.
- Tang, D., et al. (1992). *Nature* 356: 152-4.
- Tempest, P., et al. (1991). *Biotechnology (N Y)* 9: 266-71.
- Tourdot, S., et al. (2000). *Eur J Immunol* 30: 3411-21.
- Wiley, J., et al. (1987) *Current Protocols in Molecular Biology*

Table 1: Immunogenic proteins identified by bacterial surface display.

<i>S. epidermidis</i> or <i>aureus</i> anti- genic protein	Putative function (by homology)	predicted immunogenic aa*	No. of se- lected clones per ORF and screen	Location of identified im- munogenic region (aa)	Homo- logy with <i>S.</i> <i>aureus</i>	Gene distribu- tion [†]	Seq. ID (DNA, Prot.)
ORF00026	LPXTG-motif cell wall anchor domain protein	6-28, 54-59, 135-147, 193-205, 274-279, 284-291, 298-308, 342-347, 360-366, 380-386, 408-425, 437-446, 457-464, 467-477, 504-510, 517-530, 535-543, 547-553, 562-569, 573-579, 592-600, 602-613, 626-631, 638-668	A:5	396-449	32% SA2668	26/36	1, 32
ORF00027	autolysin, putative	5-24, 101-108, 111-117, 128-142, 170- 184, 205-211, 252-267, 308-316, 329- 337, 345-353, 360-371, 375-389, 393- 399, 413-419, 429-439, 446-456, 471- 485, 495-507, 541-556, 582-588, 592- 602, 607-617, 622-628, 630-640	A:3	8-21	53% SA2666	n.d.	2, 33
ORF00217	toxin resistance protein, putative	10-20, 23-33, 40-45, 59-65, 72-107, 113- 119, 127-136, 151-161	A:2	33-59	66% SA2541	29/36	3, 34
ORF00259	helicase-related protein	4-16, 28-34, 39-61, 66-79, 100-113, 120- 127, 130-137, 142-148, 150-157, 192- 201, 203-210, 228-239, 245-250, 256- 266, 268-278, 288-294, 312-322, 336- 344, 346-358, 388-396, 399-413, 425- 430, 445-461, 464-470, 476-482, 486- 492, 503-511, 520-527, 531-541, 551- 558, 566-572, 609-625, 635-642, 650- 656, 683-689, 691-705, 734-741, 750- 767, 782-789, 802-808, 812-818, 837- 844, 878-885, 907-917, 930-936	A:2	913-933	65% SA2499	n.d.	4, 35
ORF00545	tagatose 1,6-diphosphate aldolase (lacD)	5-12, 20-27, 46-78, 85-92, 104-112, 121- 132, 150-167, 179-185, 200-213, 221- 227, 240-264, 271-279, 282-290, 311- 317	A:10	177-206	90% SA2183	n.d.	5, 36
ORF00646	UDP-N-acetylglucosa- mine 2-epimerase	18-24, 31-40, 45-51, 89-97, 100-123, 127-132, 139-153, 164-170, 184-194, 200-205, 215-238, 244-255, 257-270, 272-280, 289-302, 312-318, 338-348, 356-367	A:3	132-152	72% SA2103 62% SA0151	n.d.	6, 37
ORF00742	M23/M37 peptidase do- main protein protein	7-16, 39-45, 73-83, 90-98, 118-124, 130- 136, 194-204, 269-280, 320-327, 373- 381, 389-397, 403-408, 424-430, 436- 441, 463-476, 487-499, 507-514, 527- 534, 540-550, 571-577, 593-599, 620- 629, 641-647, 650-664, 697-703, 708- 717, 729-742, 773-790, 794-805, 821- 828, 830-837, 839-851, 858-908, 910- 917, 938-947, 965-980, 1025-1033, 1050- 1056, 1073-1081, 1084-1098, 1106-1120, 1132-1140, 1164-1170, 1185-1194, 1201- 1208, 1215-1224, 1226-1234, 1267-1279, 1325-1331, 1356-1364, 1394-1411, 1426-1439, 1445-1461, 1498-1504, 1556- 1561, 1564-1573, 1613-1639, 1648-1655, 1694-1714, 1748-1755, 1778-1785, 1808- 1813, 1821-1827, 1829-1837, 1846- 1852, 1859-1865, 1874-1883, 1895-1900, 1908-1913, 1931-1937, 1964-1981, 1995-2005, 2020-2033, 2040-2047, 2103- 2109, 2118-2127, 2138-2144, 2166-2175, 2180-2187, 2220-2225, 2237-2242, 2247-2253, 2273-2281, 2286-2306, 2314-2320, 2323-2345, 2350-2355, 2371-2384, 2415-2424, 2426-2431, 2452-2472, 2584-2589, 2610-2621, 2638-2655, 2664-2670, 2681-2690, 2692-2714, 2724-2730	A:14, B:7	687-730	18% SA0379	5/36	7, 38
ORF00788	conserved hypothetical protein	10-40, 53-59, 79-85, 98-104, 117-122, 130-136, 144-158, 169-175, 180-185, 203-223, 232-237, 243-254, 295-301	B:1	254-292	none	4/36	8, 39

<i>S. epidermidis</i> or <i>aureus</i> anti- genic protein	Putative function (by homology)	predicted immunogenic aa*	No. of se- lected clones per ORF and screen	Location of identified im- munogenic region (aa)	Homo- logy with <i>S.</i> <i>aureus</i>	Gene distribu- tion†	Seq. ID (DNA, Prot.)
ORF00891 (42% OR- F01770)	cell division protein FtsK (ftsK)	28-50, 67-85, 93-115, 120-134, 144-179, 240-249, 328-340, 354-360, 368-400, 402-417, 419-427, 429-445, 447-455, 463-468, 472-480, 485-500, 502-510, 512-534, 537-546, 553-558, 582-594, 619-637, 645-654, 690-709, 735-745, 749-756, 786-792	B:5	275-316; 378- 401	69% SA1295 42% SA1791	n.d.	9, 40
ORF00894	metalloprotease, in- sulinase family, putative	5-16, 21-30, 33-40, 52-74, 101-108, 116- 122, 164-182, 185-219, 256-261, 273- 279, 285-291, 297-304, 312-328, 331- 338, 355-362, 364-371, 373-401, 411- 423	A:1	191-208	76% SA1298	n.d.	10, 41
ORF00988	membrane-bound pro- tein LytR	34-55, 67-74, 85-93, 105-115, 138-152, 161-171, 182-189, 197-205, 213-219, 232-239, 241-248, 250-263, 272-277, 288-299	A:1	216-231	74% SA1398	n.d.	11, 42
ORF01054 (31% OR- F00724)	ABC transporter, ATP- binding protein	21-27, 32-37, 43-51, 67-74, 82-92, 94- 100, 106-112, 140-149, 153-159, 164- 182, 193-215, 222-227, 260-267, 308- 322, 330-340, 378-387, 396-403, 417- 432, 435-441, 448-465, 476-482, 488- 498, 500-510	B:4	214-280	75% SA0779 28% SA2036	n.d.	12, 43
ORF01163 (38% OR- F02440)	lipoprotein YaeC, puta- tive	4-21, 29-52, 80-87, 104-123, 126-133, 141-157, 182-189, 194-202, 214-220, 227-235, 242-252	A:3, B:8	33-108	79% SA0884 35% SA0506	31/36	13, 44
ORF01182	UDP-sugar hydrolase, putative	12-18, 20-27, 29-59, 64-72, 84-90, 96- 103, 109-121, 125-155, 164-177, 179- 186, 188-201, 216-227, 235-253, 259- 274, 276-294, 296-310, 322-339, 341- 348, 369-379, 398-403, 409-421	A:3	76-96	71% SA0926	n.d.	14, 45
ORF01515	hypothetical protein	4-15, 24-41, 71-80, 104-111, 113-119, 123-130, 139-149, 168-178, 187-200	A:17	4-45	none	5/36	15, 46
ORF01596	conserved hypothetical protein	13-19, 32-37, 44-56	A:3	1-14	60% SA1972	n.d.	16, 47

<i>S. epidermidis</i> or <i>aureus</i> anti- genic protein	Putative function (by homology)	predicted immunogenic aa*	No. of se- lected clones per ORF and screen	Location of identified im- munogenic region (aa)	Homo- logy with <i>S.</i> <i>aureus</i>	Gene distribu- tion [†]	Seq. ID (DNA, Prot.)
ORF01755	Mrp protein	6-11, 16-35, 75-81, 95-100, 126-139, 206-214, 225-233, 241-259, 268-276, 319-325, 339-360, 371-401, 435-441, 452-459, 462-472, 491-503, 505-516, 549-556, 567-580, 590-595, 612-622, 624-630, 642-648, 656-662, 687-693, 698-704, 706-712, 736-750, 768-777, 784-789, 812-818, 847-858, 894-900, 922-931, 938-949, 967-984, 986-992, 1027-1032, 1041-1054, 1082-1088, 1091-1097, 1119-1124, 1234-1240, 1250-1258, 1274-1289, 1299-1305, 1392-1398, 1400-1405, 1429-1442, 1460-1474, 1505-1514, 1531-1537, 1540-1552, 1558-1571, 1582-1587, 1616-1623, 1659-1666, 1671-1677, 1680-1686, 1698-1704, 1706-1712, 1768-1774, 1783-1797, 1814-1819, 1849-1855, 1870-1876, 1890-1897, 1947-1953, 1972-1980, 1999-2013, 2044-2051, 2068-2084, 2093-2099, 2122-2131, 2142-2147, 2156-2163, 2170-2179, 2214-2220, 2235-2245, 2271-2281, 2287-2293, 2308-2317, 2352-2362, 2373-2378, 2387-2407, 2442-2448, 2458-2474, 2507-2516, 2531-2537, 2540-2551, 2555-2561, 2586-2599, 2617-2627, 2644-2649, 2661-2675, 2685-2692, 2695-2707, 2733-2739, 2741-2747, 2774-2783, 2788-2795, 2860-2870, 2891-2903, 2938-2947, 2973-2980, 2993-2999, 3004-3030, 3046-3059, 3066-3077, 3082-3088, 3120-3132, 3144-3149, 3153-3169, 3200-3212, 3232-3256, 3276-3290, 3308-3322, 3330-3338, 3353-3360, 3363-3371, 3390-3408, 3431-3447, 3454-3484, 3503-3515, 3524-3541, 3543-3550, 3560-3567, 3586-3599, 3616-3621, 3642-3647, 3663-3679	A:2, B:8	213-276; 579-621; 1516-1559	31% SA1806 28% SA2150	n.d.	17, 48
ORF02009 (32% OR- F01373 & OR- F01042)	2-oxo acid dehydroge- nase, E2 component, li- poamide	19-41, 43-49, 55-62, 67-74, 114-121, 130-140, 188-197, 208-217, 226-232, 265-287, 292-299, 301-319, 372-394, 400-410, 421-427	B:4	12-56	64% SA1560 32% SA1104 31% SA1448	n.d.	18, 49
ORF02025 (35% OR- F00861)	integrase/recombinase XerD (xerD)	6-12, 44-51, 53-60, 67-88, 91-100, 104-123, 137-142, 148-158, 161-168, 175-201, 204-210, 222-231, 239-253, 258-264, 272-282	B:3	60-138	85% SA1540 35% SA1269	n.d.	19, 50
ORF02209 (37% OR- F01212)	NADH dehydrogenase, putative	4-63, 69-104, 110-121, 124-131, 134-152, 161-187, 204-221, 223-237, 239-296, 298-310, 331-365, 380-405, 423-451, 470-552, 554-562, 574-581, 592-649, 651-658, 661-671, 673-707, 713-734, 741-748, 758-765, 773-790	A:2	509-528	66% SA0679 38% SA0955	n.d.	20, 51
ORF02289	fibrinogen-binding protein SdrG	89-94, 102-115, 123-129, 181-188, 200-206, 211-235, 239-249, 267-281, 295-310, 316-321, 331-341, 344-359, 365-386, 409-422, 443-453, 495-506, 514-521, 539-547, 553-560, 563-570, 586-596, 621-626, 633-638, 651-657, 666-683, 697-705, 731-739, 761-768, 865-883	B:2	213-265	41% SA0610 32% SA0608 30% SA0609	n.d.	21, 52
ORF02329	glutamyl-tRNA syn- thetase (gltX)	5-20, 24-34, 37-43, 92-102, 134-139, 156-162, 184-191, 193-205, 207-213, 225-231, 241-247, 259-267, 269-286, 337-350, 365-372, 378-386, 399-413, 415-421, 447-457, 467-481	A:7	145-183	82% SA0574	n.d.	22, 53
ORF02393	dimethyladenosine transferase (ksgA)	12-19, 29-41, 43-57, 80-98, 106-141, 143-156, 172-183, 185-210, 214-220, 226-234, 278-287	A:3, B:2	237-287	85% SA0536	n.d.	23, 54

<i>S. epidermidis</i> or <i>aureus</i> anti- genic protein	Putative function (by homology)	predicted immunogenic aa*	No. of se- lected clones per ORF and screen	Location of identified im- munogenic region (aa)	Homo- logy with <i>S.</i> <i>aureus</i>	Gene distribu- tion [†]	Seq. ID (DNA, Prot.)
ORF02412 (100% ORF02349 & ORF01658 & ORF00589 & ORF00701	conserved hypothetical protein	5-12, 32-48, 50-72, 75-81, 88-94	A:1, B:1	16-40	none	n.d.	24, 55
ORF02680 (74% OR- F02594)	Metallo-beta-lactamase superfamily domain pro- tein	4-21, 29-42, 48-62, 65-80, 95-101, 103- 118, 122-130, 134-140, 143-152, 155- 165, 182-192, 198-208, 232-247, 260- 268, 318-348, 364-369, 380-391, 403- 411, 413-424	A:22	208-230	98% SA0046 73% SA0064	20/36	25, 56
ORF02700	hypothetical protein (li- poprotein)	4-18, 65-75, 82-92, 123-140, 144-159, 166-172, 188-194	A:1	174-195	none	2/36	26, 57
ORF02825 (83% ORF00132, 67% ORF02706, 51% ORF00369)	malate:quinone oxidore- ductase	7-20, 58-71, 94-101, 110-119, 199-209, 231-242, 247-254, 267-277, 282-290, 297-306, 313-319, 333-342, 344-369, 390-402, 414-431, 436-448, 462-471	B:2	310-350	83% SA2623 49% SA2362	n.d.	27, 58
ORF02853	hypothetical protein	4-25, 37-44, 53-59, 72-78, 86-99, 119- 128, 197-203, 209-218, 220-226, 233- 244, 246-254, 264-271, 277-289, 407- 430, 437-445, 464-472, 482-488, 503-509	A:1	308-331	61% SA0129	n.d.	28, 59
CRF0299	Hypothetical protein	4-12, 14-43, 52-58	A:3, B:4	43-58	none	n.d.	29, 60
CRF1769	Hypothetical protein	4-14, 21-29, 35-49	A:6	38-50	none	n.d.	30, 61
SA1169	fibrinogen-binding pro- tein precursor-related protein	4-19, 31-37, 58-72, 94-108	C:2	1-72	none	n.d.	31, 62

Claims:

1. An isolated nucleic acid molecule encoding a hyperimmune serum reactive antigen or a fragment thereof comprising a nucleic acid sequence which is selected from the group consisting of:
 - a) a nucleic acid molecule having at least 70% sequence identity to a nucleic acid molecule selected from Seq ID No 1, 4, 6-9, 11-13, 15, 17, 19, 21, 25-26, 28-31,
 - b) a nucleic acid molecule which is complementary to the nucleic acid molecule of a),
 - c) a nucleic acid molecule comprising at least 15 sequential bases of the nucleic acid molecule of a) or b)
 - d) a nucleic acid molecule which anneals under stringent hybridisation conditions to the nucleic acid molecule of a), b), or c)
 - e) a nucleic acid molecule which, but for the degeneracy of the genetic code, would hybridise to the nucleic acid molecule defined in a), b), c) or d).
2. The isolated nucleic acid molecule according to claim 1, wherein the sequence identity is at least 80%, preferably at least 95%, especially 100%.
3. An isolated nucleic acid molecule encoding a hyperimmune serum reactive antigen or a fragment thereof comprising a nucleic acid sequence selected from the group consisting of
 - a) a nucleic acid molecule having at least 96% sequence identity to a nucleic acid molecule selected from Seq ID No 2-3, 5, 10, 14, 16, 18, 22-24, 27.
 - b) a nucleic acid molecule which is complementary to the nucleic acid molecule of a),
 - c) a nucleic acid molecule comprising at least 15 sequential bases of the nucleic acid molecule of a) or b)
 - d) a nucleic acid molecule which anneals under stringent hybridisation conditions to the nucleic acid molecule of a), b) or c),
 - e) a nucleic acid molecule which, but for the degeneracy of the genetic code, would hybridise to the nucleic acid defined in a), b), c) or d).
4. An isolated nucleic acid molecule comprising a nucleic acid sequence selected from the group consisting of
 - a) a nucleic acid molecule selected from Seq ID No 20,
 - b) a nucleic acid molecule which is complementary to the nucleic acid of a),
 - c) a nucleic acid molecule which, but for the degeneracy of the genetic code, would hybridise to the nucleic acid defined in a), b), c) or d).

5. The nucleic acid molecule according to any one of the claims 1, 2, 3 or 4, wherein the nucleic acid is DNA.
6. The nucleic acid molecule according to any one of the claims 1, 2, 3, 4, or 5 wherein the nucleic acid is RNA.
7. An isolated nucleic acid molecule according to any one of claims 1 to 5, wherein the nucleic acid molecule is isolated from a genomic DNA, especially from a *S. epidermidis* genomic DNA.
8. A vector comprising a nucleic acid molecule according to any one of claims 1 to 7.
9. A vector according to claim 8, wherein the vector is adapted for recombinant expression of the hyperimmune serum reactive antigens or fragment thereof encoded by the nucleic acid molecule according to any one of claims 1 to 7.
10. A host cell comprising the vector according to claim 8 or 9.
11. A hyperimmune serum-reactive antigen comprising an amino acid sequence being encoded by a nucleic acid molecule according to any one of the claims 1, 2, 5, 6 or 7 and fragments thereof, wherein the amino acid sequence is selected from the group consisting of Seq ID No 32, 35, 37-40, 42-44, 46, 48, 50, 52, 56-57, 59-62.
12. A hyperimmune serum-reactive antigen comprising an amino acid sequence being encoded by a nucleic acid molecule according to any one of the claims 3, 5, 6, or 7 and fragments thereof, wherein the amino acid sequence is selected from the group consisting of Seq ID No 33-34, 36, 41, 45, 47, 49, 53-55, 58.
13. A hyperimmune serum-reactive antigen comprising an amino acid sequence being encoded by a nucleic acid molecule according to any one of the claims 4, 5, 6, or 7 and fragments thereof, wherein the amino acid sequence is selected from the group consisting of Seq ID No 51.
14. Fragments of hyperimmune serum-reactive antigens selected from the group consisting of peptides comprising amino acid sequences of column "predicted immunogenic aa" and "location of identified immunogenic region" of Table 2; the

serum reactive epitopes of Table 2, especially peptides comprising amino acids 6-28, 54-59, 135-147, 193-205, 274-279, 284-291, 298-308, 342-347, 360-366, 380-386, 408-425, 437-446, 457-464, 467-477, 504-510, 517-530, 535-543, 547-553, 562-569, 573-579, 592-600, 602-613, 626-631, 638-668 and 396-449 of Seq ID No 32; 5-24, 101-108, 111-117, 128-142, 170-184, 205-211, 252-267, 308-316, 329-337, 345-353, 360-371, 375-389, 393-399, 413-419, 429-439, 446-456, 471-485, 495-507, 541-556, 582-588, 592-602, 607-617, 622-628, 630-640 and 8-21 of Seq ID No 33; 10-20, 23-33, 40-45, 59-65, 72-107, 113-119, 127-136, 151-161 and 33-59 of Seq ID No 34; 4-16, 28-34, 39-61, 66-79, 100-113, 120-127, 130-137, 142-148, 150-157, 192-201, 203-210, 228-239, 245-250, 256-266, 268-278, 288-294, 312-322, 336-344, 346-358, 388-396, 399-413, 425-430, 445-461, 464-470, 476-482, 486-492, 503-511, 520-527, 531-541, 551-558, 566-572, 609-625, 635-642, 650-656, 683-689, 691-705, 734-741, 750-767, 782-789, 802-808, 812-818, 837-844, 878-885, 907-917, 930-936 and 913-933 of Seq ID No 35; 5-12, 20-27, 46-78, 85-92, 104-112, 121-132, 150-167, 179-185, 200-213, 221-227, 240-264, 271-279, 282-290, 311-317 and 177-206 of Seq ID No 36; 18-24, 31-40, 45-51, 89-97, 100-123, 127-132, 139-153, 164-170, 184-194, 200-205, 215-238, 244-255, 257-270, 272-280, 289-302, 312-318, 338-348, 356-367 and 132-152 of Seq ID No 37; 7-16, 39-45, 73-83, 90-98, 118-124, 130-136, 194-204, 269-280, 320-327, 373-381, 389-397, 403-408, 424-430, 436-441, 463-476, 487-499, 507-514, 527-534, 540-550, 571-577, 593-599, 620-629, 641-647, 650-664, 697-703, 708-717, 729-742, 773-790, 794-805, 821-828, 830-837, 839-851, 858-908, 910-917, 938-947, 965-980, 1025-1033, 1050-1056, 1073-1081, 1084-1098, 1106-1120, 1132-1140, 1164-1170, 1185-1194, 1201-1208, 1215-1224, 1226-1234, 1267-1279, 1325-1331, 1356-1364, 1394-1411, 1426-1439, 1445-1461, 1498-1504, 1556-1561, 1564-1573, 1613-1639, 1648-1655, 1694-1714, 1748-1755, 1778-1785, 1808-1813, 1821-1827, 1829-1837, 1846-1852, 1859-1865, 1874-1883, 1895-1900, 1908-1913, 1931-1937, 1964-1981, 1995-2005, 2020-2033, 2040-2047, 2103-2109, 2118-2127, 2138-2144, 2166-2175, 2180-2187, 2220-2225, 2237-2242, 2247-2253, 2273-2281, 2286-2306, 2314-2320, 2323-2345, 2350-2355, 2371-2384, 2415-2424, 2426-2431, 2452-2472, 2584-2589, 2610-2621, 2638-2655, 2664-2670, 2681-2690, 2692-2714, 2724-2730 and 687-730 of Seq ID No 38; 10-40, 53-59, 79-85, 98-104, 117-122, 130-136, 144-158, 169-175, 180-185, 203-223, 232-237, 243-254, 295-301 and 254-292 of Seq ID No 39; 28-50, 67-85, 93-115, 120-134, 144-179, 240-249, 328-340, 354-360, 368-400, 402-417, 419-427, 429-445, 447-455, 463-468, 472-480, 485-500, 502-510, 512-534, 537-546, 553-558, 582-594, 619-637, 645-654, 690-709, 735-745, 749-756, 786-792, 275-316 and 378-401 of Seq ID No 40; 5-16, 21-30, 33-40, 52-74, 101-108, 116-122, 164-182, 185-219, 256-261, 273-279, 285-291, 297-304, 312-328, 331-338, 355-362, 364-371, 373-401, 411-423 and 191-208 of Seq ID No 41; 34-55, 67-74, 85-93, 105-115, 138-152, 161-171, 182-189, 197-205, 213-219, 232-

239, 241-248, 250-263, 272-277, 288-299 and 216-231 of Seq ID No 42; 21-27, 32-37, 43-51, 67-74, 82-92, 94-100, 106-112, 140-149, 153-159, 164-182, 193-215, 222-227, 260-267, 308-322, 330-340, 378-387, 396-403, 417-432, 435-441, 448-465, 476-482, 488-498, 500-510 and 214-280 of Seq ID No 43; 4-21, 29-52, 80-87, 104-123, 126-133, 141-157, 182-189, 194-202, 214-220, 227-235, 242-252 and 33-108 of Seq ID No 44; 12-18, 20-27, 29-59, 64-72, 84-90, 96-103, 109-121, 125-155, 164-177, 179-186, 188-201, 216-227, 235-253, 259-274, 276-294, 296-310, 322-339, 341-348, 369-379, 398-403, 409-421 and 76-96 of Seq ID No 45; 4-15, 24-41, 71-80, 104-111, 113-119, 123-130, 139-149, 168-178, 187-200 and 4-45 of Seq ID No 46; 13-19, 32-37, 44-56 and 1-14 of Seq ID No 47; 6-11, 16-35, 75-81, 95-100, 126-139, 206-214, 225-233, 241-259, 268-276, 319-325, 339-360, 371-401, 435-441, 452-459, 462-472, 491-503, 505-516, 549-556, 567-580, 590-595, 612-622, 624-630, 642-648, 656-662, 687-693, 698-704, 706-712, 736-750, 768-777, 784-789, 812-818, 847-858, 894-900, 922-931, 938-949, 967-984, 986-992, 1027-1032, 1041-1054, 1082-1088, 1091-1097, 1119-1124, 1234-1240, 1250-1258, 1274-1289, 1299-1305, 1392-1398, 1400-1405, 1429-1442, 1460-1474, 1505-1514, 1531-1537, 1540-1552, 1558-1571, 1582-1587, 1616-1623, 1659-1666, 1671-1677, 1680-1686, 1698-1704, 1706-1712, 1768-1774, 1783-1797, 1814-1819, 1849-1855, 1870-1876, 1890-1897, 1947-1953, 1972-1980, 1999-2013, 2044-2051, 2068-2084, 2093-2099, 2122-2131, 2142-2147, 2156-2163, 2170-2179, 2214-2220, 2235-2245, 2271-2281, 2287-2293, 2308-2317, 2352-2362, 2373-2378, 2387-2407, 2442-2448, 2458-2474, 2507-2516, 2531-2537, 2540-2551, 2555-2561, 2586-2599, 2617-2627, 2644-2649, 2661-2675, 2685-2692, 2695-2707, 2733-2739, 2741-2747, 2774-2783, 2788-2795, 2860-2870, 2891-2903, 2938-2947, 2973-2980, 2993-2999, 3004-3030, 3046-3059, 3066-3077, 3082-3088, 3120-3132, 3144-3149, 3153-3169, 3200-3212, 3232-3256, 3276-3290, 3308-3322, 3330-3338, 3353-3360, 3363-3371, 3390-3408, 3431-3447, 3454-3484, 3503-3515, 3524-3541, 3543-3550, 3560-3567, 3586-3599, 3616-3621, 3642-3647, 3663-3679, 213-276, 579-621 and 1516-1559 of Seq ID No 48; 19-41, 43-49, 55-62, 67-74, 114-121, 130-140, 188-197, 208-217, 226-232, 265-287, 292-299, 301-319, 372-394, 400-410, 421-427 and 12-56 of Seq ID No 49; 6-12, 44-51, 53-60, 67-88, 91-100, 104-123, 137-142, 148-158, 161-168, 175-201, 204-210, 222-231, 239-253, 258-264, 272-282 and 60-138 of Seq ID No 50; 4-63, 69-104, 110-121, 124-131, 134-152, 161-187, 204-221, 223-237, 239-296, 298-310, 331-365, 380-405, 423-451, 470-552, 554-562, 574-581, 592-649, 651-658, 661-671, 673-707, 713-734, 741-748, 758-765, 773-790 and 509-528 of Seq ID No 51; 89-94, 102-115, 123-129, 181-188, 200-206, 211-235, 239-249, 267-281, 295-310, 316-321, 331-341, 344-359, 365-386, 409-422, 443-453, 495-506, 514-521, 539-547, 553-560, 563-570, 586-596, 621-626, 633-638, 651-657, 666-683, 697-705, 731-739, 761-768, 865-883 and 213-265 of Seq ID No 52; 5-20, 24-34, 37-43, 92-102, 134-139, 156-162, 184-191, 193-205, 207-213, 225-231, 241-247, 259-267,

269-286, 337-350, 365-372, 378-386, 399-413, 415-421, 447-457, 467-481 and 145-183 of Seq ID No 53; 12-19, 29-41, 43-57, 80-98, 106-141, 143-156, 172-183, 185-210, 214-220, 226-234, 278-287 and 237-287 of Seq ID No 54; 5-12, 32-48, 50-72, 75-81, 88-94 and 16-40 of Seq ID No 55; 4-21, 29-42, 48-62, 65-80, 95-101, 103-118, 122-130, 134-140, 143-152, 155-165, 182-192, 198-208, 232-247, 260-268, 318-348, 364-369, 380-391, 403-411, 413-424 and 208-230 of Seq ID No 56; 4-18, 65-75, 82-92, 123-140, 144-159, 166-172, 188-194 and 174-195 of Seq ID No 57; 7-20, 58-71, 94-101, 110-119, 199-209, 231-242, 247-254, 267-277, 282-290, 297-306, 313-319, 333-342, 344-369, 390-402, 414-431, 436-448, 462-471 and 310-350 of Seq ID No 58; 4-25, 37-44, 53-59, 72-78, 86-99, 119-128, 197-203, 209-218, 220-226, 233-244, 246-254, 264-271, 277-289, 407-430, 437-445, 464-472, 482-488, 503-509 and 308-331 of Seq ID No 59; 4-12, 14-43, 52-58 and 43-58 of Seq ID No 60; 4-14, 21-29, 35-49 and 38-50 of Seq ID No 61; 4-19, 31-37, 58-72, 94-108 and 1-72 of Seq ID No 62.

15. A process for producing a *S. epidermidis* hyperimmune serum reactive antigen or a fragment thereof according to any one of the claims 11 to 14 comprising expressing the nucleic acid molecule according to any one of claims 1 to 7.

16. A process for producing a cell, which expresses a *S. epidermidis* hyperimmune serum reactive antigen or a fragment thereof according to any one of the claims 11 to 14 comprising transforming or transfecting a suitable host cell with the vector according to claim 8 or claim 9.

17. A pharmaceutical composition, especially a vaccine, comprising a hyperimmune serum-reactive antigen or a fragment thereof, as defined in any one of claims 11 to 14 or a nucleic acid molecule according to any one of claims 1 to 7.

18. A pharmaceutical composition, especially a vaccine, according to claim 17, characterized in that it further comprises an immunostimulatory substance, preferably selected from the group comprising polycationic polymers, especially polycationic peptides, immunostimulatory deoxynucleotides (ODNs), peptides containing at least two LysLeuLys motifs, neuroactive compounds, especially human growth hormone, alum, Freund's complete or incomplete adjuvants or combinations thereof.

19. Use of a nucleic acid molecule according to any one of claims 1 to 7 or a hyperimmune serum-reactive antigen or fragment thereof according to any one of claims 11 to 14 for the manufacture of a pharmaceutical preparation, especially

for the manufacture of a vaccine against *S. epidermidis* infection.

20 . An antibody, or at least an effective part thereof, which binds at least to a selective part of the hyperimmune serum-reactive antigen or a fragment thereof according to any one of claims 11 to 14.

21. An antibody according to claim 20, wherein the antibody is a monoclonal antibody.

22. An antibody according to claim 20 or 21, wherein said effective part comprises Fab fragments.

23. An antibody according to any one of claims 20 to 22, wherein the antibody is a chimeric antibody.

24. An antibody according to any one of claims 20 to 23, wherein the antibody is a humanized antibody.

25. A hybridoma cell line, which produces an antibody according to any one of claims 20 to 24.

26. A method for producing an antibody according to claim 20, characterized by the following steps:

- initiating an immune response in a non-human animal by administering an hyperimmune serum-reactive antigen or a fragment thereof, as defined in any one of the claims 11 to 14, to said animal,
- removing an antibody containing body fluid from said animal, and
- producing the antibody by subjecting said antibody containing body fluid to further purification steps.

27. Method for producing an antibody according to claim 21, characterized by the following steps:

- initiating an immune response in a non-human animal by administering an hyperimmune serum-reactive antigen or a fragment thereof, as defined in any one of the claims 12 to 15, to said animal,
- removing the spleen or spleen cells from said animal,
- producing hybridoma cells of said spleen or spleen cells,
- selecting and cloning hybridoma cells specific for said hyperimmune serum-reactive antigens or a fragment thereof,
- producing the antibody by cultivation of said cloned hybridoma cells and op-

tionally further purification steps.

28. Use of the antibodies according to any one of claims 20 to 24 for the preparation of a medicament for treating or preventing *S. epidermidis* infections.

29. An antagonist, which binds to the hyperimmune serum-reactive antigen or a fragment thereof according to any one of claims 11 to 14.

30. A method for identifying an antagonist capable of binding to the hyperimmune serum-reactive antigen or fragment thereof according to any one of claims 11 to 14 comprising:

- a) contacting an isolated or immobilized hyperimmune serum-reactive antigen or a fragment thereof according to any one of claims 11 to 14 with a candidate antagonist under conditions to permit binding of said candidate antagonist to said hyperimmune serum-reactive antigen or fragment, in the presence of a component capable of providing a detectable signal in response to the binding of the candidate antagonist to said hyperimmune serum reactive antigen or fragment thereof; and
- b) detecting the presence or absence of a signal generated in response to the binding of the antagonist to the hyperimmune serum reactive antigen or the fragment thereof.

31. A method for identifying an antagonist capable of reducing or inhibiting the interaction activity of a hyperimmune serum-reactive antigen or a fragment thereof according to any one of claims 11 to 14 to its interaction partner comprising:

- a) providing a hyperimmune serum reactive antigen or a hyperimmune
- b) fragment thereof according to any one of claims 11-14,
- c) providing an interaction partner to said hyperimmune serum reactive antigen or a fragment thereof, especially an antibody according to any one of the claims 20 to 24,
- d) allowing interaction of said hyperimmune serum reactive antigen or fragment thereof to said interaction partner to form a interaction complex,
- e) providing a candidate antagonist,
- f) allowing a competition reaction to occur between the candidate antagonist and the interaction complex,
- g) determining whether the candidate antagonist inhibits or reduces the interaction activities of the hyperimmune serum reactive antigen or the fragment thereof with the interaction partner.

32. Use of any of the hyperimmune serum reactive antigen or fragment thereof according to any one of claims 11 to 14 for the isolation and/or purification and/or identification of an interaction partner of said hyperimmune serum reactive antigen or fragment thereof.
33. A process for in vitro diagnosing a disease related to expression of the hyperimmune serum-reactive antigen or a fragment thereof according to any one of claims 11 to 14 comprising determining the presence of a nucleic acid sequence encoding said hyperimmune serum reactive antigen and fragment according to any one of claims 1 to 7 or the presence of the hyperimmune serum reactive antigen or fragment thereof according to any one of claims 11-14.
34. A process for in vitro diagnosis of a bacterial infection, especially a *S. epidermidis* infection, comprising analysing for the presence of a nucleic acid sequence encoding said hyperimmune serum reactive antigen and fragment according to any one of claims 1 to 7 or the presence of the hyperimmune serum reactive antigen or fragment thereof according to any one of claims 11 to 14.
35. Use of the hyperimmune serum reactive antigen or fragment thereof according to any one of claims 11 to 14 for the generation of a peptide binding to said hyperimmune serum reactive antigen or fragment thereof, wherein the peptide is selected from the group comprising anticalines.
36. Use of the hyperimmune serum-reactive antigen or fragment thereof according to any one of claims 11 to 14 for the manufacture of a functional nucleic acid, wherein the functional nucleic acid is selected from the group comprising aptamers and spiegelmers.
37. Use of a nucleic acid molecule according to any one of claims 11 to 14 for the manufacture of a functional ribonucleic acid, wherein the functional ribonucleic acid is selected from the group comprising ribozymes, antisense nucleic acids and siRNA.

THIS PAGE BLANK (USPTO)

1/4







Figure 1

THIS PAGE BLANK (USPTO)

2/4

A.**B.**



Total (trimmed)	409 (100,0 %)
ORF (+/+, +/-)	248 (60,7 %)
non-ORF (+/+, +/-)	93 (22,7 %)
chimeric	18 (4,4 %)
non-blastable	50 (12,2 %)

Figure 2

J009 Base Patent 30 SEP 2008

THIS PAGE BLANK (USPTO)


3/4

A**1. Round of MACS Screening****2. Round of MACS Screening****B**

1 2 3 4 5 6 7 8 9 10 11 12 13



P15-IgG




LamB

14 15 16 17 18 19 20 21 22 23 24 25 26



P15-IgG



LamB

Figure 3

THIS PAGE BLANK (USPTO)

4/4




Figure 4

THIS PAGE BLANK (USPTO)

- 1 -

SEQUENCE LISTING

<110> InterCell AG

<120> Staphylococcal Antigens

<130> InterCell S. epi antigens

<160> 62

<170> PatentIn version 3.1

<210> 1

<211> 2028

<212> DNA

<213> Staphylococcus epidermidis

<400> 1

atgaagagaa cagataaaat tgggtgtctac ctcaagctgt catgttctgc gttgttactt	60
agtggttcgc tggttggta tggcttcaca aaagatgctt ttgcagattc agaaagtaca	120
tcatcaaagtg ttgaaaatac ttctaatagt aactccatcg ctgacaaaat ccaacaagct	180
aaagatgata ttaaagattt gaaagaactt tctgacgcag atatcaaaag ttttgaagaa	240
cgtttagata aagtcgataa tcaatcaagt attgaccgta ttataaatga tgcaaaagat	300
aaaaataatc atttaaaatc gacagactct agtgccacat catcaaaaac tgaagatgac	360
gatacatctg aaaaagataa tgatgatatg actaaagact tagataaaat actgtcggat	420
ttagattcaa ttgctaaaaa tgttgataac cgtcaacaag gtgaagagag agcttctaaa	480
cctagtgact caacaaccga tgaaaaagat gattcaaata ataaagtaca cgatacaaat	540
gctagtacac gtaatgcaac tactgatgat tctgaagagt cggttattga taaattagat	600
aaaatccaac aagattttta atctgactct aataataatc cttctgaaca aagcgatcag	660
caagcatcac catctaataa aacogaaaat aacaaagaag aatctagtag gacaacaaat	720
caatccgata gtgatagtaa agacgataaa agtaatgatg gtcacgcgtc aacattagaa	780
cgtatagcat cagatactga tcaaattagg gattcaaaag atcaacatgt cacagatgaa	840
aaacaagata tacaagcaat tacacgttca ttacaaggta gtgataagat tgaaaaagca	900
cttgctaagg tacaatctga caatcaatca ctagattcta attatataaa taataaatta	960
atgaatttaa gatcactaga tacaaaagta gaggataata acactttatc tgatgataag	1020
aaacaagcgc ttaaacaaga aattgataag actaagcaaa gtattgaccg acaaagaaat	1080
attattatag atcaactcaa tgggtgctagt aataaaaaac aagcaaccga agatatctta	1140
aatagtgttt ttagcaaaaa tgaagtagaa gacataatga aacgtattaa acaaatggc	1200
cgaagtaatg aagatatcgc taatcaaatt gccaaagcaaa ttgatggctt tgcattaact	1260
tctagtgatg atattttaaa atcaatgtta gatcaatcta aagataaaga aagtttaatt	1320

- 2 -

```

aaacaattgt tgacgacacg acttggtaat gatgaagcag atcgtattgc taaaaaattg 1380
ttaagccaaa acttgtcgaa ttctcaaatt gtagaacaat taaaacgtca tttcaatagt 1440
caaggaacag ctacagctga tgatatattg aatgggtgtga ttaatgatgc taaagacaaa 1500
agacaagcga ttgaaacaat attacaaacc cgtatcaata aagacaaagc taaaattatc 1560
gctgatgtta ttgcgcggtg acaaaaggac aaatcagata tcatggatct cattcactct 1620
gcgattgaag gcaaggcaaa tgatttatta gatatagaaa aacgagcaaa acaagctaag 1680
aaagatttag aatatatttt agatcctata aagaatagac catccttggt agatcgtatt 1740
aacaaggtg tcggtgattc taattcaata ttgatagac caagtttact tgataaaactt 1800
cactcaagag gatctattct tgataaatta gatcattcgg caccggagaa tggattatct 1860
ttagataata aaggtggcct tttaagtgat ctatttgacg acgatggtaa tatctcatta 1920
ccagcgacag gtgaagtcac caaacaacat tggataccag tggctgttgt actcatgtca 1980
ttaggtgggg cgctcatctt tatggcgcggt agaaaaaac accaaaat 2028

```

```

<210> 2
<211> 1965
<212> DNA
<213> Staphylococcus epidermidis

```

```

<400> 2
atgaagaaaa ataaattttt agtatattta ctatcgacgg cgcttatcac gccaaccttc 60
gctacacaaa cagcttttgc tgaagattca tctaataaaa atacaaattc agataaaatg 120
gaacaacatc aatcacaaaa agaaacatca aaacaatctg aaaaagatga atttaacaac 180
gatgattcta aacacgattc tgatgataaa aaaagcactt ctgacagcaa ggacaaagac 240
tctaataaac cattatcagc tgattcaaca catcgtaact ataaaatgaa agatgataat 300
ttagttgatc aactttatga taattttaag tctcagtcag tagatttttc taaatactgg 360
gaaccgaata aatacgaaga cagtttttagt ttaacgtcac tcatccaaaa ttattttgat 420
tttgattctg atataacaga ttacgaacag ccacaaaaga caagccattc ttctaattgac 480
gaaaaagatc aagtagacca agcagatcag gcaaaacaac catcacaaca tcaagaacca 540
tcacagtcgt ctgctaaaca agatcaagaa ccatcaaacy atgaaaaaga aaagacaact 600
aaccaccaag ccgattctga cgtcagtgat ttacttggag aaatggataa agaagatcaa 660
gaaggcgaaa acgtagatac aaacaaaaat caatcttctt ctgagcaaca acaaactcaa 720
gcgaatgatg atagctcaga acgtaacaaa aaatattcta gtattacaga ttcagcatta 780
gactctatat tagatgaata tagtcaggac gctaagaaaa cagaaaaaga ttacaataag 840
agcaagaata caagtcacac taaaacatct caaagtgata atgccgacaa aaatccacaa 900
ttaccaacag atgatgaatt aaaacatcaa tcaaaacctg cacaatcatt tgaggatgac 960

```

- 3 -

```

attaaacgct caaatacacg ttcaacaagt cttttccaac aactacctga attagacaat 1020
ggtgacttat cttctgattc atttaatggt gttgacagtc aagacacacg tgatttcatt 1080
caatcaattg ctaaagatgc gcatcagatt ggaaaagacc aagatatata tgcacagtt 1140
atgattgctc aagctatfff agaactctgac tctggaaaaa gttcacttgc acaatcacca 1200
aatcataact tgtttggaat caaagggtgac taaaaaggac aatctgtaac ttttaatact 1260
ttagaagctg atagcagtaa tcatatgttt agtatccaag cagggtttccg taaataccca 1320
agtactaaac aatctcttga agattatgca gatttaatac aacatgggtat cgatggtaat 1380
ccgtcaattt ataaaccaac ttggaagagt gaagctctat catataaaga tgctacttca 1440
catctgtcac gctcatacgc cacagatcct aattattcta aaaaattaaa tagtattatt 1500
aaacattatc atttaacatc ttttgacaaa gaaaaaatgc ctaacatgaa gaaatataat 1560
aatcaatag gtacggatgt gtctggtaat gacttcaaac catttactga aacttccggt 1620
acatcacctt acccacatgg ccaatgtact tggatatgtg accaccgtat gaatcaattt 1680
gatgcatcca tttctggtga cttagggtgat gctcataatt ggaataaccg tgctgaaagt 1740
gaaggctata cggtaacgca cacacctaaa aatcatactg cagttgtgtt tgaagctggg 1800
caattaggtg ctgatacaca gtatgggtcat gttgccttcg ttgaaaaagt taatgacgac 1860
ggttcaattg ttatttctga atcaaagtgt aaaggattag gtgtcatttc attcagaact 1920
attgatgcag gagatgctca agatttagat tacattaaag gtaaa 1965

```

```

<210> 3
<211> 492
<212> DNA
<213> Staphylococcus epidermidis

```

```

<400> 3
atgattagat ttgcacgact agaagatctt caagatatatt tgacaattta taatgatgcc 60
atccttaata caacagctgt ttatacgtat aagccacaac aattagatga acgtcttcaa 120
tggtatcaat ctaaagcaaa aataaacgaa cctatatggg tttatgaaaa agaagggaaa 180
gtagttggtt ttgccactta tggttccttt agacaatggc cggcctatft atatactatt 240
gaacattcta tatatgttca tcaacagtac agaggactag gtatcgcttc tcaattatta 300
gagaatttaa ttcgttacgc taaagaacaa ggttatcgca ccattgttgc tgggattgat 360
gcatcgaaca tggatagtat cgcattgcat aagaagtttg acttctcaca tgcaggatca 420
attaaaaatg taggttataa atttgatcga tggctcgatt tatcatttta tcaatatgat 480
ttatctgatt ca 492

```

```

<210> 4

```

- 4 -

<211> 2856

<212> DNA

<213> Staphylococcus epidermidis

<400> 4

ttgagtaatt tgatacaaga tattaagcaa tctttatata agggatttat agataaagat	60
agttcccata aaggcaattt tgttccaaga ttactagtaa ataacaaaga agaaaatgta	120
ctttctacta ttatagatca gctgcataat tgccaatcat ttigtatttc ggttgcattt	180
ataaccgaga gtggttttagc aagtctaaaa tcacattttt atgatttaag taagaaaggc	240
gtaaaaggaa ggataataac atcaaattac ttaggtttta atagtccgaa aatgtttgag	300
gaattattga aattagagaa tgtagagggt aaattaacaa acattgaggg gttccatgct	360
aaggggtaca tatttgaaca tcataaccac acttctttta ttatagggag ttcgaattta	420
acttctaattg cattgaaatt gaattatgaa cataatttat ttttatctac tcataaaaat	480
ggagatcttg ttaacaatat taaatataaa tttgatgaac ttggggattc tagcttttct	540
ttaactaatg aatggataaa tgaatataaa cagtcttttg aatatcaaac attgcaaaaa	600
gtatttgata acactgttgt tcaaaattca gatattaaaa agtttaatga atcaaaactt	660
ataaaacca atttaatgca agaacacgca ttaaagtcac tagagtcttt gagaaatgtg	720
ggagaagaaa aggggttaat tatatctgcg acagggactg gaaaaactat tttatgcgca	780
cttgatgtaa gagcttattc tccagataaa tttctattta ttgttcataa tgaaggtata	840
ttaaataagag ctatagaaga atttaagaaa gtatttccat atgaggatga aagtaatttt	900
ggattattaa caggaaaacg aaaggatcat gatgctaaat tcctttttgc aacaattcaa	960
acactttcta aaaaggaaaa ttataaattg tttaactcta atcattttga ctacatcggt	1020
tttgacgagg ctcatcgaat tgctgcatct agttatcaga aaatatttaa ttattttaaa	1080
cctaactttt tgctaggaat gactgcaaca ccagaaagaa ctgatgaatt aaatattttt	1140
gaattgttta attataatat tgcttatgaa attcgtttac aagaggcttt agagagtaat	1200
attttatgtc cttttcatta ttttgaggtt acagattata ttcaaatga aatgagtcaa	1260
gaagatgcat ttaatctaaa atatttagca tctaataaac gtgttgaaca catcataaaa	1320
aagactaatt attatggta ttcaggtgac gttttaaagg gtttaattatt tgtagtagt	1380
aggggtgagg cgtatcaatt agcaaacc aaagtaaac gtggtatatc atcggttggt	1440
ttgacaggaa aagattctat agcttataga gctgaaacaa ttcaacaact aaaagaagga	1500
tctattaatt atataattac tgtagatttg tttaacgaag gaattgatat tcctgaaata	1560
aatcaagttg taatgttaag acctactaaa tcaagtatta tatttattca acagcttggt	1620
agaggattaa gaaaaagtac taataaagaa tttgttactg ttattgattt tatcggtaat	1680
tataaaacta actatatgat cccaatagcc ttatctggaa ataaatctca aaataaggat	1740

- 5 -

```

aattacagaa aattcttaac agatactacg gttttaaacg gtgtttcaac aataaatttt 1800
gaagaagtag ctaaaaataa aattttataat tcactagatt ctgttaaatt aaatcaacca 1860
aaattaatta aagaagcttt taacaatgta aaagaccgta taggtaaatt acctttactt 1920
atggacttta taaataacga ttcgattgat ccaagtgtga ttttctcacg ttttaaaaat 1980
tattatgagt ttttaataaa aaataaaaatt attgagaatg aattaagtat taatgaattt 2040
aaaaatttaa catTTTTtATC aagacaatta acacctggac ttaaaaaagt agatattgat 2100
gtattgaaag aaattatata aaatgacgta acttatgaaa atttaacaaa aaaaatgtta 2160
aacattaata acgatatTTTc ggaatatgat attaacactt cattaagcat tttagatttt 2220
actTTTTtca aaaagactat aggtaaaact tacggattac ctttaatata atataaggat 2280
aatcttattt gtctagcaaa tgaatttaaa gaggctttaa ataaaccact atttaacaca 2340
tttattcatg atttaattga tcttgctaata tataataatg acagatatca aaataagaaa 2400
aacagtttaa ttctatataa caaatattct agggaagatt ttgttaagtt attaaactgg 2460
gataaagatg aatctggaac aatcaatggg tatcgtatga aacatcgtaC acttccttta 2520
tttatcactt atgataaaca tgagaatatc agtgataata ctaagtacga cgatgaattt 2580
ttgagccaag acgaattgaa atggtacacg cggccaatc gtaaattaac ttcaccagaa 2640
gtacaaaata ttttaaagca tgaagaaagt aatacagata tgtatatatt tgtgaaaaaa 2700
agagatgatg aagggaaata tttctactat ttaggtaaag ccaaatatat taaaggaact 2760
gagaagcaag attatatgcc taatggaaat agcgtggtaa ctatgcatct atcaatgaat 2820
acgtccattc gagatgatat ttatagatac atcact 2856

```

<210> 5

<211> 975

<212> DNA

<213> Staphylococcus epidermidis

<400> 5

```

atgacaaaat cacaacaaaa agtgtcatca attgagaaat taagtaatca agaaggtatt 60
atttcagctt tagcatttga tcaacgtggg gcattaaaaa gaatgatggc agaacatcaa 120
tctgaaacac caacagttga acaaatagaa caattaaaag tacttgtttc tgaagaatta 180
actcaatatg cgtcttcaat tttattagat ccagaatatg gtttaccagc atcagatgct 240
cgaaataatg actgcggact attacttgca tacgaaaaaa ctggatatga tgtgaatgcg 300
aaaggctcgtt tgccagattg cttggtagaa tggctctgca aacgtttgaa agagcaaggg 360
gccaatgcag tttaaattttt actttattat gatgtagatg acacagaaga aattaacata 420
caaaagaaag catatatTga acgaattggg tcagaatgtg ttgccgaaga ttttcctttc 480

```

- 6 -

ttcttggaag ttttaacata tgacgacaat attcctgaca ataaaagtgc agaattcgct	540
aaagttaagc cacgtaaagt taatgaagca atgaagttat tctctgaaga tcgttttaat	600
gtggatgtac ttaaagttga agtacctgtg aatatgaatt ttgtggaagg attttcagaa	660
ggagaagttg ttataactaa agaagaagct gcacaacatt tccgtgatca agatgcagct	720
actcacttac catatattta ttttaagtgc ggtgtatcag cagaattgtt ccaagataca	780
ttaaaatttg cgcattgattc tgggtgcgcaa ttcaatggtg ttttatgtgg acgtgccaca	840
tggtcaggag cagttaaggt atacattgaa gaaggagagc aagctgccag agaattggtg	900
cgtacggtag gatttaagaa tattgatgat ttgaatacag tattgaaaac aacagctaca	960
tcatggaaaa acaaa	975

<210> 6
 <211> 1146
 <212> DNA
 <213> *Staphylococcus epidermidis*

<400> 6	
ttgatgaaaa aagttatgac catatttgga actaggcctg aagctataaa aatggctccg	60
ttgattaataa cgtagagaa agattctgac ctggaaccg ttgttgtagt caccgcccac	120
catagagaga tgcttgattc agtggtgaat acttttaaca taagtgcaga ttatgatttg	180
aatattatga aagctggtca aacattgtct gaagtaacat ctgaagcaat gaaaaagtta	240
gaagatatca taaaaagga agtgccctgat atggtacttg ttcattggtga tacagtgcac	300
accttttctg gagcattagc cgcattttat agtcaaacac ctataggaca tgttgaagct	360
ggattaagga gttataataa atattcacct tatcctgaag aaataaatag acaaatgggt	420
ggggtaattg cagatttgca ctttgcccca acctataatg ctgcacagaa tttagtaaaa	480
gagggtaaat tagccaaaca tatagctatc actggtaata cagctattga cgcaatgaat	540
tatacaatcg atcaccaata ttcattcatc atcatacaaa aacataaaaa taaaaacttt	600
attttactca cagcacatag acgtgaaaat ataggtaaac ctatgataaa cgtgttttaa	660
gcgattagaa agttgattga tgaatatcag gatttagcgt tggcttatcc tatgcatatg	720
aatcccaaag taagagatat tgcgcaaaaa ttttaggaa atcatcctag gattgaattg	780
atagaaccac ttgatgtggt tgattttcat aattttgcta aacaagcata tctcattatg	840
actgactctg gtggaatata agaggaggca ccatcattac acaaaccagt tttagtattg	900
agagatagta ctgaaagacc ggaggagta gatgctggaa ctttgagagt cattggtacg	960
aatgaagaag atgtctataa tgaaactaaa aaattaatag aaaaccaga cctttatcaa	1020
aaaatgagtc aagctgttaa tccatatggc gatggacaag ctagtgagag aattgtgcaa	1080
catataaat attattttta tttgacaaat gacagacca atcattttga atttacaaaa	1140

gatttta

1146

<210> 7

<211> 8271

<212> DNA

<213> *Staphylococcus epidermidis*

<400> 7

```

gtggcaagtg attttaatat aggtatatta tctaccttag agatagactc tagctcctca    60
agaaaagaaga ttaacgacac acttaaaaaat attgaagcaa atattaatag cattaaagca    120
gacttagaag tttcagatac aaagaaatca gaaaataatg ctataaaaag tgcaaacaac    180
gtaatcagaa acatcaattc aaacggtaat ttaaagaaat taaatgttga actagatgta    240
aacttaacaa aaagtagaca aaacattcaa agagcattat ctactctatc aaaagatttt    300
aagaataaga aaattgatgt tgaagttaat gctaaagcta ataaaaattc aatcggaaca    360
gttaagaatt ctattttctaa aggtgcaagt cagccactag aaattaaaga gtcccctagt    420
agtagaagca ctagtagaga tattaagaa cagcagctct taatgacagg tttagcaaata    480
tcttataaga acttagatga tttaacaaga gctttaaata caagtacatt tgaagggctt    540
agaaaaactg taaaagaaat taagaacgca gataattctc ttaaaagtta tcaagttact    600
ttagaacgtg ttaaccaaga aggtaaaaaa ttaggctctc aaagatttga ttatacccct    660
tctgcaaagt gtttgaagtt aaacaaaact caattaactg atcaaacaga taaagctcgt    720
aaagaagaaa atgctgctat taataaatta ttagaaaatg aagtttctaa gtatgatcgt    780
ttattgaata aaggtaaaat tgatattaaa caacatcaaa ctttacttca aactcttaga    840
caaattacta atgagaaaatc aaaagctaac caatttaata gaactgattt caatagagta    900
gcaaaagctg ctgctgatga agcaaaagaa tatcaatatc aaaatgatat gcttcgaaag    960
aaattagctt taacttctca aattgagcgt attgaaaaca gaatggctgc tacaattgat   1020
aagcaacaaa caaatgcttt gaaaaatcaa ttgaattctt taggtaataa tagaacacca   1080
ttcggtaaaag aagcagcttt ccatatgaac caaattcaag acaaggttcg tcaaattctt   1140
gctgaagctg aaagagcaac tagaactcag ttaagttttg ttgatcaatt cagagaagca   1200
atgacaaaat tcccagtttg gatgggtgct actaccctat tcttcggtgc cataaatggt   1260
gctaaagaaa tgcttgatgt aattactgaa attgatggaa aatgattac tcttgcaaaa   1320
gttactggtg atgacaatgc acttcaacaa acatttattg acgcaaataa tgctgcttct   1380
caattcggac agacattagg aagcgtatta gatgtatatg cagaattcgc tagacaaggt   1440
gttaaaggta atgagttatc tcaattctca aatgcagcat taattgctgc taacgttggt   1500
gagattgacg ctaaacaagc ttctgaatat ttaacttcta tgtctgctca gtgggaaacg   1560

```

actggaaacc aagctatgag acaagttgac tactcaacg aagtttccaa taaatatgct	1620
acaactgttg aaaagttagc acaaggtcaa gcaaaagctg gctctactgc taaatcaatg	1680
ggacttactt ttgatgaaac taatggtatt attggtgcat taacagctaa gactaagcaa	1740
tctggggacg aaattggtaa ctttatgaaa gccactttac ctaaacttta tagtggtaaa	1800
ggtaaatcaa ctattgaagg cttaggcatt agtatgaaag atgaaaatgg acaattaaaa	1860
tctgccattt ctcttttaga agaagtttct cagaaaacta aaaacttaga aaaagaccaa	1920
aaagccgctg ttataaatgg cttgggtgga acataccact accaacgtat gcaagtatta	1980
ttagatgatt tatctaaaac agatggctta tataaacaaa ttaaagaaag ttccgaaagt	2040
tcagctggct ctgcattaca agagaatgca aaatacatgg agtcaattga agctaaagtt	2100
aaccaagcaa aaacagcatt cgaacaattc gcattagctg ttggtgaaac atttgctaaa	2160
tcaggaaatgc ttgatggtat cagaatgggt actcaacttt taactgggtt aactcatgga	2220
attactgaat taggcacaac tgctccgatt ttcggcatgg ttggtggtgc tgccctatta	2280
atgagtaaga atgttagaag tggttttgaa ggtgctagaa gtagtggtgc taattatatt	2340
actgaggtaa ataaattagc taaagttaac aatgctgctg gtcaagttgt tggacttcaa	2400
aaagttcaaa ctggtacagc ttcacaactt cagtttaata aaaatggtga atatgataaa	2460
gctgcttcac aagcaaaggc tgctgaacaa gcaacttacc aattctctaa agctcaaaaa	2520
gatgtatcag ctagtgctat gatcgcttca ggtgcaatca acaaaacaac tgtggctacc	2580
acagcaagca ctgttgccac tcgtgctgct acacttgacg ttaatgggtt aaaattagcc	2640
tttagaggct tgttggctgc tactggtgct gggtagcaa taactggtgt ttcttttgta	2700
ctggaaaaag ttgtaggtag ttttaatgct gcaagtcaag ctgctgaaca atataaaca	2760
aaacaagagc aaacgaagca agcaatagct tctatgagta atggtgaaat taattcactt	2820
attagtagtt acgataaact acaacaaaaa atgaattctg gtagtgcat taatacagcg	2880
gaagctgaga aatataaaga agtaacaagt caattagcta atatattccc cgatttagtt	2940
actggtgaaa accgttatgg taaggaaatg gccgtaata aagaagtaat gaaacagaaa	3000
attgagttaa tcaagcaaga aatggagctt gaaagacaaa agaatgctat caaacaaaaa	3060
gaagagcaag acgcttacat caaagaacaa gatagcttag ctaagaaaaa cagaggtcaa	3120
aaatggtatc aacttggtca aacaccagag ttgaaacttc aggaacaagc acgtcctact	3180
actgtttctg ataatagtaa cattaacaaa attaatgcca ctatccaaaa agtgaagagt	3240
caagcccaag ctgaaaaagc attagaacaa gttgataagc aacttgctca atctcaaact	3300
aagaatagac aaaatgaagt tcagcactta caaaaagtta gacaagcttt acaagattat	3360
attactaaaa ctggtcaagc aaatcaggca acaagagctg cggtattaac tgcacagcaa	3420

caattcacta accagatagc aacaatgaaa aagcttggta ctactgggtca acaagtgatg 3480
 actactatctt ctaactcagt tgcgaaaaca gcaaagctctg gttaaagctgc tcaagcaacc 3540
 ttcaagtcgt ttgaaacctc attagttaaa agctcttcat tcaaaagcaa gatggctagt 3600
 tatgaagctt ctgttaagaa atttaaaaat gctgctaacc aatctgctaa aattgctgct 3660
 cttaaagacg tagaacgtga ttactctaaa gttgctaaag gtattatgca agcggcaaaa 3720
 gcggcaaaa tgagtaaata tcaaatgaaa gatttgaaaa aatctcttca acaaaatata 3780
 caagcagaaa caggcttttag agcttcagta agtaaagctg gttaaagttac tattgatcaa 3840
 tctaagaaaa tcaaacagaa tactgctgaa acaagacgta actcaagtgc taaattacaa 3900
 aatgctgacg cttcagacca agcttctgaa gaaaataaag agttagcaga ctcaatgcgt 3960
 gctgggtattg aaagttctca attacttggg aaagcgatgg gagaattaca atctcaagga 4020
 acacttagta cagaaacttt aattgaatta actgagaagt atggagacga aatttttagct 4080
 gttgctggag atcaggaagc ttttaagtaac ttcattcatgc aaaagcaaaa tgaagaaact 4140
 gataactaca acaaaaacct taaaactaaa ttagaaaact cttcatcata ctataaggcg 4200
 gtagctggag ctgactctgc cctatccaac tactttaatgg aaaactatgg tattgatact 4260
 aaaaactata agagttttaac agaagtcaaa gctaaaatta cagaccttta ctacaatggt 4320
 tcagctgaag aacaagctaa agtagtagac gctatcgcaa aagcttacca tattgactta 4380
 tctaactatg gctctctgaa tgagaaaaaa gaagcattag agaaccaatt gatgaaaatc 4440
 ttaggtagta agtggaaaaa atatattggg agcgtagcta aggatatgaa atctcttggg 4500
 gttgacgctg gtgaagttgg agcagatggg tttgatgaca gtaaaatgtt caatccgggt 4560
 gctcttatcg gtgctaacaa tttccaaaac gtttctaacc taagtaatat cagtaatgta 4620
 ttcaactcac ttaatgggtgc atttaatgaa gctaagaatg aagctgctgg tgtagtaga 4680
 ggcttagatg acgctgctag tggcttaaaa gatgttggtg acagtgctgg ctcagctggt 4740
 agtggttttag gtaaaactgc taaaggcgcg gataaagcgt ctgacagttt agatggtact 4800
 aataaagaat tagaaaaaac taaagaaaaa gctgaagaag ctggtgtcac agttaaacia 4860
 ctttataagc aattttacagt tactacttat gttgctgata aactaagtat ggcttttagat 4920
 aaaattaata ataagttaga gaaacaaaaa cttttaactg aaaaatacgc aacttgggtca 4980
 agcagttatc gtaactcact taaagcagaa aataaattgc tcgatgaaaa gaccgctaag 5040
 attaaaaaac aaatcgagtc aatgaaagaa caaatcgctc aaggtaaagt tattgagtat 5100
 ggtttagttg gtaaagatat taatgttctt tactatgaat atactgcaaa taatttagat 5160
 gatggagaaa ctggctgctat ttctcgatat accggtaatt caactcaagc taaggtttgg 5220
 aatttcttta aatctaaagg gttatctgat catgctgttg cgggtatcat gggtaatatg 5280

- 10 -

gaacgtgagt	ctagatttaa	accgggagct	caagaacaag	gcggtactgg	tattggttta	5340
gtacaacttt	catttgggcg	tgcaaataat	ttaagaaatt	atgctgctag	aagaggaaaa	5400
agctggaaaag	acttaaatac	tcaacttgac	ttcatttggg	aagaattaaa	tactactgaa	5460
gttaatgctt	tacgaggact	taaatcagct	acttcagtta	ttggtgcagc	aaactctttc	5520
caaagattat	atgaacgtgc	tggtggtgta	gcacaaggag	aacgtaatgc	ggcagctaaa	5580
aagtattaca	gacaatttaa	aggtactaat	ggttcatctg	gcttcctaag	tggtggcgtg	5640
gtcgtggaa	caaatggtaa	accacttact	tcagatagaa	acgcttatat	cttagataga	5700
caattcggac	gatataatgg	tggtggtgtc	catcacggaa	gagatatcac	gagtgtctact	5760
attaacggat	cacctattaa	agctgcacgt	tcaggatatag	ttacttttaa	aggatggact	5820
ggtggtggta	atacactatc	tatatattgat	ggtaaaaaata	cttatacata	catgcatatg	5880
aagaacccgg	caagagtggg	aaaaggacaa	cgagttaaag	ctggacaaat	tggttgtaac	5940
gttggtacta	cgcattgatag	aagattaggt	ggcttctcta	ctggccctca	ccttcacgta	6000
caagtaaact	taggaaaaac	tccttctggg	acatttatga	acactttcaa	tggtgtctcat	6060
agagcagtcg	atcctgttaa	atatggatat	actagagttt	ctggtggcgg	tagtctaaac	6120
ttaggctcgc	taacttctgg	acattcagcg	atgtctggtt	ctatcagtgc	tgcaatggct	6180
gaagacttaa	atgaagctga	acaagagcgt	ttaaacaaaa	ttgaacaagc	aattaacgca	6240
cataataaag	ctgaagaaat	gaagcaaaaa	gttgatgagc	ttagaaaaac	gttaatggat	6300
aaacagcttg	aagaagttca	aactgctaaa	gaaaaaagtg	aaaatcttta	taacatccaa	6360
aaatctcacg	tagaagaata	tgatcattgg	agaacattac	aagaagcacg	atctgctaaa	6420
ttagaatacg	aattaaacaa	aatcgaattc	gaaaaaggta	gaaatactaa	agaatggcgt	6480
aataaaaaata	aacaacttca	agcttctaga	caacttgaag	ttaatttcga	agactcaaaa	6540
atacaatata	ttaataaagc	attgaagaag	aatgcaata	aaatatttgg	taaaaataca	6600
gtaaatcgtg	atgagtttga	aacaatgaag	cgagacgctc	aacaaaatat	aagagattta	6660
aaagctggta	ttcaaactgc	ttctggtgaa	attgctactt	caatgattga	tcaaattctt	6720
gatgaatatg	aagaccgtgt	aggtaaagtt	tcagctaaaa	ttgaaaagat	gggtaaacaa	6780
aaagaaaaac	ttgatttagc	cgataataaa	caggctttga	aaagttcatc	cctaagtaga	6840
caacaagcta	aagactctaa	gtcactagct	agttacatta	atctctatat	caaacaatta	6900
gaacgccagt	taaaattaac	gggtaaaaac	catgaattac	aacaaaaagt	aaaagaacaa	6960
attaaagaaa	tgaaagttgc	ttatgatgac	gctaccctag	ccgctcatca	atatattact	7020
gaagctgctg	aagttgatac	agaaagacaa	cttcaattaa	acgctaatac	tttaagagac	7080
gcacaaaacg	agttgtctaa	agctgattat	aaagctgggt	tcatttcaca	agaatatcaa	7140

- 11 -

attgacctat accgaaaaaa tcaagaagct aagttcaaag gttactttaa agaaaaagaa 7200
 gcacttgaac aaaataaatc agaacttcaa gacatgtatg agattttataa atctgtccct 7260
 actcaagctc aaaaaatcaa agaagctcta attgaaacca aaaatgctat tagagataat 7320
 aataaaggctc tctatgatgtt gaaatatgat atggctaaca gtgtttataaa tcaaattaag 7380
 gatatctatt caaaacaact agagggttgcc acgaaagcgt atgatgatga atacaaagca 7440
 tacgaaaaaa tgatcaacaa aaagctttaa cttattgatg atgaacaaac tcaagagtca 7500
 ttcaataaag atgtccgtga tagaactgaa gcaatggata aaattagaga tgaaattgct 7560
 caaagaagtg gtgacgatag tttagctaac caaaagaaac ttaaagattt aagagaacaa 7620
 ttaaaacaac aagaagaaga ctatacgatg ttcattaaca ataaaaatcg tgatgacaga 7680
 agaaaagctt tacaagatga gctaaacgat aaaaacgaac aaatacaaga acaaaaagaa 7740
 gatttaaata aagctttcca agacttaatt ggtgatacac gaagatttaa tgcgatccaa 7800
 gagtcaacta tggaaggctca aattgataaa tataaatctc taattgotga cttaactaaa 7860
 tacgtcaacg ataatatgaa agaaattgga cgttctacta gtgaaggaaat attagatggt 7920
 cttgctgctt catttaaagg tttgtcttct ttatctaaag aacttcagaa acaagaaaaa 7980
 aataatttga acccagtacc taattcaaaa ttaaaccta ctaagggttga tgaagctaca 8040
 atcgctgcca ttaagaaagt taatggttta tcccctacta ctatacttca aggttttagat 8100
 atcaaacctg ttaaccttcc taaagatgta aaaccaagta aaacagttac taacaataat 8160
 aaaacgactg ctaaagcatt agttaacatt gaaaacttca acggtacaaa agctgaagca 8220
 gataaattag ctaataactt agcaactgcc atgagaaaac aaggcgtatt a 8271

<210> 8
 <211> 957
 <212> DNA
 <213> Staphylococcus epidermidis

<400> 8
 atggcagaaa ctaaaaaaca attcgaaaac aaagtaagcg tgacaggaac attaaaatca 60
 ttagaggtaa cagatttagt aacagctaaa aaagtcccaa tgaaaattgc tacattaaga 120
 attgaaactg gtaaaggctga aacacatata gctaaaatga tggcagttaa acattttgag 180
 cgtgatggtg ttaaaactga aaataaaagt tattctgcaa ttgaaacaat gcaaaaggaa 240
 tatgtatcaa ttgaagacat ttcagaaaac aaagctggag aagacgcaga agcaacagtt 300
 gttaacgtaa atggatcaat gtctattaat atgtataaaa ataaagcaga aaaagttggt 360
 gaaactaatc aaattgaagc tcgttttggt aatcgtgtaa aagatggtga aaatgctcaa 420
 tttggtgcag aattcacatt acaaacttac ttaatttcaa aaggacaacg tgttattaag 480
 aatgaagaag aaactgatga agtaacattc aaagcagcaa caattgatta tagaggacaa 540

gcacatccat ttgaattcac tgctaattgat gagtatggcg tagctgaatg gatcgaagat 600
 gaagttgaat taggtcaatc acttatctta caaggtttaa ttattaataa atttatogtt 660
 gagcaagtag aacgctcatc atcagctggg atcggtaaag caattggtga tactagacgt 720
 gaagtagaac gtaagttatt agttgaaggt attattccaa ttgaagatga ggatgatcca 780
 aaatacatca ctgaagaaga aattaaagaa gcaaacaaaa aatacgaaga taagaaaaca 840
 gaagtagaag cttctactaa tggaactaag aaaacagaag ttaaaaaagg tgtagcaact 900
 agcaaaccta aagctgctaa accaacaatc gaaattgatg atgacgattt accattc 957

<210> 9

<211> 2391

<212> DNA

<213> Staphylococcus epidermidis

<400> 9

ttgccacaag caaaaaaag aacatcgacg aagagaaagg gtaataaaaa aacgaataaa 60
 aaaaagcaaa atgaaacgcc tttaagatat atattctcaa taattgtagt aattcttatt 120
 atactaggcg cttttcaatt aggaatcatt ggtagaatga ttgatagctt ttttaattat 180
 ctttttggtg tgagtcgata tttaacttat atttttagtac ttattgcaac aatttttata 240
 acatactcta agcaaatacc tagaactcga cgtagtatcg gtgcaatagt ttacaatta 300
 gctttgttat ttatagcgca attgtatttt cttttttcac ataatatcac ttctcaaaga 360
 gagcctgtac tgcctttgt ttataaagct tatgaacaaa cacattttcc aaattttggg 420
 ggaggcttaa taggttttta ttactttaa ctatttatac ctctcatatc tattgtaggt 480
 gtaataataa ttactatcct attactagct tcgagtttca ttttattact taatttaaga 540
 catagagatg ttacaaaaag ttatttcgac aacctcaagt catcaagtaa tcatgcatct 600
 gagtcaataa aacaaaaaag agaacaaaat aagattaaaa aagaagaaaa agcccaatta 660
 aaagaggcaa aaattgaacg aaaaaaaca aaaaaatcac gtcagaataa taatgtcatt 720
 aaagatgtta gtgattttcc agagatttct cagtcagacg atattccaat atatggcat 780
 aatgagcaag aagataaaag accaaatact gctaaccaac gtcaaaaacg tgttttggt 840
 aatgaacaat ttcaacaatc attaccaagt accaaaaatc aatcaataaa taataatcag 900
 ccatctacaa ccgctgaaaa caatcaacaa caaagtcagg ctgaaggctc aatatctgaa 960
 gctggtgaag aagccaatat tgagtatacg gtgccacctt tctccttatt aaaacagcct 1020
 actaaacaaa aaactacttc aaaagctgaa gtccaacgta aaggtcaggt tttagaatct 1080
 aactaaaaa actttggagt taatgctaaa gtaacacaaa ttaaaatcgg tctgagctt 1140
 acgcaatatg aaattcaacc agcgcaaggt gttaaagtaa gtaaaatagt caatctccat 1200

- 13 -

aatgacattg cattagcttt ggctgcgaaa gatgtacgaa tagaagcacc tattccaggt 1260
cgctctgcgg taggaattga gggtcccaat gataaaatct cacttggtcac tctaaaagaa 1320
gttttagaag ataagttccc atctaagtat aaattagaag tcggcattgg tagagatatt 1380
tctggtgatc caatatcaat tcaattaaat gaaatgcctc acttactcgt tgctgggttca 1440
acaggaagcg gtaaatcagt ttgtattaat ggtattataa cgagtatatt actcaacaca 1500
aaaccgcacg aagttaaact tatgttaatc gatcctaaaa tggtagagtt aaatgtttac 1560
aatgggtattc ctcatctact tataccgggt gtaacaaacc cacataaagc gtctcaagct 1620
ttagaaaaaa ttgtttcaga aatggaacgt cgttatgatt tgtttcaaca ttcacgaca 1680
cgaaatattg aaggatataa ccaatatata cgcaaacaga atgaagaact tgatgaaaaa 1740
caacctgagt taccgtatat cgtcgtataa gtggatgaat tggctgattt aatgatggtt 1800
gcaggtaaag aagtagaaaa tgctatccaa cgtattactc aaatggctag agcagcgggt 1860
atacacttaa ttgtagctac tcaaagacct tccgttgatg ttattactgg tattattaaa 1920
aataacattc catcaagaat tgcgttcgct gtaagttctc aaactgactc tagaacaata 1980
attggtgctg gtggagctga aaagctactt ggtaaagggtg atatgctata tgttggtaac 2040
ggagaatcta ctacaaccg aattcaagggt gcttttttaa gtgatcaaga agtgcaagat 2100
gttggttaatt atgttgtaga gcaacagaaa gcaaatatg ttaaagaaat ggaaccagat 2160
gcacctgtag ataaatcaga aatgaagagt gaggatgctt tatatgatga agcttattta 2220
tttgtaatag aaaagcaaaa agctagtact tctttattac aacgacaatt tagaatcgg 2280
tataatcgag cttcaaggct catggatgat ttggaacgta accaagttat tgggccacaa 2340
aaaggaagta aacctagaca aatattagtt gatttagaaa atgacgaggt g 2391

<210> 10

<211> 1287

<212> DNA

<213> *Staphylococcus epidermidis*

<400> 10

atgaaaacac atcaatatga acttatagat gagaaagttt tcgaacatga gtttgataat 60
ggattgaaat tatttatcat tcctaagcct ggttttcaaa aaacgtatgt gacctacaca 120
acacagtttg gttcattgga caatcatttt aagcccatag gtagtcagca atttgtaaaa 180
gttcctgacg gtgtggcaca ttttttagaa cataaattgt ttgaaaaaga agatgaagat 240
ttatttactg catttgccga agagaatgcg caagctaattg cttttacaag ctttgatcgt 300
acgagttatt tatttagcgc aacaagtaat attgaaagta acattaaacg tctcctcaat 360
atggtagaaa caccttattt tactgaagaa acagttaata aagaaaaagg gattatagct 420
gaggaaatta aaatgtacca ggaacaacca ggatataaat taatgtttaa tactttaagg 480

- 14 -

gctatgtatt ccaagcacc gatacgggtg gatatcgctg gtagtggtga aagcatttat 540
 gaaataacaa aagatgattt atatctatgc tatgagacat tttatcatcc ctctaatatg 600
 gtgttggttg tggtaggcga tgttagtcct caatcgataa ttaaacttgt agaaaagcat 660
 gaaaatcaaa gaaataaaac ttatcaacca cgtattgaac gtgcgcaaat tgatgagcct 720
 agagagataa atcaacgggt tgtttctgag aaaatgaagt tacagtcacc acgattgatg 780
 ctaggtttta aaaatgaacc attagatgaa agtgcaacta aatttggtca aagagatttg 840
 gaaatgacat ttttctacga attgggtttt ggagaggaaa cggagtttta tcaacaactt 900
 ttaaataaag atttaataga tgaaacattc ggttatcaat ttgtattgga accgagctac 960
 agtttttcaa ttattactag tgcaacacaa cagcctgac tatttaaaaca attaataatg 1020
 gatgaattaa gaaaatataa aggaaacctt aaagatcaag aagcatttga tttgttgaaa 1080
 aagcaattta ttggagaatt catatcaagt ttaaattctc cagaatatat tgctaataca 1140
 tatgcaaac tctatttcga gggagtgagt gtatttgata tgcttgatat cgtagaaaat 1200
 attacgttag agagtgtaaa tgaaacttcc gaattattct tgaactttga ccaacttggt 1260
 gatagtcgtt tggagatgga aaataga 1287

<210> 11

<211> 987

<212> DNA

<213> *Staphylococcus epidermidis*

<400> 11

atgactgaac agaaggatat taaagaaaca gagtatcgac gacagaaagg aacaacttcg 60
 acaccttcta ggcgaagaaa taaaaaaga atgcggaagt tacottttat catttttagtc 120
 atccttatta ttttaatttc tatcattgtg tatattacc atcagtataa cagtggtagt 180
 aagtatgcta aagaacatgc taaggatggt aaggcgata aatttaattgg gaatatgaaa 240
 aatgatggga agatttcagt tcttgctcctt ggcgcggata aggctcaagg tggtaaataca 300
 cgtactgact cgattatgat tgttcaatat gattacgtac ataaaaaat gaaaatgatg 360
 tctgtcatga gagatattta tgctgatatt cctggttatg ataaatataa aattaatgcc 420
 gcatattcac ttggaggccc ggaattgtta agaaaaacac ttaacaaaaa tttagggtgtt 480
 aatcctgagt attacgctgt agtagatttt actggatttg aaaaaatgat agatgaacta 540
 cagcctaatt gtgtcccaat tgatgtggaa aaagacatgt ctgaaaatat aggtgtgtct 600
 ttgaaaaaag gacatcataa gttaaattgt aaagaattac ttggttatgc tagattccgt 660
 catgatccgg aaggcgattt tggcgtgtg agaagacaac aacaagtgat gcaaacatta 720
 aagcaagagt tagttaattt caatacagtt gcgaaactac caaaagttgc tggattttta 780

- 15 -

agaggttatg ttaatacaaa tatgcctaac tctgcgattt ttcaaacagg tataagtttt 840
 ggaattcgtg gagataaaga tgtgcaatct ttgacagtcc ctattaaagg aagctatcaa 900
 gatattaata caaataatga tggtagtgcg cttcaaatag actctgagaa aaataagcaa 960
 gcaatcaaaa atttctttga agataat 987

<210> 12
 <211> 1881
 <212> DNA
 <213> Staphylococcus epidermidis

<400> 12
 atggaagcat acaaaattga acatttaaataaat aaatcctatg cagataaaga aatttttaaat 60
 gatcttaacc tatctatatc tgagcatgaa agaattggat tagtaggtat caatggaaca 120
 ggtaaaagta cactattaaa agtcattggg ggtctagatg aagattttac tgcagatatt 180
 acccacccta atcaatatcg cattcggttat tctctcaaa aacaagacct caatggccat 240
 atgactgtgt tcgaagctgt ttttaagttcg gatactccta cattaagaat tataaaaaaa 300
 tatgaagaag cagttaatcg ctatgcgtta gatcaaagtg actctaattt taataaaatg 360
 atggaagcac aagaagaaat ggatcaaaag gatgcatggg actataatgc agaaattaaa 420
 acgattttat ctaaaactagg gattcacgat acaactaaga aaatagttga actttcgggt 480
 ggtcaacaaa aaagagttgt attggctaaa actctaatag aacaaccgga tttacttttg 540
 ctagatgaac cgacgaacca tcttgacttt gaatccatcc gttggctcat taattatgtc 600
 aagcaatata cacatacagt tttatttgta acacatgatc gctacttttt aaatgaagta 660
 tcgacgcgaa ttattgaact ggatagaggg aagttaaaaa catatccagg taattatgaa 720
 gattacatag taatgcgtgc agaaaatgaa ttagtagaac aaaaacaaca agaaaaacaa 780
 aaagcattgt ataaacaaga gttagcatgg atgcgagcag gagcaaaggc aagaactact 840
 aaacaacagg caggtatcaa tagatttaata caactagaat cagacgttaa gacgcaacat 900
 acacaagata aggggtgaact taatcttgca tattcaaggt taggtaaaca agtatatgaa 960
 ttaaagaatt tatcaaaatc aattaataat aaagttttat ttgaagatgt cactgaaatt 1020
 attcaaagtg gtagacgtat aggtattgta ggacctaatg gagcgggaaa aacaacatta 1080
 cttaatatatt taagtaatga agatcaggac tatgaggggtg agcttaaaat cggtcagact 1140
 gttaaggtag cttattttta gcaaacagaa aagacacttg accgtgatat tagagtgatt 1200
 gactacctaa gagaagaaag tgaaatggct aaagaaaaag atggtacctc aatttcagtt 1260
 acacaattgt tagaaagatt tttattttccg agcgctacac acggtaaaaa agttttataaa 1320
 ctctcaggtg gagaacaaaa acgtctgtat ttattgcgtt tacttgttca taaacctaat 1380
 gtactccttt tagatgaacc gactaatgat ttagatactg aaacacttac gatttttagaa 1440

- 16 -

gattacattg atgatttcgg tggttctgtc attacgggtca gtcattgatcg ttatttctta 1500
 aataaagtgg tacaagaata ttggtttatt catgatggta aaatcgaaaa aattattgga 1560
 tcatttgaag attatgaatc ttttaaaaag gaacatgaac gccaagccat gctatctaaa 1620
 caaactgaac aacaaaataa acataagcat caaccaaaaa agaaaacagg actatcttat 1680
 aaagagaagt tagaatacga aacaattatg acgcgtatag aaatgactga aacgcgttta 1740
 gaagaccttg aacaagaaat gattaatgca agtgataatt atgcaagaat caaagaactt 1800
 aatgaggaaa aagagcaact tgaagcaacc tatgaagcag acatcacgag atggagtga 1860
 cttgaggaaa tttaagaaca a 1881

<210> 13
 <211> 810
 <212> DNA
 <213> Staphylococcus epidermidis

<400> 13
 atgaaaaaat tattcggaat tatttttagta ttggctttaa cgattgcctt agctgcatgt 60
 ggtggaggta aagataagga aaaaactatc acagtaggtg catctccagc accacacgct 120
 gaaatttttag aaaaagcaaa accattattg aagaaaaaag gttatgattt aaaaatcaaa 180
 ccaattaacg attatacaac gcctaataaa ttattagaca aaggtgaaat cgatgcgaac 240
 ttcttccaac atacaccata cttaaatact gaaagtaaag aaaaagggtg taaaattgaa 300
 tcggctggga atgttgaatt agaacctatg gctgtatact caaaaaata taaaagctta 360
 aaagatcttc cttaaagggtgc aacagtatat gtatcaata acccagctga acaaggacga 420
 ttcttaaaat tctttgtaga tgaagggtctt attaaactta aaaaaggcgt taaaattgaa 480
 aatgctaaat ttgatgacat aactgaaaac aaaaagata ttaaatttaa caacaaacaa 540
 tcagcagaat atttaccaaa aatctatcaa aatcaagacg ctgacgcagt aatcattaat 600
 tctaactatg cgattgacca aaaattaagt cctaaaaaag attcgattgc tttagaatct 660
 cctaaagata acccatatgc aaatttaatt gcagttaaaa aaggtcataa agatgataaa 720
 aatatcaaag tattaatgga agtgctacaa tctaaagaaa ttcaagatta tattaagat 780
 aagtatgatg gagctgtcgt acctgctaag 810

<210> 14
 <211> 1317
 <212> DNA
 <213> Staphylococcus epidermidis

<400> 14
 atggaattaa caatatatca cacgaatgat attcatagtc atttaaatga atatgctcgt 60
 attcaagctt atatggcaaa acatagaccg caacttgaac atccctcact ctatatagat 120

- 17 -

atagggtgacc atgttgattt atcagcacct gtgacagaag ctacggtagg acataaaaaat 180
 atagaacttt taaatgaagc acattgtgat attgcaacca ttggaaataa tgaaggaatg 240
 acaattttctc atgatgcttt acaaaatcta tataacgacg cggattttta agtgatttgc 300
 acgaatgtca tagatgaaga gggacatctt ccacatcata ttacctcttc gtatatcaaa 360
 gaaataaaaag gaacacgtat tttatttggt gcagcaacgg caccgttcac acctttttat 420
 cgagcactgg attggattgt tactgaccca ttagcggcaa tcaaagatga aatcaatgca 480
 catcaagggtg aatatgatct tttaatgggt atgagccatg toggatctt ttttgatgaa 540
 aagttatgcc aagagattcc ggaaatagat gttatctttg gtagtcatac gcatcatcat 600
 tttgaacatg gagaaataaa caatggtggt ttgatggcag ctgccggaaa atatggctat 660
 tatttaggtg aagttaatat tacgattgaa aatggaaaaa tcgttgataa aatcgccaaa 720
 attcatccta ttgaaacact tcccttagtc gagacacatt ttgaagaaga aggaagagca 780
 cttctaagta aaccagtagt taatcatcat gtgaacttag tcaaaagaac agatgttggt 840
 acaagaacat cgtattttact ggctgaaagt gtatatgagt tttcaagggc tgattgtgca 900
 atcgtaaatg ctggacttat agttaatggc attgaagctg ataaagtgc ggaatatgat 960
 atacatcgca tgttacccca tccaatcaat attgtaagag ttcgattaac cggtaaaca 1020
 ttaaagcaag tgattcaaaa aagccaaaag caagaatata tgcacgaaca tgcacaaggt 1080
 cttgggttta gaggggatat atttggagga tataattttat ataattctagg ctttattgag 1140
 tcagaagacc gttattttat aggcgatgaa gagattcaaa atgataaaca atatacgta 1200
 ggtactgttg atatgtatac atttggaaga tatttcccat tgctaaaggg gttatctaca 1260
 gattatatta tgctgaatt tttacgtgat atttttaaag agaaattact aaaatta 1317

<210> 15

<211> 609

<212> DNA

<213> Staphylococcus epidermidis

<400> 15

atggagaaag taatttatct agctggccat attcttaatg aagcaatggt tgattataga 60
 gaaaaacaac ataaccaagt tgaagcaatt gagggagtaa aaccttatag ccctcaccaa 120
 gacaaatcta ttaatgataa gtctaatagca gttcaagaag gtttgccga gagaatttta 180
 aagaatgatt ttaccgcaat ggaaaaatca gatattctatg ttcttgatgt tttaaatgaa 240
 ggtttaggaa caatttctga gctcggaatt attattggaa tgaagaaaca agctcaaaaa 300
 acaattgata gattgagtgt cttatctgaa gaaataaaac atgatgtata tggagatcaa 360
 acagaagctt atgatttaat tcaagacgaa atctacaagc aagaaaaaat cttaaataaa 420

- 18 -

acagttctat gttactgttc agatattaga caaggacacg gaaaacctta tactgatcca 480
gaccgtgctg aattctctac taaccaatth gtatatggaa tggtagtgga agctactaat 540
ggtgaaggth ttattacttg ggatcaagth ttacatagat tagatttgth tggaagtgga 600
ctaattgth 609

<210> 16
<211> 177
<212> DNA
<213> Staphylococcus epidermidis

<400> 16
atgagcaaaa agtttagagt tgaagataaa gaaacaattg cagattgtct cgacagaatg 60
aaaaaagaag ggtttatgcc aatacgtcgt attgagaaac cagtttataa agagaacaaa 120
gatggcagta tagagattth aaaacaggat attatatttg taggtgctth aatcaa 177

<210> 17
<211> 11076
<212> DNA
<213> Staphylococcus epidermidis

<400> 17
atgaatctat ttagaaaaca gaaatttagt attagaaaat ttaatatagg tattttttca 60
gcattaatag ctacagtcgc atttttagct catccggggc aagcaacagc atcagaactg 120
gaaccttctc aaaataatga cactacagct caatctgatg gagggttaga aaacacatct 180
cagtctaatac ctataagtga ggaaaccaca aatacattat ctgggcaaac agtaccttca 240
tctactgaaa ataagcaaac acaaaatgth cctaatacata acgctcaacc aattgcaata 300
aatactgaag aagctgaatc tgctcaaaca gcatcttata ccaatatcaa tgaaaataat 360
gatacgagtg acgatgggth acatgttaat cagccgggta aacatcatat tgaagcccaa 420
tctgaagatg taacaaatca cacgaactca aatcattcaa attcatgat tccagaaaat 480
aaagctacaa cagaatcatc aagtaaacct aaaaaaagag ggaaaagatc attagataca 540
aataacggaa atgacacgac aagtacaact caaaatacgg atccaaatth aagtaataca 600
ggtccaaatg gcattaacac tgtaattaca tttgatgatt taggaattaa gacaagtact 660
aatcgctctc gacctgaggt aaaggtagth gatagtctaa atggctttac aatggthaat 720
ggtggtaagg tcggthtatt aaatagtgtg ttagaacgta caagcgtgth tgatagtgcc 780
gatccgaaaa attatcaagc aatagataat gtcgtagcct taggacgtat taaaggaaat 840
gatccgaatg atcatgatg tttcaacggt atagaaaaag aattttcagt gaaccctaata 900
tctgagataa tatttttcatt taatacaatg actgctaaaa acagaaaagg tggaactcaa 960
ttagthttta gaaatgcaga aaataatcaa gaaattgctt caactgatat tcaaggaggc 1020

- 19 -

ggcgtatatc gtttattcaa gttacctgat aacgtacata ggttaaaagt tcaattttcta	1080
cctatgaacg aaatacactc agatttttaa agaattcaac agctacatga tgggtataga	1140
tactattctt ttatagatac aattggtggt aattctggtt cacatctata tgtgaaatca	1200
agacaagtta acaaaaatgt aaagaatggt aaagaatttg aagttaatac tcgtatagag	1260
aataatggta acttcgctgc tgctataggt caaaatgaac ttacttataa agtaacacta	1320
ccagaaaatt tcgaatacgt tgataattca actgaagttt catttggttaa cggaatgtg	1380
cctaattcta cggtaaatacc gttttcagtt aatttcgata gacaaaatca tactttaacg	1440
tttagtagta atgggttttaa tttaggaaga agtgctcagg atgttgctag attcttgccc	1500
aataaaatac taaatattag atacaagctt agacctgtca acatctcaac gccacgtgaa	1560
gtgactttca atgaagcaat taaatataag acattttctg aatattacat taacactaat	1620
gacaatactg ttactgggtca acaaacacct ttcagtatta atgtcatcat gaataaagac	1680
gatttatcag aacagggtcaa taaggatatc atcccatcga actatacact tgcttcttat	1740
aataaatata ataagttgaa agaacgtgct cagactgttc tggatgaaga aacaaacaat	1800
acacctttta accaaagata ctctcaaact caaattgatg atttggtaca cgaattacaa	1860
acaacactaa taaatcgtgt gagtgcttcg agagaaatta atgataaagc tcaagaaatg	1920
actgatgctg tatatgatag tacagaatta actactgaag aaaaagatac attagttgat	1980
caaattgaaa atcataaaaa tgaaatttct aataacattg atgatgaact tacagatgat	2040
gggtgttgaag gagtcaaaga ggctggatta catactctag aaagtgtac tccacatcca	2100
gtaacaaaac caaatgcacg acaagttgtg aataacagag cagatcaaca aaagacgctt	2160
atacgtaaca atcatgaggg aactaccgaa gaacaaaatg aagcgattag acaagttgag	2220
gcacattcat ctgatgctat cgccaaaata ggtgaggcag aaacagatac cactgtaaat	2280
gaagctagag acaatggtac gaaattaata gctacagatg ttccaaatcc aactaaaaaa	2340
gcagaagcta gagcggcagt taccaacagt gcaaattcaa aaattaagga tatcaacaat	2400
aatacacaag caacattaga cgagagaaat gatgctatcg cacttggtta tagatcaaaa	2460
gatgaagcaa ttcaaaatat taacactgca caaggtaatg atgatgtcac tgaagcacia	2520
aataatggaa cgaatacgat acaacaagta ccattaactc cagtgtaaaag acaaaatgca	2580
atagcaacta tcaatgctaa agcggatgaa caaaaacgtt taattcaagc aaacaataat	2640
gcaacgactg aagaaaaagc tgatgcagag cgtaaagtta atgaagcagt cataactgca	2700
aatcaaaaata ttaccaatgc aactactaat agagatgttg atcaagcaca aacaactgga	2760
agtggtatca tatctgctat tagtcctgca acgaagatta aagaggatgc acgtgcagca	2820
gtagaagcta aagctattgc acaaaatcaa caaattaatt caaataatat ggcaacaact	2880

- 20 -

gaagaaaagg aggatgcatt aatcaagta gaagcacata agcaggccgc aatagcaact	2940
atcaatcaag cgcagtcaac tcagcaagtt tctgaagcta agaataatgg cataaatact	3000
attaatcaag atcaacctaa cgcagttaag aaaaataata caaaaataat attagaacaa	3060
aaaggaaaacg agaaaaagtc agcaatagct caaacacctg atgctaccac tgaagagaaa	3120
caagaagctg tcagtgtgtg ttgcgaagct gttaccaatg gcattacca tatcaaccaa	3180
gcaaattcta atgatgatgt tgatcaagaa cttagtaatg cagaacaaat tattactcaa	3240
actaatgtca atgttcaaaa aaaacctcaa gccagacaag cattgattgc taaaacaaat	3300
gaaaggcaga gtacgattaa tactgacaat gaaggcacta tagaagaaaa acaaaaagca	3360
attcaaagtt tgaatgatgc taaaaattta gctgatgaac aaattacaca ggctgcttct	3420
aatcaaaatg tcgacaacgc cttaaataata ggtataagta atatcagtaa aatacagact	3480
aatttcacta aaaagcaaca agctagagac caagtaaatac aaaagttcca agaaaaagaa	3540
gctgagttaa attcaacacc tcatgcaact caagatgaaa aacaagatgc gttaactaga	3600
ttaacacaag caaaggaaac tgcaactaac gacataaatc aagcacaac aaatcaaaat	3660
gtggatacag cacttactag tggaattcaa aatattcaaaa atacacaagt taatgttagg	3720
aaaaagcaag aagccaaaac tacgattaat gatattgttc aacaacataa acaaactata	3780
caaaataatg atgatgctac aactgaagag aaggaagtcg caaataatgt agttaatgca	3840
tcacagcaaaa atgtaattag taagattgat aatgctacaa cgaataatca aattgatggt	3900
attgtgagtg atggtagaca aagcataaat gcaattacac ctgatacatc aattaaaaga	3960
aatgctaaaa atgatattga tattaaagca gctgataaga aaataaaaaat tcaaagaata	4020
aatgatgcta cagatgaaga aattcaagaa gcgaatcgta aaattgaaga agctaagatt	4080
gaagcaaaag ataattattca acgcaatagt actagagatc aagtaaataga agcgaaaact	4140
aatggaataa ataaaataga aaatataaca ccagcaacta ctgtgaaatc tgaagctaga	4200
caagcagtac agaataaagc aaatgaacag attaatacata ttcaaaacac gcctgatgca	4260
actaatgaag aaaaacaaga ggcaataaat agagtaagtg ctgaattagc aagagttcaa	4320
gcacaaataa atgcagaaca tacaacccaa ggtgtcaaaa ctatcaaaga cgacgcgata	4380
acttctttat ctgaattaa tgcacaagtt gttgagaaa agtctgcaag aatgcaatc	4440
gaacaaaagg caacacaaca aacgcaatgt attaataata atgataatgc tacagatgaa	4500
gaaaaagagg tcgccaacaa tttagttatc gctacaaaac aaaaatcatt agataatatt	4560
aactccttat cttcaataa tgatgttgaa aatgctaaag tagcaggaat aatgaaata	4620
gctaacgttt taccagcaac cgctgttaag tcaaaagcaa aaaaagatat tgatcaaaaa	4680
ctcgcgcaac agattaatca aattcaaacg catcaaacctg ctacaactga ggaaaaagaa	4740

- 21 -

gcggctattc aattggcaaa tcaaaaatca aatgaagcaa gaacagcaat tcaaaatgaa	4800
catagtaaca atggtgtcgc acaagctaaa tctaacggca ttcattgaaat tgaattagtt	4860
atgccagatg cgcacaaaaa atctgatgct aaacaaagta tcgataataa atataatgag	4920
caaagtaata ctatcaacac tacaccagat gcaacagatg aagaaaagca aaaagcatta	4980
gataaattaa aaatagctaa agatgcagga tacaacaaag ttgatcaagc gcaaacaaac	5040
caacaagtat ctgatgcaaa aactgaggct atagatacga taactaatat tcaagcaaat	5100
gttgcaaaaa aaccatccgc tcgagtggaa ttagattcaa agtttgagga tttaaagcgt	5160
caaatcaatg caacgcccaa tgctacagaa gaagaaaaac aagatgcaat tcaaagattg	5220
aatggtaaaa gagatgaagt taagaatcta ataatcaag atagacgtga caatgaagtt	5280
gaacagcaca aaaatattgg acttcaagaa ttagaaacga ttcattgctaa tccaactaga	5340
aaatctgatg cgctccaaga gttacaaact aaattttattt cacaaacaga gttaattaat	5400
aataacaaag atgcaactaa tgaagaaaaa gatgaagcca aacgacttct tgagattagt	5460
aaaaataaaa ctataacaaa tatcaatcaa gcgcaacta ataatacagt tgataatgct	5520
aaagataacg gcatgaatga gattgctacc ataataccag caacaacaat taaaacagat	5580
gcaaaaacgg ctattgataa aaaagctgag caacaagtta caatcatcaa tggtacaac	5640
gatgcaacag atgaagaaaa agcagaggct agaaagctgg ttgaaaaagc gaaaattgaa	5700
gccaaatcta atattacaaa tagtgatact gaaagggag tcaatgggtgc taaaaccaat	5760
gggttagaaa aaataaacia tattcaacca tcaactcaaa ctaaaacaaa tgctaagcaa	5820
gaaataaatg acaaagctca agaacaatta atccaaatta ataacacgcc tgatgcaacc	5880
gaagaagaaa agcaagaggc aacaaataga gtcaatgctg gattagcaca agcaatacaa	5940
aatattaata atgcacatag tactcaagaa gtaaatgaat ctaaaacaaa tagtattgct	6000
acaatcaaga gtgtacaacc caatgtgatc aaaaaaccga ctgctataaa tagtttgact	6060
caagaagcta ataatacaaaa gacgttaata ggtaatgatg gtaatgctac tgatgatgaa	6120
aaagaggctg caaagcaatt agtgacccaa aaattaaatg aacaaattca aaaaattcat	6180
gaaagtacac aagataatca agttgataac gtaaaagcac aagctatcac tgcaattaaa	6240
ttgattaatg caaatgcaca taaaagacaa gatgccatta atattttgac taatctagct	6300
gaaagtaaaa aatcagatat aagagccaat caagatgcaa ctactgaaga gaaaaatacg	6360
gcaatacaat ctatagatga tacgttagca caagcacgta acaatattaa tgggtgcaaat	6420
acaaatgcgt tagtgatga gaatttagaa gatggtaagc aaaagttaca acgtattgtg	6480
ttgtcaactc aaactaaaac acaagctaaa gcagacattg ctcaagcaat aggtcaacaa	6540
aggtcgacaa tagaccagaa tcaaaatgct acaacagaag aaaaacaaga agcccttgag	6600

- 22 -

agacttaatc aagaaacaaa tggagtcaat gatagaatac aagcagcttt agcaaatcaa	6660
aatgtttacag acgaaaaaaaa taatatatta gaaacaataa gaaatgttga acctattgta	6720
attgtaaaac caaaggctaa tgaaataatt agaaaaaaaa ctgcggaaca aacgacttta	6780
ataaatcaaa atcaagatgc gacactagaa gaaaaacaaa tagcaattgg caaattagaa	6840
gaagttaaaga atgaagcggt aaatcaagta tcacaggcac actcaaataa tgatgtgaaa	6900
attgtggaaa ataatggaat tgctaaaatt tctgaggtcc atcctgagac tataattaaa	6960
cgtaatgcta aacaagaaat tgaacaagat gcgcaaagtc aaattgatac tatcaatgca	7020
aataataaat caactaatga agaaaaatca gccgctatag atagagttaa tgtagctaaa	7080
attgatgcta ttaacaatat tactaatgct acaactacac aattagttaa tgatgctaaa	7140
aatagtggta acacgagtat tagccaaata ttaccaagta cagcagtc aaactaatgca	7200
ttagcagctc tagctagcga agctaaaaat aaaaacgcta taatagatca aacaccaa	7260
gcgacagcag aagaaaaaga agaagcaaat aataaagttg atcgtcttca agaagaagca	7320
gatgctaata tcctaaaagc acacactact gatgaagtta ataattataa aaatcaagct	7380
gttcaaaaata ttaacgctgt tcaagttgaa gttatcaaga aacaaaacgc taaaaaccaa	7440
ttaaatcaat tcattgataa tcaaaagaaa attattgaaa atacgcctga tgcaacacta	7500
gaagaaaaag ctgaagctaa tagattgctt caaatgttac taacttccac atcagatgaa	7560
attgctaattg tagatcataa caacgaggtt gatcaagctt tagataaagc tagacaaaaa	7620
atcgaggcaa ttgtaccaca agttagtaag aaacgagatg ctttaaatgc aatccaagaa	7680
gcattttaatt caciaactca agaaatacaa gagaaccaag aagctacgaa tgaagaaaaa	7740
actgaagcat taaataaaat aaaccaatta cttaatcagg cttaaagtaaa tattgatcaa	7800
gcacagtcaa ataaagatgt agatagtgcg aaaacacgta gtattcaaga tatagagcaa	7860
attcaaccac atccacaaac aaaagcaacc gggcgtcaca gattaaatga aaaagctaac	7920
caacaacaaa gtactattgc aactatcct aattcaacaa ttgaagaaag acaggaagca	7980
agtgcaaaac tacaagaagt tcttaaaaaa gccatagcta aaatagataa aggtcaaacc	8040
aatgatgatg tagaaaagac tgtagtaaac ggaatagctg aaattgaaaa tatattacct	8100
gctactacag ttaaagataa agctaaagct gatgtaaatg ctgaaaaaga ggagaaaaac	8160
ctacaaatta atagtaatga tgaagcaacg actgaagaaa aattagttgc tagtgacaat	8220
ttaaatcacg ttgtcgagac aacaaatcaa gctattgagg atgcaccaga taccaaccaa	8280
gtgaatgtag aaaagaacaa aggtataggt acaattagag atattcaacc acttgtagtt	8340
aaaaaaccta ctgccaaatc taaaattgaa agcgcagtag aaaaaagaa aactgaaatt	8400
aatcaaacac aaaatgcaac tcatgatgaa gtaagagagg gtttaaatca gttaaatcaa	8460

- 23 -

attcatgaaa aagccaaaaa tgatgtaaat caatctcaaa ctaatcagca agttgaaaat	8520
gctgagcaaa atagttttaga tcaaatcaat aacttcagac cagatttttag taaaaaacgt	8580
aatgcagtag ctgaaattgt taaagcgcaa caaaacaaaa ttgatgaaat agagcaagaa	8640
tttagtgcta cacaagagga aaaagacaat gctttacaac atttagatga acagggttaaa	8700
gaaatcatta attctataaa tcaagctaata acagataatg aagtagataa tgctaaaact	8760
tctgggttga ataacataac tgaatacaga ccagaatata ataaaaagaa aaatgctata	8820
ttaaaattat atgatgtttc agatactcaa gaagctataa ttaatggtta tcctgatgca	8880
actgaagatg aacttcaaga agctaatagt aagttaaata aaatactttt agatgcaaaa	8940
aaacaaattg gtcttgcgca cacaaataat gaagttgatg atatttataa tgaagtttcc	9000
caaaaaatga aaactatttt accacgtgta gatacaaaag cggtagcacg ttctgtactt	9060
aatgcacttg ctaaacaatt gattaaaact tttgaaaata ctgcagatgt tactcacgag	9120
gaacgtaatg atgcgattaa tcatgtaaaa gaacaattat ctttagtatt caatgccatt	9180
gaaaaagacc gaaaagatat acaagttgcg caagatgaat tatttggtt aaatgaatta	9240
aatagtatat ttatcaacat aactcaaaag ccaactgcc aaaaagcaat tagtggtatg	9300
gcgagtcaat taaacaactc tatcaataat acgccatatg ctacagaaga agaacgacaa	9360
attgcactga ataaagttaa ggcgattgtt gatgatgcaa atgaaaaaat acgagaagct	9420
aacactgata gcgaagtact tggaacaaaa tcaaacgcaa taacattgtt acaagcaatc	9480
agtgcggtatg tacaagttaa accacaagca tttgaagaaa tcaatgcaca agctgaaatt	9540
caaagagaac gaattaatgg aaatagtgat gcgacaagag aagaaaaaga agaagcttta	9600
aaacaagttg atacattagt aaatcattca tttattacaa ttaataatgt taataaaaaat	9660
caagaagttt atgatactaa agacaaaacg attgaagcta ttcataaaat caaaccaata	9720
tcaactatca aaccacaagc attaaatgaa atcactattc aactagacac tcaacgtgat	9780
ttaataaaga ataataaaga gtctacagtt gaagaaaaag cctcggctat cgataaatta	9840
attaaaactg cagcaagaat agccgaatca atagataaag ctcaaacaaa tgaagaagtt	9900
aaaaatatta aaaaacaaag tattgatgaa atttctaaaa tactacctgt tattgaaatt	9960
aatcagctg caagaaatga aattcatcaa aaagcagaag ttattcgcgg attaattaat	10020
gataatgaag aagcgactaa agaagaaaaa gatatcgcat taaatcaatt agacacaact	10080
ctaacacaag caaatgtttc aattgaccaa gcattaacaa atgaagctgt taatagagct	10140
aaagaaatag caaattctga aattaataaa atttctgtca ttgccattaa aaagcctgaa	10200
gctatagcag aaattcaaga actagcagat aaaaaattaa ataaatttaa acaagtcaa	10260
gaagctacta ttgaagaaaa gcaatcagct atcaatgaat tagaacaagc tttaaaatca	10320

- 24 -

gctattaatc atattcatca atctcaaaat aatgaatcag tgagcgctgc attaaaagaa 10380
 agtatatctt taatagactc gattgaaatt caagcacata aaaaattaga agctaaagca 10440
 tacattgatg gatatagtga cgataaaaatt aatgacatat cttctagagc gactaacgaa 10500
 gaaaaacaaa tttttgtaag taaacttaaa gcattaatca atcgtaacaca taaacagatt 10560
 gacgaagctg aaacatttgt ttcagttgaa acaattgtcc gaaactttaa agttgaagcg 10620
 gataaattaa actcaattgt acgtaaaaaa gctaaagcat cgaaggaaat tgaattagaa 10680
 gcagaccatg taaagcaaatt gataaatgca aattttaagt ctagtactag agtgaaacaa 10740
 aatgctcgta cattgataaa tgaaattggt agtaacgctt taagtcaact taataaagta 10800
 accacaaata aagaagttga tgaaatagtt aacgaaacga ttgaaaaact taagtcaata 10860
 caaataagag aagataaaat attgagtagt caacgttcat caacatctat gacggaaaaa 10920
 tctaatacat gttatagttc cgagaataat acaattaaat ctctaccaga ggcaggaaat 10980
 gctgataaat cactaccatt agcaggagtt actttaatat ctggtttagc aatcatgtcc 11040
 tcacgtaaaa agaaaaaaga taaaaaagta aatgac 11076

<210> 18
 <211> 1317
 <212> DNA
 <213> *Staphylococcus epidermidis*

<400> 18
 ttggatataa aaatgcctaa gcttggtgaa agtgtgcatg aaggtacgat tgaacaatgg 60
 ttagtatcag taggagatca tgtagatgag tatgaaccat tatgtgaagt tattacagat 120
 aaagtaacag ctgaagtgcc ttcaacaatt tctggaacaa taacagaatt agtggttgaa 180
 gaaggacaaa ctgtcaatat taacacggtg atttgtaaaa tcgattcgga aaatggtcaa 240
 aatcaaacag aatcggcaaa tgagtttaag gaagaacaaa atcagcattc tcaatcaaat 300
 ataaacgtgt cacaattcga aaataatcct aaaactcatg aaagtgaggt gcatacagcc 360
 tctagtcgcg caaataacaa tggacgattt tcaccagttg tctttaaatt agcttctgaa 420
 catgatattg atttaacaca agtcaaagga actggttttg aaggtcgtgt tactaagaaa 480
 gatattcaaa atattattaa caatccaaac gatcaagaaa aagagaaaga atttaaacaa 540
 acagataaaa aagatcattc aacgaacat tgtgactttt tacatcaatc ctcaactaaa 600
 aacgaacact caccattatc aaatgaacgt gtcgtaccag ttaaaggat tagaaaagct 660
 atcgcacaaa atatggttac tagtgtcagc gaaataccac acggttgat gatggttgaa 720
 gctgatgcaa cgaatttggg tcagactaga aactatcata aagctcaatt taaacagaat 780
 gagggttaca atttaacttt ctttgcggtt tttgtaaaag ctgttgacga ggctttaaaa 840
 gtaaattccat tactcaatag tacatggcaa ggagatgaaa ttgttatcca caaagatatt 900

- 25 -

aatatctcta ttgctgttgc agacgatgat aagttgtatg tgccagtcac taaaaatgca 960
gatgaaaaat caattaaagg tatcgcgcggt gaaatcaatg atttagctac taaagcaaga 1020
ttaggaaaaat tagcacaaag tgatatgcaa aacggtacat ttacgggttaa taatactggt 1080
tcttttgggtt ctgtttcttc aatgggaatc attaatcatc cacaagctgc cattttacaa 1140
gtagaatcag tcgttaagaa acctgtagtt atagatgata tgattgcaat tagaaatatg 1200
gttaatttgt gtatttcaat cgatcatcgt attctcgatg gtgttcaaac gggaaaattt 1260
atgaatcttg ttaagaaaaa aatagaacaa tattctattg aaaacacttc tatttat 1317

<210> 19
<211> 885
<212> DNA
<213> Staphylococcus epidermidis

<400> 19
atgaatacta tcattgaaga atatttaaatt ttcattcaaa ttgaaaaagg attaaagtaac 60
aatactatag gagcgtatcg aagagattta aaaaaatata aagattatct tgaagataac 120
aagatttcac atatcgattt tattgataga caaattatcc aagagtgtct tggacacctt 180
atagatatgg ggcaatcttc aaaatctctc gcaaggttta tttctacaat aagaagcttt 240
catcagtttg cattacgcga aaaatatgct gctaaagacc caactgtttt aattgaaaca 300
cccaaatatg aaaagaaatt accagatgtg cttgaaatag acgaagtaat agcattactg 360
gaaacgcctg atttaactaa gaataatgga tatcgtgac gtacgatgtt ggagctttta 420
tacgccacag gtatgcgtgt aactgaaatt attcaattag atgttgaaga cgtaaactta 480
atgatgggat ttgtaagagt tttcgggaaa gggaaataagg aaagaatcgt tcccttagga 540
gataccgtca tcgaatatatt aactacatat attgaaaccg taagacctca attactcaaa 600
caaaccacaa ctcaagcgct atttcttaac atgcatggaa agtctttatc aagacaaggc 660
atgttgaaaa tcattaaaca atatggtttg aaagctaata tcaataaaac gcttacacca 720
catacattac ggcattcatt tgcaacacat ctcttagaaa atggtgctga ttttaagagcc 780
gtacaagaaa tgtttaggtca ctctgatatt tctacaactc aactttatac acatgtatct 840
aatcacaaa ttagaaaaat gtatacgcag tttcatccaa gagct 885

<210> 20
<211> 2400
<212> DNA
<213> Staphylococcus epidermidis

<400> 20
atgagtttag tatatcttat ggcgactaat ttattagtc tgcctcatagt tttattcact 60
ctgagtcac gtcaactaag aaagggttgcg ggctatgttg cattaatagc tcctattgtg 120

acatctacat attttattat gaaaatacca gatgtgattc gaaataagtt tattgctgtt	180
cgattaccat ggatgccttc aattgatatt aatttagatt taagattaga tggtttaagt	240
ttaatgttcg gcttaattat ttcgctaata ggtgtgggtg tattttttta tgctacgcaa	300
tatttatccc acagtaaggga caatcttctt agatttttca tctatttact attatttatg	360
ttcagtatga ttggcattgt aatagctaata aataccatct taatgtatgt attttgggaa	420
ctcacaagta tttcctcatt cttgcttata tctatttggg acaataatgg tgaaagtcaa	480
ttaggcgcca ttcaatcttt catgattaca gtgtttgggt ggctagcgtt attaacagga	540
tttatcattt tatatatcat tacaggaaca aacacaatta ctgatatcct taatcaacgc	600
aatgcaattt cagcacatcc tttatttata ccaatgattt tgatgctatt attaggtgct	660
tttaccaaat ctgcacaatt tccgtttcat atttgggttac caaaggccat ggcagcacct	720
acaccagtaa gtgcttatct tcattcggca acaatggtaa aggctggaat ctttttacta	780
tttagattta cacctttatt gggacttagt aatgtttata tttatacagt gacatttggt	840
ggtctaataa ctatgttatt tggatcttta actgctttac gacaatacga cttaaagggt	900
atactcgctt attctacaat aagtcaatta ggtatgatta tgacaatggg aggtctaggt	960
ggcggttatg ctcagcacac atcagatgaa ttgtctaagt tttatatattt agttttattt	1020
gctggcttat tccatttaat gaatcatgcg gtttttaaag gtgcattatt tatgggcgtt	1080
ggtatcattg atcacgagtc cggaacacgt gatattcgtt tgctaaatgg tatgcgtaaa	1140
gtcttcccta aaatgcatat tgtcatgttg ctgcgtgcat tatctatggc aggtgttctt	1200
tttttaaagtg gctttttaag taaggaaatg tttttagatt cgtaaactaa agcaaacgaa	1260
cttgatcaat atggcttcgt attaacgttt gtgattattt caataggtgt catcgcgagt	1320
atattgactt ttacttatgc actttacatg ataaaagaaa cattctgggg aaattacaat	1380
atagaaaaat ttaaacgtaa acaaatacat gaaccatggc tatttagttt accagctgtg	1440
attttaagtgt tactcattcc agttatcttc tttgttccaa acgttttttg caactttgtt	1500
attttgcccg caaccagatc tgtatctggg ataggtgcgg aggttgatgc atttgtgcca	1560
catatctctc agtggcatgg tgtgaatctt ccattaattt taagtatagt tgttattatt	1620
attggactta ttttagctct agttgtgaat tggaaagagg ttacgcatca aataatcaaa	1680
agtgcctcga ttacagatgg ctatcggaat atttatagag aatttgaatt atactcagcc	1740
cgtggtatac gtgcattgat gaataataaa ttgaattatt acatcatgat tacattattt	1800
atttttgtag ctattgtagt ttatggatat ttgactgtgg gttttcctca tgtacatcag	1860
cttcatatta gttctttcgg accgttggaa gttatcttat cagttgtaac attgattatc	1920
ggcatttcat taatctttat tcgtcaacga ctaacgatgg tggatttgaa tggaatgatt	1980

- 27 -

ggattcgcag ttacattata ttttattgca atgaaagctc cagatttagc ttttaacacag 2040
 ttagttgttg aaactattac gacaatctta tttattgtta gtttttcgag actacctaac 2100
 atccctcgag ttaaggcaaa tttaaaaaaa gagaccttca aaatcattgt gtcacttggt 2160
 atggcattga cgggtggtatc acttattttt gttgctcaac aagcagatgg tatgccttca 2220
 attgctaaat tttatgaaga tgcataatgaa cttacagggtg gaaaaaatat tgtcaatgct 2280
 atactagggtg acttcagagc tttagatact atgtttgaag gactagtgtt aatcatagct 2340
 ggattaggta tttatacggtt acttaattac aaagatagga gggggcaaga tgaaagagaa 2400

<210> 21
 <211> 2676
 <212> DNA
 <213> Staphylococcus epidermidis

<400> 21
 ttgtttgggt taggtcataa tgaggccaaa gctgaggaga atacagtaca agacgttaaa 60
 gattcgaata tggatgatga attatcagat agcaatgac agtccagtaa tgaagaaaag 120
 aatgatgtaa tcaataatag tcagtcaata aacaccgatg atgataacca aataaaaaaa 180
 gaagaaacga atagcaacga tgccatagaa aatcgctcta aagatataac acagtcaaca 240
 acaaatgtag atgaaaacga agcaacattt ttacaaaaga cccctcaaga taatactcag 300
 cttaaagaag aagtggtaaa agaaccctca tcagtcgaat cctcaaattc atcaatggat 360
 actgccaac aaccatctca tacaacaata aatagtgaag catctattca aacaagtgat 420
 aatgaagaaa attcccgcgt atcagatttt gctaactcta aaataataga gagtaacact 480
 gaatccaata aagaagagaa tactatagag caacctaaca aagtaagaga agattcaata 540
 acaagtcaac cgtctagcta taaaaatata gatgaaaaaa tttcaaatca agatgagtta 600
 ttaaatttac caataaatga atatgaaaat aaggtttagac cgttatctac aacatctgcc 660
 caaccatcga gtaagcgtgt aaccgtaaat caattagcgg cagaacaagg ttcgaatggt 720
 aatcatttaaa ttaaagttac tgatcaaagt attactgaag gatatgatga tagtgatggt 780
 attattaaag cacatgatgc tgaaaactta atctatgatg taacttttga agtagatgat 840
 aaggtgaaat ctggtgatac gatgacagtg aatatagata agaatacagt tccatcagat 900
 ttaaccgata gttttgcaat accaaaaata aaagataatt ctggagaaat catcgctaca 960
 ggtacttatg acaacacaaa taaacaaatt acctacactt ttacagatta tgtagataaa 1020
 tatgaaaata ttaaagcgca ccttaaatta acatcatata ttgataaatc aaaggttcca 1080
 aataataaca ctaagttaga tgtagaatat aagacggccc tttcatcagt aaataaaaca 1140
 attacggttg aatatcaaaa acctaacgaa aatcggactg ctaaccttca aagtatgttc 1200

- 28 -

```

acaaacatag atacgaaaaa ccatacagtt gagcaaacga tttatatataa ccctcttcgt 1260
tattcagcca aagaaacaaa tgtaaattatt tcagggaatg gcgatgaagg ttcaacaatt 1320
atcgacgata gtacaatcat taaagtttat aaggttggag ataatacaaaa tttaccagat 1380
agtaacagaa tttatgatta cagtgaatat gaagatgtca caaatgatga ttatgcccaa 1440
ttaggaaata ataatgacgt gaattattaat tttggtaata tagattcacc atatattatt 1500
aaagttatta gtaaataatga ccctaataag gacgattaca cgacgataca gcaaactgtg 1560
acaatgcaaa cgactataaa tgagtatact ggtgagttta gaacagcatc ctatgataat 1620
acaattgctt tctctacaag ttcagggtcaa ggacaagggtg acttgccctcc tgaaaaaact 1680
tataaaatcg gagattacgt atgggaagat gtagataaag atggtattca aaatacaaat 1740
gataatgaaa aaccgcttag taatgtattg gtaactttga cgtatcctga tggaacttca 1800
aaatcagtcga gaacagatga agaggggaaa tatcaatttg atgggttaaa aaacggattg 1860
acttataaaa ttacattcga aacaccggaa ggatatacgc cgacgcttaa acattcagga 1920
acaaatcctg cactagactc agaaggcaat tctgtatggg taactattaa cggacaagac 1980
gatatgacta ttgatagcgg attttatcaa acacctaata atagcttagg gaactatgta 2040
tggtatgaca ctaataaaga tggtattcaa ggtgatgatg aaaaaggaat ctctggagta 2100
aaagtgacgt taaaagatga aaacggaaat atcattagta caacaacaac tgatgaaaat 2160
ggaaagtatc aatttgataa tttaaatagt ggtaattata ttgttcattt tgataaacct 2220
tcagggtatga ctcaaacaac aacagattct ggtgatgatg acgaacagga tgctgatggg 2280
gaagaagtcc atgtaacaat tactgatcat gatgacttta gtatagataa cggatactat 2340
gatgacgact cagattcaga tagtgattca gactcagata gcgaogactc agactccgat 2400
agcgattccg actcagacag cgactcagat tccgatagtg attcagattc agacagtgac 2460
tcagactcag atagtgattc agattcagac agcgattccg actcagacag tgactcagga 2520
ttagacaata gctcagataa gaatacaaaa gataaattac cggatacagg agctaataa 2580
gatcatgatt ctaaaggcac attacttgga gctttatttg cagggttagg agcgttatta 2640
ttagggaagc gtcgcaaaaa tagaaaaaat aaaaat 2676

```

<210> 22

<211> 1452

<212> DNA

<213> Staphylococcus epidermidis

<400> 22

```

atgagtgaac gtatcagagt aagatatgcg ccaagtccaa caggatattt gcatattggt 60
aatgcaagaa cagcattatt caattattta tttgctaaac attataatgg tgattttggt 120
gttcgcatcg aagatacaga tagtaaactg aatttagaag atggtgaatc ttcacaattc 180

```

- 29 -

gataatctaa aatgggttagg tttggattgg gatgaatctg tcgataaaga taaagggttt 240
 ggaccttata gtcaatctga acgtgcagaa atctataatc cactaattca acagctatta 300
 gaggaagaca aagcatataa atgttatatg actgaagaag agttagaagc agagcgtgaa 360
 gctcaaattg ctogtggaga gatgccaaaga tatgggtggac aacatgogca cttaacagaa 420
 gaacagcgtc aacagtacga agcgggaagg cgtaaaccat caattcggtt ccgtgtgcct 480
 aaagatcaaa catatacttt caatgacatg gttaaaggag aaatttcctt tgaatctgac 540
 aatatcggag actgggtaat tgtaaaaaaa gatggtgttc cgacttataa ttttgcagtt 600
 gccgtagatg atcattatat gcaaatatca gatgttatac gtggtgatga ccatgtttca 660
 aatacaccta agcagttaat gatatatgaa gcatttggat gggaagcacc tcgttttgg 720
 catatgtcac tcattgttaa tgaagagcgt aaaaaattaa gcaagcgaga tgggtcaaatac 780
 ctacaattta tcgagcaata tcgtgactta ggatatcttc cagaagcatt atttaacttt 840
 attacattgt taggttggc acctgaagg gaagaggaaa tcttttctaa agaagaattt 900
 ataaagattt ttgatgaaaa acgcttgtct aagtctccag ctatgttcga tagacaaaaa 960
 cttgcttggg ttaacaatca gtatatgaaa acaaaagata cagaaacagt attcgaactt 1020
 gcattacctc atttaatcaa ggctaatactt atacctgaaa acccatcaga aaaggataga 1080
 gaatggggac gtaaatatga agcgttgtat caaaaagaaa tgagttacgc tggtgaaatt 1140
 gttccattat cagaaatgtt cttccatgaa atgccggaac ttggaaaaga tgaacaagag 1200
 gtattacaag gagaacaagt gccagaacta atgaaccatt tatatggtaa attagaatct 1260
 ttagaatcgt ttgaggcaac tgaaattaag aaaatgatta aagaagttca aaaagaaact 1320
 ggtattaaag gtaaacatt atttatgcct attcgtgttg ctgttactgg acaaatgcat 1380
 ggtcctgaat tacctaacac aattgaagta ttaggcaaag ataaagtatt gtcacgctta 1440
 aaaaaccttg tt 1452

<210> 23

<211> 888

<212> DNA

<213> Staphylococcus epidermidis

<400> 23

atggaatata aagatatagc aacaccatct cgaacacgtg ctttgcttga tcaatatggg 60
 ttttaatttta agaaaagttt aggacaaaat tttctaatag atgtaaatat cattaataaa 120
 attatcgaag cgagtcatat agattgtaca acgggtgtaa ttgaagttgg accagggtatg 180
 ggatcattga ctgaacaact tgcaaagaat gctaagaagg tgatggcttt tgaaattgat 240
 caaagattaa tacctgtgct taaagataca ctttcacat acgataatgt aacaattatc 300

- 30 -

aatgaagata tacttaaagc tgatattgct aaagctgtag atacacatct acaagattgt 360
 gacaagatta tggttgttgc taatttaccg tattatatta ccacacctat ttactttaat 420
 ttgatgcaac aggatgtacc tattgatggg tttgtcgtaa tgatgcaaaa agaggtagga 480
 gaacgtttga acgctcaagt aggtaccaa gcatacgggt cgttatcgat tgttgctcaa 540
 tactatacgg agacaagtaa agttttaaca gttcctaaaa ctgtatttat gcctcctcca 600
 aacgttgatt ctatcggtgt aaaattgatg caacgccaa aaccacttgt acagggtgat 660
 gatgaggaag gcttttttaa gttagcaaag gccgcttttg cacaacgacg taaaacaatt 720
 aataataact accaaaactt ctttaaagat ggtaagaaga ataaagaaac tatacgacag 780
 tggctagaaa gcgctgggtat tgatcctaaa agacgtggag aaacactcac gattcaagat 840
 ttcgccacat tatatgaaca aaagaaaaaa ttctccgaat taacaaat 888

<210> 24
 <211> 318
 <212> DNA
 <213> Staphylococcus epidermidis

<400> 24
 atgacgtcaa atcatcatgc cccttatgat ttgggctaca cacgtgctac aatggacaat 60
 acaaagggca gcgaaaccgc gaggtcaagc aaatcccata aagttgttct cagttcggat 120
 tgtagtctgc aactcgacta tatgaagctg gaatcgctag taatcgtaga tcagcatgct 180
 acggtgaata cgttcccggg tcttgtagac accgcccgtc acaccacgag agtttgtaac 240
 accogaagcc ggtggagtaa ccatttggag ctagccgtcg aagggtgggac aaatgattgg 300
 ggtgaagtcg taacaagg 318

<210> 25
 <211> 1326
 <212> DNA
 <213> Staphylococcus epidermidis

<400> 25
 atgtttttta aacaatttta tgataaacac ttatctcaag catcttattt aatcggttgt 60
 caaaaaactg gagaagccat gattattgat cctattcgtg acttatcttc atatattcga 120
 gttgctgatg aagaaggttt aaccattact catgcagctg aaacacatat acatgcagat 180
 tttgcttcag gaattagaga tgttgctata aagttaaagtg ctagtattta tgtatcgggt 240
 gaaagtgatg acacgttagg ttataaaaa atgcctaacc agactcattt tgttcaacat 300
 aatgatgata tttatgtagg aaatataaaa ttaaagtgct ttcatacacc tggtcacacg 360
 ccagaaagta taagtttttt acttactgat gaagggtgctg gagcacaagt tccaatggga 420
 ctattcagtg gtgattttat tttttagtaga gatatcggtg gacctgattt actagaaaaa 480

- 31 -

gctgttaaag tagaaggatc atctgaaata ggcgctaaac aaatgtttaa atctattgaa 540
 agtattaaag acttgccaaa ctacattcaa atttggcctg gccatggagc tggtagtcct 600
 tgtggtaaat ctttaggtgc tattccaaca tctactcttg gctatgaaaa acaaacaaac 660
 tgggcttttt ctgaaaaataa cgaagctacc tttatcgata aactaatttc tgaccaacct 720
 gcaccaccac atcattttgc acaaatgaaa aaaattaatc aattcgggtat gaatttatat 780
 caaccttata cggtttatcc agctacaaat acaaacagat taacttttga tctccgcagt 840
 aaggaggctt atcatggtgg acatattgaa ggtacaatca atattccata tgataaaaaat 900
 ttcacaaatc aaattggctg gtatctaaac tatgatcaag aaattaactt gattggagaa 960
 tatcaccttg tttcaaaaagc aacacacacc ttacaactca ttggatatga tgatgttgct 1020
 ggatatcaat tacctcaatc taagattcaa acacgttcca ttcatagtga agatattaca 1080
 ggtaacgaat cacatatatt agatgtacgt aatgataatg aatggaataa tggccactta 1140
 tctcaagcgg ttcatgtacc acacggcaaa cttttagaaa cagatttacc tttcaataga 1200
 aacgatgtta tttatgtaca ctgtcagtct ggcattagaa gttcgatagc tattgggtatt 1260
 ttagaacata aaggttatca caacattatt aatgtaaagtg aaggttacaa agatatacac 1320
 ctttct 1326

<210> 26

<211> 855

<212> DNA

<213> Staphylococcus epidermidis

<400> 26

ttgaaaaaaa ttctggtgtt aagttaaacg gcatttttag ttttggctgg ttgtaattca 60
 ggtgataaga ctgatactaa agataagaaa gaagaaacaa agcaaacttc aaaggcaaat 120
 aaagagaaca aagaacaaca tcataagcaa gagaatgata ataaggcttc aactcaattg 180
 tcagaaaaag aaagggttagc attagcattt tatgcggatg gagtagaaaa atatatgtta 240
 actaaaaacg aagtgttgac aggcgtgtat gattatcaaa aaggaaatga aacagagaag 300
 aaacaaatgg aacaattgat gttagaaaaa gctgattcga tgaaaaatgc gccaaaggat 360
 atgaaatfff atcaagttta tccgtctaaa ggacagttcg cttcaattgt tgggtgtaaat 420
 aaaaataaaa tatttatagg tagtacgcaa ggcgcactga ttgattatca aacattatta 480
 aataatggca aggagttaga tattagtcaa ttgtatgaag ataataaaga caatcgctca 540
 ttggaagaaa tgaagaataa aatagagatt gttgatagtg gagcagctca aaaagctgat 600
 gatcctgata aaaattctgc aaatacgtat gcacatatga gaagtcaaat ttatgaaaaa 660
 ataagtgact ttgatggtta gttagataat aaaacttatc tatgggacaa tattagaatc 720
 aatgacgatg gtaattggac agttcattac cgtaatcatg atggtgaaat tatgggtact 780

- 32 -

tataagagtg agaaaaataa aattattaaa cttgatcaaa atggaaataa aattaaagaa 840
 caacaaatgt ctaat 855

<210> 27

<211> 1494

<212> DNA

<213> Staphylococcus epidermidis

<400> 27

atggctaata aagagtcaaa aaatgttggtt attattggcg ctggtgtctt aagtacgaca 60
 tttggttcta tgattaaaga attagaacct gattggaaca tcaaactcta tgaacgctta 120
 gatcgtccag gtattgaaag ttctaacgaa agaaacaatg ccggtacagg acatgcggcg 180
 ttatgtgaat tgaactatac agtacaacaa cctgatgggtt caattgatat agaaaaagcc 240
 aaagaaatca acgaacaatt cgagatttca aaacaattct ggggtcactt agtaaaaagt 300
 ggtaacatca gtaaccctag agatttcatt aatccacttc ctcacattag tttcgtaaga 360
 ggtaaaaata acgttaaatt cttaaaaaac cgttacgaag caatgcgtaa cttccctatg 420
 ttcgataaca tcgaatatac agaagatata gaagaaatga gaaaatggat gccattaatg 480
 atgacaggtc gtactggtaa cgaaatcatg gcggctagta aaatcgacga aggtacagat 540
 gttaactacg gtgaattaac tcgtaaaatg gcaaaaagta ttgaaaaaca tccaaatgct 600
 gatgttcaat acaaccacga agtaattaat ttcaatcgtc gtaaagacgg tatTTgggaa 660
 gttaaagtta aaaaccgtaa ttctggagac gttgaaactg ttctagctga ttatgtatTT 720
 atcgggtcag gcgggtggcg tattccacta ttacaaaaaa ctggtatccc agaaagtaaa 780
 catcttggtg gattccctat cagtggtcag ttcttaatTT gtacaaaccc tgatgtaatt 840
 aatgaacatg acgtcaaagt atatggtaaa gaaccaccag gcacacctcc aatgactgta 900
 ccacatttag atacacgta tatcgatggt gaaagaacat tattatTTgg accatttgca 960
 aatattggcc ctaaattctt aagaaacggt tctaacttag acttattcaa atcagttaaa 1020
 ccttataaca tcacaacatt actagcatct gcagttaaaa acttaccttt aatcaaatac 1080
 tctatcgacc aagtattaat gactaaagaa ggttgatatga accatctacg cacgttctac 1140
 cctgaagctc gtgacgaaga ttggcaatta tacactgcag gtaaactgtg tcaagttatc 1200
 aaagatacta aagaacacgg taaaggattc attcaatTTg gtacagaagt tgttaactct 1260
 aaagaccact ctgttatcgc actattgggt gaatcacctg gagcatcaac ttcagtatca 1320
 gtagccctag aagTTTTaga gaaaaacttt gctgagtatg aaaaagattg gactccaaaa 1380
 ttacaaaaaa tgatcccatc atatggtaaa tctcttatcg atgatgttaa gttaatgaga 1440
 gcaactcgta aacaaacatc taaagattta gaattaaatt attacgaatc taaa 1494

- 33 -

<210> 28
 <211> 1548
 <212> DNA
 <213> Staphylococcus epidermidis

<400> 28
 atgaaaatat ttaaaacttt aagttctata ctagttacat ctgttctttc tgtgactgtg 60
 attccctcaa catttgcatc aacagaatct actgctacaa atcagacaca acaaacagta 120
 ctttttgata attctcatgc tcaaactgcg ggcgctgccg attgggtgat tgatggcgct 180
 ttctcagatt atgcagattc aatgagaaaag caagggtacc aagttaaaga actagaagga 240
 gaatcaaaca tttctgatca atctttacag caggcgcatg tattagttat tcccgaagct 300
 aacaatccat ttaaagaaaa tgagcagaaa gcaatcatta attttgtaa aaatggtggt 360
 agcgtcattt tcatctcaga ccattataat gccgatcgta atttaaactg tattgattct 420
 tcagaatcaa tgaatggta tcgacgtggc gcatacgaat atatgactaa agatatgaat 480
 aatgaagaaa agaattctaa cgttatgcat aacgttaaga gttctgattg gctctcacia 540
 aacttcggtg ttcgctttag atataatgca cttggagata tcaatactca aaatatcggt 600
 tcaagcaaag atagttttgg tattactaaa ggtgtacaat cagtttcgat gcacgcaggt 660
 tcaacattag caataactga tcctaataaa gctaaaggca ttatttatat gccggaacat 720
 ttaacgcata gtcaaaaatg gcctcacgca gttgatcaag gtatttacia tgggggtggc 780
 atcaacgaag gaccttatgt agccatttca aaaatcggca aaggtaaagc tgcatttatt 840
 ggcgatagct ccctcgtaga agatcggtca cctaaatata ttcgtgaaga taatgggaaa 900
 cctaaaaaaaa cgtacgatgg ttttaaagaa caagataatg gaaagttatt aaataattta 960
 acaacatggc taggcaaaaa agaattctcaa tcttctatga aagacatggg gattaaactt 1020
 gataataaaa caccgctact taactttgag caacctgaga attcaattga acctcaaaaa 1080
 gaaccgtgga ctaacccaat agaaggttac aaatggtatg atcgttcaac atttaaaaca 1140
 ggtagttatg gaagtaatca acggggtgct gacgatggag tagatgacaa aagctcttct 1200
 catcaaaatc aaaatgccaa agttgaatta actttacctc aaaatatcca accgcatcat 1260
 ccattttcaat ttacaatcaa actcacggga tatgagccta atagcacaat tagcgatgta 1320
 agagttggac tttataaaga tggaggtaag caaatcggtg gcttttcttc taaccgtaac 1380
 caattcaata ctctcggcta tagtcctggc caatcaatta aagcaaatgg tgcgggtgaa 1440
 gcttcattca cactcacagc taaagtgaca gatgaaatta aagatgctaa tattcgtggt 1500
 aaacaaggga aaaaaattct attaactcaa aaaatgaatg aaaatttt 1548

<210> 29
 <211> 252

- 34 -

<212> DNA

<213> Staphylococcus epidermidis

<400> 29

```

ggtacaccat tagaattagt ttttgtcaat actttaggac ctaaaccttg tttcgctaaa      60
ccaaataaaaa ttctactatt agaatatatt ccgctatttg ttgcagatgc tgctgctggt      120
aaaacaacaa aattaactat gccagcagca aagggaacac caattagtgt gaataattta      180
acaaacggac tactatcagg atcaacttta aaccatggaa tgacagacat gattacaagt      240
aaaccaccta ta                                     252

```

<210> 30

<211> 162

<212> DNA

<213> Staphylococcus epidermidis

<400> 30

```

tcacgtttaa gtaccataat tcctttttct ttaggagcat taggcaaatt taattctttc      60
attgagcaaaa tcataccact agaatctacc ccacgtaatt gggcatcttt aattaccatt      120
ccgcttgcca taacggcccc aacttttgca acaacgacct tc                          162

```

<210> 31

<211> 348

<212> DNA

<213> Staphylococcus aureus

<400> 31

```

atgaaattta aaaaatatat attaacagga acattagcat tactttttatc atcaactggg      60
atagcaacta tagaagggaa taaagcagat gcaagtagtc tggacaaata tttaactgaa      120
agtcagtttc atgataaacg catagcagaa gaattaagaa ctttacttaa caaatcgaat      180
gtatatgcat tagctgcagg aagcttaaat ccatattata aacgtacgat tatgatgaat      240
gaatatagag ctaaagcggc acttaagaaa aatgatttcg tatcaatggc tgatgctaaa      300
gttgcattag aaaaaatata caaagaaatt gatgaaatta taaataga                    348

```

<210> 32

<211> 676

<212> PRT

<213> Staphylococcus epidermidis

<400> 32

```

Met Lys Arg Thr Asp Lys Ile Gly Val Tyr Leu Lys Leu Ser Cys Ser
1           5           10           15

```

```

Ala Leu Leu Leu Ser Gly Ser Leu Val Gly Tyr Gly Phe Thr Lys Asp
20           25           30

```

- 35 -

Ala Phe Ala Asp Ser Glu Ser Thr Ser Ser Asn Val Glu Asn Thr Ser
 35 40 45

Asn Ser Asn Ser Ile Ala Asp Lys Ile Gln Gln Ala Lys Asp Asp Ile
 50 55 60

Lys Asp Leu Lys Glu Leu Ser Asp Ala Asp Ile Lys Ser Phe Glu Glu
 65 70 75 80

Arg Leu Asp Lys Val Asp Asn Gln Ser Ser Ile Asp Arg Ile Ile Asn
 85 90 95

Asp Ala Lys Asp Lys Asn Asn His Leu Lys Ser Thr Asp Ser Ser Ala
 100 105 110

Thr Ser Ser Lys Thr Glu Asp Asp Asp Thr Ser Glu Lys Asp Asn Asp
 115 120 125

Asp Met Thr Lys Asp Leu Asp Lys Ile Leu Ser Asp Leu Asp Ser Ile
 130 135 140

Ala Lys Asn Val Asp Asn Arg Gln Gln Gly Glu Glu Arg Ala Ser Lys
 145 150 155 160

Pro Ser Asp Ser Thr Thr Asp Glu Lys Asp Asp Ser Asn Asn Lys Val
 165 170 175

His Asp Thr Asn Ala Ser Thr Arg Asn Ala Thr Thr Asp Asp Ser Glu
 180 185 190

Glu Ser Val Ile Asp Lys Leu Asp Lys Ile Gln Gln Asp Phe Lys Ser
 195 200 205

Asp Ser Asn Asn Asn Pro Ser Glu Gln Ser Asp Gln Gln Ala Ser Pro
 210 215 220

Ser Asn Lys Thr Glu Asn Asn Lys Glu Glu Ser Ser Thr Thr Thr Asn
 225 230 235 240

Gln Ser Asp Ser Asp Ser Lys Asp Asp Lys Ser Asn Asp Gly His Arg
 245 250 255

Ser Thr Leu Glu Arg Ile Ala Ser Asp Thr Asp Gln Ile Arg Asp Ser
 260 265 270

Lys Asp Gln His Val Thr Asp Glu Lys Gln Asp Ile Gln Ala Ile Thr
 275 280 285

- 36 -

Arg Ser Leu Gln Gly Ser Asp Lys Ile Glu Lys Ala Leu Ala Lys Val
 290 295 300

Gln Ser Asp Asn Gln Ser Leu Asp Ser Asn Tyr Ile Asn Asn Lys Leu
 305 310 315 320

Met Asn Leu Arg Ser Leu Asp Thr Lys Val Glu Asp Asn Asn Thr Leu
 325 330 335

Ser Asp Asp Lys Lys Gln Ala Leu Lys Gln Glu Ile Asp Lys Thr Lys
 340 345 350

Gln Ser Ile Asp Arg Gln Arg Asn Ile Ile Ile Asp Gln Leu Asn Gly
 355 360 365

Ala Ser Asn Lys Lys Gln Ala Thr Glu Asp Ile Leu Asn Ser Val Phe
 370 375 380

Ser Lys Asn Glu Val Glu Asp Ile Met Lys Arg Ile Lys Thr Asn Gly
 385 390 395 400

Arg Ser Asn Glu Asp Ile Ala Asn Gln Ile Ala Lys Gln Ile Asp Gly
 405 410 415

Leu Ala Leu Thr Ser Ser Asp Asp Ile Leu Lys Ser Met Leu Asp Gln
 420 425 430

Ser Lys Asp Lys Glu Ser Leu Ile Lys Gln Leu Leu Thr Thr Arg Leu
 435 440 445

Gly Asn Asp Glu Ala Asp Arg Ile Ala Lys Lys Leu Leu Ser Gln Asn
 450 455 460

Leu Ser Asn Ser Gln Ile Val Glu Gln Leu Lys Arg His Phe Asn Ser
 465 470 475 480

Gln Gly Thr Ala Thr Ala Asp Asp Ile Leu Asn Gly Val Ile Asn Asp
 485 490 495

Ala Lys Asp Lys Arg Gln Ala Ile Glu Thr Ile Leu Gln Thr Arg Ile
 500 505 510

Asn Lys Asp Lys Ala Lys Ile Ile Ala Asp Val Ile Ala Arg Val Gln
 515 520 525

- 37 -

Lys Asp Lys Ser Asp Ile Met Asp Leu Ile His Ser Ala Ile Glu Gly
 530 535 540

Lys Ala Asn Asp Leu Leu Asp Ile Glu Lys Arg Ala Lys Gln Ala Lys
 545 550 555 560

Lys Asp Leu Glu Tyr Ile Leu Asp Pro Ile Lys Asn Arg Pro Ser Leu
 565 570 575

Leu Asp Arg Ile Asn Lys Gly Val Gly Asp Ser Asn Ser Ile Phe Asp
 580 585 590

Arg Pro Ser Leu Leu Asp Lys Leu His Ser Arg Gly Ser Ile Leu Asp
 595 600 605

Lys Leu Asp His Ser Ala Pro Glu Asn Gly Leu Ser Leu Asp Asn Lys
 610 615 620

Gly Gly Leu Leu Ser Asp Leu Phe Asp Asp Asp Gly Asn Ile Ser Leu
 625 630 635 640

Pro Ala Thr Gly Glu Val Ile Lys Gln His Trp Ile Pro Val Ala Val
 645 650 655

Val Leu Met Ser Leu Gly Gly Ala Leu Ile Phe Met Ala Arg Arg Lys
 660 665 670

Lys His Gln Asn
 675

<210> 33
 <211> 655
 <212> PRT
 <213> Staphylococcus epidermidis

<400> 33

Met Lys Lys Asn Lys Phe Leu Val Tyr Leu Leu Ser Thr Ala Leu Ile
 1 5 10 15

Thr Pro Thr Phe Ala Thr Gln Thr Ala Phe Ala Glu Asp Ser Ser Asn
 20 25 30

Lys Asn Thr Asn Ser Asp Lys Met Glu Gln His Gln Ser Gln Lys Glu
 35 40 45

Thr Ser Lys Gln Ser Glu Lys Asp Glu Phe Asn Asn Asp Asp Ser Lys
 50 55 60

- 38 -

His Asp Ser Asp Asp Lys Lys Ser Thr Ser Asp Ser Lys Asp Lys Asp
 65 70 75 80

Ser Asn Lys Pro Leu Ser Ala Asp Ser Thr His Arg Asn Tyr Lys Met
 85 90 95

Lys Asp Asp Asn Leu Val Asp Gln Leu Tyr Asp Asn Phe Lys Ser Gln
 100 105 110

Ser Val Asp Phe Ser Lys Tyr Trp Glu Pro Asn Lys Tyr Glu Asp Ser
 115 120 125

Phe Ser Leu Thr Ser Leu Ile Gln Asn Leu Phe Asp Phe Asp Ser Asp
 130 135 140

Ile Thr Asp Tyr Glu Gln Pro Gln Lys Thr Ser His Ser Ser Asn Asp
 145 150 155 160

Glu Lys Asp Gln Val Asp Gln Ala Asp Gln Ala Lys Gln Pro Ser Gln
 165 170 175

His Gln Glu Pro Ser Gln Ser Ser Ala Lys Gln Asp Gln Glu Pro Ser
 180 185 190

Asn Asp Glu Lys Glu Lys Thr Thr Asn His Gln Ala Asp Ser Asp Val
 195 200 205

Ser Asp Leu Leu Gly Glu Met Asp Lys Glu Asp Gln Glu Gly Glu Asn
 210 215 220

Val Asp Thr Asn Lys Asn Gln Ser Ser Ser Glu Gln Gln Gln Thr Gln
 225 230 235 240

Ala Asn Asp Asp Ser Ser Glu Arg Asn Lys Lys Tyr Ser Ser Ile Thr
 245 250 255

Asp Ser Ala Leu Asp Ser Ile Leu Asp Glu Tyr Ser Gln Asp Ala Lys
 260 265 270

Lys Thr Glu Lys Asp Tyr Asn Lys Ser Lys Asn Thr Ser His Thr Lys
 275 280 285

Thr Ser Gln Ser Asp Asn Ala Asp Lys Asn Pro Gln Leu Pro Thr Asp
 290 295 300

Asp Glu Leu Lys His Gln Ser Lys Pro Ala Gln Ser Phe Glu Asp Asp

- 39 -

305		310		315		320
Ile Lys Arg Ser Asn Thr Arg Ser Thr Ser Leu Phe Gln Gln Leu Pro						
	325			330		335
Glu Leu Asp Asn Gly Asp Leu Ser Ser Asp Ser Phe Asn Val Val Asp						
	340		345			350
Ser Gln Asp Thr Arg Asp Phe Ile Gln Ser Ile Ala Lys Asp Ala His						
	355		360			365
Gln Ile Gly Lys Asp Gln Asp Ile Tyr Ala Ser Val Met Ile Ala Gln						
	370		375			380
Ala Ile Leu Glu Ser Asp Ser Gly Lys Ser Ser Leu Ala Gln Ser Pro						
	385		390			400
Asn His Asn Leu Phe Gly Ile Lys Gly Asp Tyr Lys Gly Gln Ser Val						
	405		410			415
Thr Phe Asn Thr Leu Glu Ala Asp Ser Ser Asn His Met Phe Ser Ile						
	420		425			430
Gln Ala Gly Phe Arg Lys Tyr Pro Ser Thr Lys Gln Ser Leu Glu Asp						
	435		440			445
Tyr Ala Asp Leu Ile Lys His Gly Ile Asp Gly Asn Pro Ser Ile Tyr						
	450		455			460
Lys Pro Thr Trp Lys Ser Glu Ala Leu Ser Tyr Lys Asp Ala Thr Ser						
	465		470			475
His Leu Ser Arg Ser Tyr Ala Thr Asp Pro Asn Tyr Ser Lys Lys Leu						
	485		490			495
Asn Ser Ile Ile Lys His Tyr His Leu Thr Ser Phe Asp Lys Glu Lys						
	500		505			510
Met Pro Asn Met Lys Lys Tyr Asn Lys Ser Ile Gly Thr Asp Val Ser						
	515		520			525
Gly Asn Asp Phe Lys Pro Phe Thr Glu Thr Ser Gly Thr Ser Pro Tyr						
	530		535			540
Pro His Gly Gln Cys Thr Trp Tyr Val Tyr His Arg Met Asn Gln Phe						
	545		550			555
						560

- 40 -

Asp Ala Ser Ile Ser Gly Asp Leu Gly Asp Ala His Asn Trp Asn Asn
565 570 575

Arg Ala Glu Ser Glu Gly Tyr Thr Val Thr His Thr Pro Lys Asn His
580 585 590

Thr Ala Val Val Phe Glu Ala Gly Gln Leu Gly Ala Asp Thr Gln Tyr
595 600 605

Gly His Val Ala Phe Val Glu Lys Val Asn Asp Asp Gly Ser Ile Val
610 615 620

Ile Ser Glu Ser Asn Val Lys Gly Leu Gly Val Ile Ser Phe Arg Thr
625 630 635 640

Ile Asp Ala Gly Asp Ala Gln Asp Leu Asp Tyr Ile Lys Gly Lys
645 650 655

```
<210> 34
<211> 164
<212> PRT
<213> Staphylococcus epidermidis
```

<400> 34

Met Ile Arg Phe Ala Arg Leu Glu Asp Leu Gln Asp Ile Leu Thr Ile
1 5 10 15

Tyr Asn Asp Ala Ile Leu Asn Thr Thr Ala Val Tyr Thr Tyr Lys Pro
20 25 30

Gln Gln Leu Asp Glu Arg Leu Gln Trp Tyr Gln Ser Lys Ala Lys Ile
35 40 45

Asn Glu Pro Ile Trp Val Tyr Glu Lys Glu Gly Lys Val Val Gly Phe
50 55 60

Ala Thr Tyr Gly Ser Phe Arg Gln Trp Pro Ala Tyr Leu Tyr Thr Ile
65 70 75 80

Glu His Ser Ile Tyr Val His Gln Gln Tyr Arg Gly Leu Gly Ile Ala
85 90 95

Ser Gln Leu Leu Glu Asn Leu Ile Arg Tyr Ala Lys Glu Gln Gly Tyr
100 105 110

Arg Thr Ile Val Ala Gly Ile Asp Ala Ser Asn Met Asp Ser Ile Ala
115 120 125

- 41 -

Leu His Lys Lys Phe Asp Phe Ser His Ala Gly Thr Ile Lys Asn Val
 130 135 140

Gly Tyr Lys Phe Asp Arg Trp Leu Asp Leu Ser Phe Tyr Gln Tyr Asp
 145 150 155 160

Leu Ser Asp Ser

<210> 35
 <211> 952
 <212> PRT
 <213> Staphylococcus epidermidis

<400> 35

Leu Ser Asn Leu Ile Gln Asp Ile Lys Gln Ser Leu Tyr Lys Gly Phe
 1 5 10 15

Ile Asp Lys Asp Ser Ser His Lys Gly Asn Phe Val Pro Arg Leu Leu
 20 25 30

Val Asn Asn Lys Glu Glu Asn Val Leu Ser Thr Ile Ile Asp Gln Leu
 35 40 45

His Asn Cys Gln Ser Phe Cys Ile Ser Val Ala Phe Ile Thr Glu Ser
 50 55 60

Gly Leu Ala Ser Leu Lys Ser His Phe Tyr Asp Leu Ser Lys Lys Gly
 65 70 75 80

Val Lys Gly Arg Ile Ile Thr Ser Asn Tyr Leu Gly Phe Asn Ser Pro
 85 90 95

Lys Met Phe Glu Glu Leu Leu Lys Leu Glu Asn Val Glu Val Lys Leu
 100 105 110

Thr Asn Ile Glu Gly Phe His Ala Lys Gly Tyr Ile Phe Glu His His
 115 120 125

Asn His Thr Ser Phe Ile Ile Gly Ser Ser Asn Leu Thr Ser Asn Ala
 130 135 140

Leu Lys Leu Asn Tyr Glu His Asn Leu Phe Leu Ser Thr His Lys Asn
 145 150 155 160

Gly Asp Leu Val Asn Asn Ile Lys Tyr Lys Phe Asp Glu Leu Trp Asp

- 42 -

165	170	175
Ser Ser Phe Ser Leu Thr Asn Glu Trp Ile Asn Glu Tyr Lys Gln Ser		
180	185	190
Phe Glu Tyr Gln Thr Leu Gln Lys Val Phe Asp Asn Thr Val Val Gln		
195	200	205
Asn Ser Asp Ile Lys Lys Phe Asn Glu Ser Lys Leu Ile Lys Pro Asn		
210	215	220
Leu Met Gln Glu His Ala Leu Lys Ser Leu Glu Ser Leu Arg Asn Val		
225	230	235
Gly Glu Glu Lys Gly Leu Ile Ile Ser Ala Thr Gly Thr Gly Lys Thr		
245	250	255
Ile Leu Cys Ala Leu Asp Val Arg Ala Tyr Ser Pro Asp Lys Phe Leu		
260	265	270
Phe Ile Val His Asn Glu Gly Ile Leu Asn Arg Ala Ile Glu Glu Phe		
275	280	285
Lys Lys Val Phe Pro Tyr Glu Asp Glu Ser Asn Phe Gly Leu Leu Thr		
290	295	300
Gly Lys Arg Lys Asp His Asp Ala Lys Phe Leu Phe Ala Thr Ile Gln		
305	310	315
Thr Leu Ser Lys Lys Glu Asn Tyr Lys Leu Phe Asn Ser Asn His Phe		
325	330	335
Asp Tyr Ile Val Phe Asp Glu Ala His Arg Ile Ala Ala Ser Ser Tyr		
340	345	350
Gln Lys Ile Phe Asn Tyr Phe Lys Pro Asn Phe Leu Leu Gly Met Thr		
355	360	365
Ala Thr Pro Glu Arg Thr Asp Glu Leu Asn Ile Phe Glu Leu Phe Asn		
370	375	380
Tyr Asn Ile Ala Tyr Glu Ile Arg Leu Gln Glu Ala Leu Glu Ser Asn		
385	390	395
Ile Leu Cys Pro Phe His Tyr Phe Gly Val Thr Asp Tyr Ile Gln Asn		
405	410	415

- 43 -

Glu Met Ser Gln Glu Asp Ala Phe Asn Leu Lys Tyr Leu Ala Ser Asn
 420 425 430

Glu Arg Val Glu His Ile Ile Lys Lys Thr Asn Tyr Tyr Gly Tyr Ser
 435 440 445

Gly Asp Val Leu Lys Gly Leu Ile Phe Val Ser Ser Arg Gly Glu Ala
 450 455 460

Tyr Gln Leu Ala Asn Gln Leu Ser Lys Arg Gly Ile Ser Ser Val Gly
 465 470 475 480

Leu Thr Gly Lys Asp Ser Ile Ala Tyr Arg Ala Glu Thr Ile Gln Gln
 485 490 495

Leu Lys Glu Gly Ser Ile Asn Tyr Ile Ile Thr Val Asp Leu Phe Asn
 500 505 510

Glu Gly Ile Asp Ile Pro Glu Ile Asn Gln Val Val Met Leu Arg Pro
 515 520 525

Thr Lys Ser Ser Ile Ile Phe Ile Gln Gln Leu Gly Arg Gly Leu Arg
 530 535 540

Lys Ser Thr Asn Lys Glu Phe Val Thr Val Ile Asp Phe Ile Gly Asn
 545 550 555 560

Tyr Lys Thr Asn Tyr Met Ile Pro Ile Ala Leu Ser Gly Asn Lys Ser
 565 570 575

Gln Asn Lys Asp Asn Tyr Arg Lys Phe Leu Thr Asp Thr Thr Val Leu
 580 585 590

Asn Gly Val Ser Thr Ile Asn Phe Glu Glu Val Ala Lys Asn Lys Ile
 595 600 605

Tyr Asn Ser Leu Asp Ser Val Lys Leu Asn Gln Pro Lys Leu Ile Lys
 610 615 620

Glu Ala Phe Asn Asn Val Lys Asp Arg Ile Gly Lys Leu Pro Leu Leu
 625 630 635 640

Met Asp Phe Ile Asn Asn Asp Ser Ile Asp Pro Ser Val Ile Phe Ser
 645 650 655

Arg Phe Lys Asn Tyr Tyr Glu Phe Leu Ile Lys Asn Lys Ile Ile Glu

- 44 -

660	665	670
Asn Glu Leu Ser Ile Asn Glu Phe Lys Asn Leu Thr Phe Leu Ser Arg 675 680 685		
Gln Leu Thr Pro Gly Leu Lys Lys Val Asp Ile Asp Val Leu Lys Glu 690 695 700		
Ile Ile Gln Asn Asp Val Thr Tyr Glu Asn Leu Thr Lys Lys Met Leu 705 710 715 720		
Asn Ile Asn Asn Asp Ile Ser Glu Tyr Asp Ile Asn Thr Ser Leu Ser 725 730 735		
Ile Leu Asp Phe Thr Phe Phe Lys Lys Thr Ile Gly Lys Thr Tyr Gly 740 745 750		
Leu Pro Leu Ile Gln Tyr Lys Asp Asn Leu Ile Cys Leu Ala Asn Glu 755 760 765		
Phe Lys Glu Ala Leu Asn Lys Pro Leu Phe Asn Thr Phe Ile His Asp 770 775 780		
Leu Ile Asp Leu Ala Asn Tyr Asn Asn Asp Arg Tyr Gln Asn Lys Lys 785 790 795 800		
Asn Ser Leu Ile Leu Tyr Asn Lys Tyr Ser Arg Glu Asp Phe Val Lys 805 810 815		
Leu Leu Asn Trp Asp Lys Asp Glu Ser Gly Thr Ile Asn Gly Tyr Arg 820 825 830		
Met Lys His Arg Thr Leu Pro Leu Phe Ile Thr Tyr Asp Lys His Glu 835 840 845		
Asn Ile Ser Asp Asn Thr Lys Tyr Asp Asp Glu Phe Leu Ser Gln Asp 850 855 860		
Glu Leu Lys Trp Tyr Thr Arg Ser Asn Arg Lys Leu Thr Ser Pro Glu 865 870 875 880		
Val Gln Asn Ile Leu Lys His Glu Glu Ser Asn Thr Asp Met Tyr Ile 885 890 895		
Phe Val Lys Lys Arg Asp Asp Glu Gly Lys Tyr Phe Tyr Tyr Leu Gly 900 905 910		

- 45 -

Lys Ala Lys Tyr Ile Lys Gly Thr Glu Lys Gln Asp Tyr Met Pro Asn
 915 920 925

Gly Asn Ser Val Val Thr Met His Leu Ser Met Asn Thr Ser Ile Arg
 930 935 940

Asp Asp Ile Tyr Arg Tyr Ile Thr
 945 950

<210> 36
 <211> 325
 <212> PRT
 <213> Staphylococcus epidermidis

<400> 36

Met Thr Lys Ser Gln Gln Lys Val Ser Ser Ile Glu Lys Leu Ser Asn
 1 5 10 15

Gln Glu Gly Ile Ile Ser Ala Leu Ala Phe Asp Gln Arg Gly Ala Leu
 20 25 30

Lys Arg Met Met Ala Glu His Gln Ser Glu Thr Pro Thr Val Glu Gln
 35 40 45

Ile Glu Gln Leu Lys Val Leu Val Ser Glu Glu Leu Thr Gln Tyr Ala
 50 55 60

Ser Ser Ile Leu Leu Asp Pro Glu Tyr Gly Leu Pro Ala Ser Asp Ala
 65 70 75 80

Arg Asn Asn Asp Cys Gly Leu Leu Leu Ala Tyr Glu Lys Thr Gly Tyr
 85 90 95

Asp Val Asn Ala Lys Gly Arg Leu Pro Asp Cys Leu Val Glu Trp Ser
 100 105 110

Ala Lys Arg Leu Lys Glu Gln Gly Ala Asn Ala Val Lys Phe Leu Leu
 115 120 125

Tyr Tyr Asp Val Asp Asp Thr Glu Glu Ile Asn Ile Gln Lys Lys Ala
 130 135 140

Tyr Ile Glu Arg Ile Gly Ser Glu Cys Val Ala Glu Asp Ile Pro Phe
 145 150 155 160

Phe Leu Glu Val Leu Thr Tyr Asp Asp Asn Ile Pro Asp Asn Lys Ser
 165 170 175

- 46 -

Ala Glu Phe Ala Lys Val Lys Pro Arg Lys Val Asn Glu Ala Met Lys
 180 185 190

Leu Phe Ser Glu Asp Arg Phe Asn Val Asp Val Leu Lys Val Glu Val
 195 200 205

Pro Val Asn Met Asn Phe Val Glu Gly Phe Ser Glu Gly Glu Val Val
 210 215 220

Tyr Thr Lys Glu Glu Ala Ala Gln His Phe Arg Asp Gln Asp Ala Ala
 225 230 235 240

Thr His Leu Pro Tyr Ile Tyr Leu Ser Ala Gly Val Ser Ala Glu Leu
 245 250 255

Phe Gln Asp Thr Leu Lys Phe Ala His Asp Ser Gly Ala Gln Phe Asn
 260 265 270

Gly Val Leu Cys Gly Arg Ala Thr Trp Ser Gly Ala Val Lys Val Tyr
 275 280 285

Ile Glu Glu Gly Glu Gln Ala Ala Arg Glu Trp Leu Arg Thr Val Gly
 290 295 300

Phe Lys Asn Ile Asp Asp Leu Asn Thr Val Leu Lys Thr Thr Ala Thr
 305 310 315 320

Ser Trp Lys Asn Lys
 325

<210> 37
 <211> 382
 <212> PRT
 <213> Staphylococcus epidermidis

<400> 37

Leu Met Lys Lys Val Met Thr Ile Phe Gly Thr Arg Pro Glu Ala Ile
 1 5 10 15

Lys Met Ala Pro Leu Ile Lys Thr Leu Glu Lys Asp Ser Asp Leu Glu
 20 25 30

Pro Val Val Val Val Thr Ala Gln His Arg Glu Met Leu Asp Ser Val
 35 40 45

Leu Asn Thr Phe Asn Ile Ser Ala Asp Tyr Asp Leu Asn Ile Met Lys

- 47 -

50

55

60

Ala Gly Gln Thr Leu Ser Glu Val Thr Ser Glu Ala Met Lys Lys Leu
65 70 75 80

Glu Asp Ile Ile Gln Lys Glu Val Pro Asp Met Val Leu Val His Gly
85 90 95

Asp Thr Val Thr Thr Phe Ser Gly Ala Leu Ala Ala Phe Tyr Ser Gln
100 105 110

Thr Pro Ile Gly His Val Glu Ala Gly Leu Arg Ser Tyr Asn Lys Tyr
115 120 125

Ser Pro Tyr Pro Glu Glu Ile Asn Arg Gln Met Val Gly Val Met Ala
130 135 140

Asp Leu His Phe Ala Pro Thr Tyr Asn Ala Ala Gln Asn Leu Val Lys
145 150 155 160

Glu Gly Lys Leu Ala Lys His Ile Ala Ile Thr Gly Asn Thr Ala Ile
165 170 175

Asp Ala Met Asn Tyr Thr Ile Asp His Gln Tyr Ser Ser Ser Ile Ile
180 185 190

Gln Lys His Lys Asn Lys Asn Phe Ile Leu Leu Thr Ala His Arg Arg
195 200 205

Glu Asn Ile Gly Lys Pro Met Ile Asn Val Phe Lys Ala Ile Arg Lys
210 215 220

Leu Ile Asp Glu Tyr Gln Asp Leu Ala Leu Val Tyr Pro Met His Met
225 230 235 240

Asn Pro Lys Val Arg Asp Ile Ala Gln Lys Tyr Leu Gly Asn His Pro
245 250 255

Arg Ile Glu Leu Ile Glu Pro Leu Asp Val Val Asp Phe His Asn Phe
260 265 270

Ala Lys Gln Ala Tyr Leu Ile Met Thr Asp Ser Gly Gly Ile Gln Glu
275 280 285

Glu Ala Pro Ser Leu His Lys Pro Val Leu Val Leu Arg Asp Ser Thr
290 295 300

- 48 -

Glu Arg Pro Glu Gly Val Asp Ala Gly Thr Leu Arg Val Ile Gly Thr
 305 310 315 320

Asn Glu Glu Asp Val Tyr Asn Glu Thr Lys Lys Leu Ile Glu Asn Pro
 325 330 335

Asp Leu Tyr Gln Lys Met Ser Gln Ala Val Asn Pro Tyr Gly Asp Gly
 340 345 350

Gln Ala Ser Glu Arg Ile Val Gln His Ile Lys Tyr Tyr Phe Asn Leu
 355 360 365

Thr Asn Asp Arg Pro Asn His Phe Glu Phe Thr Lys Asp Leu
 370 375 380

<210> 38
 <211> 2757
 <212> PRT
 <213> Staphylococcus epidermidis

<400> 38

Val Ala Ser Asp Phe Asn Ile Gly Ile Leu Ser Thr Leu Glu Ile Asp
 1 5 10 15

Ser Ser Ser Ser Arg Lys Lys Ile Asn Asp Thr Leu Lys Asn Ile Glu
 20 25 30

Ala Asn Ile Asn Ser Ile Lys Ala Asp Leu Glu Val Ser Asp Thr Lys
 35 40 45

Lys Ser Glu Asn Asn Ala Ile Lys Ser Ala Asn Asn Val Ile Arg Asn
 50 55 60

Ile Asn Ser Asn Gly Asn Leu Lys Lys Leu Asn Val Glu Leu Asp Val
 65 70 75 80

Asn Leu Thr Lys Ser Arg Gln Asn Ile Gln Arg Ala Leu Ser Thr Leu
 85 90 95

Ser Lys Asp Phe Lys Asn Lys Lys Ile Asp Val Glu Val Asn Ala Lys
 100 105 110

Ala Asn Lys Asn Ser Ile Gly Gln Val Lys Asn Ser Ile Ser Lys Gly
 115 120 125

Ala Ser Gln Pro Leu Glu Ile Lys Glu Ser Pro Ser Ser Arg Ser Thr
 130 135 140

- 49 -

Ser Arg Asp Ile Lys Glu Gln Gln Ser Leu Met Thr Gly Leu Ala Asn
 145 150 155 160

Ser Tyr Lys Asn Leu Asp Asp Leu Thr Arg Ala Leu Asn Thr Ser Thr
 165 170 175

Phe Glu Gly Leu Arg Lys Thr Val Lys Glu Ile Lys Asn Ala Asp Asn
 180 185 190

Ser Leu Lys Ser Tyr Gln Val Thr Leu Glu Arg Val Asn Gln Glu Gly
 195 200 205

Lys Lys Leu Gly Ser Gln Arg Phe Asp Tyr Thr Pro Ser Ala Asn Gly
 210 215 220

Leu Lys Leu Asn Lys Thr Gln Leu Thr Asp Gln Thr Asp Lys Ala Arg
 225 230 235 240

Lys Glu Glu Asn Ala Ala Ile Asn Lys Leu Leu Glu Asn Glu Val Ser
 245 250 255

Lys Tyr Asp Arg Leu Leu Asn Lys Gly Lys Ile Asp Ile Lys Gln His
 260 265 270

Gln Thr Leu Leu Gln Thr Leu Arg Gln Ile Thr Asn Glu Lys Ser Lys
 275 280 285

Ala Asn Gln Phe Asn Arg Thr Asp Phe Asn Arg Val Ala Lys Ala Ala
 290 295 300

Ala Asp Glu Ala Lys Glu Tyr Gln Tyr Gln Asn Asp Met Leu Arg Lys
 305 310 315 320

Lys Leu Ala Leu Thr Ser Gln Ile Glu Arg Ile Glu Asn Arg Met Ala
 325 330 335

Ala Thr Ile Asp Lys Gln Gln Thr Asn Ala Leu Lys Asn Gln Leu Asn
 340 345 350

Ser Leu Gly Asn Asn Arg Thr Pro Phe Gly Lys Glu Ala Ala Phe His
 355 360 365

Met Asn Gln Ile Gln Asp Lys Val Arg Gln Ile Ser Ala Glu Ala Glu
 370 375 380

- 50 -

Arg Ala Thr Arg Thr Gln Leu Ser Phe Val Asp Gln Phe Arg Glu Ala
 385 390 395 400

Met Thr Lys Phe Pro Val Trp Met Gly Ala Thr Thr Leu Phe Phe Gly
 405 410 415

Ala Ile Asn Gly Ala Lys Glu Met Leu Asp Val Ile Thr Glu Ile Asp
 420 425 430

Gly Lys Met Ile Thr Leu Ala Lys Val Thr Gly Asp Asp Asn Ala Leu
 435 440 445

Gln Gln Thr Phe Ile Asp Ala Asn Asn Ala Ala Ser Gln Phe Gly Gln
 450 455 460

Thr Leu Gly Ser Val Leu Asp Val Tyr Ala Glu Phe Ala Arg Gln Gly
 465 470 475 480

Val Lys Gly Asn Glu Leu Ser Gln Phe Ser Asn Ala Ala Leu Ile Ala
 485 490 495

Ala Asn Val Gly Glu Ile Asp Ala Lys Gln Ala Ser Glu Tyr Leu Thr
 500 505 510

Ser Met Ser Ala Gln Trp Glu Thr Thr Gly Asn Gln Ala Met Arg Gln
 515 520 525

Val Asp Ser Leu Asn Glu Val Ser Asn Lys Tyr Ala Thr Thr Val Glu
 530 535 540

Lys Leu Ala Gln Gly Gln Ala Lys Ala Gly Ser Thr Ala Lys Ser Met
 545 550 555 560

Gly Leu Thr Phe Asp Glu Thr Asn Gly Ile Ile Gly Ala Leu Thr Ala
 565 570 575

Lys Thr Lys Gln Ser Gly Asp Glu Ile Gly Asn Phe Met Lys Ala Thr
 580 585 590

Leu Pro Lys Leu Tyr Ser Gly Lys Gly Lys Ser Thr Ile Glu Gly Leu
 595 600 605

Gly Ile Ser Met Lys Asp Glu Asn Gly Gln Leu Lys Ser Ala Ile Ser
 610 615 620

Leu Leu Glu Glu Val Ser Gln Lys Thr Lys Asn Leu Glu Lys Asp Gln
 625 630 635 640

- 51 -

Lys Ala Ala Val Ile Asn Gly Leu Gly Gly Thr Tyr His Tyr Gln Arg
 645 650 655

Met Gln Val Leu Leu Asp Asp Leu Ser Lys Thr Asp Gly Leu Tyr Lys
 660 665 670

Gln Ile Lys Glu Ser Ser Glu Ser Ser Ala Gly Ser Ala Leu Gln Glu
 675 680 685

Asn Ala Lys Tyr Met Glu Ser Ile Glu Ala Lys Val Asn Gln Ala Lys
 690 695 700

Thr Ala Phe Glu Gln Phe Ala Leu Ala Val Gly Glu Thr Phe Ala Lys
 705 710 715 720

Ser Gly Met Leu Asp Gly Ile Arg Met Val Thr Gln Leu Leu Thr Gly
 725 730 735

Leu Thr His Gly Ile Thr Glu Leu Gly Thr Thr Ala Pro Ile Phe Gly
 740 745 750

Met Val Gly Gly Ala Ala Ser Leu Met Ser Lys Asn Val Arg Ser Gly
 755 760 765

Phe Glu Gly Ala Arg Ser Ser Val Ala Asn Tyr Ile Thr Glu Val Asn
 770 775 780

Lys Leu Ala Lys Val Asn Asn Ala Ala Gly Gln Val Val Gly Leu Gln
 785 790 795 800

Lys Val Gln Thr Gly Thr Ala Ser Gln Leu Gln Phe Asn Lys Asn Gly
 805 810 815

Glu Tyr Asp Lys Ala Ala Ser Gln Ala Lys Ala Ala Glu Gln Ala Thr
 820 825 830

Tyr Gln Phe Ser Lys Ala Gln Lys Asp Val Ser Ala Ser Ala Met Ile
 835 840 845

Ala Ser Gly Ala Ile Asn Lys Thr Thr Val Ala Thr Thr Ala Ser Thr
 850 855 860

Val Ala Thr Arg Ala Ala Thr Leu Ala Val Asn Gly Leu Lys Leu Ala
 865 870 875 880

- 52 -

Phe Arg Gly Leu Leu Ala Ala Thr Gly Val Gly Leu Ala Ile Thr Gly
 885 890 895

Val Ser Phe Val Leu Glu Lys Val Val Gly Ser Phe Asn Ala Ala Ser
 900 905 910

Gln Ala Ala Glu Gln Tyr Lys Gln Lys Gln Glu Gln Thr Lys Gln Ala
 915 920 925

Ile Ala Ser Met Ser Asn Gly Glu Ile Asn Ser Leu Ile Ser Ser Tyr
 930 935 940

Asp Lys Leu Gln Gln Lys Met Asn Ser Gly Ser Ala Phe Asn Thr Ala
 945 950 955 960

Glu Ala Glu Lys Tyr Lys Glu Val Thr Ser Gln Leu Ala Asn Ile Phe
 965 970 975

Pro Asp Leu Val Thr Gly Glu Asn Arg Tyr Gly Lys Glu Met Ala Gly
 980 985 990

Asn Lys Glu Val Met Lys Gln Lys Ile Glu Leu Ile Lys Gln Glu Met
 995 1000 1005

Glu Leu Glu Arg Gln Lys Asn Ala Ile Lys Gln Lys Glu Glu Gln
 1010 1015 1020

Asp Ala Tyr Ile Lys Glu Gln Asp Ser Leu Ala Lys Lys Asn Arg
 1025 1030 1035

Gly Gln Lys Trp Tyr Gln Leu Gly Gln Thr Pro Glu Leu Lys Leu
 1040 1045 1050

Gln Glu Gln Ala Arg Pro Thr Thr Val Ser Asp Asn Ser Asn Ile
 1055 1060 1065

Asn Lys Ile Asn Ala Thr Ile Gln Lys Val Lys Ser Gln Ala Gln
 1070 1075 1080

Ala Glu Lys Ala Leu Glu Gln Val Asp Lys Gln Leu Ala Gln Ser
 1085 1090 1095

Gln Thr Lys Asn Arg Gln Asn Glu Val Gln His Leu Gln Lys Val
 1100 1105 1110

Arg Gln Ala Leu Gln Asp Tyr Ile Thr Lys Thr Gly Gln Ala Asn
 1115 1120 1125

- 54 -

Tyr	Gly	Asp	Glu	Ile	Leu	Ala	Val	Ala	Gly	Asp	Gln	Glu	Ala	Leu
1355						1360					1365			
Ser	Asn	Phe	Ile	Met	Gln	Lys	Gln	Asn	Glu	Glu	Thr	Asp	Asn	Tyr
1370						1375					1380			
Asn	Lys	Asn	Leu	Lys	Thr	Lys	Leu	Glu	Asn	Ser	Ser	Ser	Tyr	Tyr
1385						1390					1395			
Lys	Ala	Val	Ala	Gly	Ala	Asp	Ser	Ala	Leu	Ser	Asn	Tyr	Leu	Met
1400						1405					1410			
Glu	Asn	Tyr	Gly	Ile	Asp	Thr	Lys	Asn	Tyr	Lys	Ser	Leu	Thr	Glu
1415						1420					1425			
Val	Lys	Ala	Lys	Ile	Thr	Asp	Leu	Tyr	Tyr	Asn	Gly	Ser	Ala	Glu
1430						1435					1440			
Glu	Gln	Ala	Lys	Val	Val	Asp	Ala	Ile	Ala	Lys	Ala	Tyr	His	Ile
1445						1450					1455			
Asp	Leu	Ser	Asn	Tyr	Gly	Ser	Leu	Asn	Glu	Lys	Lys	Glu	Ala	Leu
1460						1465					1470			
Glu	Asn	Gln	Leu	Met	Lys	Ile	Leu	Gly	Ser	Lys	Trp	Lys	Lys	Tyr
1475						1480					1485			
Ile	Gly	Ser	Val	Ala	Lys	Asp	Met	Lys	Ser	Leu	Gly	Val	Asp	Ala
1490						1495					1500			
Gly	Glu	Val	Gly	Ala	Asp	Gly	Phe	Asp	Asp	Ser	Lys	Met	Phe	Asn
1505						1510					1515			
Pro	Gly	Ala	Leu	Ile	Gly	Ala	Asn	Asn	Phe	Gln	Asn	Val	Ser	Asn
1520						1525					1530			
Leu	Ser	Asn	Ile	Ser	Asn	Val	Phe	Asn	Ser	Leu	Asn	Gly	Ala	Phe
1535						1540					1545			
Asn	Glu	Ala	Lys	Asn	Glu	Ala	Ala	Gly	Val	Ser	Arg	Gly	Leu	Asp
1550						1555					1560			
Asp	Ala	Ala	Ser	Gly	Leu	Lys	Asp	Val	Gly	Asp	Ser	Ala	Gly	Ser
1565						1570					1575			
Ala	Gly	Ser	Gly	Leu	Gly	Lys	Thr	Ala	Lys	Gly	Ala	Asp	Lys	Ala
1580						1585					1590			

- 55 -

Ser	Asp	Ser	Leu	Asp	Gly	Thr	Asn	Lys	Glu	Leu	Glu	Lys	Thr	Lys
1595						1600					1605			
Glu	Lys	Ala	Glu	Glu	Ala	Gly	Val	Thr	Val	Lys	Gln	Leu	Tyr	Lys
1610						1615					1620			
Gln	Phe	Thr	Val	Thr	Thr	Tyr	Val	Ala	Asp	Lys	Leu	Ser	Met	Ala
1625						1630					1635			
Leu	Asp	Lys	Ile	Asn	Asn	Lys	Leu	Glu	Lys	Gln	Lys	Leu	Leu	Thr
1640						1645					1650			
Glu	Lys	Tyr	Ala	Thr	Trp	Ser	Ser	Ser	Tyr	Arg	Asn	Ser	Leu	Lys
1655						1660					1665			
Ala	Glu	Asn	Lys	Leu	Leu	Asp	Glu	Lys	Thr	Ala	Lys	Ile	Lys	Lys
1670						1675					1680			
Gln	Ile	Glu	Ser	Met	Lys	Glu	Gln	Ile	Ala	Gln	Gly	Lys	Val	Ile
1685						1690					1695			
Glu	Tyr	Gly	Leu	Val	Gly	Lys	Asp	Ile	Asn	Val	Pro	Tyr	Tyr	Glu
1700						1705					1710			
Tyr	Thr	Ala	Asn	Asn	Leu	Asp	Asp	Gly	Glu	Thr	Gly	Arg	Ile	Ser
1715						1720					1725			
Arg	Tyr	Thr	Gly	Asn	Ser	Thr	Gln	Ala	Lys	Val	Trp	Asn	Phe	Phe
1730						1735					1740			
Lys	Ser	Lys	Gly	Leu	Ser	Asp	His	Ala	Val	Ala	Gly	Ile	Met	Gly
1745						1750					1755			
Asn	Met	Glu	Arg	Glu	Ser	Arg	Phe	Lys	Pro	Gly	Ala	Gln	Glu	Gln
1760						1765					1770			
Gly	Gly	Thr	Gly	Ile	Gly	Leu	Val	Gln	Leu	Ser	Phe	Gly	Arg	Ala
1775						1780					1785			
Asn	Asn	Leu	Arg	Asn	Tyr	Ala	Ala	Arg	Arg	Gly	Lys	Ser	Trp	Lys
1790						1795					1800			
Asp	Leu	Asn	Thr	Gln	Leu	Asp	Phe	Ile	Trp	Lys	Glu	Leu	Asn	Thr
1805						1810					1815			

- 56 -

Thr	Glu	Val	Asn	Ala	Leu	Arg	Gly	Leu	Lys	Ser	Ala	Thr	Ser	Val
1820						1825					1830			
Ile	Gly	Ala	Ala	Asn	Ser	Phe	Gln	Arg	Leu	Tyr	Glu	Arg	Ala	Gly
1835						1840					1845			
Val	Val	Ala	Gln	Gly	Glu	Arg	Asn	Ala	Ala	Ala	Lys	Lys	Tyr	Tyr
1850						1855					1860			
Arg	Gln	Phe	Lys	Gly	Thr	Asn	Gly	Ser	Ser	Gly	Phe	Leu	Ser	Gly
1865						1870					1875			
Gly	Val	Val	Ala	Gly	Thr	Asn	Gly	Lys	Pro	Leu	Thr	Ser	Asp	Arg
1880						1885					1890			
Asn	Ala	Tyr	Ile	Leu	Asp	Arg	Gln	Phe	Gly	Arg	Tyr	Asn	Gly	Gly
1895						1900					1905			
Gly	Val	His	His	Gly	Arg	Asp	Ile	Thr	Ser	Ala	Thr	Ile	Asn	Gly
1910						1915					1920			
Ser	Pro	Ile	Lys	Ala	Ala	Arg	Ser	Gly	Ile	Val	Thr	Phe	Lys	Gly
1925						1930					1935			
Trp	Thr	Gly	Gly	Gly	Asn	Thr	Leu	Ser	Ile	Phe	Asp	Gly	Lys	Asn
1940						1945					1950			
Thr	Tyr	Thr	Tyr	Met	His	Met	Lys	Asn	Pro	Ala	Arg	Val	Val	Lys
1955						1960					1965			
Gly	Gln	Arg	Val	Lys	Ala	Gly	Gln	Ile	Val	Gly	Asn	Val	Gly	Thr
1970						1975					1980			
Thr	His	Asp	Arg	Arg	Leu	Gly	Gly	Phe	Ser	Thr	Gly	Pro	His	Leu
1985						1990					1995			
His	Val	Gln	Val	Asn	Leu	Gly	Lys	Thr	Pro	Ser	Gly	Thr	Phe	Met
2000						2005					2010			
Asn	Thr	Phe	Asn	Gly	Ala	His	Arg	Ala	Val	Asp	Pro	Val	Lys	Tyr
2015						2020					2025			
Gly	Tyr	Thr	Arg	Val	Ser	Gly	Gly	Gly	Ser	Leu	Asn	Leu	Gly	Ser
2030						2035					2040			
Leu	Thr	Ser	Gly	His	Ser	Ala	Met	Ser	Gly	Ser	Ile	Ser	Ala	Ala
2045						2050					2055			

- 57 -

Met	Ala	Glu	Asp	Leu	Asn	Glu	Ala	Glu	Gln	Glu	Arg	Leu	Asn	Lys
2060						2065					2070			
Ile	Glu	Gln	Ala	Ile	Asn	Ala	His	Asn	Lys	Ala	Glu	Glu	Met	Lys
2075						2080					2085			
Gln	Lys	Val	Asp	Glu	Leu	Arg	Lys	Thr	Leu	Met	Asp	Lys	Gln	Leu
2090						2095					2100			
Glu	Glu	Val	Gln	Thr	Ala	Lys	Glu	Lys	Ser	Glu	Asn	Leu	Tyr	Asn
2105						2110					2115			
Ile	Gln	Lys	Ser	His	Val	Glu	Glu	Tyr	Asp	His	Trp	Arg	Thr	Leu
2120						2125					2130			
Gln	Glu	Ala	Arg	Ser	Ala	Lys	Leu	Glu	Tyr	Glu	Leu	Asn	Lys	Ile
2135						2140					2145			
Glu	Phe	Glu	Lys	Gly	Arg	Asn	Thr	Lys	Glu	Trp	Arg	Asn	Lys	Asn
2150						2155					2160			
Lys	Gln	Leu	Gln	Ala	Ser	Arg	Gln	Leu	Glu	Val	Asn	Phe	Glu	Asp
2165						2170					2175			
Ser	Lys	Ile	Gln	Tyr	Ile	Asn	Lys	Ala	Leu	Lys	Lys	Asn	Ala	Asn
2180						2185					2190			
Lys	Ile	Phe	Gly	Lys	Asn	Thr	Val	Asn	Arg	Asp	Glu	Phe	Glu	Thr
2195						2200					2205			
Met	Lys	Arg	Asp	Ala	Gln	Gln	Asn	Ile	Arg	Asp	Leu	Lys	Ala	Gly
2210						2215					2220			
Ile	Gln	Thr	Ala	Ser	Gly	Glu	Ile	Ala	Thr	Ser	Met	Ile	Asp	Gln
2225						2230					2235			
Ile	Leu	Asp	Glu	Tyr	Glu	Asp	Arg	Val	Gly	Lys	Val	Ser	Ala	Lys
2240						2245					2250			
Ile	Glu	Lys	Met	Gly	Lys	Gln	Lys	Glu	Lys	Leu	Asp	Leu	Ala	Asp
2255						2260					2265			
Asn	Lys	Gln	Ala	Leu	Lys	Ser	Ser	Ser	Leu	Ser	Arg	Gln	Gln	Ala
2270						2275					2280			

- 58 -

Lys	Asp	Ser	Lys	Ser	Leu	Ala	Ser	Tyr	Ile	Asn	Phe	Tyr	Ile	Lys
2285						2290					2295			
Gln	Leu	Glu	Arg	Gln	Leu	Lys	Leu	Thr	Gly	Lys	Asn	His	Glu	Leu
2300						2305					2310			
Gln	Gln	Lys	Val	Lys	Glu	Gln	Ile	Lys	Glu	Met	Lys	Val	Ala	Tyr
2315						2320					2325			
Asp	Asp	Ala	Thr	Leu	Ala	Ala	His	Gln	Tyr	Ile	Thr	Glu	Ala	Ala
2330						2335					2340			
Glu	Val	Asp	Thr	Glu	Arg	Gln	Leu	Gln	Leu	Asn	Ala	Asn	Arg	Leu
2345						2350					2355			
Arg	Asp	Ala	Gln	Asn	Glu	Leu	Ser	Lys	Ala	Asp	Tyr	Lys	Ala	Gly
2360						2365					2370			
Phe	Ile	Ser	Gln	Glu	Tyr	Gln	Ile	Asp	Leu	Tyr	Arg	Lys	Asn	Gln
2375						2380					2385			
Glu	Ala	Lys	Phe	Lys	Gly	Tyr	Leu	Lys	Glu	Lys	Glu	Ala	Leu	Glu
2390						2395					2400			
Gln	Asn	Lys	Ser	Glu	Leu	Gln	Asp	Met	Tyr	Glu	Ile	Tyr	Lys	Ser
2405						2410					2415			
Val	Pro	Thr	Gln	Ala	Gln	Lys	Ile	Lys	Glu	Ala	Leu	Ile	Glu	Thr
2420						2425					2430			
Lys	Asn	Ala	Ile	Arg	Asp	Asn	Asn	Lys	Gly	Leu	Tyr	Asp	Leu	Lys
2435						2440					2445			
Tyr	Asp	Met	Ala	Asn	Ser	Val	Ile	Asn	Gln	Ile	Lys	Asp	Ile	Tyr
2450						2455					2460			
Ser	Lys	Gln	Leu	Glu	Val	Ala	Thr	Lys	Ala	Tyr	Asp	Asp	Glu	Tyr
2465						2470					2475			
Lys	Ala	Tyr	Glu	Lys	Met	Ile	Asn	Lys	Lys	Leu	Lys	Leu	Ile	Asp
2480						2485					2490			
Asp	Glu	Gln	Thr	Gln	Glu	Ser	Phe	Asn	Lys	Asp	Val	Arg	Asp	Arg
2495						2500					2505			
Thr	Glu	Ala	Met	Asp	Lys	Ile	Arg	Asp	Glu	Ile	Ala	Gln	Arg	Ser
2510						2515					2520			

- 59 -

Gly	Asp	Asp	Ser	Leu	Ala	Asn	Gln	Lys	Lys	Leu	Lys	Asp	Leu	Arg
2525						2530					2535			
Glu	Gln	Leu	Lys	Gln	Gln	Glu	Glu	Asp	Tyr	Thr	Met	Phe	Ile	Asn
2540						2545					2550			
Asn	Lys	Asn	Arg	Asp	Asp	Arg	Arg	Lys	Ala	Leu	Gln	Asp	Glu	Leu
2555						2560					2565			
Asn	Asp	Lys	Asn	Glu	Gln	Ile	Gln	Glu	Gln	Lys	Glu	Asp	Leu	Asn
2570						2575					2580			
Lys	Ala	Phe	Gln	Asp	Leu	Ile	Gly	Asp	Thr	Arg	Arg	Phe	Asn	Ala
2585						2590					2595			
Ile	Gln	Glu	Ser	Leu	Met	Glu	Gly	Gln	Ile	Asp	Lys	Tyr	Lys	Ser
2600						2605					2610			
Leu	Ile	Ala	Asp	Leu	Thr	Lys	Tyr	Val	Asn	Asp	Asn	Met	Lys	Glu
2615						2620					2625			
Ile	Gly	Arg	Ser	Thr	Ser	Glu	Gly	Ile	Leu	Asp	Gly	Leu	Ala	Ala
2630						2635					2640			
Ser	Phe	Lys	Gly	Leu	Ser	Ser	Leu	Ser	Lys	Glu	Leu	Gln	Lys	Gln
2645						2650					2655			
Glu	Lys	Asn	Asn	Leu	Asn	Pro	Val	Pro	Asn	Ser	Lys	Leu	Lys	Pro
2660						2665					2670			
Thr	Lys	Val	Asp	Glu	Ala	Thr	Ile	Ala	Ala	Ile	Lys	Lys	Val	Asn
2675						2680					2685			
Gly	Leu	Ser	Pro	Thr	Thr	Ile	Leu	Gln	Gly	Leu	Asp	Ile	Lys	Pro
2690						2695					2700			
Val	Asn	Leu	Pro	Lys	Asp	Val	Lys	Pro	Ser	Lys	Thr	Val	Thr	Asn
2705						2710					2715			
Asn	Asn	Lys	Thr	Thr	Ala	Lys	Ala	Leu	Val	Asn	Ile	Glu	Asn	Phe
2720						2725					2730			
Asn	Gly	Thr	Lys	Ala	Glu	Ala	Asp	Lys	Leu	Ala	Asn	Asn	Leu	Ala
2735						2740					2745			

- 60 -

Thr Ala Met Arg Lys Gln Gly Val Leu
 2750 2755

<210> 39
 <211> 319
 <212> PRT
 <213> Staphylococcus epidermidis

<400> 39

Met Ala Glu Thr Lys Lys Gln Phe Glu Asn Lys Val Ser Val Thr Gly
 1 5 10 15

Thr Leu Lys Ser Leu Glu Val Thr Asp Leu Val Thr Ala Lys Lys Val
 20 25 30

Pro Met Lys Ile Ala Thr Leu Arg Ile Glu Thr Gly Lys Gly Glu Thr
 35 40 45

His Thr Ala Lys Met Met Ala Val Lys His Phe Glu Arg Asp Gly Val
 50 55 60

Lys Thr Glu Asn Lys Ser Tyr Ser Ala Ile Glu Thr Met Gln Lys Glu
 65 70 75 80

Tyr Val Ser Ile Glu Asp Ile Ser Glu Asn Lys Ala Gly Glu Asp Ala
 85 90 95

Glu Ala Thr Val Val Asn Val Asn Gly Ser Met Ser Ile Asn Met Tyr
 100 105 110

Lys Asn Lys Ala Glu Lys Val Val Glu Thr Asn Gln Ile Glu Ala Arg
 115 120 125

Phe Val Asn Arg Val Lys Asp Val Glu Asn Ala Gln Phe Gly Ala Glu
 130 135 140

Phe Thr Leu Gln Thr Tyr Leu Ile Ser Lys Gly Gln Arg Val Ile Lys
 145 150 155 160

Asn Glu Glu Glu Thr Asp Glu Val Thr Phe Lys Ala Ala Thr Ile Asp
 165 170 175

Tyr Arg Gly Gln Ala His Pro Phe Glu Phe Thr Ala Asn Asp Glu Tyr
 180 185 190

Gly Val Ala Glu Trp Ile Glu Asp Glu Val Glu Leu Gly Gln Ser Leu
 195 200 205

- 61 -

Ile Leu Gln Gly Leu Ile Ile Asn Lys Phe Ile Val Glu Gln Val Glu
 210 215 220

Arg Ser Ser Ser Ala Gly Ile Gly Lys Ala Ile Val Asp Thr Arg Arg
 225 230 235 240

Glu Val Glu Arg Lys Leu Leu Val Glu Gly Ile Ile Pro Ile Glu Asp
 245 250 255

Glu Asp Asp Pro Lys Tyr Ile Thr Glu Glu Glu Ile Lys Glu Ala Asn
 260 265 270

Lys Lys Tyr Glu Asp Lys Lys Thr Glu Val Glu Ala Ser Thr Asn Gly
 275 280 285

Thr Lys Lys Thr Glu Val Lys Lys Gly Val Ala Thr Ser Lys Pro Lys
 290 295 300

Ala Ala Lys Pro Thr Ile Glu Ile Asp Asp Asp Asp Leu Pro Phe
 305 310 315

<210> 40

<211> 797

<212> PRT

<213> Staphylococcus epidermidis

<400> 40

Leu Pro Gln Ala Lys Lys Arg Thr Ser Thr Lys Arg Lys Gly Asn Lys
 1 5 10 15

Lys Thr Asn Lys Lys Lys Gln Asn Glu Thr Pro Leu Arg Tyr Ile Phe
 20 25 30

Ser Ile Ile Val Val Ile Leu Ile Ile Leu Gly Ala Phe Gln Leu Gly
 35 40 45

Ile Ile Gly Arg Met Ile Asp Ser Phe Phe Asn Tyr Leu Phe Gly Met
 50 55 60

Ser Arg Tyr Leu Thr Tyr Ile Leu Val Leu Ile Ala Thr Ile Phe Ile
 65 70 75 80

Thr Tyr Ser Lys Gln Ile Pro Arg Thr Arg Arg Ser Ile Gly Ala Ile
 85 90 95

Val Leu Gln Leu Ala Leu Leu Phe Ile Ala Gln Leu Tyr Phe His Phe
 100 105 110

- 62 -

Ser His Asn Ile Thr Ser Gln Arg Glu Pro Val Leu Ser Phe Val Tyr
 115 120 125

Lys Ala Tyr Glu Gln Thr His Phe Pro Asn Phe Gly Gly Gly Leu Ile
 130 135 140

Gly Phe Tyr Leu Leu Lys Leu Phe Ile Pro Leu Ile Ser Ile Val Gly
 145 150 155 160

Val Ile Ile Ile Thr Ile Leu Leu Leu Ala Ser Ser Phe Ile Leu Leu
 165 170 175

Leu Asn Leu Arg His Arg Asp Val Thr Lys Ser Leu Phe Asp Asn Leu
 180 185 190

Lys Ser Ser Ser Asn His Ala Ser Glu Ser Ile Lys Gln Lys Arg Glu
 195 200 205

Gln Asn Lys Ile Lys Lys Glu Glu Lys Ala Gln Leu Lys Glu Ala Lys
 210 215 220

Ile Glu Arg Lys Lys Gln Lys Lys Ser Arg Gln Asn Asn Asn Val Ile
 225 230 235 240

Lys Asp Val Ser Asp Phe Pro Glu Ile Ser Gln Ser Asp Asp Ile Pro
 245 250 255

Ile Tyr Gly His Asn Glu Gln Glu Asp Lys Arg Pro Asn Thr Ala Asn
 260 265 270

Gln Arg Gln Lys Arg Val Leu Asp Asn Glu Gln Phe Gln Gln Ser Leu
 275 280 285

Pro Ser Thr Lys Asn Gln Ser Ile Asn Asn Asn Gln Pro Ser Thr Thr
 290 295 300

Ala Glu Asn Asn Gln Gln Gln Ser Gln Ala Glu Gly Ser Ile Ser Glu
 305 310 315 320

Ala Gly Glu Glu Ala Asn Ile Glu Tyr Thr Val Pro Pro Leu Ser Leu
 325 330 335

Leu Lys Gln Pro Thr Lys Gln Lys Thr Thr Ser Lys Ala Glu Val Gln
 340 345 350

- 63 -

Arg Lys Gly Gln Val Leu Glu Ser Thr Leu Lys Asn Phe Gly Val Asn
 355 360 365

Ala Lys Val Thr Gln Ile Lys Ile Gly Pro Ala Val Thr Gln Tyr Glu
 370 375 380

Ile Gln Pro Ala Gln Gly Val Lys Val Ser Lys Ile Val Asn Leu His
 385 390 395 400

Asn Asp Ile Ala Leu Ala Leu Ala Ala Lys Asp Val Arg Ile Glu Ala
 405 410 415

Pro Ile Pro Gly Arg Ser Ala Val Gly Ile Glu Val Pro Asn Asp Lys
 420 425 430

Ile Ser Leu Val Thr Leu Lys Glu Val Leu Glu Asp Lys Phe Pro Ser
 435 440 445

Lys Tyr Lys Leu Glu Val Gly Ile Gly Arg Asp Ile Ser Gly Asp Pro
 450 455 460

Ile Ser Ile Gln Leu Asn Glu Met Pro His Leu Leu Val Ala Gly Ser
 465 470 475 480

Thr Gly Ser Gly Lys Ser Val Cys Ile Asn Gly Ile Ile Thr Ser Ile
 485 490 495

Leu Leu Asn Thr Lys Pro His Glu Val Lys Leu Met Leu Ile Asp Pro
 500 505 510

Lys Met Val Glu Leu Asn Val Tyr Asn Gly Ile Pro His Leu Leu Ile
 515 520 525

Pro Val Val Thr Asn Pro His Lys Ala Ser Gln Ala Leu Glu Lys Ile
 530 535 540

Val Ser Glu Met Glu Arg Arg Tyr Asp Leu Phe Gln His Ser Ser Thr
 545 550 555 560

Arg Asn Ile Glu Gly Tyr Asn Gln Tyr Ile Arg Lys Gln Asn Glu Glu
 565 570 575

Leu Asp Glu Lys Gln Pro Glu Leu Pro Tyr Ile Val Val Ile Val Asp
 580 585 590

Glu Leu Ala Asp Leu Met Met Val Ala Gly Lys Glu Val Glu Asn Ala
 595 600 605

- 64 -

Ile Gln Arg Ile Thr Gln Met Ala Arg Ala Ala Gly Ile His Leu Ile
 610 615 620

Val Ala Thr Gln Arg Pro Ser Val Asp Val Ile Thr Gly Ile Ile Lys
 625 630 635 640

Asn Asn Ile Pro Ser Arg Ile Ala Phe Ala Val Ser Ser Gln Thr Asp
 645 650 655

Ser Arg Thr Ile Ile Gly Ala Gly Gly Ala Glu Lys Leu Leu Gly Lys
 660 665 670

Gly Asp Met Leu Tyr Val Gly Asn Gly Glu Ser Thr Thr Thr Arg Ile
 675 680 685

Gln Gly Ala Phe Leu Ser Asp Gln Glu Val Gln Asp Val Val Asn Tyr
 690 695 700

Val Val Glu Gln Gln Lys Ala Asn Tyr Val Lys Glu Met Glu Pro Asp
 705 710 715 720

Ala Pro Val Asp Lys Ser Glu Met Lys Ser Glu Asp Ala Leu Tyr Asp
 725 730 735

Glu Ala Tyr Leu Phe Val Ile Glu Lys Gln Lys Ala Ser Thr Ser Leu
 740 745 750

Leu Gln Arg Gln Phe Arg Ile Gly Tyr Asn Arg Ala Ser Arg Leu Met
 755 760 765

Asp Asp Leu Glu Arg Asn Gln Val Ile Gly Pro Gln Lys Gly Ser Lys
 770 775 780

Pro Arg Gln Ile Leu Val Asp Leu Glu Asn Asp Glu Val
 785 790 795

<210> 41

<211> 429

<212> PRT

<213> Staphylococcus epidermidis

<400> 41

Met Lys Thr His Gln Tyr Glu Leu Ile Asp Glu Lys Val Phe Glu His
 1 5 10 15

Glu Phe Asp Asn Gly Leu Lys Leu Phe Ile Ile Pro Lys Pro Gly Phe

- 65 -

20	25	30
Gln Lys Thr Tyr Val Thr Tyr Thr Thr Gln Phe Gly Ser Leu Asp Asn		
35	40	45
His Phe Lys Pro Ile Gly Ser Gln Gln Phe Val Lys Val Pro Asp Gly		
50	55	60
Val Ala His Phe Leu Glu His Lys Leu Phe Glu Lys Glu Asp Glu Asp		
65	70	75
Leu Phe Thr Ala Phe Ala Glu Glu Asn Ala Gln Ala Asn Ala Phe Thr		
85	90	95
Ser Phe Asp Arg Thr Ser Tyr Leu Phe Ser Ala Thr Ser Asn Ile Glu		
100	105	110
Ser Asn Ile Lys Arg Leu Leu Asn Met Val Glu Thr Pro Tyr Phe Thr		
115	120	125
Glu Glu Thr Val Asn Lys Glu Lys Gly Ile Ile Ala Glu Glu Ile Lys		
130	135	140
Met Tyr Gln Glu Gln Pro Gly Tyr Lys Leu Met Phe Asn Thr Leu Arg		
145	150	155
Ala Met Tyr Ser Lys His Pro Ile Arg Val Asp Ile Ala Gly Ser Val		
165	170	175
Glu Ser Ile Tyr Glu Ile Thr Lys Asp Asp Leu Tyr Leu Cys Tyr Glu		
180	185	190
Thr Phe Tyr His Pro Ser Asn Met Val Leu Phe Val Val Gly Asp Val		
195	200	205
Ser Pro Gln Ser Ile Ile Lys Leu Val Glu Lys His Glu Asn Gln Arg		
210	215	220
Asn Lys Thr Tyr Gln Pro Arg Ile Glu Arg Ala Gln Ile Asp Glu Pro		
225	230	235
Arg Glu Ile Asn Gln Arg Phe Val Ser Glu Lys Met Lys Leu Gln Ser		
245	250	255
Pro Arg Leu Met Leu Gly Phe Lys Asn Glu Pro Leu Asp Glu Ser Ala		
260	265	270

- 66 -

Thr Lys Phe Val Gln Arg Asp Leu Glu Met Thr Phe Phe Tyr Glu Leu
 275 280 285

Val Phe Gly Glu Glu Thr Glu Phe Tyr Gln Gln Leu Leu Asn Lys Asp
 290 295 300

Leu Ile Asp Glu Thr Phe Gly Tyr Gln Phe Val Leu Glu Pro Ser Tyr
 305 310 315 320

Ser Phe Ser Ile Ile Thr Ser Ala Thr Gln Gln Pro Asp Leu Phe Lys
 325 330 335

Gln Leu Ile Met Asp Glu Leu Arg Lys Tyr Lys Gly Asn Leu Lys Asp
 340 345 350

Gln Glu Ala Phe Asp Leu Leu Lys Lys Gln Phe Ile Gly Glu Phe Ile
 355 360 365

Ser Ser Leu Asn Ser Pro Glu Tyr Ile Ala Asn Gln Tyr Ala Lys Leu
 370 375 380

Tyr Phe Glu Gly Val Ser Val Phe Asp Met Leu Asp Ile Val Glu Asn
 385 390 395 400

Ile Thr Leu Glu Ser Val Asn Glu Thr Ser Glu Leu Phe Leu Asn Phe
 405 410 415

Asp Gln Leu Val Asp Ser Arg Leu Glu Met Glu Asn Arg
 420 425

<210> 42

<211> 329

<212> PRT

<213> Staphylococcus epidermidis

<400> 42

Met Thr Glu Gln Lys Asp Ile Lys Glu Thr Glu Tyr Arg Arg Gln Lys
 1 5 10 15

Gly Thr Thr Ser Thr Pro Ser Arg Arg Arg Asn Lys Lys Arg Met Arg
 20 25 30

Lys Leu Pro Phe Ile Ile Leu Val Ile Leu Ile Ile Leu Ile Ser Ile
 35 40 45

Ile Val Tyr Ile Thr His Gln Tyr Asn Ser Gly Met Lys Tyr Ala Lys
 50 55 60

- 67 -

Glu His Ala Lys Asp Val Lys Val His Lys Phe Asn Gly Asn Met Lys
65 70 75 80

Asn Asp Gly Lys Ile Ser Val Leu Val Leu Gly Ala Asp Lys Ala Gln
85 90 95

Gly Gly Lys Ser Arg Thr Asp Ser Ile Met Ile Val Gln Tyr Asp Tyr
100 105 110

Val His Lys Lys Met Lys Met Met Ser Val Met Arg Asp Ile Tyr Ala
115 120 125

Asp Ile Pro Gly Tyr Asp Lys Tyr Lys Ile Asn Ala Ala Tyr Ser Leu
130 135 140

Gly Gly Pro Glu Leu Leu Arg Lys Thr Leu Asn Lys Asn Leu Gly Val
145 150 155 160

Asn Pro Glu Tyr Tyr Ala Val Val Asp Phe Thr Gly Phe Glu Lys Met
165 170 175

Ile Asp Glu Leu Gln Pro Asn Gly Val Pro Ile Asp Val Glu Lys Asp
180 185 190

Met Ser Glu Asn Ile Gly Val Ser Leu Lys Lys Gly His His Lys Leu
195 200 205

Asn Gly Lys Glu Leu Leu Gly Tyr Ala Arg Phe Arg His Asp Pro Glu
210 215 220

Gly Asp Phe Gly Arg Val Arg Arg Gln Gln Gln Val Met Gln Thr Leu
225 230 235 240

Lys Gln Glu Leu Val Asn Phe Asn Thr Val Ala Lys Leu Pro Lys Val
245 250 255

Ala Gly Ile Leu Arg Gly Tyr Val Asn Thr Asn Met Pro Asn Ser Ala
260 265 270

Ile Phe Gln Thr Gly Ile Ser Phe Gly Ile Arg Gly Asp Lys Asp Val
275 280 285

Gln Ser Leu Thr Val Pro Ile Lys Gly Ser Tyr Gln Asp Ile Asn Thr
290 295 300

- 68 -

Asn Asn Asp Gly Ser Ala Leu Gln Ile Asp Ser Glu Lys Asn Lys Gln
 305 310 315 320

Ala Ile Lys Asn Phe Phe Glu Asp Asn
 325

<210> 43

<211> 627

<212> PRT

<213> Staphylococcus epidermidis

<400> 43

Met Glu Ala Tyr Lys Ile Glu His Leu Asn Lys Ser Tyr Ala Asp Lys
 1 5 10 15

Glu Ile Phe Asn Asp Leu Asn Leu Ser Ile Ser Glu His Glu Arg Ile
 20 25 30

Gly Leu Val Gly Ile Asn Gly Thr Gly Lys Ser Thr Leu Leu Lys Val
 35 40 45

Ile Gly Gly Leu Asp Glu Asp Phe Thr Ala Asp Ile Thr His Pro Asn
 50 55 60

Gln Tyr Arg Ile Arg Tyr Ser Ser Gln Lys Gln Asp Leu Asn Gly His
 65 70 75 80

Met Thr Val Phe Glu Ala Val Leu Ser Ser Asp Thr Pro Thr Leu Arg
 85 90 95

Ile Ile Lys Lys Tyr Glu Glu Ala Val Asn Arg Tyr Ala Leu Asp Gln
 100 105 110

Ser Asp Ser Asn Phe Asn Lys Met Met Glu Ala Gln Glu Glu Met Asp
 115 120 125

Gln Lys Asp Ala Trp Asp Tyr Asn Ala Glu Ile Lys Thr Ile Leu Ser
 130 135 140

Lys Leu Gly Ile His Asp Thr Thr Lys Lys Ile Val Glu Leu Ser Gly
 145 150 155 160

Gly Gln Gln Lys Arg Val Val Leu Ala Lys Thr Leu Ile Glu Gln Pro
 165 170 175

Asp Leu Leu Leu Leu Asp Glu Pro Thr Asn His Leu Asp Phe Glu Ser
 180 185 190

- 69 -

Ile Arg Trp Leu Ile Asn Tyr Val Lys Gln Tyr Pro His Thr Val Leu
 195 200 205

Phe Val Thr His Asp Arg Tyr Phe Leu Asn Glu Val Ser Thr Arg Ile
 210 215 220

Ile Glu Leu Asp Arg Gly Lys Leu Lys Thr Tyr Pro Gly Asn Tyr Glu
 225 230 235 240

Asp Tyr Ile Val Met Arg Ala Glu Asn Glu Leu Val Glu Gln Lys Gln
 245 250 255

Gln Glu Lys Gln Lys Ala Leu Tyr Lys Gln Glu Leu Ala Trp Met Arg
 260 265 270

Ala Gly Ala Lys Ala Arg Thr Thr Lys Gln Gln Ala Arg Ile Asn Arg
 275 280 285

Phe Asn Gln Leu Glu Ser Asp Val Lys Thr Gln His Thr Gln Asp Lys
 290 295 300

Gly Glu Leu Asn Leu Ala Tyr Ser Arg Leu Gly Lys Gln Val Tyr Glu
 305 310 315 320

Leu Lys Asn Leu Ser Lys Ser Ile Asn Asn Lys Val Leu Phe Glu Asp
 325 330 335

Val Thr Glu Ile Ile Gln Ser Gly Arg Arg Ile Gly Ile Val Gly Pro
 340 345 350

Asn Gly Ala Gly Lys Thr Thr Leu Leu Asn Ile Leu Ser Asn Glu Asp
 355 360 365

Gln Asp Tyr Glu Gly Glu Leu Lys Ile Gly Gln Thr Val Lys Val Ala
 370 375 380

Tyr Phe Lys Gln Thr Glu Lys Thr Leu Asp Arg Asp Ile Arg Val Ile
 385 390 395 400

Asp Tyr Leu Arg Glu Glu Ser Glu Met Ala Lys Glu Lys Asp Gly Thr
 405 410 415

Ser Ile Ser Val Thr Gln Leu Leu Glu Arg Phe Leu Phe Pro Ser Ala
 420 425 430

Thr His Gly Lys Lys Val Tyr Lys Leu Ser Gly Gly Glu Gln Lys Arg

- 70 -

435 440 445
 Leu Tyr Leu Leu Arg Leu Leu Val His Lys Pro Asn Val Leu Leu Leu
 450 455 460
 Asp Glu Pro Thr Asn Asp Leu Asp Thr Glu Thr Leu Thr Ile Leu Glu
 465 470 475 480
 Asp Tyr Ile Asp Asp Phe Gly Gly Ser Val Ile Thr Val Ser His Asp
 485 490 495
 Arg Tyr Phe Leu Asn Lys Val Val Gln Glu Tyr Trp Phe Ile His Asp
 500 505 510
 Gly Lys Ile Glu Lys Ile Ile Gly Ser Phe Glu Asp Tyr Glu Ser Phe
 515 520 525
 Lys Lys Glu His Glu Arg Gln Ala Met Leu Ser Lys Gln Thr Glu Gln
 530 535 540
 Gln Asn Lys His Lys His Gln Pro Lys Lys Lys Thr Gly Leu Ser Tyr
 545 550 555 560
 Lys Glu Lys Leu Glu Tyr Glu Thr Ile Met Thr Arg Ile Glu Met Thr
 565 570 575
 Glu Thr Arg Leu Glu Asp Leu Glu Gln Glu Met Ile Asn Ala Ser Asp
 580 585 590
 Asn Tyr Ala Arg Ile Lys Glu Leu Asn Glu Glu Lys Glu Gln Leu Glu
 595 600 605
 Ala Thr Tyr Glu Ala Asp Ile Thr Arg Trp Ser Glu Leu Glu Glu Ile
 610 615 620
 Lys Glu Gln
 625

<210> 44
 <211> 270
 <212> PRT
 <213> Staphylococcus epidermidis

<400> 44

Met Lys Lys Leu Phe Gly Ile Ile Leu Val Leu Ala Leu Thr Ile Ala
 1 5 10 15

- 71 -

Leu Ala Ala Cys Gly Gly Gly Lys Asp Lys Glu Lys Thr Ile Thr Val
20 25 30

Gly Ala Ser Pro Ala Pro His Ala Glu Ile Leu Glu Lys Ala Lys Pro
35 40 45

Leu Leu Lys Lys Lys Gly Tyr Asp Leu Lys Ile Lys Pro Ile Asn Asp
50 55 60

Tyr Thr Thr Pro Asn Lys Leu Leu Asp Lys Gly Glu Ile Asp Ala Asn
65 70 75 80

Phe Phe Gln His Thr Pro Tyr Leu Asn Thr Glu Ser Lys Glu Lys Gly
85 90 95

Tyr Lys Ile Glu Ser Ala Gly Asn Val Glu Leu Glu Pro Met Ala Val
100 105 110

Tyr Ser Lys Lys Tyr Lys Ser Leu Lys Asp Leu Pro Lys Gly Ala Thr
115 120 125

Val Tyr Val Ser Asn Asn Pro Ala Glu Gln Gly Arg Phe Leu Lys Phe
130 135 140

Phe Val Asp Glu Gly Leu Ile Lys Leu Lys Lys Gly Val Lys Ile Glu
145 150 155 160

Asn Ala Lys Phe Asp Asp Ile Thr Glu Asn Lys Lys Asp Ile Lys Phe
165 170 175

Asn Asn Lys Gln Ser Ala Glu Tyr Leu Pro Lys Ile Tyr Gln Asn Gln
180 185 190

Asp Ala Asp Ala Val Ile Ile Asn Ser Asn Tyr Ala Ile Asp Gln Lys
195 200 205

Leu Ser Pro Lys Lys Asp Ser Ile Ala Leu Glu Ser Pro Lys Asp Asn
210 215 220

Pro Tyr Ala Asn Leu Ile Ala Val Lys Lys Gly His Lys Asp Asp Lys
225 230 235 240

Asn Ile Lys Val Leu Met Glu Val Leu Gln Ser Lys Glu Ile Gln Asp
245 250 255

Tyr Ile Lys Asp Lys Tyr Asp Gly Ala Val Val Pro Ala Lys
260 265 270

- 72 -

<210> 45

<211> 439

<212> PRT

<213> Staphylococcus epidermidis

<400> 45

Met Glu Leu Thr Ile Tyr His Thr Asn Asp Ile His Ser His Leu Asn
 1 5 10 15

Glu Tyr Ala Arg Ile Gln Ala Tyr Met Ala Lys His Arg Pro Gln Leu
 20 25 30

Glu His Pro Ser Leu Tyr Ile Asp Ile Gly Asp His Val Asp Leu Ser
 35 40 45

Ala Pro Val Thr Glu Ala Thr Val Gly His Lys Asn Ile Glu Leu Leu
 50 55 60

Asn Glu Ala His Cys Asp Ile Ala Thr Ile Gly Asn Asn Glu Gly Met
 65 70 75 80

Thr Ile Ser His Asp Ala Leu Gln Asn Leu Tyr Asn Asp Ala Asp Phe
 85 90 95

Lys Val Ile Cys Thr Asn Val Ile Asp Glu Glu Gly His Leu Pro His
 100 105 110

His Ile Thr Ser Ser Tyr Ile Lys Glu Ile Lys Gly Thr Arg Ile Leu
 115 120 125

Phe Val Ala Ala Thr Ala Pro Phe Thr Pro Phe Tyr Arg Ala Leu Asp
 130 135 140

Trp Ile Val Thr Asp Pro Leu Ala Ala Ile Lys Asp Glu Ile Asn Ala
 145 150 155 160

His Gln Gly Glu Tyr Asp Leu Leu Met Val Met Ser His Val Gly Ile
 165 170 175

Phe Phe Asp Glu Lys Leu Cys Gln Glu Ile Pro Glu Ile Asp Val Ile
 180 185 190

Phe Gly Ser His Thr His His His Phe Glu His Gly Glu Ile Asn Asn
 195 200 205

Gly Val Leu Met Ala Ala Ala Gly Lys Tyr Gly Tyr Tyr Leu Gly Glu

- 73 -

210	215	220
Val Asn Ile Thr Ile Glu Asn Gly Lys Ile Val Asp Lys Ile Ala Lys		
225	230	235 240
Ile His Pro Ile Glu Thr Leu Pro Leu Val Glu Thr His Phe Glu Glu		
	245	250 255
Glu Gly Arg Ala Leu Leu Ser Lys Pro Val Val Asn His His Val Asn		
	260	265 270
Leu Val Lys Arg Thr Asp Val Val Thr Arg Thr Ser Tyr Leu Leu Ala		
	275	280 285
Glu Ser Val Tyr Glu Phe Ser Arg Ala Asp Cys Ala Ile Val Asn Ala		
	290	295 300
Gly Leu Ile Val Asn Gly Ile Glu Ala Asp Lys Val Thr Glu Tyr Asp		
305	310	315 320
Ile His Arg Met Leu Pro His Pro Ile Asn Ile Val Arg Val Arg Leu		
	325	330 335
Thr Gly Lys Gln Leu Lys Gln Val Ile Gln Lys Ser Gln Lys Gln Glu		
	340	345 350
Tyr Met His Glu His Ala Gln Gly Leu Gly Phe Arg Gly Asp Ile Phe		
	355	360 365
Gly Gly Tyr Ile Leu Tyr Asn Leu Gly Phe Ile Glu Ser Glu Asp Arg		
	370	375 380
Tyr Phe Ile Gly Asp Glu Glu Ile Gln Asn Asp Lys Gln Tyr Thr Leu		
385	390	395 400
Gly Thr Val Asp Met Tyr Thr Phe Gly Arg Tyr Phe Pro Leu Leu Lys		
	405	410 415
Gly Leu Ser Thr Asp Tyr Ile Met Pro Glu Phe Leu Arg Asp Ile Phe		
	420	425 430
Lys Glu Lys Leu Leu Lys Leu		
	435	

<210> 46
 <211> 203
 <212> PRT

- 74 -

<213> Staphylococcus epidermidis

<400> 46

Met	Glu	Lys	Val	Ile	Tyr	Leu	Ala	Gly	His	Ile	Leu	Asn	Glu	Ala	Met
1				5					10					15	

Val	Asp	Tyr	Arg	Glu	Lys	Gln	His	Asn	Gln	Val	Glu	Ala	Ile	Glu	Gly
			20					25					30		

Val	Lys	Pro	Tyr	Ser	Pro	His	Gln	Asp	Lys	Ser	Ile	Asn	Asp	Lys	Ser
		35					40					45			

Asn	Ala	Val	Gln	Glu	Gly	Leu	Ala	Glu	Arg	Ile	Leu	Lys	Asn	Asp	Phe
	50					55					60				

Thr	Ala	Met	Glu	Lys	Ser	Asp	Ile	Tyr	Val	Leu	Asp	Val	Leu	Asn	Glu
65						70				75					80

Gly	Leu	Gly	Thr	Ile	Ser	Glu	Leu	Gly	Ile	Ile	Ile	Gly	Met	Lys	Lys
				85					90					95	

Gln	Ala	Gln	Lys	Thr	Ile	Asp	Arg	Leu	Ser	Val	Leu	Ser	Glu	Glu	Ile
			100					105					110		

Lys	His	Asp	Val	Tyr	Gly	Asp	Gln	Thr	Glu	Ala	Tyr	Asp	Leu	Ile	Gln
		115					120					125			

Asp	Glu	Ile	Tyr	Lys	Gln	Glu	Lys	Ile	Leu	Asn	Lys	Thr	Val	Leu	Cys
	130					135					140				

Tyr	Cys	Ser	Asp	Ile	Arg	Gln	Gly	His	Gly	Lys	Pro	Tyr	Thr	Asp	Pro
145					150					155					160

Asp	Arg	Ala	Glu	Phe	Ser	Thr	Asn	Gln	Phe	Val	Tyr	Gly	Met	Val	Leu
				165					170					175	

Glu	Ala	Thr	Asn	Gly	Glu	Gly	Phe	Ile	Thr	Trp	Asp	Gln	Val	Leu	His
			180					185					190		

Arg	Leu	Asp	Leu	Phe	Gly	Ser	Gly	Leu	Ile	Val
		195					200			

<210> 47

<211> 59

<212> PRT

<213> Staphylococcus epidermidis

<400> 47

- 75 -

Met Ser Lys Lys Phe Arg Val Glu Asp Lys Glu Thr Ile Ala Asp Cys
 1 5 10 15

Leu Asp Arg Met Lys Lys Glu Gly Phe Met Pro Ile Arg Arg Ile Glu
 20 25 30

Lys Pro Val Tyr Lys Glu Asn Lys Asp Gly Ser Ile Glu Ile Leu Lys
 35 40 45

Gln Asp Ile Ile Phe Val Gly Ala Leu Ile Gln
 50 55

<210> 48
 <211> 3692
 <212> PRT
 <213> Staphylococcus epidermidis

<400> 48

Met Asn Leu Phe Arg Lys Gln Lys Phe Ser Ile Arg Lys Phe Asn Ile
 1 5 10 15

Gly Ile Phe Ser Ala Leu Ile Ala Thr Val Ala Phe Leu Ala His Pro
 20 25 30

Gly Gln Ala Thr Ala Ser Glu Leu Glu Pro Ser Gln Asn Asn Asp Thr
 35 40 45

Thr Ala Gln Ser Asp Gly Gly Leu Glu Asn Thr Ser Gln Ser Asn Pro
 50 55 60

Ile Ser Glu Glu Thr Thr Asn Thr Leu Ser Gly Gln Thr Val Pro Ser
 65 70 75 80

Ser Thr Glu Asn Lys Gln Thr Gln Asn Val Pro Asn His Asn Ala Gln
 85 90 95

Pro Ile Ala Ile Asn Thr Glu Glu Ala Glu Ser Ala Gln Thr Ala Ser
 100 105 110

Tyr Thr Asn Ile Asn Glu Asn Asn Asp Thr Ser Asp Asp Gly Leu His
 115 120 125

Val Asn Gln Pro Ala Lys His His Ile Glu Ala Gln Ser Glu Asp Val
 130 135 140

Thr Asn His Thr Asn Ser Asn His Ser Asn Ser Ser Ile Pro Glu Asn
 145 150 155 160

- 76 -

Lys Ala Thr Thr Glu Ser Ser Ser Lys Pro Lys Lys Arg Gly Lys Arg
 165 170 175

Ser Leu Asp Thr Asn Asn Gly Asn Asp Thr Thr Ser Thr Thr Gln Asn
 180 185 190

Thr Asp Pro Asn Leu Ser Asn Thr Gly Pro Asn Gly Ile Asn Thr Val
 195 200 205

Ile Thr Phe Asp Asp Leu Gly Ile Lys Thr Ser Thr Asn Arg Ser Arg
 210 215 220

Pro Glu Val Lys Val Val Asp Ser Leu Asn Gly Phe Thr Met Val Asn
 225 230 235 240

Gly Gly Lys Val Gly Leu Leu Asn Ser Val Leu Glu Arg Thr Ser Val
 245 250 255

Phe Asp Ser Ala Asp Pro Lys Asn Tyr Gln Ala Ile Asp Asn Val Val
 260 265 270

Ala Leu Gly Arg Ile Lys Gly Asn Asp Pro Asn Asp His Asp Gly Phe
 275 280 285

Asn Gly Ile Glu Lys Glu Phe Ser Val Asn Pro Asn Ser Glu Ile Ile
 290 295 300

Phe Ser Phe Asn Thr Met Thr Ala Lys Asn Arg Lys Gly Gly Thr Gln
 305 310 315 320

Leu Val Leu Arg Asn Ala Glu Asn Asn Gln Glu Ile Ala Ser Thr Asp
 325 330 335

Ile Gln Gly Gly Gly Val Tyr Arg Leu Phe Lys Leu Pro Asp Asn Val
 340 345 350

His Arg Leu Lys Val Gln Phe Leu Pro Met Asn Glu Ile His Ser Asp
 355 360 365

Phe Lys Arg Ile Gln Gln Leu His Asp Gly Tyr Arg Tyr Tyr Ser Phe
 370 375 380

Ile Asp Thr Ile Gly Val Asn Ser Gly Ser His Leu Tyr Val Lys Ser
 385 390 395 400

- 77 -

Arg Gln Val Asn Lys Asn Val Lys Asn Gly Lys Glu Phe Glu Val Asn
 405 410 415

Thr Arg Ile Glu Asn Asn Gly Asn Phe Ala Ala Ala Ile Gly Gln Asn
 420 425 430

Glu Leu Thr Tyr Lys Val Thr Leu Pro Glu Asn Phe Glu Tyr Val Asp
 435 440 445

Asn Ser Thr Glu Val Ser Phe Val Asn Gly Asn Val Pro Asn Ser Thr
 450 455 460

Val Asn Pro Phe Ser Val Asn Phe Asp Arg Gln Asn His Thr Leu Thr
 465 470 475 480

Phe Ser Ser Asn Gly Leu Asn Leu Gly Arg Ser Ala Gln Asp Val Ala
 485 490 495

Arg Phe Leu Pro Asn Lys Ile Leu Asn Ile Arg Tyr Lys Leu Arg Pro
 500 505 510

Val Asn Ile Ser Thr Pro Arg Glu Val Thr Phe Asn Glu Ala Ile Lys
 515 520 525

Tyr Lys Thr Phe Ser Glu Tyr Tyr Ile Asn Thr Asn Asp Asn Thr Val
 530 535 540

Thr Gly Gln Gln Thr Pro Phe Ser Ile Asn Val Ile Met Asn Lys Asp
 545 550 555 560

Asp Leu Ser Glu Gln Val Asn Lys Asp Ile Ile Pro Ser Asn Tyr Thr
 565 570 575

Leu Ala Ser Tyr Asn Lys Tyr Asn Lys Leu Lys Glu Arg Ala Gln Thr
 580 585 590

Val Leu Asp Glu Glu Thr Asn Asn Thr Pro Phe Asn Gln Arg Tyr Ser
 595 600 605

Gln Thr Gln Ile Asp Asp Leu Leu His Glu Leu Gln Thr Thr Leu Ile
 610 615 620

Asn Arg Val Ser Ala Ser Arg Glu Ile Asn Asp Lys Ala Gln Glu Met
 625 630 635 640

Thr Asp Ala Val Tyr Asp Ser Thr Glu Leu Thr Thr Glu Glu Lys Asp
 645 650 655

- 78 -

Thr Leu Val Asp Gln Ile Glu Asn His Lys Asn Glu Ile Ser Asn Asn
660 665 670

Ile Asp Asp Glu Leu Thr Asp Asp Gly Val Glu Arg Val Lys Glu Ala
675 680 685

Gly Leu His Thr Leu Glu Ser Asp Thr Pro His Pro Val Thr Lys Pro
690 695 700

Asn Ala Arg Gln Val Val Asn Asn Arg Ala Asp Gln Gln Lys Thr Leu
705 710 715 720

Ile Arg Asn Asn His Glu Ala Thr Thr Glu Glu Gln Asn Glu Ala Ile
725 730 735

Arg Gln Val Glu Ala His Ser Ser Asp Ala Ile Ala Lys Ile Gly Glu
740 745 750

Ala Glu Thr Asp Thr Thr Val Asn Glu Ala Arg Asp Asn Gly Thr Lys
755 760 765

Leu Ile Ala Thr Asp Val Pro Asn Pro Thr Lys Lys Ala Glu Ala Arg
770 775 780

Ala Ala Val Thr Asn Ser Ala Asn Ser Lys Ile Lys Asp Ile Asn Asn
785 790 795 800

Asn Thr Gln Ala Thr Leu Asp Glu Arg Asn Asp Ala Ile Ala Leu Val
805 810 815

Asn Arg Ser Lys Asp Glu Ala Ile Gln Asn Ile Asn Thr Ala Gln Gly
820 825 830

Asn Asp Asp Val Thr Glu Ala Gln Asn Asn Gly Thr Asn Thr Ile Gln
835 840 845

Gln Val Pro Leu Thr Pro Val Lys Arg Gln Asn Ala Ile Ala Thr Ile
850 855 860

Asn Ala Lys Ala Asp Glu Gln Lys Arg Leu Ile Gln Ala Asn Asn Asn
865 870 875 880

Ala Thr Thr Glu Glu Lys Ala Asp Ala Glu Arg Lys Val Asn Glu Ala
885 890 895

- 79 -

Val Ile Thr Ala Asn Gln Asn Ile Thr Asn Ala Thr Thr Asn Arg Asp
 900 905 910

Val Asp Gln Ala Gln Thr Thr Gly Ser Gly Ile Ile Ser Ala Ile Ser
 915 920 925

Pro Ala Thr Lys Ile Lys Glu Asp Ala Arg Ala Ala Val Glu Ala Lys
 930 935 940

Ala Ile Ala Gln Asn Gln Gln Ile Asn Ser Asn Asn Met Ala Thr Thr
 945 950 955 960

Glu Glu Lys Glu Asp Ala Leu Asn Gln Val Glu Ala His Lys Gln Ala
 965 970 975

Ala Ile Ala Thr Ile Asn Gln Ala Gln Ser Thr Gln Gln Val Ser Glu
 980 985 990

Ala Lys Asn Asn Gly Ile Asn Thr Ile Asn Gln Asp Gln Pro Asn Ala
 995 1000 1005

Val Lys Lys Asn Asn Thr Lys Ile Ile Leu Glu Gln Lys Gly Asn
 1010 1015 1020

Glu Lys Lys Ser Ala Ile Ala Gln Thr Pro Asp Ala Thr Thr Glu
 1025 1030 1035

Glu Lys Gln Glu Ala Val Ser Ala Val Ser Gln Ala Val Thr Asn
 1040 1045 1050

Gly Ile Thr His Ile Asn Gln Ala Asn Ser Asn Asp Asp Val Asp
 1055 1060 1065

Gln Glu Leu Ser Asn Ala Glu Gln Ile Ile Thr Gln Thr Asn Val
 1070 1075 1080

Asn Val Gln Lys Lys Pro Gln Ala Arg Gln Ala Leu Ile Ala Lys
 1085 1090 1095

Thr Asn Glu Arg Gln Ser Thr Ile Asn Thr Asp Asn Glu Gly Thr
 1100 1105 1110

Ile Glu Glu Lys Gln Lys Ala Ile Gln Ser Leu Asn Asp Ala Lys
 1115 1120 1125

Asn Leu Ala Asp Glu Gln Ile Thr Gln Ala Ala Ser Asn Gln Asn
 1130 1135 1140

Val	Asp	Asn	Ala	Leu	Asn	Ile	Gly	Ile	Ser	Asn	Ile	Ser	Lys	Ile
1145						1150					1155			
Gln	Thr	Asn	Phe	Thr	Lys	Lys	Gln	Gln	Ala	Arg	Asp	Gln	Val	Asn
1160						1165					1170			
Gln	Lys	Phe	Gln	Glu	Lys	Glu	Ala	Glu	Leu	Asn	Ser	Thr	Pro	His
1175						1180					1185			
Ala	Thr	Gln	Asp	Glu	Lys	Gln	Asp	Ala	Leu	Thr	Arg	Leu	Thr	Gln
1190						1195					1200			
Ala	Lys	Glu	Thr	Ala	Leu	Asn	Asp	Ile	Asn	Gln	Ala	Gln	Thr	Asn
1205						1210					1215			
Gln	Asn	Val	Asp	Thr	Ala	Leu	Thr	Ser	Gly	Ile	Gln	Asn	Ile	Gln
1220						1225					1230			
Asn	Thr	Gln	Val	Asn	Val	Arg	Lys	Lys	Gln	Glu	Ala	Lys	Thr	Thr
1235						1240					1245			
Ile	Asn	Asp	Ile	Val	Gln	Gln	His	Lys	Gln	Thr	Ile	Gln	Asn	Asn
1250						1255					1260			
Asp	Asp	Ala	Thr	Thr	Glu	Glu	Lys	Glu	Val	Ala	Asn	Asn	Leu	Val
1265						1270					1275			
Asn	Ala	Ser	Gln	Gln	Asn	Val	Ile	Ser	Lys	Ile	Asp	Asn	Ala	Thr
1280						1285					1290			
Thr	Asn	Asn	Gln	Ile	Asp	Gly	Ile	Val	Ser	Asp	Gly	Arg	Gln	Ser
1295						1300					1305			
Ile	Asn	Ala	Ile	Thr	Pro	Asp	Thr	Ser	Ile	Lys	Arg	Asn	Ala	Lys
1310						1315					1320			
Asn	Asp	Ile	Asp	Ile	Lys	Ala	Ala	Asp	Lys	Lys	Ile	Lys	Ile	Gln
1325						1330					1335			
Arg	Ile	Asn	Asp	Ala	Thr	Asp	Glu	Glu	Ile	Gln	Glu	Ala	Asn	Arg
1340						1345					1350			
Lys	Ile	Glu	Glu	Ala	Lys	Ile	Glu	Ala	Lys	Asp	Asn	Ile	Gln	Arg
1355						1360					1365			

- 81 -

Asn	Ser	Thr	Arg	Asp	Gln	Val	Asn	Glu	Ala	Lys	Thr	Asn	Gly	Ile
1370						1375						1380		
Asn	Lys	Ile	Glu	Asn	Ile	Thr	Pro	Ala	Thr	Thr	Val	Lys	Ser	Glu
1385						1390					1395			
Ala	Arg	Gln	Ala	Val	Gln	Asn	Lys	Ala	Asn	Glu	Gln	Ile	Asn	His
1400						1405					1410			
Ile	Gln	Asn	Thr	Pro	Asp	Ala	Thr	Asn	Glu	Glu	Lys	Gln	Glu	Ala
1415						1420					1425			
Ile	Asn	Arg	Val	Ser	Ala	Glu	Leu	Ala	Arg	Val	Gln	Ala	Gln	Ile
1430						1435					1440			
Asn	Ala	Glu	His	Thr	Thr	Gln	Gly	Val	Lys	Thr	Ile	Lys	Asp	Asp
1445						1450					1455			
Ala	Ile	Thr	Ser	Leu	Ser	Arg	Ile	Asn	Ala	Gln	Val	Val	Glu	Lys
1460						1465					1470			
Glu	Ser	Ala	Arg	Asn	Ala	Ile	Glu	Gln	Lys	Ala	Thr	Gln	Gln	Thr
1475						1480					1485			
Gln	Phe	Ile	Asn	Asn	Asn	Asp	Asn	Ala	Thr	Asp	Glu	Glu	Lys	Glu
1490						1495					1500			
Val	Ala	Asn	Asn	Leu	Val	Ile	Ala	Thr	Lys	Gln	Lys	Ser	Leu	Asp
1505						1510					1515			
Asn	Ile	Asn	Ser	Leu	Ser	Ser	Asn	Asn	Asp	Val	Glu	Asn	Ala	Lys
1520						1525					1530			
Val	Ala	Gly	Ile	Asn	Glu	Ile	Ala	Asn	Val	Leu	Pro	Ala	Thr	Ala
1535						1540					1545			
Val	Lys	Ser	Lys	Ala	Lys	Lys	Asp	Ile	Asp	Gln	Lys	Leu	Ala	Gln
1550						1555					1560			
Gln	Ile	Asn	Gln	Ile	Gln	Thr	His	Gln	Thr	Ala	Thr	Thr	Glu	Glu
1565						1570					1575			
Lys	Glu	Ala	Ala	Ile	Gln	Leu	Ala	Asn	Gln	Lys	Ser	Asn	Glu	Ala
1580						1585					1590			
Arg	Thr	Ala	Ile	Gln	Asn	Glu	His	Ser	Asn	Asn	Gly	Val	Ala	Gln
1595						1600					1605			

Ala Lys Ser Asn Gly Ile His Glu Ile Glu Leu Val Met Pro Asp
 1610 1615 1620

Ala His Lys Lys Ser Asp Ala Lys Gln Ser Ile Asp Asn Lys Tyr
 1625 1630 1635

Asn Glu Gln Ser Asn Thr Ile Asn Thr Thr Pro Asp Ala Thr Asp
 1640 1645 1650

Glu Glu Lys Gln Lys Ala Leu Asp Lys Leu Lys Ile Ala Lys Asp
 1655 1660 1665

Ala Gly Tyr Asn Lys Val Asp Gln Ala Gln Thr Asn Gln Gln Val
 1670 1675 1680

Ser Asp Ala Lys Thr Glu Ala Ile Asp Thr Ile Thr Asn Ile Gln
 1685 1690 1695

Ala Asn Val Ala Lys Lys Pro Ser Ala Arg Val Glu Leu Asp Ser
 1700 1705 1710

Lys Phe Glu Asp Leu Lys Arg Gln Ile Asn Ala Thr Pro Asn Ala
 1715 1720 1725

Thr Glu Glu Glu Lys Gln Asp Ala Ile Gln Arg Leu Asn Gly Lys
 1730 1735 1740

Arg Asp Glu Val Lys Asn Leu Ile Asn Gln Asp Arg Arg Asp Asn
 1745 1750 1755

Glu Val Glu Gln His Lys Asn Ile Gly Leu Gln Glu Leu Glu Thr
 1760 1765 1770

Ile His Ala Asn Pro Thr Arg Lys Ser Asp Ala Leu Gln Glu Leu
 1775 1780 1785

Gln Thr Lys Phe Ile Ser Gln Thr Glu Leu Ile Asn Asn Asn Lys
 1790 1795 1800

Asp Ala Thr Asn Glu Glu Lys Asp Glu Ala Lys Arg Leu Leu Glu
 1805 1810 1815

Ile Ser Lys Asn Lys Thr Ile Thr Asn Ile Asn Gln Ala Gln Thr
 1820 1825 1830

- 83 -

Asn Asn Gln Val Asp Asn Ala Lys Asp Asn Gly Met Asn Glu Ile
 1835 1840 1845

Ala Thr Ile Ile Pro Ala Thr Thr Ile Lys Thr Asp Ala Lys Thr
 1850 1855 1860

Ala Ile Asp Lys Lys Ala Glu Gln Gln Val Thr Ile Ile Asn Gly
 1865 1870 1875

Asn Asn Asp Ala Thr Asp Glu Glu Lys Ala Glu Ala Arg Lys Leu
 1880 1885 1890

Val Glu Lys Ala Lys Ile Glu Ala Lys Ser Asn Ile Thr Asn Ser
 1895 1900 1905

Asp Thr Glu Arg Glu Val Asn Gly Ala Lys Thr Asn Gly Leu Glu
 1910 1915 1920

Lys Ile Asn Asn Ile Gln Pro Ser Thr Gln Thr Lys Thr Asn Ala
 1925 1930 1935

Lys Gln Glu Ile Asn Asp Lys Ala Gln Glu Gln Leu Ile Gln Ile
 1940 1945 1950

Asn Asn Thr Pro Asp Ala Thr Glu Glu Glu Lys Gln Glu Ala Thr
 1955 1960 1965

Asn Arg Val Asn Ala Gly Leu Ala Gln Ala Ile Gln Asn Ile Asn
 1970 1975 1980

Asn Ala His Ser Thr Gln Glu Val Asn Glu Ser Lys Thr Asn Ser
 1985 1990 1995

Ile Ala Thr Ile Lys Ser Val Gln Pro Asn Val Ile Lys Lys Pro
 2000 2005 2010

Thr Ala Ile Asn Ser Leu Thr Gln Glu Ala Asn Asn Gln Lys Thr
 2015 2020 2025

Leu Ile Gly Asn Asp Gly Asn Ala Thr Asp Asp Glu Lys Glu Ala
 2030 2035 2040

Ala Lys Gln Leu Val Thr Gln Lys Leu Asn Glu Gln Ile Gln Lys
 2045 2050 2055

Ile His Glu Ser Thr Gln Asp Asn Gln Val Asp Asn Val Lys Ala
 2060 2065 2070

Gln Ala Ile Thr Ala Ile Lys Leu Ile Asn Ala Asn Ala His Lys
 2075 2080 2085

Arg Gln Asp Ala Ile Asn Ile Leu Thr Asn Leu Ala Glu Ser Lys
 2090 2095 2100

Lys Ser Asp Ile Arg Ala Asn Gln Asp Ala Thr Thr Glu Glu Lys
 2105 2110 2115

Asn Thr Ala Ile Gln Ser Ile Asp Asp Thr Leu Ala Gln Ala Arg
 2120 2125 2130

Asn Asn Ile Asn Gly Ala Asn Thr Asn Ala Leu Val Asp Glu Asn
 2135 2140 2145

Leu Glu Asp Gly Lys Gln Lys Leu Gln Arg Ile Val Leu Ser Thr
 2150 2155 2160

Gln Thr Lys Thr Gln Ala Lys Ala Asp Ile Ala Gln Ala Ile Gly
 2165 2170 2175

Gln Gln Arg Ser Thr Ile Asp Gln Asn Gln Asn Ala Thr Thr Glu
 2180 2185 2190

Glu Lys Gln Glu Ala Leu Glu Arg Leu Asn Gln Glu Thr Asn Gly
 2195 2200 2205

Val Asn Asp Arg Ile Gln Ala Ala Leu Ala Asn Gln Asn Val Thr
 2210 2215 2220

Asp Glu Lys Asn Asn Ile Leu Glu Thr Ile Arg Asn Val Glu Pro
 2225 2230 2235

Ile Val Ile Val Lys Pro Lys Ala Asn Glu Ile Ile Arg Lys Lys
 2240 2245 2250

Ala Ala Glu Gln Thr Thr Leu Ile Asn Gln Asn Gln Asp Ala Thr
 2255 2260 2265

Leu Glu Glu Lys Gln Ile Ala Leu Gly Lys Leu Glu Glu Val Lys
 2270 2275 2280

Asn Glu Ala Leu Asn Gln Val Ser Gln Ala His Ser Asn Asn Asp
 2285 2290 2295

- 85 -

Val	Lys	Ile	Val	Glu	Asn	Asn	Gly	Ile	Ala	Lys	Ile	Ser	Glu	Val
2300						2305					2310			
His	Pro	Glu	Thr	Ile	Ile	Lys	Arg	Asn	Ala	Lys	Gln	Glu	Ile	Glu
2315						2320					2325			
Gln	Asp	Ala	Gln	Ser	Gln	Ile	Asp	Thr	Ile	Asn	Ala	Asn	Asn	Lys
2330						2335					2340			
Ser	Thr	Asn	Glu	Glu	Lys	Ser	Ala	Ala	Ile	Asp	Arg	Val	Asn	Val
2345						2350					2355			
Ala	Lys	Ile	Asp	Ala	Ile	Asn	Asn	Ile	Thr	Asn	Ala	Thr	Thr	Thr
2360						2365					2370			
Gln	Leu	Val	Asn	Asp	Ala	Lys	Asn	Ser	Gly	Asn	Thr	Ser	Ile	Ser
2375						2380					2385			
Gln	Ile	Leu	Pro	Ser	Thr	Ala	Val	Lys	Thr	Asn	Ala	Leu	Ala	Ala
2390						2395					2400			
Leu	Ala	Ser	Glu	Ala	Lys	Asn	Lys	Asn	Ala	Ile	Ile	Asp	Gln	Thr
2405						2410					2415			
Pro	Asn	Ala	Thr	Ala	Glu	Glu	Lys	Glu	Glu	Ala	Asn	Asn	Lys	Val
2420						2425					2430			
Asp	Arg	Leu	Gln	Glu	Glu	Ala	Asp	Ala	Asn	Ile	Leu	Lys	Ala	His
2435						2440					2445			
Thr	Thr	Asp	Glu	Val	Asn	Asn	Ile	Lys	Asn	Gln	Ala	Val	Gln	Asn
2450						2455					2460			
Ile	Asn	Ala	Val	Gln	Val	Glu	Val	Ile	Lys	Lys	Gln	Asn	Ala	Lys
2465						2470					2475			
Asn	Gln	Leu	Asn	Gln	Phe	Ile	Asp	Asn	Gln	Lys	Lys	Ile	Ile	Glu
2480						2485					2490			
Asn	Thr	Pro	Asp	Ala	Thr	Leu	Glu	Glu	Lys	Ala	Glu	Ala	Asn	Arg
2495						2500					2505			
Leu	Leu	Gln	Asn	Val	Leu	Thr	Ser	Thr	Ser	Asp	Glu	Ile	Ala	Asn
2510						2515					2520			
Val	Asp	His	Asn	Asn	Glu	Val	Asp	Gln	Ala	Leu	Asp	Lys	Ala	Arg
2525						2530					2535			

- 86 -

Pro Lys	Ile Glu	Ala Ile	Val	Pro Gln	Val Ser	Lys	Lys Arg	Asp
2540			2545			2550		
Ala Leu	Asn Ala	Ile Gln	Glu	Ala Phe	Asn Ser	Gln	Thr Gln	Glu
2555			2560			2565		
Ile Gln	Glu Asn	Gln Glu	Ala	Thr Asn	Glu Glu	Lys	Thr Glu	Ala
2570			2575			2580		
Leu Asn	Lys Ile	Asn Gln	Leu	Leu Asn	Gln Ala	Lys	Val Asn	Ile
2585			2590			2595		
Asp Gln	Ala Gln	Ser Asn	Lys	Asp Val	Asp Ser	Ala	Lys Thr	Arg
2600			2605			2610		
Ser Ile	Gln Asp	Ile Glu	Gln	Ile Gln	Pro His	Pro	Gln Thr	Lys
2615			2620			2625		
Ala Thr	Gly Arg	His Arg	Leu	Asn Glu	Lys Ala	Asn	Gln Gln	Gln
2630			2635			2640		
Ser Thr	Ile Ala	Thr His	Pro	Asn Ser	Thr Ile	Glu	Glu Arg	Gln
2645			2650			2655		
Glu Ala	Ser Ala	Lys Leu	Gln	Glu Val	Leu Lys	Lys	Ala Ile	Ala
2660			2665			2670		
Lys Ile	Asp Lys	Gly Gln	Thr	Asn Asp	Asp Val	Glu	Lys Thr	Val
2675			2680			2685		
Val Asn	Gly Ile	Ala Glu	Ile	Glu Asn	Ile Leu	Pro	Ala Thr	Thr
2690			2695			2700		
Val Lys	Asp Lys	Ala Lys	Ala	Asp Val	Asn Ala	Glu	Lys Glu	Glu
2705			2710			2715		
Lys Asn	Leu Gln	Ile Asn	Ser	Asn Asp	Glu Ala	Thr	Thr Glu	Glu
2720			2725			2730		
Lys Leu	Val Ala	Ser Asp	Asn	Leu Asn	His Val	Val	Glu Thr	Thr
2735			2740			2745		
Asn Gln	Ala Ile	Glu Asp	Ala	Pro Asp	Thr Asn	Gln	Val Asn	Val
2750			2755			2760		

- 87 -

Glu	Lys	Asn	Lys	Gly	Ile	Gly	Thr	Ile	Arg	Asp	Ile	Gln	Pro	Leu
2765						2770					2775			
Val	Val	Lys	Lys	Pro	Thr	Ala	Lys	Ser	Lys	Ile	Glu	Ser	Ala	Val
2780						2785					2790			
Glu	Lys	Lys	Lys	Thr	Glu	Ile	Asn	Gln	Thr	Gln	Asn	Ala	Thr	His
2795						2800					2805			
Asp	Glu	Val	Arg	Glu	Gly	Leu	Asn	Gln	Leu	Asn	Gln	Ile	His	Glu
2810						2815					2820			
Lys	Ala	Lys	Asn	Asp	Val	Asn	Gln	Ser	Gln	Thr	Asn	Gln	Gln	Val
2825						2830					2835			
Glu	Asn	Ala	Glu	Gln	Asn	Ser	Leu	Asp	Gln	Ile	Asn	Asn	Phe	Arg
2840						2845					2850			
Pro	Asp	Phe	Ser	Lys	Lys	Arg	Asn	Ala	Val	Ala	Glu	Ile	Val	Lys
2855						2860					2865			
Ala	Gln	Gln	Asn	Lys	Ile	Asp	Glu	Ile	Glu	Gln	Glu	Phe	Ser	Ala
2870						2875					2880			
Thr	Gln	Glu	Glu	Lys	Asp	Asn	Ala	Leu	Gln	His	Leu	Asp	Glu	Gln
2885						2890					2895			
Val	Lys	Glu	Ile	Ile	Asn	Ser	Ile	Asn	Gln	Ala	Asn	Thr	Asp	Asn
2900						2905					2910			
Glu	Val	Asp	Asn	Ala	Lys	Thr	Ser	Gly	Leu	Asn	Asn	Ile	Thr	Glu
2915						2920					2925			
Tyr	Arg	Pro	Glu	Tyr	Asn	Lys	Lys	Lys	Asn	Ala	Ile	Leu	Lys	Leu
2930						2935					2940			
Tyr	Asp	Val	Ser	Asp	Thr	Gln	Glu	Ala	Ile	Ile	Asn	Gly	Tyr	Pro
2945						2950					2955			
Asp	Ala	Thr	Glu	Asp	Glu	Leu	Gln	Glu	Ala	Asn	Ser	Lys	Leu	Asn
2960						2965					2970			
Lys	Ile	Leu	Leu	Asp	Ala	Lys	Lys	Gln	Ile	Gly	Leu	Ala	His	Thr
2975						2980					2985			
Asn	Asn	Glu	Val	Asp	Asp	Ile	Tyr	Asn	Glu	Val	Ser	Gln	Lys	Met
2990						2995					3000			

- 88 -

Lys Thr Ile Leu Pro Arg Val Asp Thr Lys Ala Val Ala Arg Ser
 3005 3010 3015
 Val Leu Asn Ala Leu Ala Lys Gln Leu Ile Lys Thr Phe Glu Asn
 3020 3025 3030
 Thr Ala Asp Val Thr His Glu Glu Arg Asn Asp Ala Ile Asn His
 3035 3040 3045
 Val Lys Glu Gln Leu Ser Leu Val Phe Asn Ala Ile Glu Lys Asp
 3050 3055 3060
 Arg Lys Asp Ile Gln Val Ala Gln Asp Glu Leu Phe Gly Leu Asn
 3065 3070 3075
 Glu Leu Asn Ser Ile Phe Ile Asn Ile Thr Gln Lys Pro Thr Ala
 3080 3085 3090
 Arg Lys Ala Ile Ser Gly Met Ala Ser Gln Leu Asn Asn Ser Ile
 3095 3100 3105
 Asn Asn Thr Pro Tyr Ala Thr Glu Glu Glu Arg Gln Ile Ala Leu
 3110 3115 3120
 Asn Lys Val Lys Ala Ile Val Asp Asp Ala Asn Glu Lys Ile Arg
 3125 3130 3135
 Glu Ala Asn Thr Asp Ser Glu Val Leu Gly Thr Lys Ser Asn Ala
 3140 3145 3150
 Ile Thr Leu Leu Gln Ala Ile Ser Ala Asp Val Gln Val Lys Pro
 3155 3160 3165
 Gln Ala Phe Glu Glu Ile Asn Ala Gln Ala Glu Ile Gln Arg Glu
 3170 3175 3180
 Arg Ile Asn Gly Asn Ser Asp Ala Thr Arg Glu Glu Lys Glu Glu
 3185 3190 3195
 Ala Leu Lys Gln Val Asp Thr Leu Val Asn His Ser Phe Ile Thr
 3200 3205 3210
 Ile Asn Asn Val Asn Lys Asn Gln Glu Val Tyr Asp Thr Lys Asp
 3215 3220 3225

- 89 -

Lys Thr	Ile Glu Ala Ile His	Lys Ile Lys Pro Ile	Ser Thr Ile
3230	3235	3240	
Lys Pro	Gln Ala Leu Asn Glu	Ile Thr Ile Gln Leu	Asp Thr Gln
3245	3250	3255	
Arg Asp	Leu Ile Lys Asn Asn	Lys Glu Ser Thr Val	Glu Glu Lys
3260	3265	3270	
Ala Ser	Ala Ile Asp Lys Leu	Ile Lys Thr Ala Ala	Arg Ile Ala
3275	3280	3285	
Glu Ser	Ile Asp Lys Ala Gln	Thr Asn Glu Glu Val	Lys Asn Ile
3290	3295	3300	
Lys Lys	Gln Ser Ile Asp Glu	Ile Ser Lys Ile Leu	Pro Val Ile
3305	3310	3315	
Glu Ile	Lys Ser Ala Ala Arg	Asn Glu Ile His Gln	Lys Ala Glu
3320	3325	3330	
Val Ile	Arg Gly Leu Ile Asn	Asp Asn Glu Glu Ala	Thr Lys Glu
3335	3340	3345	
Glu Lys	Asp Ile Ala Leu Asn	Gln Leu Asp Thr Thr	Leu Thr Gln
3350	3355	3360	
Ala Asn	Val Ser Ile Asp Gln	Ala Leu Thr Asn Glu	Ala Val Asn
3365	3370	3375	
Arg Ala	Lys Glu Ile Ala Asn	Ser Glu Ile Asn Lys	Ile Ser Val
3380	3385	3390	
Ile Ala	Ile Lys Lys Pro Glu	Ala Ile Ala Glu Ile	Gln Glu Leu
3395	3400	3405	
Ala Asp	Lys Lys Leu Asn Lys	Phe Lys Gln Ser Gln	Glu Ala Thr
3410	3415	3420	
Ile Glu	Glu Lys Gln Ser Ala	Ile Asn Glu Leu Glu	Gln Ala Leu
3425	3430	3435	
Lys Ser	Ala Ile Asn His Ile	His Gln Ser Gln Asn	Asn Glu Ser
3440	3445	3450	
Val Ser	Ala Ala Leu Lys Glu	Ser Ile Ser Leu Ile	Asp Ser Ile
3455	3460	3465	

- 90 -

Glu Ile Gln Ala His Lys Lys Leu Glu Ala Lys Ala Tyr Ile Asp
 3470 3475 3480

Gly Tyr Ser Asp Asp Lys Ile Asn Asp Ile Ser Ser Arg Ala Thr
 3485 3490 3495

Asn Glu Glu Lys Gln Ile Phe Val Ser Lys Leu Lys Ala Leu Ile
 3500 3505 3510

Asn Arg Thr His Lys Gln Ile Asp Glu Ala Glu Thr Phe Val Ser
 3515 3520 3525

Val Glu Thr Ile Val Arg Asn Phe Lys Val Glu Ala Asp Lys Leu
 3530 3535 3540

Asn Ser Ile Val Arg Lys Lys Ala Lys Ala Ser Lys Glu Ile Glu
 3545 3550 3555

Leu Glu Ala Asp His Val Lys Gln Met Ile Asn Ala Asn Leu Ser
 3560 3565 3570

Ala Ser Thr Arg Val Lys Gln Asn Ala Arg Thr Leu Ile Asn Glu
 3575 3580 3585

Ile Val Ser Asn Ala Leu Ser Gln Leu Asn Lys Val Thr Thr Asn
 3590 3595 3600

Lys Glu Val Asp Glu Ile Val Asn Glu Thr Ile Glu Lys Leu Lys
 3605 3610 3615

Ser Ile Gln Ile Arg Glu Asp Lys Ile Leu Ser Ser Gln Arg Ser
 3620 3625 3630

Ser Thr Ser Met Thr Glu Lys Ser Asn Gln Cys Tyr Ser Ser Glu
 3635 3640 3645

Asn Asn Thr Ile Lys Ser Leu Pro Glu Ala Gly Asn Ala Asp Lys
 3650 3655 3660

Ser Leu Pro Leu Ala Gly Val Thr Leu Ile Ser Gly Leu Ala Ile
 3665 3670 3675

Met Ser Ser Arg Lys Lys Lys Lys Asp Lys Lys Val Asn Asp
 3680 3685 3690

- 91 -

<210> 49
 <211> 439
 <212> PRT
 <213> Staphylococcus epidermidis

<400> 49

Leu Asp Ile Lys Met Pro Lys Leu Gly Glu Ser Val His Glu Gly Thr
 1 5 10 15

Ile Glu Gln Trp Leu Val Ser Val Gly Asp His Val Asp Glu Tyr Glu
 20 25 30

Pro Leu Cys Glu Val Ile Thr Asp Lys Val Thr Ala Glu Val Pro Ser
 35 40 45

Thr Ile Ser Gly Thr Ile Thr Glu Leu Val Val Glu Glu Gly Gln Thr
 50 55 60

Val Asn Ile Asn Thr Val Ile Cys Lys Ile Asp Ser Glu Asn Gly Gln
 65 70 75 80

Asn Gln Thr Glu Ser Ala Asn Glu Phe Lys Glu Glu Gln Asn Gln His
 85 90 95

Ser Gln Ser Asn Ile Asn Val Ser Gln Phe Glu Asn Asn Pro Lys Thr
 100 105 110

His Glu Ser Glu Val His Thr Ala Ser Ser Arg Ala Asn Asn Asn Gly
 115 120 125

Arg Phe Ser Pro Val Val Phe Lys Leu Ala Ser Glu His Asp Ile Asp
 130 135 140

Leu Thr Gln Val Lys Gly Thr Gly Phe Glu Gly Arg Val Thr Lys Lys
 145 150 155 160

Asp Ile Gln Asn Ile Ile Asn Asn Pro Asn Asp Gln Glu Lys Glu Lys
 165 170 175

Glu Phe Lys Gln Thr Asp Lys Lys Asp His Ser Thr Asn His Cys Asp
 180 185 190

Phe Leu His Gln Ser Ser Thr Lys Asn Glu His Ser Pro Leu Ser Asn
 195 200 205

Glu Arg Val Val Pro Val Lys Gly Ile Arg Lys Ala Ile Ala Gln Asn
 210 215 220

- 92 -

Met Val Thr Ser Val Ser Glu Ile Pro His Gly Trp Met Met Val Glu
 225 230 235 240

Ala Asp Ala Thr Asn Leu Val Gln Thr Arg Asn Tyr His Lys Ala Gln
 245 250 255

Phe Lys Gln Asn Glu Gly Tyr Asn Leu Thr Phe Phe Ala Phe Phe Val
 260 265 270

Lys Ala Val Ala Glu Ala Leu Lys Val Asn Pro Leu Leu Asn Ser Thr
 275 280 285

Trp Gln Gly Asp Glu Ile Val Ile His Lys Asp Ile Asn Ile Ser Ile
 290 295 300

Ala Val Ala Asp Asp Asp Lys Leu Tyr Val Pro Val Ile Lys Asn Ala
 305 310 315 320

Asp Glu Lys Ser Ile Lys Gly Ile Ala Arg Glu Ile Asn Asp Leu Ala
 325 330 335

Thr Lys Ala Arg Leu Gly Lys Leu Ala Gln Ser Asp Met Gln Asn Gly
 340 345 350

Thr Phe Thr Val Asn Asn Thr Gly Ser Phe Gly Ser Val Ser Ser Met
 355 360 365

Gly Ile Ile Asn His Pro Gln Ala Ala Ile Leu Gln Val Glu Ser Val
 370 375 380

Val Lys Lys Pro Val Val Ile Asp Asp Met Ile Ala Ile Arg Asn Met
 385 390 395 400

Val Asn Leu Cys Ile Ser Ile Asp His Arg Ile Leu Asp Gly Val Gln
 405 410 415

Thr Gly Lys Phe Met Asn Leu Val Lys Lys Lys Ile Glu Gln Tyr Ser
 420 425 430

Ile Glu Asn Thr Ser Ile Tyr
 435

<210> 50

<211> 295

<212> PRT

<213> Staphylococcus epidermidis

- 93 -

<400> 50

Met Asn Thr Ile Ile Glu Glu Tyr Leu Asn Phe Ile Gln Ile Glu Lys
 1 5 10 15

Gly Leu Ser Asn Asn Thr Ile Gly Ala Tyr Arg Arg Asp Leu Lys Lys
 20 25 30

Tyr Lys Asp Tyr Leu Glu Asp Asn Lys Ile Ser His Ile Asp Phe Ile
 35 40 45

Asp Arg Gln Ile Ile Gln Glu Cys Leu Gly His Leu Ile Asp Met Gly
 50 55 60

Gln Ser Ser Lys Ser Leu Ala Arg Phe Ile Ser Thr Ile Arg Ser Phe
 65 70 75 80

His Gln Phe Ala Leu Arg Glu Lys Tyr Ala Ala Lys Asp Pro Thr Val
 85 90 95

Leu Ile Glu Thr Pro Lys Tyr Glu Lys Lys Leu Pro Asp Val Leu Glu
 100 105 110

Ile Asp Glu Val Ile Ala Leu Leu Glu Thr Pro Asp Leu Thr Lys Asn
 115 120 125

Asn Gly Tyr Arg Asp Arg Thr Met Leu Glu Leu Leu Tyr Ala Thr Gly
 130 135 140

Met Arg Val Thr Glu Ile Ile Gln Leu Asp Val Glu Asp Val Asn Leu
 145 150 155 160

Met Met Gly Phe Val Arg Val Phe Gly Lys Gly Asn Lys Glu Arg Ile
 165 170 175

Val Pro Leu Gly Asp Thr Val Ile Glu Tyr Leu Thr Thr Tyr Ile Glu
 180 185 190

Thr Val Arg Pro Gln Leu Leu Lys Gln Thr Thr Thr Gln Ala Leu Phe
 195 200 205

Leu Asn Met His Gly Lys Ser Leu Ser Arg Gln Gly Ile Trp Lys Ile
 210 215 220

Ile Lys Gln Tyr Gly Leu Lys Ala Asn Ile Asn Lys Thr Leu Thr Pro
 225 230 235 240

His Thr Leu Arg His Ser Phe Ala Thr His Leu Leu Glu Asn Gly Ala
245 250 255

Asp Leu Arg Ala Val Gln Glu Met Leu Gly His Ser Asp Ile Ser Thr
260 265 270

Thr Gln Leu Tyr Thr His Val Ser Lys Ser Gln Ile Arg Lys Met Tyr
275 280 285

Thr Gln Phe His Pro Arg Ala
290 295

```
<210> 51
<211> 800
<212> PRT
<213> Staphylococcus epidermidis
```

<400> 51

Met Ser Leu Val Tyr Leu Met Ala Thr Asn Leu Leu Val Met Leu Ile
1 5 10 15

Val Leu Phe Thr Leu Ser His Arg Gln Leu Arg Lys Val Ala Gly Tyr
20 25 30

Val Ala Leu Ile Ala Pro Ile Val Thr Ser Thr Tyr Phe Ile Met Lys
35 40 45

Ile Pro Asp Val Ile Arg Asn Lys Phe Ile Ala Val Arg Leu Pro Trp
50 55 60

Met Pro Ser Ile Asp Ile Asn Leu Asp Leu Arg Leu Asp Gly Leu Ser
65 70 75 80

Leu Met Phe Gly Leu Ile Ile Ser Leu Ile Gly Val Gly Val Phe Phe
85 90 95

Tyr Ala Thr Gln Tyr Leu Ser His Ser Thr Asp Asn Leu Pro Arg Phe
100 105 110

Phe Ile Tyr Leu Leu Leu Phe Met Phe Ser Met Ile Gly Ile Val Ile
115 120 125

Ala Asn Asn Thr Ile Leu Met Tyr Val Phe Trp Glu Leu Thr Ser Ile
130 135 140

Ser Ser Phe Leu Leu Ile Ser Tyr Trp Tyr Asn Asn Gly Glu Ser Gln
145 150 155 160

- 95 -

Leu Gly Ala Ile Gln Ser Phe Met Ile Thr Val Phe Gly Gly Leu Ala
 165 170 175

Leu Leu Thr Gly Phe Ile Ile Leu Tyr Ile Ile Thr Gly Thr Asn Thr
 180 185 190

Ile Thr Asp Ile Leu Asn Gln Arg Asn Ala Ile Ser Arg His Pro Leu
 195 200 205

Phe Ile Pro Met Ile Leu Met Leu Leu Leu Gly Ala Phe Thr Lys Ser
 210 215 220

Ala Gln Phe Pro Phe His Ile Trp Leu Pro Lys Ala Met Ala Ala Pro
 225 230 235 240

Thr Pro Val Ser Ala Tyr Leu His Ser Ala Thr Met Val Lys Ala Gly
 245 250 255

Ile Phe Leu Leu Phe Arg Phe Thr Pro Leu Leu Gly Leu Ser Asn Val
 260 265 270

Tyr Ile Tyr Thr Val Thr Phe Val Gly Leu Ile Thr Met Leu Phe Gly
 275 280 285

Ser Leu Thr Ala Leu Arg Gln Tyr Asp Leu Lys Gly Ile Leu Ala Tyr
 290 295 300

Ser Thr Ile Ser Gln Leu Gly Met Ile Met Thr Met Val Gly Leu Gly
 305 310 315 320

Gly Gly Tyr Ala Gln His Thr Ser Asp Glu Leu Ser Lys Phe Tyr Ile
 325 330 335

Leu Val Leu Phe Ala Gly Leu Phe His Leu Met Asn His Ala Val Phe
 340 345 350

Lys Cys Ala Leu Phe Met Gly Val Gly Ile Ile Asp His Glu Ser Gly
 355 360 365

Thr Arg Asp Ile Arg Leu Leu Asn Gly Met Arg Lys Val Phe Pro Lys
 370 375 380

Met His Ile Val Met Leu Leu Ala Ala Leu Ser Met Ala Gly Val Pro
 385 390 395 400

Phe Leu Asn Gly Phe Leu Ser Lys Glu Met Phe Leu Asp Ser Leu Thr

- 96 -

405	410	415
Lys Ala Asn Glu Leu Asp Gln Tyr Gly Phe Val Leu Thr Phe Val Ile 420 425 430		
Ile Ser Ile Gly Val Ile Ala Ser Ile Leu Thr Phe Thr Tyr Ala Leu 435 440 445		
Tyr Met Ile Lys Glu Thr Phe Trp Gly Asn Tyr Asn Ile Glu Lys Phe 450 455 460		
Lys Arg Lys Gln Ile His Glu Pro Trp Leu Phe Ser Leu Pro Ala Val 465 470 475 480		
Ile Leu Met Leu Leu Ile Pro Val Ile Phe Phe Val Pro Asn Val Phe 485 490 495		
Gly Asn Phe Val Ile Leu Pro Ala Thr Arg Ser Val Ser Gly Ile Gly 500 505 510		
Ala Glu Val Asp Ala Phe Val Pro His Ile Ser Gln Trp His Gly Val 515 520 525		
Asn Leu Pro Leu Ile Leu Ser Ile Val Val Ile Ile Ile Gly Leu Ile 530 535 540		
Leu Ala Leu Val Val Asn Trp Lys Glu Val Thr His Gln Ile Ile Lys 545 550 555 560		
Ser Ala Ser Ile Thr Asp Gly Tyr Arg Lys Ile Tyr Arg Glu Phe Glu 565 570 575		
Leu Tyr Ser Ala Arg Gly Ile Arg Ala Leu Met Asn Asn Lys Leu Asn 580 585 590		
Tyr Tyr Ile Met Ile Thr Leu Phe Ile Phe Val Ala Ile Val Val Tyr 595 600 605		
Gly Tyr Leu Thr Val Gly Phe Pro His Val His Gln Leu His Ile Ser 610 615 620		
Ser Phe Gly Pro Leu Glu Val Ile Leu Ser Val Val Thr Leu Ile Ile 625 630 635 640		
Gly Ile Ser Leu Ile Phe Ile Arg Gln Arg Leu Thr Met Val Val Leu 645 650 655		

- 97 -

Asn Gly Met Ile Gly Phe Ala Val Thr Leu Tyr Phe Ile Ala Met Lys
660 665 670

Ala Pro Asp Leu Ala Leu Thr Gln Leu Val Val Glu Thr Ile Thr Thr
675 680 685

```

Ile Leu Phe Ile Val Ser Phe Ser Arg Leu Pro Asn Ile Pro Arg Val
    690                      695                      700

```

Lys Ala Asn Leu Lys Lys Glu Thr Phe Lys Ile Ile Val Ser Leu Val
705 710 715 720

Met Ala Leu Thr Val Val Ser Leu Ile Phe Val Ala Gln Gln Ala Asp
725 730 735

Gly Met Pro Ser Ile Ala Lys Phe Tyr Glu Asp Ala Tyr Glu Leu Thr
740 745 750

Gly Gly Lys Asn Ile Val Asn Ala Ile Leu Gly Asp Phe Arg Ala Leu
755 760 765

Asp Thr Met Phe Glu Gly Leu Val Leu Ile Ile Ala Gly Leu Gly Ile
770 775 780

Tyr Thr Leu Leu Asn Tyr Lys Asp Arg Arg Gly Gln Asp Glu Arg Glu
785 790 795 800

```
<210> 52
<211> 892
<212> PRT
<213> Staphylococcus epidermidis
```

<400> 52

Leu Phe Gly Leu Gly His Asn Glu Ala Lys Ala Glu Glu Asn Thr Val
1 5 10 15

Gln Asp Val Lys Asp Ser Asn Met Asp Asp Glu Leu Ser Asp Ser Asn
20 25 30

Asp Gln Ser Ser Asn Glu Glu Lys Asn Asp Val Ile Asn Asn Ser Gln
35 40 45

Ser Ile Asn Thr Asp Asp Asp Asn Gln Ile Lys Lys Glu Glu Thr Asn
50 55 60

Ser Asn Asp Ala Ile Glu Asn Arg Ser Lys Asp Ile Thr Gln Ser Thr
65 70 75 80

- 98 -

Thr Asn Val Asp Glu Asn Glu Ala Thr Phe Leu Gln Lys Thr Pro Gln
 85 90 95

Asp Asn Thr Gln Leu Lys Glu Glu Val Val Lys Glu Pro Ser Ser Val
 100 105 110

Glu Ser Ser Asn Ser Ser Met Asp Thr Ala Gln Gln Pro Ser His Thr
 115 120 125

Thr Ile Asn Ser Glu Ala Ser Ile Gln Thr Ser Asp Asn Glu Glu Asn
 130 135 140

Ser Arg Val Ser Asp Phe Ala Asn Ser Lys Ile Ile Glu Ser Asn Thr
 145 150 155 160

Glu Ser Asn Lys Glu Glu Asn Thr Ile Glu Gln Pro Asn Lys Val Arg
 165 170 175

Glu Asp Ser Ile Thr Ser Gln Pro Ser Ser Tyr Lys Asn Ile Asp Glu
 180 185 190

Lys Ile Ser Asn Gln Asp Glu Leu Leu Asn Leu Pro Ile Asn Glu Tyr
 195 200 205

Glu Asn Lys Val Arg Pro Leu Ser Thr Thr Ser Ala Gln Pro Ser Ser
 210 215 220

Lys Arg Val Thr Val Asn Gln Leu Ala Ala Glu Gln Gly Ser Asn Val
 225 230 235 240

Asn His Leu Ile Lys Val Thr Asp Gln Ser Ile Thr Glu Gly Tyr Asp
 245 250 255

Asp Ser Asp Gly Ile Ile Lys Ala His Asp Ala Glu Asn Leu Ile Tyr
 260 265 270

Asp Val Thr Phe Glu Val Asp Asp Lys Val Lys Ser Gly Asp Thr Met
 275 280 285

Thr Val Asn Ile Asp Lys Asn Thr Val Pro Ser Asp Leu Thr Asp Ser
 290 295 300

Phe Ala Ile Pro Lys Ile Lys Asp Asn Ser Gly Glu Ile Ile Ala Thr
 305 310 315 320

Gly Thr Tyr Asp Asn Thr Asn Lys Gln Ile Thr Tyr Thr Phe Thr Asp
325 330 335

Tyr Val Asp Lys Tyr Glu Asn Ile Lys Ala His Leu Lys Leu Thr Ser
340 345 350

Tyr Ile Asp Lys Ser Lys Val Pro Asn Asn Asn Thr Lys Leu Asp Val
355 360 365

Glu Tyr Lys Thr Ala Leu Ser Ser Val Asn Lys Thr Ile Thr Val Glu
370 375 380

Tyr Gln Lys Pro Asn Glu Asn Arg Thr Ala Asn Leu Gln Ser Met Phe
385 390 395 400

Thr Asn Ile Asp Thr Lys Asn His Thr Val Glu Gln Thr Ile Tyr Ile
405 410 415

Asn Pro Leu Arg Tyr Ser Ala Lys Glu Thr Asn Val Asn Ile Ser Gly
420 425 430

Asn Gly Asp Glu Gly Ser Thr Ile Ile Asp Asp Ser Thr Ile Ile Lys
 . 435 440 445

Val Tyr Lys Val Gly Asp Asn Gln Asn Leu Pro Asp Ser Asn Arg Ile
450 455 460

Tyr Asp Tyr Ser Glu Tyr Glu Asp Val Thr Asn Asp Asp Tyr Ala Gln
465 470 475 480

Leu Gly Asn Asn Asn Asp Val Asn Ile Asn Phe Gly Asn Ile Asp Ser
485 490 495

Pro Tyr Ile Ile Lys Val Ile Ser Lys Tyr Asp Pro Asn Lys Asp Asp
500 505 510

Tyr Thr Thr Ile Gln Gln Thr Val Thr Met Gln Thr Thr Ile Asn Glu
515 520 525

Tyr Thr Gly Glu Phe Arg Thr Ala Ser Tyr Asp Asn Thr Ile Ala Phe
530 535 540

Ser Thr Ser Ser Gly Gln Gly Gln Gly Asp Leu Pro Pro Glu Lys Thr
545 550 555 560

Tyr Lys Ile Gly Asp Tyr Val Trp Glu Asp Val Asp Lys Asp Gly Ile
565 570 575

Pro Arg Tyr Gly Gly Gln His Ala His Leu Thr Glu Glu Gln Arg Gln
130 135 140

- 102 -

Gln Tyr Glu Ala Glu Gly Arg Lys Pro Ser Ile Arg Phe Arg Val Pro
 145 150 155 160

Lys Asp Gln Thr Tyr Thr Phe Asn Asp Met Val Lys Gly Glu Ile Ser
 165 170 175

Phe Glu Ser Asp Asn Ile Gly Asp Trp Val Ile Val Lys Lys Asp Gly
 180 185 190

Val Pro Thr Tyr Asn Phe Ala Val Ala Val Asp Asp His Tyr Met Gln
 195 200 205

Ile Ser Asp Val Ile Arg Gly Asp Asp His Val Ser Asn Thr Pro Lys
 210 215 220

Gln Leu Met Ile Tyr Glu Ala Phe Gly Trp Glu Ala Pro Arg Phe Gly
 225 230 235 240

His Met Ser Leu Ile Val Asn Glu Glu Arg Lys Lys Leu Ser Lys Arg
 245 250 255

Asp Gly Gln Ile Leu Gln Phe Ile Glu Gln Tyr Arg Asp Leu Gly Tyr
 260 265 270

Leu Pro Glu Ala Leu Phe Asn Phe Ile Thr Leu Leu Gly Trp Ser Pro
 275 280 285

Glu Gly Glu Glu Glu Ile Phe Ser Lys Glu Glu Phe Ile Lys Ile Phe
 290 295 300

Asp Glu Lys Arg Leu Ser Lys Ser Pro Ala Met Phe Asp Arg Gln Lys
 305 310 315 320

Leu Ala Trp Val Asn Asn Gln Tyr Met Lys Thr Lys Asp Thr Glu Thr
 325 330 335

Val Phe Glu Leu Ala Leu Pro His Leu Ile Lys Ala Asn Leu Ile Pro
 340 345 350

Glu Asn Pro Ser Glu Lys Asp Arg Glu Trp Gly Arg Lys Leu Ile Ala
 355 360 365

Leu Tyr Gln Lys Glu Met Ser Tyr Ala Gly Glu Ile Val Pro Leu Ser
 370 375 380

Glu Met Phe Phe His Glu Met Pro Glu Leu Gly Lys Asp Glu Gln Glu

```

385                               390                               395                               400

Val Leu Gln Gly Glu Gln Val Pro Glu Leu Met Asn His Leu Tyr Gly
      405                               410                               415

Lys Leu Glu Ser Leu Glu Ser Phe Glu Ala Thr Glu Ile Lys Lys Met
      420                               425                               430

Ile Lys Glu Val Gln Lys Glu Thr Gly Ile Lys Gly Lys Gln Leu Phe
      435                               440                               445

Met Pro Ile Arg Val Ala Val Thr Gly Gln Met His Gly Pro Glu Leu
      450                               455                               460

Pro Asn Thr Ile Glu Val Leu Gly Lys Asp Lys Val Leu Ser Arg Leu
465                               470                               475                               480

Lys Asn Leu Val

<210> 54
<211> 296
<212> PRT
<213> Staphylococcus epidermidis

<400> 54

Met Glu Tyr Lys Asp Ile Ala Thr Pro Ser Arg Thr Arg Ala Leu Leu
1      5      10      15

Asp Gln Tyr Gly Phe Asn Phe Lys Lys Ser Leu Gly Gln Asn Phe Leu
      20      25      30

Ile Asp Val Asn Ile Ile Asn Lys Ile Ile Glu Ala Ser His Ile Asp
      35      40      45

Cys Thr Thr Gly Val Ile Glu Val Gly Pro Gly Met Gly Ser Leu Thr
      50      55      60

Glu Gln Leu Ala Lys Asn Ala Lys Lys Val Met Ala Phe Glu Ile Asp
65      70      75      80

Gln Arg Leu Ile Pro Val Leu Lys Asp Thr Leu Ser Pro Tyr Asp Asn
      85      90      95

Val Thr Ile Ile Asn Glu Asp Ile Leu Lys Ala Asp Ile Ala Lys Ala
      100      105      110

```

- 104 -

Val Asp Thr His Leu Gln Asp Cys Asp Lys Ile Met Val Val Ala Asn
 115 120 125

Leu Pro Tyr Tyr Ile Thr Thr Pro Ile Leu Leu Asn Leu Met Gln Gln
 130 135 140

Asp Val Pro Ile Asp Gly Phe Val Val Met Met Gln Lys Glu Val Gly
 145 150 155 160

Glu Arg Leu Asn Ala Gln Val Gly Thr Lys Ala Tyr Gly Ser Leu Ser
 165 170 175

Ile Val Ala Gln Tyr Tyr Thr Glu Thr Ser Lys Val Leu Thr Val Pro
 180 185 190

Lys Thr Val Phe Met Pro Pro Pro Asn Val Asp Ser Ile Val Val Lys
 195 200 205

Leu Met Gln Arg Gln Glu Pro Leu Val Gln Val Asp Asp Glu Glu Gly
 210 215 220

Phe Phe Lys Leu Ala Lys Ala Ala Phe Ala Gln Arg Arg Lys Thr Ile
 225 230 235 240

Asn Asn Asn Tyr Gln Asn Phe Phe Lys Asp Gly Lys Lys Asn Lys Glu
 245 250 255

Thr Ile Arg Gln Trp Leu Glu Ser Ala Gly Ile Asp Pro Lys Arg Arg
 260 265 270

Gly Glu Thr Leu Thr Ile Gln Asp Phe Ala Thr Leu Tyr Glu Gln Lys
 275 280 285

Lys Lys Phe Ser Glu Leu Thr Asn
 290 295

<210> 55

<211> 106

<212> PRT

<213> Staphylococcus epidermidis

<400> 55

Met Thr Ser Asn His His Ala Pro Tyr Asp Leu Gly Tyr Thr Arg Ala
 1 5 10 15

Thr Met Asp Asn Thr Lys Gly Ser Glu Thr Ala Arg Ser Ser Lys Ser
 20 25 30

- 105 -

His Lys Val Val Leu Ser Ser Asp Cys Ser Leu Gln Leu Asp Tyr Met
 35 40 45

Lys Leu Glu Ser Leu Val Ile Val Asp Gln His Ala Thr Val Asn Thr
 50 55 60

Phe Pro Gly Leu Val His Thr Ala Arg His Thr Thr Arg Val Cys Asn
 65 70 75 80

Thr Arg Ser Arg Trp Ser Asn His Leu Glu Leu Ala Val Glu Gly Gly
 85 90 95

Thr Asn Asp Trp Gly Glu Val Val Thr Arg
 100 105

<210> 56
 <211> 442
 <212> PRT
 <213> Staphylococcus epidermidis

<400> 56

Met Phe Phe Lys Gln Phe Tyr Asp Lys His Leu Ser Gln Ala Ser Tyr
 1 5 10 15

Leu Ile Gly Cys Gln Lys Thr Gly Glu Ala Met Ile Ile Asp Pro Ile
 20 25 30

Arg Asp Leu Ser Ser Tyr Ile Arg Val Ala Asp Glu Glu Gly Leu Thr
 35 40 45

Ile Thr His Ala Ala Glu Thr His Ile His Ala Asp Phe Ala Ser Gly
 50 55 60

Ile Arg Asp Val Ala Ile Lys Leu Asn Ala Ser Ile Tyr Val Ser Gly
 65 70 75 80

Glu Ser Asp Asp Thr Leu Gly Tyr Lys Asn Met Pro Asn Gln Thr His
 85 90 95

Phe Val Gln His Asn Asp Asp Ile Tyr Val Gly Asn Ile Lys Leu Lys
 100 105 110

Val Leu His Thr Pro Gly His Thr Pro Glu Ser Ile Ser Phe Leu Leu
 115 120 125

Thr Asp Glu Gly Ala Gly Ala Gln Val Pro Met Gly Leu Phe Ser Gly
 130 135 140

- 106 -

Asp Phe Ile Phe Val Gly Asp Ile Gly Arg Pro Asp Leu Leu Glu Lys
 145 150 155 160

Ala Val Lys Val Glu Gly Ser Ser Glu Ile Gly Ala Lys Gln Met Phe
 165 170 175

Lys Ser Ile Glu Ser Ile Lys Asp Leu Pro Asn Tyr Ile Gln Ile Trp
 180 185 190

Pro Gly His Gly Ala Gly Ser Pro Cys Gly Lys Ser Leu Gly Ala Ile
 195 200 205

Pro Thr Ser Thr Leu Gly Tyr Glu Lys Gln Thr Asn Trp Ala Phe Ser
 210 215 220

Glu Asn Asn Glu Ala Thr Phe Ile Asp Lys Leu Ile Ser Asp Gln Pro
 225 230 235 240

Ala Pro Pro His His Phe Ala Gln Met Lys Lys Ile Asn Gln Phe Gly
 245 250 255

Met Asn Leu Tyr Gln Pro Tyr Thr Val Tyr Pro Ala Thr Asn Thr Asn
 260 265 270

Arg Leu Thr Phe Asp Leu Arg Ser Lys Glu Ala Tyr His Gly Gly His
 275 280 285

Ile Glu Gly Thr Ile Asn Ile Pro Tyr Asp Lys Asn Phe Ile Asn Gln
 290 295 300

Ile Gly Trp Tyr Leu Asn Tyr Asp Gln Glu Ile Asn Leu Ile Gly Glu
 305 310 315 320

Tyr His Leu Val Ser Lys Ala Thr His Thr Leu Gln Leu Ile Gly Tyr
 325 330 335

Asp Asp Val Ala Gly Tyr Gln Leu Pro Gln Ser Lys Ile Gln Thr Arg
 340 345 350

Ser Ile His Ser Glu Asp Ile Thr Gly Asn Glu Ser His Ile Leu Asp
 355 360 365

Val Arg Asn Asp Asn Glu Trp Asn Asn Gly His Leu Ser Gln Ala Val
 370 375 380

- 107 -

His Val Pro His Gly Lys Leu Leu Glu Thr Asp Leu Pro Phe Asn Arg
 385 390 395 400

Asn Asp Val Ile Tyr Val His Cys Gln Ser Gly Ile Arg Ser Ser Ile
 405 410 415

Ala Ile Gly Ile Leu Glu His Lys Gly Tyr His Asn Ile Ile Asn Val
 420 425 430

Asn Glu Gly Tyr Lys Asp Ile His Leu Ser
 435 440

<210> 57

<211> 285

<212> PRT

<213> Staphylococcus epidermidis

<400> 57

Leu Lys Lys Ile Leu Val Leu Ser Leu Thr Ala Phe Leu Val Leu Ala
 1 5 10 15

Gly Cys Asn Ser Gly Asp Lys Thr Asp Thr Lys Asp Lys Lys Glu Glu
 20 25 30

Thr Lys Gln Thr Ser Lys Ala Asn Lys Glu Asn Lys Glu Gln His His
 35 40 45

Lys Gln Glu Asn Asp Asn Lys Ala Ser Thr Gln Leu Ser Glu Lys Glu
 50 55 60

Arg Leu Ala Leu Ala Phe Tyr Ala Asp Gly Val Glu Lys Tyr Met Leu
 65 70 75 80

Thr Lys Asn Glu Val Leu Thr Gly Val Tyr Asp Tyr Gln Lys Gly Asn
 85 90 95

Glu Thr Glu Lys Lys Gln Met Glu Gln Leu Met Leu Glu Lys Ala Asp
 100 105 110

Ser Met Lys Asn Ala Pro Lys Asp Met Lys Phe Tyr Gln Val Tyr Pro
 115 120 125

Ser Lys Gly Gln Phe Ala Ser Ile Val Gly Val Asn Lys Asn Lys Ile
 130 135 140

Phe Ile Gly Ser Thr Gln Gly Ala Leu Ile Asp Tyr Gln Thr Leu Leu
 145 150 155 160

- 108 -

Asn Asn Gly Lys Glu Leu Asp Ile Ser Gln Leu Tyr Glu Asp Asn Lys
165 170 175

Asp Asn Arg Ser Leu Glu Glu Met Lys Asn Lys Ile Glu Ile Val Asp
180 185 190

Ser Gly Ala Ala Gln Lys Ala Asp Asp Pro Asp Lys Asn Ser Ala Asn
195 200 205

Thr Met Ala His Met Arg Ser Gln Ile Tyr Glu Lys Ile Ser Asp Phe
210 215 220

Asp Gly Lys Leu Asp Asn Lys Thr Tyr Leu Trp Asp Asn Ile Arg Ile
225 230 235 240

Asn Asp Asp Gly Asn Trp Thr Val His Tyr Arg Asn His Asp Gly Glu
245 250 255

Ile Met Gly Thr Tyr Lys Ser Glu Lys Asn Lys Ile Ile Lys Leu Asp
260 265 270

Gln Asn Gly Asn Lys Ile Lys Glu Gln Gln Met Ser Asn
275 280 285

<210> 58

<211> 498

<212> PRT

<213> Staphylococcus epidermidis

<400> 58

Met Ala Asn Lys Glu Ser Lys Asn Val Val Ile Ile Gly Ala Gly Val
1 5 10 15

Leu Ser Thr Thr Phe Gly Ser Met Ile Lys Glu Leu Glu Pro Asp Trp
20 25 30

Asn Ile Lys Leu Tyr Glu Arg Leu Asp Arg Pro Gly Ile Glu Ser Ser
35 40 45

Asn Glu Arg Asn Asn Ala Gly Thr Gly His Ala Ala Leu Cys Glu Leu
50 55 60

Asn Tyr Thr Val Gln Gln Pro Asp Gly Ser Ile Asp Ile Glu Lys Ala
65 70 75 80

Lys Glu Ile Asn Glu Gln Phe Glu Ile Ser Lys Gln Phe Trp Gly His
85 90 95

- 109 -

Leu Val Lys Ser Gly Asn Ile Ser Asn Pro Arg Asp Phe Ile Asn Pro
 100 105 110

Leu Pro His Ile Ser Phe Val Arg Gly Lys Asn Asn Val Lys Phe Leu
 115 120 125

Lys Asn Arg Tyr Glu Ala Met Arg Asn Phe Pro Met Phe Asp Asn Ile
 130 135 140

Glu Tyr Thr Glu Asp Ile Glu Glu Met Arg Lys Trp Met Pro Leu Met
 145 150 155 160

Met Thr Gly Arg Thr Gly Asn Glu Ile Met Ala Ala Ser Lys Ile Asp
 165 170 175

Glu Gly Thr Asp Val Asn Tyr Gly Glu Leu Thr Arg Lys Met Ala Lys
 180 185 190

Ser Ile Glu Lys His Pro Asn Ala Asp Val Gln Tyr Asn His Glu Val
 195 200 205

Ile Asn Phe Asn Arg Arg Lys Asp Gly Ile Trp Glu Val Lys Val Lys
 210 215 220

Asn Arg Asn Ser Gly Asp Val Glu Thr Val Leu Ala Asp Tyr Val Phe
 225 230 235 240

Ile Gly Ala Gly Gly Gly Ala Ile Pro Leu Leu Gln Lys Thr Gly Ile
 245 250 255

Pro Glu Ser Lys His Leu Gly Gly Phe Pro Ile Ser Gly Gln Phe Leu
 260 265 270

Ile Cys Thr Asn Pro Asp Val Ile Asn Glu His Asp Val Lys Val Tyr
 275 280 285

Gly Lys Glu Pro Pro Gly Thr Pro Pro Met Thr Val Pro His Leu Asp
 290 295 300

Thr Arg Tyr Ile Asp Gly Glu Arg Thr Leu Leu Phe Gly Pro Phe Ala
 305 310 315 320

Asn Ile Gly Pro Lys Phe Leu Arg Asn Gly Ser Asn Leu Asp Leu Phe
 325 330 335

- 110 -

Lys Ser Val Lys Pro Tyr Asn Ile Thr Thr Leu Leu Ala Ser Ala Val
340 345 350

Lys Asn Leu Pro Leu Ile Lys Tyr Ser Ile Asp Gln Val Leu Met Thr
355 360 365

Lys Glu Gly Cys Met Asn His Leu Arg Thr Phe Tyr Pro Glu Ala Arg
370 375 380

Asp Glu Asp Trp Gln Leu Tyr Thr Ala Gly Lys Arg Val Gln Val Ile
385 390 395 400

Lys Asp Thr Lys Glu His Gly Lys Gly Phe Ile Gln Phe Gly Thr Glu
405 410 415

Val Val Asn Ser Lys Asp His Ser Val Ile Ala Leu Leu Gly Glu Ser
420 425 430

Pro Gly Ala Ser Thr Ser Val Ser Val Ala Leu Glu Val Leu Glu Lys
435 440 445

Asn Phe Ala Glu Tyr Glu Lys Asp Trp Thr Pro Lys Leu Gln Lys Met
450 455 460

Ile Pro Ser Tyr Gly Lys Ser Leu Ile Asp Asp Val Lys Leu Met Arg
465 470 475 480

Ala Thr Arg Lys Gln Thr Ser Lys Asp Leu Glu Leu Asn Tyr Tyr Glu
485 490 495

Ser Lys

```
<210> 59
<211> 516
<212> PRT
<213> Staphylococcus epidermidis
```

<400> 59

Met Lys Ile Phe Lys Thr Leu Ser Ser Ile Leu Val Thr Ser Val Leu
1 5 10 15

Ser Val Thr Val Ile Pro Ser Thr Phe Ala Ser Thr Glu Ser Thr Ala
20 25 30

Thr Asn Gln Thr Gln Gln Thr Val Leu Phe Asp Asn Ser His Ala Gln
35 40 45

- 111 -

Thr Ala Gly Ala Ala Asp Trp Val Ile Asp Gly Ala Phe Ser Asp Tyr
 50 55 60

Ala Asp Ser Met Arg Lys Gln Gly Tyr Gln Val Lys Glu Leu Glu Gly
 65 70 75 80

Glu Ser Asn Ile Ser Asp Gln Ser Leu Gln Gln Ala His Val Leu Val
 85 90 95

Ile Pro Glu Ala Asn Asn Pro Phe Lys Glu Asn Glu Gln Lys Ala Ile
 100 105 110

Ile Asn Phe Val Lys Asn Gly Gly Ser Val Ile Phe Ile Ser Asp His
 115 120 125

Tyr Asn Ala Asp Arg Asn Leu Asn Arg Ile Asp Ser Ser Glu Ser Met
 130 135 140

Asn Gly Tyr Arg Arg Gly Ala Tyr Glu Asn Met Thr Lys Asp Met Asn
 145 150 155 160

Asn Glu Glu Lys Asn Ser Asn Val Met His Asn Val Lys Ser Ser Asp
 165 170 175

Trp Leu Ser Gln Asn Phe Gly Val Arg Phe Arg Tyr Asn Ala Leu Gly
 180 185 190

Asp Ile Asn Thr Gln Asn Ile Val Ser Ser Lys Asp Ser Phe Gly Ile
 195 200 205

Thr Lys Gly Val Gln Ser Val Ser Met His Ala Gly Ser Thr Leu Ala
 210 215 220

Ile Thr Asp Pro Asn Lys Ala Lys Gly Ile Ile Tyr Met Pro Glu His
 225 230 235 240

Leu Thr His Ser Gln Lys Trp Pro His Ala Val Asp Gln Gly Ile Tyr
 245 250 255

Asn Gly Gly Gly Ile Asn Glu Gly Pro Tyr Val Ala Ile Ser Lys Ile
 260 265 270

Gly Lys Gly Lys Ala Ala Phe Ile Gly Asp Ser Ser Leu Val Glu Asp
 275 280 285

Arg Ser Pro Lys Tyr Leu Arg Glu Asp Asn Gly Lys Pro Lys Lys Thr

- 112 -

290

295

300

Tyr Asp Gly Phe Lys Glu Gln Asp Asn Gly Lys Leu Leu Asn Asn Leu
 305 310 315 320

Thr Thr Trp Leu Gly Lys Lys Glu Ser Gln Ser Ser Met Lys Asp Met
 325 330 335

Gly Ile Lys Leu Asp Asn Lys Thr Pro Leu Leu Asn Phe Glu Gln Pro
 340 345 350

Glu Asn Ser Ile Glu Pro Gln Lys Glu Pro Trp Thr Asn Pro Ile Glu
 355 360 365

Gly Tyr Lys Trp Tyr Asp Arg Ser Thr Phe Lys Thr Gly Ser Tyr Gly
 370 375 380

Ser Asn Gln Arg Gly Ala Asp Asp Gly Val Asp Asp Lys Ser Ser Ser
 385 390 395 400

His Gln Asn Gln Asn Ala Lys Val Glu Leu Thr Leu Pro Gln Asn Ile
 405 410 415

Gln Pro His His Pro Phe Gln Phe Thr Ile Lys Leu Thr Gly Tyr Glu
 420 425 430

Pro Asn Ser Thr Ile Ser Asp Val Arg Val Gly Leu Tyr Lys Asp Gly
 435 440 445

Gly Lys Gln Ile Gly Ser Phe Ser Ser Asn Arg Asn Gln Phe Asn Thr
 450 455 460

Leu Gly Tyr Ser Pro Gly Gln Ser Ile Lys Ala Asn Gly Ala Gly Glu
 465 470 475 480

Ala Ser Phe Thr Leu Thr Ala Lys Val Thr Asp Glu Ile Lys Asp Ala
 485 490 495

Asn Ile Arg Val Lys Gln Gly Lys Lys Ile Leu Leu Thr Gln Lys Met
 500 505 510

Asn Glu Asn Phe
 515

<210> 60
 <211> 84
 <212> PRT

- 113 -

<213> Staphylococcus epidermidis

<400> 60

Gly Thr Pro Leu Glu Leu Val Phe Val Asn Thr Leu Gly Pro Lys Pro
 1 5 10 15

Cys Phe Ala Lys Pro Asn Lys Ile Leu Leu Leu Glu Tyr Ile Pro Leu
 20 25 30

Phe Val Ala Asp Ala Ala Ala Val Lys Thr Thr Lys Leu Thr Met Pro
 35 40 45

Ala Ala Lys Gly Thr Pro Ile Ser Val Asn Asn Leu Thr Asn Gly Leu
 50 55 60

Leu Ser Gly Ser Thr Leu Asn His Gly Met Thr Asp Met Ile Thr Ser
 65 70 75 80

Lys Pro Pro Ile

<210> 61

<211> 54

<212> PRT

<213> Staphylococcus epidermidis

<400> 61

Ser Ser Leu Ser Thr Ile Ile Pro Phe Ser Leu Gly Ala Leu Gly Lys
 1 5 10 15

Phe Asn Ser Phe Ile Glu Gln Ile Ile Pro Leu Glu Ser Thr Pro Arg
 20 25 30

Asn Trp Ala Ser Leu Ile Thr Ile Pro Leu Gly Ile Thr Ala Pro Thr
 35 40 45

Phe Ala Thr Thr Thr Phe
 50

<210> 62

<211> 116

<212> PRT

<213> Staphylococcus aureus

<400> 62

Met Lys Phe Lys Lys Tyr Ile Leu Thr Gly Thr Leu Ala Leu Leu Leu
 1 5 10 15

- 114 -

Ser Ser Thr Gly Ile Ala Thr Ile Glu Gly Asn Lys Ala Asp Ala Ser
20 25 30

Ser Leu Asp Lys Tyr Leu Thr Glu Ser Gln Phe His Asp Lys Arg Ile
35 40 45

Ala Glu Glu Leu Arg Thr Leu Leu Asn Lys Ser Asn Val Tyr Ala Leu
50 55 60

Ala Ala Gly Ser Leu Asn Pro Tyr Tyr Lys Arg Thr Ile Met Met Asn
65 70 75 80

Glu Tyr Arg Ala Lys Ala Ala Leu Lys Lys Asn Asp Phe Val Ser Met
85 90 95

Ala Asp Ala Lys Val Ala Leu Glu Lys Ile Tyr Lys Glu Ile Asp Glu
100 105 110

Ile Ile Asn Arg
115

This Page is inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☒ BLACK BORDERS
- ☒ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☐ BLURED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☒ COLORED OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REPERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images
problems checked, please do not report the
problems to the IFW Image Problem Mailbox**

THIS PAGE BLANK (USPTO)